Research in the News

Most people with a spinal cord injury above T6 know what autonomic dysreflexia feels like when it announces itself — the pounding headache, the sweating above the injury level, the flushed skin. You look for the trigger, you deal with it, the blood pressure comes down.

The problem is the episodes that never announce themselves. A Canadian study presented at the American Congress of Rehabilitation Medicine has found that people with more severe sleep apnoea have significantly more of these silent episodes during the night — and that the apnoea itself looks like the trigger.

What they measured

Researchers at a tertiary spinal cord rehabilitation centre in Canada recruited 45 adults with cervical or high-thoracic SCI (at T6 or higher) who were at least a month past injury. The group was deliberately broad: 38 had cervical injuries, injuries ranged from motor complete (AIS-A and AIS-B) to incomplete (AIS-C and AIS-D), and time since injury ran from six weeks to 52 years.

Each participant did an unattended home or hospital sleep screening test, which produces an apnoea-hypopnoea index (AHI) — the average number of times per hour that breathing stops completely (apnoea) or becomes dangerously shallow (hypopnoea). An AHI of 15 or more is generally classed as moderate-to-severe sleep apnoea.

Blood pressure was tracked through the night. An episode of autonomic dysreflexia was counted when systolic blood pressure jumped by at least 20 mmHg. Critically, the team excluded any episode that had an obvious cause other than a breathing event — so a full bladder or a pressure point wouldn't be counted as an apnoea-driven spike.

What they found

The average AHI across the group was 16.0 events per hour, with a range from 0.8 to 51.7. In other words, this was a group where sleep apnoea was common and often substantial.

The AHI showed no relationship at all with overnight systolic blood pressure, diastolic blood pressure, mean arterial pressure or heart rate. Taken alone, those averages would suggest sleep apnoea wasn't doing anything to the cardiovascular system.

But when the researchers counted discrete blood pressure spikes rather than averages, the picture changed. AHI was significantly and positively correlated with the number of silent dysreflexia episodes during sleep (mean 3.6 episodes per night; R² = 0.220, p = 0.001). The more apnoea someone had, the more spikes they had.

The authors describe this as the first time that link has been shown.

Why the "silent" part matters

Autonomic dysreflexia is not just uncomfortable. Repeated surges in blood pressure are a plausible contributor to the elevated stroke and cardiovascular risk seen after high-level SCI, and a severe episode can be dangerous on its own.

An episode you can feel gets treated. An episode that happens while you are asleep, with no headache to wake you, does not. If this finding holds, a meaningful fraction of the cardiovascular load carried by people with high injuries could be accumulating at night, unnoticed and unaddressed.

The obvious follow-up is whether treating the apnoea removes the spikes. CPAP — continuous positive airway pressure, a mask that keeps the airway open overnight — is the standard treatment for obstructive sleep apnoea, and there are already published case reports of early-morning dysreflexia settling once CPAP was started. The authors of this study explicitly call for trials testing exactly that.

The honest limitations

This is a cross-sectional study of 45 people, presented as a conference abstract rather than a full peer-reviewed paper. It shows a correlation, not causation — the R² of 0.220 means apnoea severity explains roughly 22% of the variation in episode counts, so plenty else is going on. The sleep testing used a home screening device rather than full in-lab polysomnography. And no one has yet shown that treating the apnoea reduces the episodes.

What it does is make a specific, testable case for something that costs very little to act on: screening for sleep apnoea after a high-level spinal cord injury.

Reader Q&A

Should I ask for a sleep study? That is a conversation to have with your own doctor, but the case for it is reasonable if you have a cervical or high-thoracic injury. Sleep-disordered breathing is far more common after SCI than in the general population — respiratory muscle weakness, medication, and body position all contribute — and it is frequently undiagnosed. This study adds a cardiovascular reason to the existing reasons.

How would I know if I'm having silent episodes? By definition, you wouldn't — that is the point. Snoring, waking unrefreshed, daytime sleepiness, or morning headaches are the usual signs of sleep apnoea itself. Overnight blood pressure monitoring is the only way to see the spikes.

Does this prove CPAP would help? No. It shows an association between apnoea severity and episode frequency. Whether treating one fixes the other is an open question, and it is the study the authors say should happen next.

Is 3.6 episodes a night a lot? It is more than most people would guess, given none of them were noticed. Whether that number translates into long-term harm hasn't been established — that would need a study following people over years, not a single night's measurement.

One of the most stubborn problems in spinal cord repair is not getting nerve fibres to grow. It is getting them to grow *to the right place*.

Researchers can already coax axons — the long, cable-like projections neurons use to reach other cells — to sprout across a damaged area. What they cannot reliably do is tell those axons where to go once they are moving. A fibre that grows a centimetre in the wrong direction is not a repair.

A team at Brown University's Carney Institute for Brain Science, led by associate professor of brain science Alexander Jaworski, has published findings in *PNAS* that change how the field thinks about that steering problem.

The old assumption, and what replaced it

During embryonic development, axons travel long distances. The axon of a motor neuron controlling foot movement runs all the way from the base of the spine to the foot. To manage that journey, axons don't navigate in one go — they stop at intermediate checkpoints called waystations, pivot, and aim for the next one. This is called axon pathfinding.

The conventional explanation was that the navigation happened locally, at the growth cone — the exploring tip of the axon. Axons are long and respond fast, so it seemed reasonable that the decision-making sat at the front end, reading chemical cues in the surrounding tissue.

Jaworski's team found something different. The instructions are being issued from the cell body — the neuron's main compartment, often a long way back from the tip.

"We discovered that during development, neurons turn on and off entire groups of genes that allow their axons to grow through different sections of their path," Jaworski said. "That's surprising."

How they found it

The team studied commissural neurons — the neurons that connect the left and right sides of the central nervous system. They are a useful test case because their axons make a sharp, unmistakable change of direction as they cross the midline of the spinal cord. If a turn is being commanded from somewhere, this is where you would see it.

Using a custom genetic tool, the researchers isolated commissural neurons from rodent tissue at four different stages of development, then read the gene activity of individual cells using single-cell RNA sequencing (a technique that measures which genes are switched on in one cell at a time, rather than averaging across a whole tissue sample).

The pattern was clear. As axons passed through the midline waystation, the neurons shifted their gene expression — a genetic switch that caused a different set of guidance molecules to appear at the axon tip, redirecting it toward the next checkpoint.

Why this could matter for injury repair

If the turn-by-turn directions are written in the cell body's gene programme, then in principle they are addressable. You would not have to recreate the entire chemical landscape of an embryo in an injured adult spinal cord. You would need to switch the right genes back on in the right neurons.

"Now that we know about this genetic switch in the neuron, we might be one step closer to finding a way to actually turn on the specific genes that allow axons to grow back to their correct targets," Jaworski said.

That is a long way from a treatment, and the researchers do not claim otherwise. This is developmental biology in rodent embryos, not a repair study in injured animals, and nobody has yet shown that reactivating an embryonic gene programme in an adult neuron produces correctly targeted regrowth.

The atlas

The work also produced something with value beyond this one question. The team mapped gene activity across more than 12,000 developing neurons at multiple stages — far more than are involved in pathfinding alone. That dataset is now a reference resource for anyone studying the spinal cord, and it will likely be reused by labs working on questions the Brown team never asked.

Reader Q&A

Does this mean axons can now be made to regrow after injury? No. This study is about how axons navigate during normal embryonic development. It identifies a control mechanism that was not previously understood. Using it to guide regrowth after injury is a hypothesis for future work, not a result.

Why does "where" matter more than "how much"? Because a reconnected circuit only restores function if the fibres land on the correct targets. Growth that ends in the wrong place can produce no benefit at all — and in some cases contributes to problems like neuropathic pain or spasticity rather than useful movement.

Was this done in humans? No. The experiments used rodent cells. The genes and guidance molecules involved are broadly conserved across mammals, which is why the work is relevant, but human confirmation has not been done.

What is the realistic timescale? Unclear, and it would be dishonest to put a number on it. This is foundational research. Its value is that it corrects an assumption the field has been working under — which is exactly the kind of correction that redirects a lot of downstream effort.

Bladder management rarely makes headlines, but ask people with spinal cord injury what actually shapes their week and it comes up long before walking does. So this one is worth paying attention to.

On 14 September 2026, the Paris- and New York-based company Cyllene Therapeutics (formerly EG 427) announced that the US FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its lead candidate, EG110A, for neurogenic detrusor overactivity with urinary incontinence.

What the condition is

Neurogenic detrusor overactivity (NDO) is what happens when the nerve control of the bladder is disrupted by injury or disease. The detrusor — the muscle in the bladder wall that squeezes to empty it — contracts when it shouldn't. The result is urgency, incontinence, and high pressures inside the bladder.

The pressure part is the dangerous part. Sustained high bladder pressure pushes urine back toward the kidneys and drives repeated urinary tract infections. Cyllene's release notes that UTIs can lead to death in 5–10% of the SCI population — a blunt statistic, but an accurate reflection of why bladder care is treated as a life-expectancy issue rather than a comfort issue.

NDO is common in SCI, multiple sclerosis and Parkinson's disease, affecting at least two million people across the seven major healthcare markets.

What EG110A actually does

EG110A is a non-replicating HSV-1 vector — a herpes simplex virus stripped of its ability to copy itself, repurposed as a delivery vehicle for genetic material. Herpes viruses naturally home in on sensory nerves, which is what makes them useful here rather than dangerous.

It is injected directly into the bladder wall (intradetrusor injection, done during a cystoscopy). From there it targets CGRP+ sensory neurons — the "type C" nerve fibres that report bladder fullness and, when overactive, trigger the involuntary contractions. EG110A is designed to quieten those specific fibres while leaving normal bladder function intact.

Two features distinguish it from conventional gene therapy. It is non-systemic — it acts where it is put, rather than circulating. And because the vector does not replicate and does not integrate into the genome, it is redosable: if the effect wears off, it can in principle be given again. Most gene therapies cannot make that claim.

The evidence so far

The RMAT designation is based on an ongoing Phase 1b/2a trial in the US, in people with NDO-related incontinence following spinal cord injury who use clean intermittent catheterisation. Reported results to date describe substantial and sustained reductions in incontinence episodes lasting at least nine months after a single treatment.

Full interim results are due to be presented at the International Continence Society annual conference in Maastricht on 7 October 2026. Until then, the detail available is what the company has chosen to release — not peer-reviewed data, and not enough to judge how consistent the effect is across patients.

What RMAT means (and doesn't)

RMAT designation is a regulatory pathway tool. It gives the developer more frequent access to the FDA, guidance on trial design, and the possibility of using surrogate endpoints to support accelerated approval. To qualify, preliminary clinical evidence has to suggest the therapy could address a serious unmet need.

It is not an approval, and it is not a statement that the therapy works. It is the FDA agreeing the early signal is strong enough to warrant a faster conversation. EG110A already held Fast Track designation from October 2025; this builds on it.

A Phase 2b/3 study is planned for 2027.

Reader Q&A

How is this different from Botox injections for the bladder? Botox is currently the main second-line option and is also injected into the bladder wall, but it works by blocking the nerve signal to the muscle and typically needs repeating every six to nine months. EG110A targets the sensory side — the fibres reporting fullness — and the company is aiming for a considerably longer duration from a single course. Whether it delivers that is the question the Phase 2b/3 trial has to answer.

Is a herpes virus safe to use this way? The vector is engineered so it cannot replicate, and non-replicating HSV vectors have an established clinical safety record. The company reports a good safety profile in the trial so far. That said, this is the first human study using this vector type against sensory-neuron disease, so the long-term safety picture is still being built.

When could this be available? Not soon. A Phase 2b/3 trial starting in 2027 means results some years after that, then a regulatory review. RMAT can compress parts of that timeline but does not remove the need for the trial.

Does it help with bladder emptying too? No. It targets overactivity and incontinence. Emptying — and the need for catheterisation — is a separate problem that this therapy is not designed to solve.

About 69% of adults with spinal cord injury live with neuropathic pain, and the drugs available for it are, frankly, not good enough. They often don't work, and when they do they bring side effects that people trade off against the pain itself.

A pilot randomised controlled trial from the University of Minnesota, published in *Frontiers in Pain Research* on 11 September 2026, tested a different approach — one that treats the pain as partly a problem of body awareness rather than purely a problem of nerve signalling.

The idea behind it

When sensory input from part of the body is reduced or lost, the brain's internal model of that body part degrades. Researchers call this a deficit in mental body representations (MBR) — essentially, your brain's map of where your body is and what it feels like. There is growing evidence that when that map goes blurry, neuropathic pain gets worse.

Cognitive Multisensory Rehabilitation (CMR) is a physical therapy designed to rebuild that map. Rather than strength or cardiovascular work, sessions involve guided attention tasks — discriminating textures, positions and movements, often with eyes closed — combined with movement imagery. The aim is to restore the brain's ability to integrate whatever sensory information is still arriving.

An earlier pilot from the same group had found lasting pain reduction with CMR. This trial was built to test feasibility and to look at what happens in the brain.

What they did

Sixteen adults were randomised to either CMR or adaptive fitness — exercise adapted for wheelchair users, which served as the comparison arm. Both groups did 45-minute sessions, three times a week, for eight weeks. One participant withdrew, leaving eight in CMR and seven in fitness.

Participants averaged 52 years old and 13 years post-injury — a chronic group, well past the window where spontaneous recovery is expected. Ten had neuropathic pain rated 3/10 or higher.

Assessments were done at baseline, immediately after the eight weeks, and again at three months, using the Numeric Pain Rating Scale, the ASIA Impairment Scale (the standard clinical measure of sensory and motor function after SCI) and the Neuromuscular Recovery Scale. Functional MRI captured brain activity during resting state and four tasks: imagining feeling the left leg, imagining moving it, whole-body movement imagery, and a real sensation task — gently brushing the big toes with a towel.

What they found

After CMR, the within-group effect sizes on the ASIA scale were large: touch d=1.54, pinprick d=1.83, lower limb motor function d=1.32. (Cohen's *d* expresses change relative to the variability in the data; anything above about 0.8 is conventionally "large".) On the Neuromuscular Recovery Scale, core function showed a very large effect (d=2.19), with moderate effects for arm (d=0.69) and leg (d=0.74) function.

The adaptive fitness group showed smaller, non-significant changes on the same measures — touch d=0.49, pinprick d=0.53, lower limb motor d=0.74 — and leg function on the NRS did not move at all (d=0.00).

On pain, CMR exceeded the minimal clinically important difference — the smallest change a person would actually notice — for average pain immediately after the intervention, and for highest pain at three months. Pain after adaptive fitness was essentially unchanged.

The benefits were still present at three-month follow-up.

On imaging, CMR increased brain connectivity and activation during leg movement imagery, and produced widespread activation increases during whole-body imagery. Adaptive fitness produced only spatially limited increases.

How much weight to put on this

Fifteen people who completed, split across two arms. That is a feasibility study, and the authors describe the results as preliminary and call for larger confirmatory trials. Effect sizes calculated on groups of seven and eight are unstable — a single strong responder moves them considerably.

There is also no blinding possible here. Participants knew which therapy they were doing, and both pain ratings and effort during assessment are open to expectation effects.

What makes it more interesting than a typical underpowered pilot is that three different kinds of measure moved in the same direction: patient-reported pain, clinician-scored sensory and motor function, and fMRI activity. That coherence doesn't prove the effect is real, but it is harder to explain away than a change in one outcome alone.

Reader Q&A

Is CMR available where I live? It is not widely available. The approach originates from the Centro Studi di Riabilitazione Neurocognitiva in Italy, and the SCI trials have been run out of the University of Minnesota. It requires trained therapists, and outside research settings it is scarce.

Does this mean exercise doesn't help? No — and that would be the wrong reading. Adaptive fitness has well-established cardiovascular, metabolic and wellbeing benefits. This trial says it did not reduce neuropathic pain in these participants, which is a narrower claim.

Sensory and motor gains 13 years after injury — is that plausible? It is more plausible than it sounds, because these are scored measures of what a person can detect and do, and both can improve with better use of surviving pathways without any new nerve growth. That said, ASIA scoring in unblinded chronic participants is exactly where measurement drift is most likely, which is part of why a larger blinded-assessor trial matters.

Why would retraining body awareness reduce pain? The working theory is that neuropathic pain is amplified when the brain's model of the body conflicts with the sparse sensory information it receives. Reducing that mismatch reduces the pain signal. It is a reasonable model with supporting evidence in other conditions, but it is still a model.

Most of the lasting damage from a spinal cord injury doesn't happen at the moment of impact. It unfolds over days and weeks afterwards, in what's known as secondary injury — inflammation, poor blood supply, and cell death spreading outward from the original wound.

A paper published in the *Journal of Nanobiotechnology* on 12 September 2026, from teams at Nanjing Medical University and Soochow University, adds a mechanism to that list that has had surprisingly little attention: the surviving neurons appear to grow old.

Neurons that stop working but don't die

Cellular senescence is a state where a damaged cell shuts down its ability to divide and repair, but doesn't die. Instead it sits there leaking inflammatory signals — a behaviour researchers call the senescence-associated secretory phenotype (SASP). It's a well-studied driver of ageing and of neurodegenerative disease.

The researchers found widespread senescence signatures across the injured mouse spinal cord, and they were most concentrated in neurons — the cells you least want to lose.

That matters because it sets up a loop. Injury causes inflammation. Inflammation pushes neurons into senescence. Senescent neurons pump out more inflammatory signals. The authors describe it as an inflammation–senescence feedforward loop — a cycle that keeps itself running long after the original injury.

Getting taurine where it needs to go

Taurine is an amino acid found naturally in the body and in the diet, with known antioxidant and cell-protective properties. The problem with using it as a treatment is aim: swallow it or inject it into the bloodstream and it goes everywhere, with very little reaching the specific neurons that need it.

The team's solution was a delivery vehicle. They packed taurine inside extracellular vesicles — tiny membrane-bound packages that cells naturally use to shuttle cargo to one another — and engineered their surface with RVG, a peptide derived from the rabies virus that binds to receptors found on neurons. Rabies is very good at finding nerve cells; borrowing the part of it that does the finding turns a general-purpose vesicle into a neuron-seeking one.

The resulting particles, labelled EV^RVG-Taurine, delivered taurine preferentially to neurons.

What happened

In mice with spinal cord injury, the treatment reduced neuronal senescence, calmed neuroinflammation, promoted axon regrowth, and improved functional recovery. Motor function was tracked with the Basso Mouse Scale, the standard locomotor rating used in rodent SCI studies.

The mechanism the authors traced runs like this. Taurine boosts the activity of SIRT1, an enzyme that chemically modifies other proteins. SIRT1 strips an acetyl group from a protein called HSPA9 at a specific point (lysine 409). That change switches on mitophagy — the cell's quality-control process for identifying broken mitochondria and clearing them out.

Why that matters: damaged mitochondria leak their own DNA into the cell interior. Mitochondrial DNA (mtDNA) out of place looks, to the cell's immune sensors, like a bacterial invasion — which makes evolutionary sense, since mitochondria descend from ancient bacteria. A sensor called cGAS–STING picks it up and triggers an inflammatory response.

So: clear the broken mitochondria before they leak, and the false alarm never fires. Less cGAS–STING activation, less SASP signalling, and the feedforward loop is interrupted.

Caveats, stated plainly

This is a mouse study. Every result here comes from animals, and the history of SCI research is full of mechanisms that worked beautifully in rodents and did nothing in people.

The mechanistic chain — SIRT1 to HSPA9 to mitophagy to mtDNA to cGAS–STING — is long, and long chains are where translation usually breaks. There is no information on treatment window, dosing, or whether the effect holds in chronic injury rather than acute. Manufacturing engineered extracellular vesicles at clinical scale is its own unsolved problem.

Reader Q&A

Should I take taurine supplements? No — nothing here supports that. The entire point of the study is that free taurine doesn't reach the target; the effect depended on a targeted delivery system that does not exist outside a lab. Taurine is present in energy drinks and supplements, but that has no bearing on these findings.

Is "neurons ageing" a real thing or a metaphor? It's a real, measurable cellular state with specific molecular markers, not a figure of speech. Whether it is as central to SCI outcomes as this paper suggests is the open question — this is among the first studies to map it in detail in the injured cord.

How far is this from a treatment? Early. There is no human trial, no safety data in people, and the delivery platform would need substantial development before one was possible.

Why use a rabies-derived peptide? Only the targeting fragment is used — not the virus, and nothing infectious. Rabies evolved to find and enter neurons very efficiently, so the part of it responsible for that recognition is a useful tool for steering drug carriers to nerve cells.

Ask someone with a cervical spinal cord injury what actually ruins a day and there is a fair chance the answer is not what an outsider would guess. It is often the dizziness on sitting up. Or the pounding headache and sweating that arrives because a catheter kinked.

Both are blood pressure problems, and both come from the same root cause: the injury cut the wiring between the brain and the nerves that regulate the cardiovascular system.

On 4 September the University of Arkansas for Medical Sciences announced it has joined Empower BP, a global pivotal study run by Onward Medical testing an implanted stimulator designed to do something about it.

The two failures

Orthostatic hypotension (OH) is the low-pressure failure. Move from lying down to upright and blood pools in the legs and abdomen. Normally the nervous system responds within seconds by tightening blood vessels and nudging the heart rate up. After a high spinal cord injury that reflex is unreliable, so pressure falls — dizziness, blurred vision, fatigue, sometimes fainting.

Autonomic dysreflexia (AD) is the opposite. A stimulus below the level of injury — a full bladder, a pressure sore, an ingrown toenail — sets off a reflex the brain can no longer damp down. Blood pressure climbs sharply and dangerously, with a splitting headache, sweating and goosebumps as warning signs.

How common is it, really?

Onward cites the Spinal Cord Injury Community Survey, which collected self-reported data from 1,479 people living with chronic SCI. Among respondents with tetraplegia, 78% had been diagnosed with orthostatic hypotension. Of those, only 28% were being treated at all — and of the people who *were* treated, 91% still had symptoms.

The autonomic dysreflexia numbers are similar: 82% diagnosed, 30% treated, and 98% of those treated still symptomatic.

Read that carefully. It is not primarily a story about people going undiagnosed. It is a story about existing treatment barely working.

What the device does

The investigational ARC-IM System is a purpose-built neurostimulator connected to a lead placed over what Onward calls the "hemodynamic hotspot" — a region spanning the last three segments of the lower thoracic spinal cord that is unusually dense in the neurons controlling blood vessel tone.

The idea is not to reconnect the brain to those neurons. It is to stimulate them directly, from below the injury, so that blood pressure can be supported without the signal from above.

This is a different application of stimulation from the ones that usually make headlines. There is no walking involved. The target is autonomic function, and the underlying science was published in Nature Medicine in 2025, alongside a companion Nature paper mapping the neuronal architecture behind autonomic dysreflexia.

The trial design

Empower BP is randomised, controlled and double-blinded — meaning neither participants nor assessors know who is receiving active therapy. For an implanted device trial in a field where open-label results have often looked better than they turned out to be, that matters a great deal.

Sites are open in the US, Canada and Europe, with more planned. To be eligible you need to be 18–75, more than a year post-injury, with a traumatic injury between C2 and T6, an ASIA grade of A, B, C or D, and sustained low blood pressure (systolic ≤110 mmHg) that was not present before the injury. Participation runs 24–28 months, including roughly 15 days of in-person visits.

Exclusions include ventilator use, an existing active implant such as a baclofen pump or pacemaker, recent cardiac events, kidney or liver disease, and anything that rules out a spinal MRI.

The protocol received IRB approval in August 2025 and is registered as NCT07147296.

Reader Q&A

Is this available to me now? No. ARC-IM is an investigational device, available only inside the study, and the FDA has not approved it. That is not a formality — the whole point of a pivotal trial is that nobody yet knows whether it works.

I already take midodrine. Would this replace it? That is what the trial is designed to find out, and it is worth noting the survey data above: most people on existing drug treatment for OH still report symptoms. But nothing here demonstrates superiority yet.

Does it help with walking? No. This is a different lead placement and a different target from the movement-focused stimulation work. Blood pressure is the endpoint.

Why does blood pressure matter beyond feeling dizzy? Persistently low pressure reduces blood flow to the brain and, over time, is linked to worse cardiovascular health and cognitive effects. Autonomic dysreflexia at the other extreme can be a medical emergency. Neither is only about comfort.

On 3 September the FDA published a recall notice for the Infinion CX Lead, a component of a Boston Scientific spinal cord stimulator (SCS) system. It is classified as a Class I recall — the agency's most serious category.

That phrase understandably alarms people who have one of these implanted. So the most important line first, taken directly from the FDA notice: "This action does not affect the devices that have already been implanted."

What a recall actually means here

In everyday use "recall" suggests something being taken back. In FDA terms it covers a range of corrective actions, and this one is a removal of unused stock — Boston Scientific has asked customers to stop using and distributing affected leads and return them.

Class I is the FDA's designation for a situation where a device "may cause serious injury or death if you continue to use it." The classification describes the potential severity of the hazard, not the number of people currently harmed.

The technical problem

A spinal cord stimulator has three parts: a pulse generator (the battery unit, usually in the buttock or abdomen), one or more leads — thin insulated wires carrying current to electrodes placed in the epidural space over the spinal cord — and an anchor, a small sleeve that fixes the lead in place so it does not migrate.

Boston Scientific reported that the lead body may experience mechanical stress at the anchor site. Over time that can produce high impedance readings or an outright lead fracture.

Impedance is simply electrical resistance in the circuit. If it rises abnormally, current does not reach the electrodes properly, and stimulation becomes inadequate or stops. The consequence is not usually a shock or a burn; it is that the therapy quietly stops working, and correcting it may require surgery to remove and replace the lead.

A June field safety notice put the fracture rate at roughly 1% across devices from September 2014 to April 2026. As of 27 May 2026, Boston Scientific had reported 1,081 serious injuries and no deaths.

The timeline

- 17 June 2026 — Boston Scientific letters affected customers, advising them to stop use, segregate stock and return product - 5 August 2026 — FDA classifies the recall as Class I - 3 September 2026 — FDA publishes its public recall notice

Affected products are the Infinion CX Lead Kit in 50 cm (SC-2317-50) and 70 cm (SC-2317-70) versions.

What the guidance says for patients

Boston Scientific's own advice to clinicians is that "no additional patient monitoring beyond routine clinical follow-up is recommended."

If you have an Infinion CX lead implanted and it is working, nothing in this notice asks you to do anything differently. If your stimulation has become weaker, inconsistent, or has stopped, that is worth raising with your implanting team — as it would have been anyway.

A note on the SCI context

The Infinion CX is indicated for management of chronic pain of the back and limbs, which is the long-established use of spinal cord stimulation. That is a different application from the investigational stimulation work aimed at movement, blood pressure or bladder function after spinal cord injury — though the hardware is closely related, and lead durability is a shared engineering problem across all of it.

Reader Q&A

I have this device. Should I get it removed? Nothing in the FDA notice recommends that. The recall covers unused stock only, and the advice is routine follow-up. Any decision about an implanted device is one for you and your clinical team, based on how yours is performing.

How would I know if my lead had fractured? Typically by loss or change of stimulation — the therapy stops covering the area it used to, or stops working. Your team can check impedance directly at a programming visit.

Is 1,081 injuries a lot? It has to be read against the number implanted since 2014, which is far larger; the reported fracture rate is about 1%. It is a meaningful signal about a design weakness, not evidence that most devices fail.

Does this affect other Boston Scientific leads? The notice names only the Infinion CX Lead Kit in the 50 cm and 70 cm versions.

On 3 September, Matricelf Ltd. announced it had received written feedback from the US Food and Drug Administration on the design of the first human trial of NewRal, its engineered neural tissue transplant for traumatic spinal cord injury.

This is a real step forward. It is also worth being precise about what it is and is not, because company announcements in this field are frequently read as more than they are.

What NewRal actually is

Most cell therapies for spinal cord injury deliver cells — stem cells, progenitor cells — into or around the injury site. Matricelf is attempting something more ambitious: growing a piece of neural tissue outside the body and implanting it.

The recipe starts with the patient. A tissue sample is taken and split in two directions.

Some cells are reprogrammed into induced pluripotent stem cells (iPSC) — adult cells rewound to an embryonic-like state from which they can be pushed to become almost any cell type, in this case spinal cord neurons and support cells. The technique won a Nobel Prize in 2012 and its main appeal here is that the cells are the patient's own, so there is no immune rejection and no need for lifelong immunosuppressant drugs.

The rest of the sample is processed into a scaffold — a three-dimensional gel made from the patient's own extracellular matrix (ECM), the structural protein mesh that sits between cells and gives tissue its shape. Growing neurons in a scaffold rather than injecting them loose gives the cells somewhere to organise.

Put together, the result is an autologous — self-derived — engineered implant. The underlying science came out of Tel Aviv University.

What the FDA agreed with

The feedback came through a *Written Response Only* interaction, based on a limited trial synopsis rather than a full application. Within those limits, the agency agreed with:

- The patient population — adults with chronic, complete traumatic thoracic spinal cord injury, classified AIS A. AIS A is the American Spinal Injury Association's grade for a complete injury: no motor or sensory function preserved in the lowest sacral segments. - The trial design — open-label (everyone knows who gets what), single-arm (no control group), with 12 months of follow-up, as appropriate for a first look at safety and tolerability. - The assessments — primary safety measures, plus exploratory efficacy measures: ISNCSCI for neurological change, the Modified Ashworth Scale for spasticity, and SCIM III for functional independence.

The FDA specifically noted those efficacy measures are *exploratory*. The trial's job is to establish safety.

What the FDA still wants

The agency asked Matricelf to address several things in a future Investigational New Drug (IND) submission: trial stopping rules, objective criteria for discharging patients, more detail on the surgical procedure itself, and imaging criteria for selecting patients.

These are not trivial. Stopping rules and surgical detail are exactly where a first-in-human implant trial either earns confidence or does not.

How far along is this?

Matricelf completed a GLP safety study earlier in 2026 and has been working through manufacturing and enrolment preparation. NewRal has not been approved by any regulator and has never been given to a human.

The company's own release is unusually direct about this: the feedback "does not constitute review or clearance of a complete IND application or authorization to initiate a clinical trial," and there is no assurance an IND will be submitted or that a trial will begin on any particular timeline.

Reader Q&A

Does this mean a trial is starting? No. The next milestone is submitting an IND, which the FDA then reviews. Only after that can a trial open. Today's news is guidance on what the application should contain.

Why only complete thoracic injuries? Two reasons. Thoracic surgery avoids the additional risk of operating near the cervical cord, where complications can affect breathing and arm function. And in a complete injury there is less preserved function to put at risk — which matters when a treatment has never been tested in a person.

Is a personalised implant realistic at scale? That is the open question for the whole autologous approach. Making a bespoke tissue graft for each patient sidesteps rejection entirely, but it means a manufacturing run per person, which is slow and expensive. Trials come first; scale is a later problem.

How much should I read into "FDA agreement"? Modestly. Agreeing that a proposed patient population and trial structure are reasonable is a long way from agreeing that a therapy works. Nothing in this announcement is evidence about whether NewRal helps anyone.

A 12-year-old Russian girl named Vera was admitted to the Second Affiliated Hospital of Zhejiang University School of Medicine in Hangzhou in April 2026, with lower-limb paralysis following a car accident.

Three months after surgery, she was taking voluntary steps with an assistive device. According to China News Service, she is the first international patient with a severe spinal cord injury in China to reach voluntary stepping with the technology.

What was implanted

The system is described as a closed-loop spinal neural interface: implanted stimulation electrodes over the spinal cord, driven by a wireless, rechargeable pulse generator.

"Closed-loop" means the stimulation is not a fixed setting running in the background. It adjusts. In Vera's case, AI algorithms were used to change stimulation parameters as her condition changed over the course of rehabilitation.

The stated principle is worth quoting carefully, because it is what separates this from a brain-computer interface: rather than replacing commands from the brain, the system amplifies weakened neural signals so they can cross the injured section of the cord and reach the muscles.

That framing only works if some signal is still getting through — and it is the key detail in this case.

Why she was a candidate

Neurological examination found her spinal pathways were severely but incompletely damaged. Incomplete means some connection across the injury survives, even if it is too weak to produce useful movement.

Epidural and transcutaneous stimulation approaches generally work by raising the excitability of the spinal circuits below the injury, so that faint surviving descending signals become strong enough to trigger movement. Someone with a genuinely complete injury — no surviving connection — is a much harder problem, and this result should not be read as applying to that group.

The reported timeline

- April 2026 — admitted and assessed - One month post-surgery — able to stand steadily with support; improved sensation in her feet - Three months of rehabilitation — voluntary stepping with an assistive device

Throughout, stimulation was paired with targeted movement training. This is consistent with everything the field has learned: stimulation alone does not produce walking. It creates a window in which intensive, repetitive training can do its work.

How much weight to put on this

This is a single case, reported through a state news agency rather than in a peer-reviewed journal. There is no published protocol, no control comparison, no formal outcome scale such as ISNCSCI or WISCI, and no detail on injury level or how much function she had before surgery.

None of that means the result is untrue. It means it cannot yet be evaluated the way a study can. Individual dramatic recoveries appear regularly in SCI reporting from every country, and the ones that hold up are the ones that later show up in a journal with numbers attached.

What is genuinely notable is the direction of travel: China now has multiple neuromodulation and brain-computer interface programmes moving through clinical use, and has begun treating patients from abroad.

Reader Q&A

Is this the same as the Swiss epidural stimulation work? Similar family, different system. The general principle — implanted stimulation over the spinal cord plus intensive training, amplifying surviving signals — is shared. This is a China-developed device with its own hardware and control algorithms.

Could an adult with a complete injury get this? Nothing here supports that. The case explicitly rests on the injury being incomplete. Complete injuries remain a substantially different challenge.

Is it available? It was delivered in a hospital setting in Hangzhou. No regulatory approval status, cost, or eligibility criteria have been published in the coverage, and there is no indication of availability elsewhere.

Why does her age matter? Paediatric SCI is under-served almost everywhere, and children are usually excluded from implant trials. A 12-year-old receiving a spinal implant is unusual in its own right — though it also means less is known about long-term effects as she grows.

There is a long-standing puzzle in spinal cord research: a nerve fibre in your arm can regrow after being severed, but the same fibre inside your spinal cord will not. The wiring is similar. The difference is the neighbourhood.

In the late 1980s, Martin Schwab and colleagues in Zurich identified one reason why. A protein in the myelin sheath — the fatty insulation wrapped around nerve fibres in the central nervous system — actively tells growing nerve fibres to stop. They named it Nogo-A. Block it, the reasoning went, and the brakes come off.

On 2 September, NovaGo Therapeutics AG, the company built around that work, announced it had closed a CHF 24 million (USD 30 million) Series B financing to take an anti-Nogo-A antibody into a proof-of-concept trial in acute spinal cord injury. Schwab is the company's Chief Scientific Officer.

What Nogo-A does, in plain terms

Think of a severed nerve fibre trying to regrow across an injury. The stump has to navigate through debris, scar tissue and damaged myelin. Nogo-A sits on that myelin and, on contact, causes the growing tip to collapse and retreat.

Why would the body have such a thing? The prevailing view is that it stabilises adult brain wiring — you do not want circuits rearranging themselves at random. That stability is a liability after injury.

An antibody that neutralises Nogo-A is designed to lift that inhibition locally, giving spared fibres a window in which to sprout new connections and giving rehabilitation something to work with. Note the wording: this is about plasticity and sprouting of surviving fibres, not regrowing a severed cord from scratch.

The trial being funded

The proceeds fund a fully randomised, double-blind study enrolling 120 patients with acute spinal cord injury, across sites in Germany, Spain and Switzerland.

Both design features matter. Acute SCI trials are notoriously difficult to read because some spontaneous recovery happens in the first year regardless of treatment; without a blinded control group it is very hard to tell a drug effect from natural recovery.

The lead antibody, NG004, was discovered at Neurimmune and has completed a Phase 1 study. Company statements describe those Phase 1 results as "encouraging" — Phase 1 is primarily a safety study, so that language should be read as "no red flags," not as evidence of benefit.

Who is paying

The round was co-led by Neurimmune and Pureos Bioventures, with existing and new investors participating. Alongside the equity, there is non-dilutive funding — money that does not buy shares — from the Swiss Paraplegic Foundation and Wings for Life, the spinal cord research foundation.

That combination is worth noticing. Acute SCI is a small market by pharmaceutical standards and a hard one to run trials in, which is precisely why charitable research funders exist to bridge the gap. Wings for Life and the Swiss Paraplegic Foundation both fund from the patient community's side.

NovaGo's stated goal is "the first regenerative treatment for patients with acute spinal cord injury." The company also lists stroke and secondary progressive multiple sclerosis as targets for the same mechanism.

The honest framing

As NovaGo's own release puts it: "There are currently no approved regenerative treatment options that restore lost neurological function." That is the reason this is interesting, and also the reason to be careful. The anti-Nogo-A approach has been in and out of clinical development for two decades; a previous multicentre trial of a related antibody did not produce a clear win.

A funded, blinded, 120-patient study is the right way to settle the question. It is not an answer.

Reader Q&A

Is this for new injuries or existing ones? Acute — treatment given soon after injury, while spared fibres are still capable of sprouting. This trial says nothing about chronic injury.

How is this different from a stem cell therapy? Completely different mechanism. No cells are transplanted. It is an antibody that blocks a growth-inhibiting protein already present in your own tissue, so surviving nerve fibres have more freedom to form new connections.

When would results be available? No timeline has been announced. Enrolling 120 acute SCI patients across three countries and then following them long enough to measure neurological outcomes is realistically a multi-year undertaking.

Has anti-Nogo-A been tried in humans before? Yes — this is not a first attempt, which is part of why a properly powered, blinded study matters so much this time.

Here is a gap that is easy to miss. Over 150 people worldwide now have an implanted brain-computer interface. Devices are moving toward commercial availability. And not one of those recipients is a child.

A paper by Mariana Branco, Eli Kinney-Lang, Nicolas Ruest, Helen Carlson and colleagues in *Neurorehabilitation and Neural Repair* argues that this is a problem worth solving deliberately, and sets out a roadmap for doing it. The work comes out of the paediatric BCI community in Canada, and represents roughly two years of coordinated effort.

What an implanted BCI does

A brain-computer interface (BCI) reads electrical activity from the brain and translates it into commands for a computer or device. Non-invasive versions use electrodes on the scalp — easy to fit, but the signal is muffled by skull and skin.

An implanted BCI (iBCI) places electrodes on or in the brain itself. The signal is far cleaner, which means control can be continuous, fast and accurate enough for real use: moving a cursor, typing, driving a wheelchair, operating a robotic arm. The trade-off is neurosurgery, and everything that comes with it.

Why children have been excluded

The paper's framing is that this exclusion is not the result of a considered decision. It is the accumulated effect of caution.

Trials recruit adults who can give their own informed consent. Devices are designed and tested on adult anatomy. Regulatory pathways for paediatric implants are slower and narrower. And every one of those choices is individually defensible.

The consequence, though, is that the group the authors describe as representing "a large proportion of the global burden of complex and severe disability" — people whose conditions began in childhood — has no route into a technology built precisely for severe motor impairment.

Who this is about

Pediatric-onset conditions here means a broad group: cerebral palsy, childhood-onset neuromuscular disease, brainstem stroke, and spinal cord injury sustained in childhood.

For a young person with a high cervical injury or severe cerebral palsy, the functional case for an iBCI is not weaker than the adult case. It is arguably stronger, because they face more decades of living with it.

What a "roadmap" contributes

It is fair to ask what a roadmap paper actually does. It is not a study; nobody was implanted.

What it does is make the problem addressable. The authors describe the work as community-and-partner-engaged — meaning the priorities were set with young people, families and clinicians rather than for them — and as a world-first roadmap covering design, development and implementation.

In practice this means specifying what needs to happen before a paediatric iBCI trial is defensible: how consent and assent should work when the person cannot speak for themselves in the usual way; how hardware should account for a growing skull and brain; what the ethical framework looks like for an irreversible implant in a minor; and what outcomes should even be measured, given that a child's goals differ from an adult's.

Fields that skip this step tend to stall. Fields that do it get trials that pass ethics review.

What this paper is not

It is a position and planning paper, not evidence that paediatric iBCIs are safe or effective. No child has received one. The risks — infection, hardware failure, the fact that an implant in a growing brain is genuinely different from one in an adult — are real and largely unquantified.

The honest read is that this is the field organising itself to ask a question it has so far avoided.

Reader Q&A

Would this apply to a child with a spinal cord injury? Potentially, yes. Paediatric-onset conditions include childhood SCI, and high cervical injury is exactly the profile where an implanted BCI offers the most — control of communication and devices when the body cannot execute movement.

Why not just use a non-invasive BCI? For some purposes you can, and paediatric non-invasive BCI research is well established. But scalp electrodes give a noisier signal, which limits speed and reliability, and the setup burden is significant for daily use. Implanted systems are what make continuous, high-fidelity control possible.

Is anyone actually planning to implant a child? Not yet, as far as this paper indicates. It is groundwork for making such a trial possible and properly governed — which is a prerequisite, not a commitment.

How long might this take? No timeline is set out. Regulatory and ethical work of this kind, followed by device adaptation and a first trial, is realistically measured in years.

Here is a number worth sitting with: 20 to 30 one-hour sessions. According to Jan Black, a physical therapist and clinic director at Neuroworx in Sandy, Utah, that is the typical limit insurers place on rehabilitation after a spinal cord or other neurological injury — regardless of how severe the injury is. And once you subtract paperwork and admin, she says, each "hour" is closer to 48 minutes.

"It's insane to think that any therapist is going to get anywhere, get anyone back to some sort of functional ability, in that timeframe," Black told the Deseret News.

Neuroworx exists because of that gap.

How it started

In 1999, Dr Dale Hull was injured in a trampoline accident and left paralysed from the upper rib cage down. Inpatient therapy gave him back some neurological function, but he ran into a wall that will be familiar to a lot of readers.

"I quickly realised that the insurance limitations were going to prevent the therapist from working on me where I want," Hull said. "I wanted this opportunity to make more progress, and they were just hamstrung by the system."

Seven months after his injury he met Jan Black. Working with her through an intensive regimen — paid for out of his own pocket — Hull recovered enough to carry the Olympic torch at the 2002 Salt Lake City Winter Games. He now walks with a walker.

The obvious question followed: what about everyone who cannot self-fund?

In 2004 Hull and Black opened a 1,000-square-foot clinic in a strip mall. They deliberately set it up as a non-profit, because the maths of what they wanted to do does not work otherwise.

"We said, OK, we're going to try and do this a different way. We're gonna give people what they need, not what we can bill for," Hull said. "What I always say is that it was the worst business model in the world."

Today they occupy a purpose-built 24,000-square-foot facility and take clients from across the United States.

What's actually in the building

The equipment leans heavily on unweighting — reducing the load of gravity so someone can practise a movement that would otherwise be impossible. That includes a pool, since moving in water is often far easier than on land for people with paralysis.

There is also a car with no wheels or engine, height-adjustable, for practising transfers in and out of a vehicle, and a rig for learning hand-only driving controls. Spinal cord stimulation is used in therapy sessions. Alongside the clinical work there are dance classes, a wheelchair basketball development team for 8- to 12-year-olds and a junior team for 12- to 18-year-olds. Black notes that Division 1 wheelchair basketball scholarships exist and several of their players have won full rides; the clinic has also produced a Paralympian who competed in Tokyo and Paris.

About a third of Neuroworx patients have exhausted their insurance coverage entirely. The clinic says it has never turned anyone away, though there is a waiting list.

The argument they're making to insurers

This is the part with implications beyond Utah. Hull and Black are gathering data to argue that longer rehabilitation is not just better medicine but cheaper, because it prevents the expensive complications.

"If someone got a pressure sore, the cost of hospitalisation and treatment could average $80,000 to $90,000," Hull said. "You know how much therapy we could provide for $80,000? We could probably do 10 people and give them the care they needed for $80,000 easy."

Pressure sores, urinary tract infections, falls and rehospitalisation are the recurring costs of inadequate early rehab — and they land on the same payers who capped the therapy in the first place.

They have had some legislative success: the Utah Spinal Cord Injury and Brain Injury Rehabilitation Fund, adopted by the state legislature in 2012, helps fund exactly this kind of extended therapy.

The catch

Neuroworx has to raise $500,000 to $800,000 every year simply to keep operating. An endowment campaign launched a few years ago aims to raise $10 million and is currently about halfway there.

Black is direct about what that means: "You're never going to not have that negative number every year. This isn't a business that anybody's going to get rich doing."

That is the honest limitation of the model. It works, and it depends permanently on charitable giving — which makes it hard to replicate somewhere without Utah's donation culture, and vulnerable in a bad year.

Reader Q&A

Is this a treatment breakthrough? No — and it doesn't claim to be. Neuroworx delivers conventional intensive physiotherapy and activity-based training, just far more of it than insurance normally funds. The claim being tested is about *dose*, not about a new therapy.

Does more therapy actually produce more recovery? Recovery varies enormously between individuals and nobody at Neuroworx suggests otherwise. What the clinic argues is that people should get the chance to find out before being told to stop. Black frames it as letting patients say: "Let me do everything I can before I decide that I'm going to be OK, whatever that turns out to be." The cost-saving argument is still being built — they are gathering the data now, not presenting finished evidence.

Do these limits apply outside the US? The specific 20–30 session cap is an American insurance figure. Publicly funded systems limit access differently — through waiting lists, discharge criteria and regional availability rather than a session count — but the underlying pattern of therapy ending while progress is still possible is not unique to the US.

Why cover a single clinic? Because it's a working example of the counter-argument. The debate about rehab funding is usually abstract; Neuroworx is 22 years of one organisation actually running the alternative model and documenting what it costs.

Chronic pain has a maddening quality: the original injury heals, and the pain does not stop. That is because at some point the pain stops being a report about tissue damage and becomes a self-sustaining state of the nervous system.

A study in Nature put a map to that idea. A team led by Xiaoke Chen at Stanford University traced an actual anatomical loop — spinal cord to brain and back to spinal cord — that appears to keep chronic mechanical pain running in mice, and showed that breaking the loop at *any* point switches the pain off.

The paper was published online on 1 April 2026 and has been picking up wider press coverage this month.

What a "loop" means here

Textbook pain science describes two one-way streets. Ascending pathways carry pain signals from the body up to the brain. Descending pathways run the other way, from the brain back down to the spinal cord, where they turn the incoming signal up or down — this is the system that lets you barely notice a cut in the middle of a football match.

One key node in the descending system is the rostral ventromedial medulla (RVM), a small cluster of cells at the base of the brainstem. Some RVM cells project directly down to the spinal cord; researchers call these RVM^SC neurons. They can dampen pain — but after nerve injury they can flip and start *amplifying* it instead. That flip has been known about for years. What nobody had shown was how a peripheral injury reaches those cells in the first place.

Chen's team found the missing wiring, and it turns out the ascending and descending streets connect into a circle.

The five stops

The loop the team traced runs:

1. Spinal cord — where the signal from the injured body part enters 2. Ventral posterolateral thalamus and posterior complex — thalamic relay stations that pass sensory information onward 3. Primary somatosensory cortex — the strip of cortex that maps touch and location on the body 4. Lateral superior colliculus — a midbrain structure better known for orienting responses 5. μ-opioid-receptor-expressing RVM^SC neurons — which project back down to the spinal cord, closing the circle

That fifth stop is notable. μ-opioid receptors are the docking sites that morphine and related drugs act on, which puts this circuit squarely in the territory of existing painkillers — though the study is about the circuit, not about a drug.

What happened when they interfered

Two experiments matter.

Silencing. The researchers switched off each node in turn. In healthy mice this had almost no effect — normal pain sensing was intact. But in mice with inflammatory pain or nerve-injury (neuropathic) pain, silencing any single node eliminated mechanical hypersensitivity — the state where light touch registers as painful — and restored normal response thresholds.

That selectivity is the important part. A treatment that removes chronic pain while leaving acute, protective pain intact is exactly what the field wants and rarely gets. Most systemic painkillers blunt everything.

Activation. Running it the other way, the team repeatedly activated each node in otherwise healthy mice. Repeated stimulation — not a single acute burst — was enough to produce robust, lasting mechanical hypersensitivity in animals that had no injury at all.

So the loop is not just involved in chronic pain. In these experiments, driving it was sufficient to *create* chronic pain.

What this does and doesn't mean for SCI

Be careful here, because the gap is real.

These are mice, and the pain models are peripheral — tissue inflammation and peripheral nerve injury. This study did not test spinal cord injury. Central neuropathic pain after SCI arises from damage to the spinal cord itself and is not guaranteed to run through the same machinery.

What makes it relevant anyway is that the loop passes *through the spinal cord at both ends*, and the RVM's descending control of spinal pain processing is one of the mechanisms already suspected in at- and below-level SCI pain. If the same loop turns out to be involved, it offers something the field currently lacks: a set of specific cellular targets rather than a general instruction to reduce excitability.

The authors put the payoff modestly — the work "could enable the identification of cellular targets for treating chronic pain." That is a fair description. No treatment follows from this paper directly.

Reader Q&A

Could this lead to a drug? Eventually, possibly. The most obvious lead is the μ-opioid receptor population in the RVM, because drugs that act on those receptors already exist. But acting selectively on one node of one circuit is very different from taking an opioid systemically, and there is no candidate compound attached to this work yet.

Does this apply to neuropathic pain after spinal cord injury? Unknown. The models used were peripheral inflammation and peripheral nerve injury. Testing whether the loop drives pain in spinal cord injury models is a separate piece of work that would need to be done.

How did they silence a brain region in a mouse? Using genetic and chemical tools that let researchers switch defined populations of neurons on and off on demand. It is precise, reversible and completely unavailable in humans — which is the main reason findings like this take years to translate.

Why does "repeated but not acute" activation matter? It fits the clinical picture. Chronic pain typically develops over weeks after an injury rather than appearing instantly, and this result gives a mechanism for that: it takes sustained, repeated traffic through the loop to lock the system into its hypersensitive state.

On 19 August, the Burke Neurological Institute petitioned Westchester Supreme Court in New York to dissolve the charity, citing inadequate finances. It is the formal end of an organisation that, on its own website, called itself "the only research institute in the U.S. dedicated to finding treatments to repair the brain and spinal cord."

For the spinal cord injury research community, this is a real loss, and it is worth understanding what happened.

What Burke was

Founded in 1978 and incorporated as a charity in 1986, the Burke Neurological Institute sat on the campus of Burke Rehabilitation Hospital in White Plains, New York. It was a non-profit research institute affiliated with Weill Cornell Medicine and supported by the Winifred Masterson Burke Foundation. It is a separate organisation from the rehabilitation hospital itself, which Montefiore Health System bought in 2016.

At its height the institute ran ten labs and employed around 45 staff alongside ten principal investigators. Its research covered spinal cord injury, stroke, traumatic brain injury, cerebral palsy and dementia — including work on how motor networks in the brain's cortex behave after spinal cord injury, and how nerve projections from the cortex reach the spinal cord during development.

How it unravelled

The financial picture had been deteriorating for over a decade. According to the institute's publicly filed tax returns, expenses exceeded revenue by at least 10 percent in ten of the fifteen years from 2010 to 2024. By the end of 2024 it carried more than $13 million in total debt, including a $1.7 million loan from the Burke Foundation and over $5 million in accounts payable and accrued expenses. Net liabilities stood at nearly $5.9 million.

On 11 April 2026, the foundation notified the institute it would stop providing financial support. No replacement funder was found. Research ceased on 22 May. Most of the workforce was laid off on 5 June. On 5 August the board authorised the petition to the New York Attorney General, and the court filing followed two weeks later.

What happens to the science

When a research institute closes, the immediate question is what happens to the work in progress.

One Burke faculty member, Gary Gibson, had a clinical trial running at 47 US sites testing a potential treatment to slow Alzheimer's progression, backed by a $45 million grant from the National Institutes of Health awarded to Burke. Weill Cornell Medicine has said the trial will continue there and that it is working with Burke and the NIH to transfer it.

The fate of the spinal cord injury labs is less clear. Whether individual investigators can relocate their labs — and whether postdoctoral researchers on work visas can find placements in time — has not been publicly reported.

Why researchers are calling it a tragedy

Two things made Burke unusual. It was small, and it was rigorously basic-science-focused in a clinical field where that combination is rare.

Tom Carmichael, chair of neurology at UCLA, described Burke as a model for a research approach to brain and spinal cord injury that could be "fundamentally focused on science, and yet still be so meaningful for what otherwise isn't the most science-based clinical specialty."

Takaki Komiyama, professor of neurobiology at UC San Diego, put it more simply: "This is a tragedy. It is an institute that houses talented researchers who have been doing important work."

A former employee, speaking anonymously, suggested the collapse was not inevitable: "if two years ago there'd been a concerted effort to tighten the belt and do certain things, I think it wouldn't have gotten to [this] point."

Reader Q&A

Does this affect Burke Rehabilitation Hospital? No. The rehabilitation hospital is a separate organisation, purchased by Montefiore Health System in 2016. Patient services there are not part of this filing.

Was any specific spinal cord injury treatment lost? Nothing that had reached patients. Burke's spinal cord work was largely upstream — understanding how motor circuits reorganise after injury, which informs later treatment development rather than producing therapies directly. The loss is to the pipeline, not to anything currently available.

Is this part of a wider pattern in US research funding? Burke's problems were long-running and specific to its own finances — the deficits go back to at least 2010, and the decisive event was a single funder withdrawing. That said, small independent research institutes that depend on a narrow funding base are structurally fragile, and Burke is a case study in how quickly that can unwind.

Could it still be rescued? A spokesperson said in June that Burke continued to seek strategic options, funding and partners. But research has been stopped since May, the workforce is largely gone, and the board has now asked a court to dissolve the charity. Reversal at this stage would be unusual.

If you have ever looked into joining a clinical trial after a spinal cord injury, you will know the frustrating part is rarely the trial itself. It is the screening — the months of scans, assessments and paperwork that end, often enough, with a letter saying you are not eligible.

A reported collaboration between Neuralink and the Swedish preventive-health company Neko Health is aimed squarely at that bottleneck. According to a report published on 22 August, the two companies are running a survey that uses Neko's body-scan data to help identify people who might qualify for Neuralink's clinical trials.

Two important caveats before anything else. First, the story surfaced through a social media announcement rather than a press release, and as of 23 August no formal partnership had been confirmed through official channels by either company. Second, this is secondary coverage — we were not able to access a primary announcement from Neuralink or Neko Health.

Why this matters for people with SCI

Neuralink's flagship trial is the PRIME Study (Precise Robotically Implanted Brain-Computer Interface). It enrols people with quadriplegia — paralysis affecting all four limbs — caused by cervical spinal cord injury or ALS (amyotrophic lateral sclerosis, a progressive motor neurone disease). Participants receive an implanted brain-computer interface, or BCI: a device that reads electrical activity from the brain's movement areas and translates the intention to move into control of a computer or phone.

The eligibility criteria are deliberately narrow. This is brain surgery, and implanting a device in someone who turns out to be unsuitable carries real consequences. So the screening is thorough, slow, and — for the many people who are ultimately turned down — exhausting.

As of mid-2026, PRIME and its international counterparts had enrolled somewhere in the mid-twenties of participants across the US, UK, Canada and the UAE. That is a small number relative to the interest, which tells you something about how much of the constraint sits in screening rather than in willingness.

What Neko actually measures

Neko Health, co-founded by Spotify's Daniel Ek, sells a one-hour full-body scan. Its sensors assess skin, cardiovascular function and a range of other biological markers, producing what the company describes as millions of individual data points per session. The scan costs $499 in the US. Neko closed a $700 million funding round in July 2026 and is due to open its first American clinic in New York on 24 September.

The proposed idea is that consented scan data could be run through an eligibility survey to flag people early — either ruling them out because of a disqualifying condition, or confirming they meet baseline health requirements before they ever attend a neurosurgery clinic.

The obvious limitation

Here is the thing worth being clear-eyed about: a Neko scan does not diagnose a spinal cord injury or stage ALS. Those require specialist neurological assessment. Skin and cardiovascular data cannot tell you someone's ASIA classification or level of injury.

So this is realistically a first-pass filter rather than a screening tool — useful for ruling people out on general health grounds before the expensive neurological work begins, not for identifying suitable candidates in the first place. That is still worth something, but it is a narrower claim than the headline suggests.

There is also the consent question. The arrangement reportedly involves consented data, meaning Neko customers would have to actively opt in. How that consent is obtained, how specific it is, and what happens to the data afterwards has not been described.

Reader Q&A

Does this mean it will be easier to get into a Neuralink trial? Not directly, and not yet. Even if the collaboration is real and works as described, it filters an existing pool of Neko customers — people who have paid for a private full-body scan. It does not open a new route in for people with SCI who are not Neko customers. If you want to be considered for PRIME, the patient registry on Neuralink's own site remains the route.

Is a brain-computer interface the same as something that restores movement? No. PRIME is about controlling external devices — a cursor, a keyboard, a phone — by thinking about moving. It does not reconnect the brain to the body's own muscles. Separate research programmes are working on that, but it is a different problem.

Should I be concerned about a health-scan company sharing my data with a device manufacturer? It is a reasonable question to ask, and one worth asking of any company holding your health data. The reported arrangement is opt-in, but the details have not been published. If you use a service like this, it is fair to ask what specific consent you have given and to whom.

How solid is this story? Moderately. The underlying facts about Neko's funding, pricing and expansion and about Neuralink's PRIME criteria are all well established. The collaboration itself rests on a single social media announcement and secondary reporting, with no official confirmation from either company. Treat it as plausible but unconfirmed.

In the first days after a spinal cord injury, one of the most dangerous things that can happen has nothing to do with the cord itself. It is a blood clot.

Immobility, trauma and surgery together make venous thromboembolism — a clot that forms in a deep vein, usually in the leg, and can break loose and travel to the lungs — one of the most common serious complications after acute spinal cord injury. The standard defence is a blood-thinning drug started as soon as it is safe.

The problem has always been that phrase: *as soon as it is safe*. Start too early after spinal surgery and you risk bleeding around the operation site, which can mean another trip to theatre. Start too late and you leave a window for clots to form.

Why the guidelines have been shaky

Most existing recommendations on timing are consensus-based — meaning a panel of experts agreed on what seemed sensible, rather than deriving it from large-scale data. That is not nothing, but it is a weaker footing than most people assume when they hear "guideline."

A new study in The Spine Journal, led by Aazad Abbas, Robert Koucheki and Jay Toor, set out to put real numbers under the question.

What they did

The researchers ran a retrospective cohort study using the American College of Surgeons Trauma Quality Improvement Program (TQIP) — a database pooling records from North American trauma centres — covering 2017 to 2022.

They included 15,960 patients: adults aged 16 and over with acute spinal cord injury from blunt trauma, who underwent surgical decompression within 24 hours of arriving. "Retrospective" means they analysed records of care that had already happened rather than assigning treatments themselves.

What they found

Starting thromboprophylaxis by postoperative day 1 was associated with:

- a lower risk of venous thromboembolism - fewer returns to the operating room overall - no increase in returns to theatre for a related spine procedure

That last point is the one that matters most. The whole argument for delaying blood thinners is fear of a bleed that needs surgical correction. In this dataset, at this scale, that fear was not borne out.

How to read this honestly

This is observational data, not a randomised trial, and that limits what it can prove.

In a database like TQIP, the patients who received early thromboprophylaxis were not randomly chosen — their surgeons decided. Surgeons may reasonably have started blood thinners early in the patients who looked stable and delayed in those who looked like a bleeding risk. If so, some of the apparent benefit of early treatment could reflect who was selected for it rather than the timing itself. Statistical methods can adjust for measured differences between groups, but not for the clinical judgement that never made it into the record.

What the study does establish is that across nearly 16,000 real patients at real trauma centres, early treatment was not associated with the surgical harm that has justified caution. That is a meaningful argument for tightening guidelines, and a reasonable basis for a randomised trial.

Reader Q&A

Does this apply to me if my injury was years ago? No. This study covers the acute phase — specifically people who had decompression surgery within 24 hours of injury. Long-term clot risk after spinal cord injury is a different question with different management.

Should someone in hospital now ask about this? Timing of blood thinners is a decision that depends on the individual's bleeding risk, other injuries and the specifics of their surgery. If a family wants to understand why a particular timing was chosen, that is a fair question to put to the treating team — but this study is a population-level finding, not a rule for any one patient.

Why does the "no increase in return to theatre" finding matter so much? Because it is the counterweight. Early anticoagulation was always plausibly good for clot prevention; the reason it was not universal is the bleeding risk. Showing that the expected downside did not appear at scale is what makes the finding actionable.

Is a randomised trial likely? It would be the logical next step, and the study's authors frame their work as filling a gap left by consensus-based guidance. Whether one gets funded and run is a separate matter — randomised trials in acute trauma are difficult to conduct ethically and practically.

*Note: the full text of this paper was not directly accessible at the time of writing. This summary is based on the published abstract and study description.*

If you follow spinal cord injury research, you will have noticed something frustrating: every year brings promising results from stem cells, from biomaterials, from stimulation implants — and every year the treatments stay in the lab.

A new review published in the journal Engineering tries to explain why, and what to do about it. Led by researchers at Tianjin Medical University General Hospital and Shandong University, the team searched PubMed, ScienceDirect and Google Scholar for work published between 2015 and 2025, and screened 657 qualifying studies down into a single map of the field.

Their conclusion is blunt. Single interventions keep failing because spinal cord injury is not one problem.

Why one treatment is never enough

The review separates the primary injury — the mechanical damage done at the moment of the accident — from the secondary injury cascade that follows it over hours, days and years.

That cascade runs in phases. In the acute phase there is an inflammatory storm and oxidative stress (a flood of unstable molecules that damage cell membranes and DNA). In the subacute phase, cells continue to die and the injury site reorganises. In the chronic phase, a glial-fibrotic scar forms — a dense wall of support cells and connective tissue that seals the wound but also physically and chemically blocks nerve fibres from regrowing through it.

Each phase creates a different obstacle. That is why, the authors argue, single conventional interventions such as high-dose methylprednisolone (a steroid given soon after injury to damp down inflammation) or surgical decompression on its own have delivered so little. They address one link in a chain of many.

The five engineering branches

The review organises the field into five categories.

Neuromodulation — using electricity, ultrasound, magnetic fields, light (photobiomodulation), or genetically light-sensitive neurons (optogenetics) to change how surviving circuits behave, plus brain-computer interfaces. Of all of these, epidural spinal cord stimulation is described as the most widely adopted, reactivating dormant spinal circuits and improving both motor and autonomic function in people with chronic paralysis.

Cell therapy — transplanting neural stem cells, mesenchymal stromal cells or olfactory ensheathing cells, often modified beforehand through gene editing or "preconditioning" (exposing cells to mild stress in the dish so they survive better once transplanted).

Biomaterials — hydrogels, 3D-printed scaffolds, microspheres, nanomaterials and stimuli-responsive "smart" substrates, used as carriers for cells, as slow-release drug depots, or as physical guides that give regrowing nerve fibres a direction to follow.

Surgical technique — refinements in how and when the cord is decompressed and stabilised.

Targeted drugs and gene interventions — compounds aimed at specific inflammatory and regenerative signalling pathways rather than blanket suppression.

Where each one gets stuck

The most useful part of the review is its honesty about failure points.

Transplanted cells die at high rates. Implanted electrodes provoke tissue reactions over the long term that degrade the signal. Biomaterial scaffolds are often not mechanically stable enough to survive in a moving spine. And stimulation parameters vary so much between clinical trials that comparing results across studies is close to meaningless.

That last point matters more than it sounds. If two teams report different outcomes from epidural stimulation but used different frequencies, electrode placements and training protocols, nobody can tell whether the treatment or the settings made the difference.

The proposed way forward

The authors argue for multimodal combinations — pairing a biomaterial scaffold with a cell transplant so the cells have somewhere to live, or coupling neuromodulation with rehabilitation training so the reactivated circuits are actually used.

They also call for standardised evaluation systems, a serious reckoning with why the same treatment works well in one person and not another, and a cleaner pipeline running from cell culture, to rodent models, to non-human primates, to tiered human trials.

It is a roadmap rather than a result. But roadmaps are useful when a field has a lot of promising side roads and no clear main route.

Reader Q&A

Is this new research, or a summary of old research? It is a review — a structured summary and analysis of work already published between 2015 and 2025. No new experiments were run. Its value is in the synthesis and in the translational framework it proposes, not in new data.

Does this mean combination treatments are coming soon? Not soon in any specific sense. The review identifies combinations as the most promising direction, but combining two experimental therapies means combining two sets of unknowns, and regulators require each component to be characterised. This is a research direction, not a timeline.

Why does epidural stimulation come out so well? Because it is the one branch with a substantial track record in humans rather than only animals. It has restored voluntary movement, blood pressure control and other autonomic functions in people with chronic injuries. That does not make it a cure — it makes it the most clinically mature of the five.

What about the scar? Can it be removed? The review treats the glial-fibrotic scar as one of several barriers rather than a single villain. The scar also does useful work sealing the injury, so approaches now tend to focus on modifying the chemistry that blocks regrowth rather than removing the scar wholesale.

When a company reports that an experimental treatment improved movement in injured animals, the obvious next question is: *why?* What actually changed inside the spinal cord to produce that result?

NurExone Biologic — a Toronto- and Haifa-based company developing exosome therapies for central nervous system injury — has just published its attempt to answer that for ExoPTEN, its lead candidate. On 14 August it reported new tissue-analysis findings from spinal cords collected during an earlier efficacy study, the one that produced the functional recovery it announced back in July 2025.

What ExoPTEN is

ExoPTEN is built on exosomes — tiny membrane-wrapped packages that cells naturally release to ferry molecules to other cells. They are small enough to slip into tissue that is difficult to reach, which makes them attractive as delivery vehicles.

NurExone takes naïve exosomes from bone marrow and loads them with siRNA (a short piece of genetic material that switches off a specific gene) aimed at PTEN. PTEN is a brake. In neurons it suppresses the growth machinery that would otherwise let a damaged nerve fibre regrow. Turning PTEN down, temporarily and locally, is a long-standing idea in regeneration research — the appeal of ExoPTEN is the delivery method, which is intended to be minimally invasive rather than requiring direct surgical injection into the cord.

What the new analysis found

The company went back to spinal cord tissue from the earlier rat study and stained it for three markers:

- NeuN — labels neuronal nuclei and cell bodies - NF200 — labels neuronal axons and cell bodies - MBP (myelin basic protein) — labels myelin, the fatty insulating sheath wrapped around nerve fibres

Three regions were assessed separately: the injury site itself, the region *rostral* to it (towards the head) and the region *caudal* to it (towards the tail).

The headline result is about myelin. Two months after injury, ExoPTEN-treated animals had significantly more MBP-positive cells than controls in both the rostral region (p=0.01) and the caudal region (p=0.04). Myelin matters because a nerve fibre without its insulation is a wire with the coating stripped off — the signal degrades or fails. More surviving myelin on both sides of the lesion is consistent with tissue having been protected rather than lost.

"Nerve cells depend on a protective coating, much like electrical wires depend on insulation, to carry signals," said Dr Tali Kizhner, NurExone's director of R&D. The company frames the finding as biological support for the movement improvements it had already reported, not as a new efficacy result.

How much weight this carries

Some honest framing is needed here.

This is a company press release about preclinical work in rats, not a peer-reviewed paper. ExoPTEN has not been tested in humans and its safety and efficacy in people are unknown. The company says so plainly in its own disclosures.

It is also a retrospective analysis of tissue from a study that had already reported a positive result. That is a completely legitimate thing to do — it is how you build a mechanistic story — but it is not independent confirmation. The p-values (0.01 and 0.04) are statistically significant but not overwhelming, and no sample sizes were given in the announcement.

What is genuinely useful is that the myelin result points in the same direction as the functional result. Preclinical programmes fall apart when the biology and the behaviour disagree. Here they agree, which is a reasonable, if modest, step forward for a company heading towards regulatory submissions and eventual clinical trials.

Reader Q&A

Is this a treatment I could get?

No. ExoPTEN is a preclinical candidate. It has not been approved by any regulator and has not entered human trials. NurExone has an orphan drug designation, which helps with the regulatory pathway, but that is not approval and says nothing about whether it works in people.

Would it help someone with a long-standing injury?

ExoPTEN is being developed for *acute* spinal cord injury — given in the window shortly after the trauma, when the goal is protecting tissue that is still dying. The mechanism here is neuroprotection, not repair of an injury that is years old. Chronic injury would be a different and much harder problem.

Why should more myelin translate into better function?

In principle, preserved myelin means preserved conduction — surviving fibres can still carry signals past the damaged zone. But this study measured myelin-positive cells, not signal conduction, and the link between the two is inferred rather than demonstrated. It is a plausible explanation for the earlier functional result, not proof of one.

Rats have been "cured" of spinal cord injury many times. Why is this different?

It may not be. The gap between rodent recovery and human benefit is the single biggest problem in this field, and plenty of promising animal results have gone nowhere. The reasonable position is interest without expectation: watch what happens when it reaches a human trial, and judge it then.

Ask almost anyone with a spinal cord injury what helped most in the first year and a surprising number will name a person rather than a treatment — someone a few years further down the road who had already worked out how to get a wheelchair into a car, or what to say to an employer, or that the bad months do end.

Peer support is one of the least technological things the SCI world does and one of the most consistently valued. It is also, historically, one of the hardest to prove. Funders ask what a programme achieved; organisations reach for attendance numbers and testimonials, because nothing better existed.

Spinal Cord Injury BC has now reported that it is using a purpose-built measurement tool to change that.

What the tool is

The SCI Peer Support Evaluation Tool is a 20-question instrument. Each question measures one outcome, and the twenty outcomes were chosen as the ones that matter most in SCI peer support specifically — not borrowed from general mental health or chronic disease questionnaires.

It was developed in Canada and published in the journal *Spinal Cord* in September 2024 by a team led by researchers including Kathleen Martin Ginis at the University of British Columbia, working with community organisations across the country. The recent news item from SCI BC is about implementation — the tool moving out of the development paper and into actual programme evaluation — rather than a new study.

How it was built

The development followed COSMIN, an international standard for building health measurement instruments that sets out how to do it properly rather than by intuition. The process ran in four steps:

1. A Delphi process — repeated anonymous rounds of expert and community rating until agreement emerges — identified the 20 most important outcomes of SCI peer support. 2. Literature review and drafting produced 97 candidate questions to measure those outcomes. 3. Rating and consensus methods cut the 97 down to one question per outcome — 20 in total. 4. Testing established content and face validity (does it measure what it claims, and does it look sensible to the people answering it) and test-retest reliability (does the same person give consistent answers over time).

The thing that stands out is who was in the room. The work was co-constructed with executives and staff from community SCI organisations, people with SCI who had received peer support as mentees, people who had provided it as mentors, and researchers. The outcomes being measured were defined by the people the programmes are for.

Why a short tool is the point

Twenty single-item questions is deliberately lightweight. Long questionnaires get abandoned halfway, and community organisations running peer support on small budgets do not have research staff to administer them. A tool that a volunteer coordinator can actually use, repeatedly, across a whole programme is worth more in practice than a psychometrically luxurious one that nobody completes.

The trade-off is real: one question per outcome means less precision on each individual outcome than a multi-item scale would give. The authors chose breadth and usability over depth, which is a defensible call for programme evaluation as opposed to research measurement.

Reader Q&A

Is this new research?

No, and it is worth being clear about that. The validation study was published in 2024. What is new is that organisations such as SCI BC are now reporting using it to plan and evaluate their programmes. That is a normal and often slow part of research reaching the real world.

Does it prove peer support works?

Not by itself. A measurement tool is a ruler, not a result. What it does is make it possible to collect comparable evidence across programmes and over time — so that in a few years there may be a real answer rather than a collection of anecdotes.

Is it only for Canada?

It was developed for and with Canadian community-based SCI organisations, and the outcomes reflect that context. Nothing about the questions is uniquely Canadian, but an organisation elsewhere would want to check the outcomes match what its own members value before adopting it wholesale.

Where can I read it?

The development paper is open access in *Spinal Cord* (volume 62, 2024) and freely available through PubMed Central.

Almost every personal exoskeleton cleared for home use so far has asked the same thing of the person wearing it: hold yourself up. Crutches or a walker do the balancing; the machine does the stepping. That works, but it occupies both hands, which rules out most of the things people actually want to stand up to do — reach a shelf, carry a plate, cook something.

On 11 August the FDA cleared Wandercraft's Eve, and the difference is that Eve balances itself. It is the first self-balancing exoskeleton approved for personal, prescribed use rather than clinic-only rehabilitation, and it leaves the user's hands free.

What "self-balancing" actually means

Wandercraft's technology continuously computes and adjusts the device's own centre of mass while it walks — the same problem a bipedal robot has to solve. The user is not propping the system up; the system is keeping itself, and the person in it, upright.

The company has been building toward this for over a decade. Its first device, Atalante (later Atalante X), brought self-balancing walking into rehabilitation facilities and is now reported to be in use at more than 150 rehab and research centres worldwide. Eve is that same concept scaled down for someone's home.

Who it's for — and the fine print

Wandercraft says Eve may be used by eligible adults with spinal cord injury at any level, provided the person can operate the device's remote control. That is a notably broader description than most personal exoskeletons, which have historically been limited by injury level because the user needed working arms and trunk control to manage crutches.

"At any level" does not mean everyone qualifies. Every prospective user still goes through a clinical assessment, an individual fitting, and training — five two-hour sessions, potentially inside a week, covering transfers, remote operation, walking on level ground, moving through tight spaces, daily activities, and emergency procedures.

The clearance itself is specific and worth reading plainly:

- Level indoor surfaces, plus level outdoor areas immediately adjacent to a building — patios, terraces. Not pavements, not uneven ground. - Use under the supervision of a specially trained companion. This is not an independent-use device. - Wandercraft describes Eve explicitly as a complement to a wheelchair, not a replacement. It is for additional opportunities to be upright, not for getting around.

What the trial showed

The clearance was supported by a three-site trial run through the James J. Peters VA Medical Center in the Bronx, the Kessler Foundation in New Jersey, and Walk in New York. It looked at safety, function, training and usability — specifically, whether users and their companions could learn the device and use it in tasks representative of real home life.

Wandercraft reports that participants met key walking and usability endpoints. Participants also reported improvements in health status, psychological wellbeing, endurance during daily activities, lower-limb spasticity and sitting balance, with some reporting better sleep and bladder and bowel function.

Treat that second list carefully. Those are participant-reported outcomes from a device trial, not results from a controlled study designed to test whether standing improves bowel function. They are consistent with what a lot of people describe from regular standing, but they are not proof of a treatment effect.

The money question

Medicare opened a reimbursement route for personal exoskeletons in 2024, treating qualifying systems as braces and allowing a lump-sum payment through the durable medical equipment programme. Wandercraft expects Eve to become eligible under that established pathway (code K1007) within 60 to 90 days.

Expects, not has. FDA clearance does not create Medicare coverage, and individual approval will still turn on documentation, medical necessity and what a given payer decides. Wandercraft says it has an access team to help with claims and financing, and it has lined up distribution: National Seating & Mobility as the exclusive complex rehab technology partner, Walk US for evaluation and training, Good Shepherd Rehabilitation in Pennsylvania's Lehigh Valley, and USVetServ to distribute to VA facilities.

That infrastructure matters as much as the hardware. Personal exoskeletons have historically stalled not on engineering but on the unglamorous parts — who assesses you, who trains you, who fixes it, who pays.

US commercial launch is set for 17 September 2026, with an unveiling in New York in partnership with the United Spinal Association.

Reader Q&A

Does this mean I could walk without crutches?

If you qualify and complete training, yes — Eve handles balance, so your hands are free. But within the cleared conditions: level surfaces, indoors or immediately outside a building, with a trained companion present. It is not a device for walking down the street on your own.

Is "any injury level" real, or marketing?

It is real in the sense that the balance requirement — the thing that historically excluded higher injuries — has been removed. The remaining requirement is being able to operate a remote control. But eligibility is decided by clinical assessment, so the honest answer is that it widens the door rather than opening it to everyone.

What will it cost me?

Unknown at this stage. Wandercraft is projecting Medicare eligibility under the K1007 brace pathway in the next few months, which if it lands would be the most realistic funding route in the US. Outside the US, nothing has been announced.

Should I expect health benefits from using it?

Possibly, but don't buy it for that. Trial participants reported improvements in spasticity, sleep, endurance and bowel and bladder function, and there is a broader literature suggesting regular standing helps with several secondary conditions. None of that was tested here as a controlled outcome. The cleared purpose is upright mobility and daily activities.

NervGen has announced a major operational update for RESTORE, its planned Phase 3 clinical trial of the experimental spinal cord injury drug NVG-291.

The company says it has now finalised the selection of trial sites in the United States and Canada, with specialist spinal cord injury and neurorehabilitation centres being prioritised. Site activation and participant screening are expected to begin in September 2026, with the first participant expected to receive treatment shortly afterwards.

What is RESTORE?

RESTORE is the large Phase 3 study designed to test whether the promising results seen in NervGen's earlier CONNECT SCI trial can be repeated in a much larger group.

Phase 3 is the stage where an experimental treatment has to prove itself in a larger, carefully controlled study before it can potentially move towards approval.

NervGen plans to enrol around 150 adults with chronic incomplete tetraplegia — meaning a long-term neck-level spinal cord injury where some nerve signals still pass through the injury.

Participants are expected to have injuries at C7 or above, be classified as AIS C or AIS D, and be between one and ten years post-injury.

The study is therefore not currently aimed at every type of spinal cord injury. People with AIS A or AIS B injuries, or injuries more than ten years old, are not part of the announced Phase 3 population.

What will participants receive?

Participants will be randomly assigned to receive either NVG-291 or placebo as a once-daily injection under the skin for 12 weeks.

A placebo looks like the treatment but does not contain the active drug. Using a placebo allows researchers to compare the two groups fairly and see whether any improvement is really caused by NVG-291.

The main measurement will be GRASSP Quantitative Prehension, a test that looks at practical hand function in people with tetraplegia.

This is important because even relatively small improvements in hand use can make a major difference to daily independence.

Why is this update important?

Until now, RESTORE had mainly been discussed as an upcoming Phase 3 study.

This announcement shows that the practical work needed to start the trial is now moving forward: centres have been selected, activation is underway, and screening is expected to begin next month.

NervGen also says additional sites will open on a rolling basis rather than all at once.

The company currently expects enrolment to be completed in the second half of 2027, with the main Phase 3 results expected in the first half of 2028.

NervGen has also recently raised substantial funding and says its current cash position is expected to support operations through the anticipated RESTORE results. That matters because large Phase 3 trials are expensive, and a promising treatment still needs enough financial backing to actually complete the study.

What has not happened yet?

RESTORE has not yet produced any Phase 3 results, and NervGen has not yet announced that the first participant has been treated.

NVG-291 also remains an experimental treatment and has not been approved for spinal cord injury.

The next major milestones will be the opening of recruitment at individual centres, the first participant being screened and dosed, and eventually the Phase 3 results themselves.

Reader Q&A

Can people apply for RESTORE now? Not yet through a full public recruitment system. NervGen says screening is expected to begin in September 2026. Individual trial centres are expected to open on a rolling basis, and recruitment details should become clearer as those sites activate.

Is NVG-291 a stem cell treatment or surgery? No. NVG-291 is an experimental drug given by injection under the skin. It is designed to interfere with biological signals that normally make nerve repair and regrowth more difficult after spinal cord injury.

Does this mean NVG-291 has been proven to work? No. The earlier CONNECT SCI study produced encouraging results, but it was small. RESTORE is the much larger Phase 3 trial designed to find out whether those results can be repeated reliably.

When might we know the Phase 3 result? NervGen currently expects the main RESTORE results in the first half of 2028.

A 53-year-old man wakes at 3am with a crushing headache. His blood pressure is 190/120 mmHg. His caregiver thinks it's a stroke. It isn't. A full bladder has set off a dangerous chain reaction in his nervous system.

That scenario — drawn from Dr. Jan Elaine Soriano's prize-winning essay published in Science this week — describes something experienced by most people living with spinal cord injury at or above the sixth thoracic vertebra (T6). It has a name: autonomic dysreflexia. And until now, there has been no way to prevent it, only to manage it once it starts.

Soriano's work changes that picture significantly.

What autonomic dysreflexia actually is

The autonomic nervous system controls the functions you don't consciously think about: blood pressure, heart rate, bladder, digestion, temperature regulation. Normally, it operates under careful control from the brainstem. After a high-level spinal cord injury, that control connection is severed.

The spinal cord below the injury doesn't simply go quiet — it reorganises. Neurons that were once tightly regulated by the brain become hyperactive. When a sensory signal arrives from below the injury — a full bladder, constipation, a pressure sore, tight clothing — it can trigger a massive, unchecked sympathetic (fight-or-flight) discharge. Blood pressure surges to dangerous levels. The heart races then slows in a competing reflex. Above the injury, the person experiences a pounding headache, flushing, sweating, goosebumps. Left untreated, it can cause a stroke.

The current approach is reactive: identify and remove the trigger. There has been no way to stop the next episode from happening.

Who Soriano is and what she set out to find

Jan Elaine Soriano is a postdoctoral researcher at NeuroRestore, part of École Polytechnique Fédérale de Lausanne (EPFL) in Lausanne, Switzerland. She completed her PhD at the University of Calgary, where she worked directly with people with high-level SCI experiencing severe autonomic dysreflexia episodes. Watching patients live in fear of the next crisis — unable to prevent it even after identifying individual triggers — drove her to find the neuronal source.

The fundamental problem was that nobody had mapped which neurons in the spinal cord were responsible for triggering these episodes. Without a cellular target, no therapy could be designed.

Finding the neurons responsible

Soriano began by mapping spinal cord activity during AD episodes in chronically injured mice using cFos labelling — a technique that marks neurons that have recently fired. The strongest activation appeared consistently in two regions: the lower thoracic cord (T8–T12, mid-back) and the lumbosacral cord (L1–S5, lower back and sacral region).

To identify which specific cells were driving the response, she used single-cell transcriptomics — a method that reads the gene activity of individual cells — and compared mice that experienced AD against those that didn't. Both regions pointed to the same cell type: an excitatory interneuron (relay cell) expressing a transcription factor called Vsx2. These neurons had been studied before in the context of motor function. Their role in blood pressure regulation had never been described.

How the spinal cord rewires after injury

The crucial next finding was what happens to Vsx2 neurons after SCI. In uninjured mice, Vsx2 neurons in the lumbosacral cord had no significant connections to Vsx2 neurons in the lower thoracic cord. After injury, those lumbosacral neurons sprouted dense new projections — a circuit that doesn't exist in the healthy spinal cord.

When Soriano removed Vsx2 neurons from either region in injured mice, autonomic dysreflexia was prevented without affecting blood pressure in uninjured animals. The Vsx2 circuit was responsible. The spinal cord had literally rewired itself — maladaptively — into a system that amplified ordinary sensory signals into blood pressure crises.

Turning it off with electrical stimulation

The therapeutic insight built on work Soriano had been conducting in parallel: epidural electrical stimulation (EES), in which electrodes placed over the spinal cord deliver precisely timed electrical pulses to specific spinal circuits. EES was already being used to engage Vsx2 neurons in the thoracic cord to restore walking function after SCI. Soriano asked whether targeting those same neurons might address autonomic dysreflexia.

In chronically injured mice, a four-week regimen of daily EES abolished autonomic dysreflexia in every single animal tested. The mechanism wasn't simple suppression: repeated stimulation gradually retrained the spinal cord, shifting its reorganisation toward steadier autonomic output and dismantling the maladaptive Vsx2 circuit that had formed after injury.

Moving to human data, participants in ongoing clinical trials using EES for blood pressure management after SCI reported significantly fewer headaches and heart palpitations — two of the most prominent AD symptoms — compared to before treatment (p=0.02118). The human nervous system appears to respond to the same retraining principle seen in mice.

What comes next

These findings directly shaped the design of a new multisite clinical trial: Empower BP, run by ONWARD Medical, which will formally assess epidural electrical stimulation for blood pressure management in SCI, with autonomic dysreflexia as a primary outcome measure. It is the first trial of its kind powered specifically to measure prevention of AD episodes.

For her work identifying the neuronal circuit and demonstrating a therapeutic path, Soriano received the Grand Prize in the 2026 Science & PINS Prize for Neuromodulation, an award from the American Association for the Advancement of Science (AAAS) and the PINS Medical Research Institute recognising exceptional research applying neurostimulation to treat nervous system disorders. The prize essay was published in Science on 30 July 2026.

Reader Q&A

Who is at risk of autonomic dysreflexia? Generally anyone with SCI at or above T6. At that level, sympathetic nervous system outflow is disconnected from brainstem regulation. Cervical and upper thoracic injuries carry the highest risk; below T6 the reflex cannot build the same pressure surge because the sympathetic control circuits remain connected to higher regulation.

What are the common triggers? Bladder distension is the most common — a full bladder or blocked catheter. Bowel distension and constipation are close behind. Others include pressure sores, skin irritation, constrictive clothing, medical procedures, and in some cases even nail cutting or ingrown toenails. The common thread is any sensory signal from below the injury that enters a cord that can no longer process it in proportion.

Is EES currently available specifically for autonomic dysreflexia? Not yet as a formal indication. EES devices are being used in clinical trials for blood pressure management in SCI through the ONWARD program, with participants reporting reduced AD frequency as a secondary finding. Empower BP will be the trial to formally test this. Current management of acute episodes relies on removing the trigger and, when needed, short-acting medications such as nifedipine, captopril, or GTN spray. People with frequent severe episodes may be on daily antihypertensives in the interim.

What does Soriano's prize mean for the field? It's notable not just as recognition for the work, but because the Science & PINS Prize is specifically awarded for research at the intersection of neurostimulation and clinical translation. That the panel chose AD prevention — a problem affecting the majority of people with high-level SCI and with no current solution — reflects how significant this mechanistic advance is considered to be.

Most people with a high cervical spinal cord injury spend the rest of their lives on a ventilator. Not because their lungs have failed. Not because their diaphragm has stopped working. But because the signal the brain sends to start breathing — travelling down through the spinal cord to the phrenic nerve, the nerve that controls the diaphragm — can no longer get through.

That signal pathway is broken at the cord. But the phrenic nerve itself, in most high cervical injuries, is completely intact. And that is the opening that phrenic nerve stimulation — also called diaphragmatic pacing — exploits.

On 30 July 2026, Oklahoma Children's OU Health published the story of Maverick, a Missouri toddler who suffered a catastrophic cervical SCI in a road crash at 18 months old. He became the youngest person in the world to have phrenic nerve stimulators implanted following a spinal cord injury — at just over two years old, in January 2026. He is now breathing with his own diaphragm, electrically triggered, without a ventilator for stretches of time and progressing further.

His family says they wish more people knew this procedure existed. They're right to say so.

Why breathing fails after high cervical SCI

The phrenic nerves originate in the cervical spinal cord at the C3, C4, and C5 levels — roughly mid-neck. They travel down through the chest and connect to each side of the diaphragm, the dome-shaped muscle that does most of the work of breathing. When the brain signals a breath, the message travels down the cord, exits at C3–C5, and drives the diaphragm to contract and pull air into the lungs.

A spinal cord injury above C3 severs this chain at the cord. The phrenic nerves below the injury remain intact. The diaphragm remains intact. There is simply no signal reaching either of them.

This is where the ventilator steps in: it pushes air into the lungs mechanically, doing the work the diaphragm can no longer do. It is life-saving. But it has real downsides — which is exactly why phrenic nerve stimulation exists.

What phrenic nerve stimulation is

The procedure places small electrodes surgically around or near the phrenic nerve (or at the nerve's entry points into the diaphragm, depending on approach). These electrodes connect to a receiver implanted under the skin. An external control unit transmits electrical pulses through the skin to the receiver, which passes them on to the electrodes, which cause the phrenic nerve to fire — and the diaphragm to contract. A breath follows.

The timing and intensity of those pulses are adjusted to produce a normal breathing rhythm. With conditioning over weeks to months — the diaphragm is a muscle, and needs to be rebuilt after disuse — many patients go from a few hours off the ventilator each day to spending most or all of the day breathing with the pacer. Some transition off the ventilator entirely.

There are two main device types. The conventional approach uses an electrode on the phrenic nerve connected to a subcutaneous receiver and an external radiofrequency transmitter worn on the skin. The Diaphragmatic Pacing System (DPS) places four electrodes directly into the diaphragm at the nerve insertion points, connected to an external pulse generator through a socket at the skin surface. Each approach has clinical uses; the DPS in particular allows stimulation even when the phrenic nerve higher up is partially compromised.

Who qualifies

The key requirement is that the phrenic nerve itself must be intact and functional. Before surgery, phrenic nerve conduction studies — electrical tests of nerve function — confirm whether the nerve can carry a signal.

Patients with SCI above C3 are the clearest candidates: the injury is above where the phrenic roots exit the cord, so the nerve below is undamaged and can be stimulated at the neck, chest, or diaphragm.

Mid-cervical injuries (at C3–C5 itself) are more complex, since the injury may directly involve the nerve roots. In these cases, direct diaphragmatic pacing through the DPS system can sometimes still work by stimulating the nerve at the diaphragm rather than higher up.

Beyond SCI, the procedure is used in congenital central alveolar hypoventilation syndrome (where the brain's breathing control fails), brainstem tumours, Arnold-Chiari malformations, and certain neuromuscular conditions.

How the surgery is done

Surgeons can reach the phrenic nerve three ways. The cervical approach accesses the nerve directly in the neck — the most direct route, typically used for high SCI. The thoracic approach uses keyhole video-assisted chest surgery (VATS) to reach the nerve as it runs alongside the heart. The diaphragmatic approach is laparoscopic — small incisions in the abdomen — and places electrodes where the nerve meets the diaphragm. This is the route used for the DPS device and is available even when the nerve higher up is unreliable.

Both sides are usually done two weeks apart to allow recovery between procedures.

Why it beats a ventilator for most patients

Ventilators save lives, and many people with high SCI live full lives on them. But the practical burden is real: a ventilator requires a tracheostomy (a permanent opening in the windpipe), carries ongoing infection risk, needs an uninterrupted power supply, and is a disconnection risk. Speaking is harder. Taste diminishes over time. Mobility is constrained.

Phrenic nerve stimulators are a closed system once implanted. Most patients keep their tracheostomy initially as a safety backup, but the breathing itself comes through the pacer rather than the machine. Speech follows the natural rhythm of the pacer. Taste is preserved. The device is small and unobtrusive. Because the diaphragm contracts naturally — even if electrically triggered — breathing mechanics are closer to normal, which is better for long-term lung health.

In February 2026, NICE in the UK issued guidance (HTG727) formally endorsing phrenic nerve pacing for ventilator-dependent patients with high cervical SCI — a signal that clinical consensus around the technology is consolidating.

Why it isn't more widely known

Phrenic nerve stimulation has existed since the 1970s — Christopher Reeve used a diaphragmatic pacer in his later years. The technology has improved significantly: devices are smaller, laparoscopic implantation is less invasive than early open surgery, and FDA approval has made the DPS accessible across the US.

But it remains a specialist procedure, concentrated at a small number of centres with specific experience. Awareness among patients, families, and even some clinicians is still limited — which means people who might benefit are sometimes not told it exists. Maverick's case, as the youngest patient in the world to undergo the procedure after SCI, brings it to a wider audience at a moment when guidance and availability are both moving in the right direction.

Reader Q&A

Does everyone with a high cervical SCI qualify?

Not automatically — phrenic nerve function has to be confirmed first through nerve conduction tests. Most people with injuries above C3 do qualify, since the phrenic nerve below the injury is typically intact. People with injuries at C3–C5 need careful assessment, but some still qualify via the diaphragmatic approach. A specialist centre with experience in the procedure is the right place to be evaluated.

Can it replace the ventilator completely?

For many patients, yes, at least for daytime use. Some manage without the ventilator at all. The process involves a conditioning phase — the diaphragm has usually weakened from disuse and needs time to rebuild — which takes weeks to months. Others use the pacer during the day and non-invasive ventilation at night. The combination depends on the individual. Tracheostomies are often kept in place initially as backup, and removed later once breathing is stable.

What age can it be used from?

Maverick's surgery extends the known lower age limit to just over two years old. The Christopher & Dana Reeve Foundation notes that paediatric use of diaphragmatic pacing has actually driven adoption faster than in adults, partly because children's developing nervous systems are more adaptable. Surgeons experienced in paediatric implantation are needed for young patients — but the procedure is not age-restricted in principle.

Is it available in the UK?

Yes, at specialist centres, and with growing clinical support. The February 2026 NICE guidance (HTG727) formalises it as a recommended option for ventilator-dependent high cervical SCI patients, which should strengthen access through NHS pathways. Referral to a specialist spinal or respiratory centre is the starting point.

If you had to describe myelin to someone who'd never heard of it, you'd probably reach for the insulation analogy: the fatty sheath around a nerve fibre that speeds up electrical signals and prevents energy loss, like the plastic sleeve around a copper wire. That's accurate as far as it goes.

New research published in Nature Neuroscience on 31 July 2026 shows it doesn't go far enough. Myelin sheaths are not passive insulating material. They contain a continuous internal network of living cytoplasm — the gel-like interior of the cell — threaded through with microtubules (tiny protein tubes that serve as cargo tracks) and populated by organelles (cellular machinery). And this system is running active, motor-driven deliveries around the clock.

The research team from the University of Glasgow and Max Planck Institute for Multidisciplinary Sciences in Göttingen have named it the TRAM: Transport Route Across Myelin.

Why myelin sheaths have spaces inside them

Myelin is produced by oligodendrocytes — specialised cells in the brain and spinal cord that extend long arms and wrap them repeatedly around nearby axons (nerve fibres). Each wrap is a layer of membrane. But the wrapping process doesn't compress everything out: at the edges and ends of the sheath, thin channels of cytoplasm remain, filled with organelles. There's the inner tongue (running alongside the axon), the outer tongue (on the outside surface of the sheath), and the paranodal loops (at the ends of each myelin segment, where they meet the regularly-spaced gaps in the insulation called nodes of Ranvier).

These cytoplasmic channels are connected back to the oligodendrocyte's cell body through its long cellular arm. Previous research had noticed organelles in these spaces and assumed they were likely leftovers from the developmental process that had originally laid down the sheath. Nobody had looked closely at what they were doing once the myelin was established.

When the Glasgow/Göttingen team did look — using live fluorescence microscopy in genetically engineered mice — they found the organelles were not sitting still.

Watching organelles move inside living myelin

The team used mice with fluorescently labelled peroxisomes (organelles that protect cells against oxidative stress by breaking down harmful lipids and reactive oxygen species) specifically in their oligodendrocytes. Under a confocal microscope trained on living myelin sheaths, they watched these glowing organelles over ten-minute imaging windows.

Around 16% of myelin peroxisomes were moving at any given time in baseline conditions, travelling up to 44 micrometres — the full length of a myelin segment. The movement was not random drift: it depended on intact microtubule tracks. When the researchers applied nocodazole, a drug that disrupts microtubules, peroxisome motility dropped sharply. When they deleted KIF21B — a kinesin motor protein, the molecular machine that walks along microtubule tracks while carrying cargo — oligodendrocytes could no longer maintain the transport. The system is genuinely active: motor-driven, microtubule-dependent, and purposeful.

The neuron controls the delivery schedule

The most striking finding is that the rate of transport inside the myelin sheath responds to how active the neuron inside it is.

In cell cultures, blocking neuronal firing with tetrodotoxin (a drug that blocks the electrical impulses of neurons) significantly reduced peroxisome motility in the surrounding myelin. Then, in an in-vivo experiment: mice implanted with a transparent window over the spinal cord were imaged while walking voluntarily on a treadmill — motor neurons actively firing — and then again while anaesthetised. Walking: 28.3% of myelin peroxisomes moving. Anaesthetised: 16.8%.

The neuron is effectively calling in its supply deliveries in proportion to how hard it is working. The myelin responds. When neuronal activity increases, the rate of organelle movement within the sheath increases to match.

What happens when TRAM fails

The consequence of TRAM failure was made clear by the KIF21B knockout mice. Without the kinesin motor, organelle transport in myelin stopped. Over the following months, a specific protein began to disappear from the inner surface of the sheath: MCT1, a monocarboxylate transporter (a protein that moves energy metabolites — lactate and pyruvate — from the oligodendrocyte into the axon for fuel). MCT1 delivery to the axon-facing surface depends on TRAM. Without it, the axon is progressively starved of metabolic support.

By six to nine months of age, KIF21B knockout mice showed accumulations of trapped organelles and early axon degeneration. By nine to twelve months, axon loss was widespread. The myelin itself was structurally present, but it had stopped working as a support system.

The same picture emerged in two other models: mice lacking CNP (a protein that maintains the cytoplasmic channels in myelin) and aged mice at 24 months, where intramyelin transport rates were significantly reduced, MCT1 was roughly halved compared to young animals, and axon counts were lower. White matter degeneration in ageing appears to involve, at least in part, a slow failure of the TRAM supply system.

Why this matters for MS and SCI

In multiple sclerosis (MS) — an autoimmune condition where immune cells attack and strip myelin from axons — this discovery offers a new explanation for something that has long puzzled neurologists. Axons in MS frequently degenerate months or years after the initial immune attack, long after the inflammatory episode appears to have resolved. The prevailing assumption has been that immune damage somehow lingers.

The TRAM findings point to a different mechanism: immune attack on myelin disrupts the cytoplasmic channels and knocks out TRAM, cutting off MCT1 delivery to the axon. The axon then degenerates slowly from metabolic starvation — not from ongoing immune attack, but from the loss of its supply line. The finding that KIF21B is upregulated roughly tenfold in MS white matter — and that genetic variants in KIF21B are associated with MS susceptibility — makes the connection harder to ignore.

For SCI specifically, this paper doesn't study the injured spinal cord. But the implications for repair are direct. After SCI, axons that physically survive the initial injury may still be demyelinated — stripped of their sheaths — or may receive new myelin from remyelination therapies or stem cell transplants in the future. For that new or restored myelin to actually support the axon long-term, the TRAM system within it needs to function. This paper defines, for the first time, what that means mechanistically and what the failure mode looks like.

Reader Q&A

What is an oligodendrocyte and why does it matter for SCI? An oligodendrocyte is the cell that produces myelin in the brain and spinal cord. Each one can myelinate dozens of separate axons. After SCI, many oligodendrocytes die — and even when axons survive the initial injury, losing their myelin leaves them functionally impaired and metabolically vulnerable. Remyelination (getting surviving axons re-wrapped) is a significant target in SCI repair research, and understanding what myelin must do to support those axons long-term is central to making remyelination therapies succeed.

Does the same supply system exist in peripheral nerves? Peripheral nerves (outside the brain and spinal cord) are myelinated by Schwann cells rather than oligodendrocytes, and their myelin architecture is somewhat different — they retain more cytoplasm throughout the sheath. The TRAM findings are specific to central nervous system myelin (oligodendrocytes), which has the thin cytoplasmic channels this paper characterises. Whether an equivalent active transport system operates in peripheral myelin is an open question.

Does this explain why some MS patients' symptoms worsen years after their last relapse? Potentially in part, yes. The paper provides a mechanism for secondary axon degeneration that is independent of active inflammation — which could explain progressive disability accumulation in secondary progressive MS without obvious ongoing immune activity. It does not account for everything happening in MS, which involves multiple overlapping processes, but it adds a well-defined mechanistic explanation for delayed axon loss that the field did not have before.

Ian Blyth was referred to physiotherapy in 2020 for knee and lower back pain. The investigations found degenerative disc disease underneath it — and, separately, an injury that could have killed him.

He had sustained a Hangman's fracture: a break through the second cervical vertebra, C2. A procedure saved his life. It did not give him his old one back. The 52-year-old father of two was left disabled, in severe ongoing pain, medically retired, and now fully dependent on a wheelchair he cannot propel himself.

What a Hangman's fracture is

The name is grim but literal. C2 — the axis — is the second bone down in the neck, and it forms a bony ring around the spinal cord at one of the most vulnerable points in the body. The classic mechanism is violent hyperextension of the neck, historically judicial hanging, today far more often a road traffic collision or a fall.

The fracture runs through the parts of the ring that connect the front and back of the vertebra. What makes it survivable at all is the geometry: when the ring breaks in that particular pattern, it tends to widen rather than narrow, which can spare the cord from being crushed. Many people with a Hangman's fracture have no neurological injury whatsoever and heal in a collar.

When it does go the other way, or when nerve damage develops around the injury, the consequences are permanent. Nerve tissue in and around the cord does not regenerate meaningfully after trauma — that is the central problem the entire spinal cord injury research field exists to solve, and it is not solved yet.

That is the part Ian's daughter Katie wants people to understand.

The bit nobody talks about

"I think spinal injuries aren't spoken about enough, especially the nerve damage that can come afterwards," Katie Blyth told *Edinburgh Live*.

"They typically don't heal at all after a traumatic injury. The pain I have witnessed my dad endure every day since his injury has been awful."

Neuropathic pain after spinal injury is one of the least visible and least well managed consequences. It is not the pain of a healing wound. It is the nervous system itself misfiring — burning, electric, often worst at rest, and frequently poorly controlled by standard painkillers. Estimates vary, but a substantial proportion of people with spinal cord injury live with chronic neuropathic pain, and for many it affects daily life more than the paralysis does.

It is also a poor fit for the way disability is usually depicted. A wheelchair is legible in a photograph. Constant nerve pain is not.

What the fundraiser is for

Katie launched a fundraiser to buy her father a specially powered wheelchair. The goal is specific and unglamorous: so that he does not have to be pushed by another person, and can leave the house on his own.

That single change — self-propulsion — is one of the largest determinants of quality of life after a spinal injury, and it is routinely underestimated by people who have not experienced the alternative. Needing someone else present in order to go outside does not just restrict where you go. It restricts when you go, how long you stay, and whether you go at all on a day when asking feels like too much.

Katie is now preparing for what she calls the biggest challenge of her life: multiple triathlons, under a social media campaign called Every mile for Ian. She is seeking business sponsorship and hoping to organise a fundraising day with local companies.

"We're hoping to have business sponsorships because I think it would be good for me to get the word out there," she said. "The aim is for my dad's story to be national and have businesses come together to work on a great cause."

The family says the response so far has caught them off guard. "My dad has been through a lot of emotion because we [were] blown away from the support we have had from strangers. It's just been crazy."

Katie's framing of why she is doing it is the sharpest line in the piece: "People who have been through something similar deserve freedom. People shouldn't be forced to live like that."

Reader Q&A

Why would someone need to fundraise for a wheelchair?

In the UK, NHS Wheelchair Services provide chairs, but provision varies significantly by area and the criteria for a powered chair — particularly one suited to independent outdoor use — are tighter than most people expect. Voucher schemes exist and can be topped up privately, but the gap between what is funded and what actually delivers independence is often several thousand pounds. Charitable grants and family fundraising fill that gap far more often than they should have to.

Is a Hangman's fracture always this serious?

No — and this is worth saying clearly. Most Hangman's fractures are neurologically intact and treated conservatively in a rigid collar or halo, with good outcomes. Ian Blyth's situation reflects an unusually difficult course, complicated by pre-existing degenerative disc disease. It is not the typical trajectory.

Can nerve damage improve over time?

Some recovery is possible in the first year to eighteen months, particularly where the injury was incomplete, as swelling settles and surviving pathways reorganise. Beyond that, spontaneous recovery becomes much less likely with current treatment. Rehabilitation after that point focuses on function, pain management and equipment rather than reversal — which is precisely why the regenerative research covered elsewhere on this site matters so much.

What helps with neuropathic pain?

First-line drug options are typically gabapentinoids such as pregabalin or gabapentin, and certain antidepressants including duloxetine or amitriptyline, which act on pain pathways rather than mood. Beyond medication, there is reasonable evidence for pain management programmes, and emerging work on neuromodulation. Realistically, most people end up with partial relief from a combination rather than a solution from any one thing, and it is worth asking for referral to a specialist pain service if that has not happened.

On 14 July, the US government formally accepted a building from its contractor. That sounds like paperwork, and it is — but for around 850 veterans with spinal cord injuries across Southern California, Arizona and Nevada, it is the end of a wait that has run considerably longer than anyone intended.

The new VA Spinal Cord Injury and Disorders Hospital and Community Living Center sits beside the main hospital at the Jennifer Moreno VA Medical Center in San Diego. It cost $205 million, covers almost 200,000 square feet, and took five years to build.

It was originally projected to open in autumn 2024.

What took so long

The construction contract was awarded in 2021 and overseen by the US Army Corps of Engineers. A March 2023 press release put the opening in autumn 2024. By August 2025 that had slipped to "later" that year. It is now July 2026, and the VA says the goal is to start accepting patients early in 2027.

VA San Diego spokesperson David Haas attributed the delays to "infrastructure and technical issues" found during construction and inspection. "To ensure the facility met operational and safety requirements, VA needed to address infrastructure and technical issues that were identified during the construction and inspection processes," he said.

Roughly a three-year overrun on a specialist hospital is not unusual by the standards of large healthcare construction. It is still three years.

Why a dedicated SCI centre matters

The existing San Diego centre is one of 25 SCI centres run by the VA across the United States. That network is genuinely unusual — no other health system in the world runs a comparable number of dedicated, lifelong spinal cord injury services under one roof.

Louis Irvin, executive director of the San Diego chapter of Paralyzed Veterans of America (PVA), said the local need for a new building was recognised around sixteen years ago. What the new hospital provides is 50 patient beds, twenty of them designated for long-term care.

That long-term care figure is the important one. "There's a massive need for long-term care for spinal cord injuries," Irvin said. Most acute rehabilitation systems are built around a defined stay and a discharge. Ageing with a spinal cord injury — secondary complications, pressure injuries, respiratory problems, shoulders that have done fifty years of work they were not designed for — needs something different, and there is far less of it.

Richard Johnson has used a wheelchair for sixty years. He cofounded the San Diego PVA chapter and later served as president of the national organisation, and he was part of the group that campaigned for the *current* centre more than forty years ago.

His argument for the VA is not about buildings. "The keyword that I want to use is 'continuity,'" he said. "Continuity of care, which I've had since 1965. There's no place else I can go and show up and they know me and they know about me. It's critical — it's life saving."

The design details that actually matter

All 50 beds are in private rooms. The twenty long-term care beds are arranged in what PVA describes as a "homelike environment" — private, but with places to be around other people, which is a harder balance to strike than it sounds.

The one PVA singled out as most needed is the outdoor recreation space. The existing centre's outdoor area has been closed for construction.

"There's not a lot of places for veterans with spinal cord injuries to go to get outside and congregate and speak to one another," said Jesse Robinson, president of the San Diego PVA chapter. "That's been very difficult."

That is not a small complaint. For someone in the first year after injury, informal contact with people further down the same road is one of the more powerful things available, and it mostly happens in corridors, day rooms and outdoor spaces rather than in scheduled sessions.

Robinson put the point plainly: "All of us are sitting here, you know, to help the people that come behind us. We've already been through this, but we're here to promote and encourage and shift and change and educate and advocate for the guy that shows up tomorrow."

PVA is now working with the VA on final design elements, equipment and furnishings.

Reader Q&A

Is this actually open?

Not yet. The building has been handed over from the contractor to the VA, which is a real milestone but not the same as admitting patients. Fit-out, equipment installation and commissioning still have to happen. The stated target is early 2027.

Does this affect anyone outside the US?

Not directly. But it is a useful reference point. The VA's 25-centre SCI network, with dedicated long-term care beds, is far more extensive than what most national health systems provide, and campaigners elsewhere routinely cite it when arguing for lifelong specialist follow-up rather than discharge-and-hope.

Why do spinal cord injuries need a specialist centre at all?

Because the complications are specific and the general hospital system handles them badly. Autonomic dysreflexia, pressure injuries, neurogenic bladder and bowel, respiratory management in higher injuries — all of these are routine to an SCI unit and frequently missed elsewhere. Staff who see SCI every day catch things early. Staff who see it twice a year do not.

Fifty beds for 850 veterans — is that enough?

It is more than the current facility offers and it adds twenty long-term care beds that did not previously exist in that configuration. Whether it is enough depends on how much of the 850's care is outpatient, which most of it is. The long-term care capacity is the constraint worth watching.

Nicholette Peoples was driving to work on two hours' sleep, days before her junior year of high school, when her car slid on wet grass and hit a tree.

She broke her back, fractured every rib, punctured a lung and broke her collarbone. She was airlifted to a hospital in Philadelphia. The surgeons saved her life and told her she might never walk again. The injury was at T4 — roughly nipple level, meaning paralysis from the chest down with full arm and hand function.

The part she says she could not accept was losing the outdoors.

"I just couldn't accept giving that part of me up — so I didn't," she told *People*.

Getting the chair

Peoples started researching adaptive equipment and found what she needed: a mountain wheelchair, sometimes called a mountain trike — an off-road chair with rugged wheels, hand-lever drive and, on many models, an electric assist for climbs.

She could not afford it. These are specialist machines and they are priced accordingly.

Her community bought it for her, in memory of Carissa Dartt — a woman who had also sustained a spinal cord injury and who died following her own accident.

"Her family giving me my mountain trike gave me an opportunity that opened up the world to me in ways I can never repay Carissa and her family for," Peoples says. "I always keep that close to my heart when hiking."

What followed was not a montage. "There were so many trial and errors, failures, tears and one search-and-rescue call, but we just never stopped trying," she says. Some hikes worked. Some did not.

She and her boyfriend of seven years, Brian Morgantini, eventually built a camper van so they could spend longer periods in national parks.

Bryce Canyon

In March they went to Bryce Canyon in Utah.

The preparation was serious: hours with maps, videos and park rangers, looking for a route that a mountain wheelchair could plausibly manage. The park's famous trails were far too steep. They found a lesser-known approach starting from the town of Tropic that reached Queens Garden by a gentler line.

They could not find a single record of anyone doing it in a chair like hers.

"Nature can't always be accessible, so I knew I was attempting an inaccessible hike," she says.

The first obstacle arrived before the trail did. The entrance gate they had been told would be open was locked, so she had to get herself over a set of steps just to start.

"Right away it showed this isn't for wheelchair users," she says. "It was discouraging, but it also made us both want to complete this to show wheelchair users are out here hiking too and our access matters."

About a mile in, the electric assist failed. Every incline from that point was arms only.

Then came four steep dry creek crossings, and then a slot canyon barely wider than the chair.

"To get into the narrow area I had to be on the edge of a steep drop with only an inch to spare," she says. "We weren't even sure I'd fit, and we knew we couldn't turn around easily. In this moment I questioned if it would be possible. I didn't fit, so we backed up a bit, Brian carried me through and then my chair, and we got past it."

They reached the Queens Garden arch after more than two miles and four major obstacles.

What she actually says about it

Peoples and Morgantini posted the footage. It reached roughly 20 million views.

What is notable is what they choose to post. They document the ordinary days and the failed attempts as well as the summit shots — deliberately.

"We hope by sharing the failures and the success[es] that people get a realistic look at overcoming disability to live an exceptional life," she says.

There is a version of this story that flattens into inspiration content, and that version is not much use to anyone. The more useful reading is in the details: the gate was locked, the assist failed, the chair did not fit, and she needed a strong partner and a $10,000-class piece of equipment that somebody else paid for. Those are access problems, not attitude problems. Each one is fixable by someone other than Nicholette Peoples.

What she offers as advice is deliberately modest. "Once I stopped focusing on the things I couldn't do and just tried my best with what I could do, my entire world opened up."

And: "It's still hiking even if you're using a wheelchair."

Reader Q&A

What is a mountain wheelchair?

An off-road chair built for rough terrain — typically three wheels, mountain-bike tyres, hydraulic disc brakes and hand levers rather than pushrims, because levers give better mechanical advantage on climbs. Many models offer an optional electric assist. Brands include Mountain Trike and GRIT Freedom Chair among others.

How much do they cost?

Broadly in the £3,000–£10,000 range depending on model and whether electric assist is included. They are rarely funded by health services, since they are classified as recreational rather than medical equipment. Charitable grants and community fundraising are the usual routes — which is exactly how Peoples got hers.

Could someone with a higher injury do this?

It depends heavily on hand and triceps function. Peoples' T4 injury leaves her arms fully intact, which is what makes lever-driven off-road propulsion possible. For cervical injuries with limited hand function, powered off-road chairs and all-terrain track chairs are the more realistic route — heavier and less nimble, but they exist, and a number of US and UK parks now loan them free of charge.

Where can I find accessible trails?

In the US, AllTrails has a wheelchair-accessible filter and many national parks publish accessibility guides; several loan all-terrain chairs on site. In the UK and Ireland, Countryside Mobility, the Miles Without Stiles network in the Lake District, and Coillte's accessible trail listings are good starting points. The honest caveat is that trail grading is inconsistent and, as Peoples found, a gate marked open is not necessarily open.

For over a century, the accepted story of how the nervous system talks to the immune system has had one main character: the brain. The spinal cord was cast as the cable — carrying signals up and instructions down, but not doing much thinking of its own.

Phillip Popovich thinks that story is missing a chapter.

Popovich is professor and chair of neuroscience at Ohio State, and executive director of the Wexner Medical Center's Belford Center for Spinal Cord Injury. His lab has just been awarded $1.2 million by the W.M. Keck Foundation to test a genuinely unorthodox idea: that the spinal cord has its own pathway for detecting infection and signalling the immune system, entirely bypassing the brain.

"Our research suggests the spinal cord isn't just a cable carrying messages up to the brain and back," Popovich said. "It may have its own pathway for detecting infection and signaling the immune system without involving the brain."

Why this matters if you have a spinal cord injury

This is where the story gets closer to home, because Popovich's lab is not new to this territory. His group's earlier work established something that many people living with spinal cord injury already know from experience: after injury, the immune system does not work properly.

The condition has a name — spinal cord injury-induced immune deficiency syndrome. It describes a lasting weakening of immune function following injury, and it is part of why infections are such a persistent and serious problem after spinal cord injury. Urinary tract infections, chest infections, wounds that are slow to resolve: these are not simply the result of catheters, reduced mobility, or bad luck. The immune system itself has been changed.

That earlier work established that the spinal cord is *required* for a healthy immune system. What it never explained was how.

"That circuitry has been a black box," Popovich said. "This project is our attempt to finally open it, by studying the healthy spinal-immune connection instead of the injured one. We spent decades documenting what happens when this system is broken. Now we're pivoting to map how it works when it's healthy, using the same spinal cord expertise but pointed at a completely new question."

The cells at the centre of it

The team has already identified a previously unknown group of spinal cord cells they have named immune synergy encoding (ISE) neurons. These cells become active when inflammation occurs somewhere in the body — which is a strange thing for a spinal neuron to do, and precisely why they are interesting. If neurons in the cord are responding to an immune event elsewhere in the body, something is sensing it and something is relaying it.

The project runs in three stages:

1. Map it. Build a detailed map of which spinal cord nerve cells respond to infection or inflammation, and where they send their signals. The team uses genetically engineered mice that permanently tag a neuron the moment it responds to an immune challenge — a kind of biological timestamp. "We can go back later, and map exactly which cells lit up and where they connect," Popovich explained. 2. Model it. Feed that map into an AI-powered computational model to predict which neurons are doing the heaviest lifting. 3. Test it. Switch those specific neurons on and off in mice, and see whether the immune response and behaviour actually change. This is the step that separates correlation from cause.

Alongside Popovich, the team includes Qin Ma (bioinformatics and computational biology), Eugene Oltz (microbial infection and immunity), and Andrea Tedeschi (neuroscience) — a deliberate mix of spinal cord, immunology and computational expertise.

Being honest about the timeline

This is a grant announcement, not a result. Nothing has been proven yet, the work will be done in mice, and even if the hypothesis holds up completely, translating it into something that helps a person manage infections after spinal cord injury is a long road.

But it is worth noting what kind of research this is. Grants for genuinely unorthodox ideas — ones that challenge a century-old assumption — are hard to get. The Keck Foundation specifically funds high-risk, high-reward science that conventional funders tend to pass over. That a spinal cord injury lab won one, to study the healthy spinal-immune connection, is a reasonable signal that the preliminary data is interesting.

And the strategic logic is sound. If you want to understand why the immune system fails after spinal cord injury, understanding how it is supposed to work first is not a detour. It is the shortest route.

Reader Q&A

Could this lead to something that helps with infections after spinal cord injury?

Potentially, but it is early. If the team can identify the specific neurons and pathways that direct immune responses, that opens the door to targeting them. Whether that becomes a treatment — and how long it takes — is genuinely unknown at this stage.

Is the immune deficiency after spinal cord injury actually a real, documented thing?

Yes. Spinal cord injury-induced immune deficiency syndrome is an established finding, described in part by this same research group. It is one reason infection rates after spinal cord injury are high, alongside the more obvious mechanical factors like catheter use and reduced mobility.

This is mouse research. How much should I read into it?

Take the mechanism seriously and the timeline cautiously. Mapping neural circuits and switching individual neurons on and off is work that currently can only be done in animals. The immune-nervous system link is broadly conserved between mice and humans, so the findings should be informative — but "informative" is not the same as "applies directly."

When will we know anything?

Projects on this scale typically report first findings over two to four years. We will follow it.

BMI is a blunt instrument at the best of times. After a spinal cord injury, it gets blunter.

The reason is straightforward. BMI is just weight divided by height squared — it has no idea what that weight is made of. After spinal cord injury, body composition changes substantially and fairly quickly: muscle mass below the level of injury declines, fat accumulates, and fat tends to infiltrate the muscle that remains. Two people can weigh exactly the same and be in very different metabolic situations. Someone with a spinal cord injury can therefore have a "normal" BMI on paper while carrying enough fat, and little enough muscle, to be at real cardiometabolic risk.

That is why researchers proposed a spinal-cord-injury-specific obesity threshold some years ago: a BMI above 22 rather than the general-population 30. The logic is that the lower bar catches people the standard bar misses.

A study published in the *Archives of Physical Medicine and Rehabilitation* set out to check whether that lower threshold actually earns its keep.

What they did

This was a multicentre cross-sectional study — meaning data collected across several sites at a single point in time, rather than following people over years. The sample was substantial: 1,523 adults with traumatic spinal cord injury, 78.7% men, mean age 45.7, and 56.7% with tetraplegia.

The researchers ran the same analysis twice, once using each obesity threshold, and looked at how well each one lined up with three groups of self-reported outcomes:

- Cardiometabolic: diabetes, high blood pressure, high cholesterol - Physical: arthritis, pressure injuries, urinary tract infections, falls, rehospitalisations - Psychosocial: measures of psychological and social wellbeing

The question was simple: which cut-off better discriminates between people who do and don't have these problems?

What they found

Both thresholds were associated with cardiometabolic risk. Whether you used BMI over 22 or BMI over 30, higher body mass tracked with diabetes, hypertension and abnormal lipids. This isn't surprising, but it's a useful confirmation: the relationship between excess weight and metabolic disease holds in the spinal cord injury population, and it shows up even at BMI levels that would be considered unremarkable in the general population.

Neither threshold was significantly associated with psychosocial outcomes. This is arguably the more interesting result. There is a tendency — in healthcare generally and in disability care specifically — to assume weight and mood travel together. In this large sample, once you looked at psychological and social wellbeing, the association wasn't there. Weight was a cardiometabolic issue, not a psychosocial one.

Why "neurogenic obesity" is a different problem

It is worth naming the mechanism, because it changes how the finding should be read.

The weight gain that commonly follows spinal cord injury has a specific name: neurogenic obesity. Several things drive it at once. Muscle below the injury level cannot be voluntarily used, so it shrinks and burns far fewer calories at rest. Autonomic function — the automatic control of things like heart rate and blood vessel tone — is often disrupted, which affects how the body handles energy. Activity levels drop. And appetite does not automatically recalibrate downward to match a lower energy requirement.

The result is a mismatch between energy in and energy out that is largely structural rather than behavioural. That distinction matters, because "just eat less and move more" is advice that ignores the fact that the machinery for both has changed.

What to do with this

The practical implication is not dramatic, but it is real: if you have a spinal cord injury and your BMI is somewhere between 22 and 30, the standard chart says you are fine and this line of research says you might not be. That is a reasonable prompt to ask your GP or SCI clinic about actual cardiometabolic markers — fasting glucose or HbA1c, a lipid panel, blood pressure — rather than relying on a number that was never designed for your body.

It is also worth saying what the study does not support: using BMI as a proxy for how someone is doing psychologically. It didn't hold up.

Reader Q&A

Should I be worried if my BMI is 25?

Worried isn't the useful response; curious is. A BMI of 25 sits in the range this research suggests may carry cardiometabolic risk after spinal cord injury even though standard charts call it merely "overweight". The sensible step is asking for the actual blood markers rather than guessing from BMI. Those tests are routine and cheap.

Does this mean I should try to lose weight?

That's a conversation for you and your clinician, not something a cross-sectional study can answer. This study shows an association between higher BMI and cardiometabolic conditions — it did not test whether losing weight improves those conditions in people with spinal cord injury. Those are different questions.

Why does the study rely on self-reported conditions?

Because collecting verified clinical data on 1,523 people across multiple sites is enormously expensive. Self-report is the practical trade-off, and it's a genuine limitation: people misremember diagnoses, and some conditions go undiagnosed entirely. It means the associations should be read as solid in direction but imprecise in size.

What's the biggest weakness here?

It's cross-sectional — a snapshot. It cannot tell you whether obesity caused the cardiometabolic problems, whether the cardiometabolic problems and their treatment contributed to weight gain, or whether something else drives both. Association is not causation, and a single point in time cannot untangle the sequence.

Sexual function is among the most personal consequences of spinal cord injury, and among the least talked about. Yet when people with SCI are asked what aspects of their condition most affect quality of life, sexual function regularly appears alongside bowel and bladder — often ranked higher than walking.

A review published in the *Journal of Spinal Cord Medicine* by clinicians at Thomas Jefferson University in Philadelphia pulls together what SCI medicine has learned about the physiology of sexual arousal — and what those insights mean practically for people living with spinal cord injury. It covers both men and women, blends historical observations with modern neuroscience, and makes a nuanced case that understanding *how* arousal works — not just *whether* it works — determines which approaches are likely to help.

Two pathways to arousal

The first thing to understand is that sexual arousal is not a single pathway. There are two distinct routes from stimulus to genital response.

The first is psychogenic arousal: the brain processes a sexual thought, image, or emotion and sends signals downward through the spinal cord to the genitals. This pathway requires intact descending connections from brain to the lower cord — specifically through the T11–L2 spinal levels (the thoracic–lumbar junction in the lower back). If SCI damages or disrupts those pathways, psychogenic arousal is impaired or lost.

The second is reflexogenic arousal: direct physical touch to the genitals triggers a local reflex arc in the sacral spinal cord (at the S2–S4 level, near the base of the spine), which drives genital response without any input from the brain. This pathway can survive a spinal cord injury above the sacral level — it's self-contained in the cord below.

People with complete SCI above the lower thoracic level — where neither motor signals nor sensation reliably cross the injury — have confirmed reflexogenic arousal in response to local touch, even with no conscious sensation and no psychogenic pathway available. This was first systematically demonstrated in the 1960s by interviewing men with SCI, and later confirmed in a lab study of women with complete injuries conducted by Sipski and colleagues. The finding was important: it proved that a reflex pathway for genital response exists within the spinal cord, independent of the brain. In people with incomplete injuries, both pathways may partially survive, with a more variable picture.

What type of injury matters — a lot

The distinction between upper motor neuron (UMN) and lower motor neuron (LMN) injury is one of the most clinically important in SCI medicine, and it directly affects sexual function.

In simple terms: UMN injuries are those where damage occurs above the sacral segments of the cord (i.e. most SCI above the lower back). The sacral reflex arcs — the local circuits that control reflexive erection and the anal/bladder sphincters — are physically intact below the injury, even if disconnected from the brain. In UMN injury, reflexogenic arousal is typically preserved: touch to the genitals still works through the local reflex.

LMN injuries involve damage at or below the sacral cord itself, or to the nerve roots that emerge there. In this case, the local reflex circuits are damaged directly. Reflexogenic arousal is impaired or absent.

This distinction predicts which treatments are likely to work. PDE5 inhibitors — the drug class that includes sildenafil (Viagra), tadalafil (Cialis), and others — work by amplifying the body's own arousal chemistry: they block the enzyme (PDE5) that breaks down a signalling molecule (cGMP) involved in smooth muscle relaxation and genital blood flow. If the local reflex arc is intact (UMN injury), the body is still generating cGMP in response to touch, and the drug extends its effect. Studies in men with complete UMN SCI have confirmed sildenafil works for many of them. A study in women suggested a positive trend but didn't reach statistical significance.

In LMN injury, however, the reflex arc is damaged and the body isn't generating that initial arousal signal — so PDE5 inhibitors have much less to work with. Injectable medications that directly stimulate the relevant chemistry (such as alprostadil, a synthetic prostaglandin) may be more effective, but the underlying response is still impaired. This is why knowing injury type — specifically, whether the sacral reflex arc is intact — matters before reaching for medication.

The bulbocavernosus reflex: the clinical test that matters

The bulbocavernosus reflex (BCR) is a brief clinical examination — a gentle squeeze or tap on the glans of the penis or clitoris — that tests whether the sacral reflex arc (S2–S4) is intact. A positive BCR (contraction of the anal sphincter or bulbocavernosus muscle in response to the stimulus) indicates the arc is functional. An absent BCR suggests LMN damage.

Clinically, the BCR is used to assess bowel, bladder, and sexual function potential after SCI. The review notes it's also one of the first reflexes to return after the period of "spinal shock" (the temporary suppression of all reflex activity immediately after SCI). An intact BCR is specifically associated with preserved reflexogenic erection in men with SCI. It's also functionally involved in the arousal response itself — the muscles it tests (the bulbocavernosus and ischiocavernosus) play an active role in maintaining erection by blocking blood drainage and, at higher levels of arousal, pressurising the erectile tissue.

Recurrent erection: when reflex becomes a problem

The preservation of reflexogenic arousal can also create problems. In people with chronic SCI and intact sacral reflex arcs, reflex erections can occur involuntarily and repeatedly — triggered by routine stimuli (clothing, catheter use, positioning). This is termed recurrent priapism (priapism meaning a sustained erection that isn't related to sexual desire and doesn't resolve quickly).

The review covers treatment options, which include baclofen (the first-line spasticity drug, which also reduces reflex activity in the sexual circuits), low-dose PDE5 inhibitors taken regularly (counterintuitively, these can settle the reflex cycle when used continuously rather than on-demand), and other agents that increase smooth muscle tone. The risk of certain hormonal treatments is noted — they increase the risk of blood clots, already a concern in SCI.

What about pelvic floor exercise?

The ischiocavernosus and bulbocavernosus muscles — the same ones tested by the BCR — play an active role in pressurising the erectile tissue and maintaining rigidity. In men without SCI, pelvic floor muscle (PFM) training has been shown in randomised controlled trials to improve erectile dysfunction to a degree comparable to medication. A systematic review in women showed similar benefit for sexual function in those with pelvic floor dysfunction.

The review raises this in the SCI context as a potential avenue — for those with sufficient voluntary pelvic floor control — that has been underexplored.

Women and SCI: the less-understood picture

The physiology of sexual arousal in women follows similar principles — parallel mechanisms for clitoral response — but the full picture is less well understood, and the research literature is considerably smaller. Women with complete SCI above the lower thoracic level have confirmed reflexogenic clitoral response to local stimulation, established in Sipski's lab studies. Psychogenic arousal is similarly impaired when the T11–L2 pathways are disrupted.

Beyond clitoral response, women's arousal involves labial engorgement, vaginal lubrication, and vaginal wall changes. Whether these follow the same hydraulic mechanisms as penile erection (increased blood flow, pooling, obstruction of outflow) remains incompletely understood. The review notes this as a significant gap in the research.

Reader Q&A

If I have a complete injury, does that mean sexual function is gone?

Not necessarily — and this is one of the most important practical messages in the paper. "Complete" injury (AIS A — no voluntary motor or sensory function below the injury level) doesn't mean all function below that level is gone. The sacral reflex arcs can remain intact even in a complete injury above that level. Many people with complete cervical or thoracic SCI retain reflexogenic arousal. What's typically lost or impaired is the psychogenic route — arousal in response to mental stimulation, without physical touch.

How do I know if PDE5 inhibitors (like Viagra or Cialis) might work for me?

The best predictor is whether your sacral reflex arc is intact — which can be assessed by the BCR test during a clinical exam. If the BCR is present (indicating UMN-type injury with preserved sacral reflexes), PDE5 inhibitors have a reasonable basis for working. If the BCR is absent (LMN-type injury), the reflex pathway is damaged and PDE5 inhibitors are likely to have limited effect. A conversation with a spinal cord medicine specialist or urologist familiar with SCI is the right starting point.

What's the difference between a UMN and LMN injury in simple terms?

Think of the spinal cord as a relay system. UMN injury means damage to the "cable" running from the brain down — but the local relay stations (the sacral reflexes at the base of the cord) are still intact and can operate on their own. LMN injury means the local relay station itself is damaged. UMN injury generally preserves reflexes below the injury level. LMN injury abolishes them.

Can pelvic floor exercises help after SCI?

For people with sufficient voluntary pelvic floor muscle control — more likely with incomplete or lower-level injuries — the evidence from non-SCI populations suggests it's worth exploring. The muscles involved (bulbocavernosus and ischiocavernosus) have a direct mechanical role in the arousal response. A physiotherapist with expertise in neurological or pelvic floor rehabilitation is the right point of referral.

Most spinal cord injuries have an obvious cause. A car, a fall, a rugby tackle. Sydney Fowler's did not.

She was 13. She was an athlete. And then she wasn't — and for a while, nobody could tell her why.

Speaking to *People*, Fowler described the period as a "medical mystery". The eventual answer was a staph infection that had reached her spine. Staphylococcus is an extremely common bacterium — most of us carry it harmlessly on our skin — but when it establishes itself in or around the spinal column, it can form an abscess that presses on the cord. Pressure on the cord starves it of blood supply, and nerve tissue does not tolerate that for long.

Fowler underwent two emergency spinal surgeries to clear the infection and decompress the cord. But by then the damage was done: significant injury at the T4/T5 level, leaving her paralysed from the lower chest down.

The gap between "not dying" and "living"

There is a stretch after an injury like this where the medical system has done its job — the infection is cleared, the surgery worked, you are alive — and yet almost nothing about your actual life has been addressed. You are 13. You were an athlete. Now you use a wheelchair and nobody has told you what your Saturday mornings look like from here.

Fowler has been open about what carried her through that stretch, and it isn't a treatment or a device. It was her community. The people who kept showing up.

This is not sentimentality. It is one of the more robust findings in rehabilitation research: social support is among the strongest predictors of how people do after a spinal cord injury, independent of the injury itself. Two people with identical injuries and identical medical care can have very different lives depending on who stayed.

Where sport came back in

What Fowler eventually found was adaptive sport, and she did not find it modestly.

She joined Clemson University's wheelchair tennis team in 2023 — one of a small number of US collegiate programmes offering wheelchair tennis at that level. She took up adaptive water skiing. And she has competed at the CrossFit Games, placing fourth in the world in the adaptive division.

It is worth pausing on what that list actually represents. Wheelchair tennis is one of the most physically brutal sports there is — you are propelling a chair, changing direction, and hitting a ball, all with the same set of arms, at a level where the ball is coming at you fast. Adaptive CrossFit at world level is not a participation exercise. And water skiing requires a degree of trust in your own body and equipment that most people never test.

Seven years after being told she would never walk again, Fowler is not doing a scaled-down version of her old athletic life. She is doing a different one, at a comparable intensity.

Why these stories are worth reading, and how to read them

There is a version of this story that would be irritating: the inspirational disabled athlete, presented as proof that attitude conquers everything. That framing is unhelpful — it quietly implies that people who *aren't* competing at the CrossFit Games have simply not tried hard enough.

So let's be clear about what is actually useful here. Fowler had access to two emergency surgeries, a university with a wheelchair tennis programme, adaptive sport infrastructure, and a community that stayed. Those are not distributed evenly. Her story is a demonstration of what is possible when access exists — which makes it an argument for building that access, not for individual willpower.

What is genuinely transferable is narrower and more practical: adaptive sport exists, it is more developed than most newly injured people realise, and finding it changes things. Not everyone will place fourth in the world. Almost everyone benefits from finding the thing.

Reader Q&A

Can a staph infection really cause paralysis?

Yes, though it is uncommon. A spinal epidural abscess — a pocket of infection in the space around the spinal cord — can compress the cord and cause permanent damage. It is treatable if caught early, which is why unexplained severe back pain with fever is taken seriously in emergency medicine. Fowler's case is a reminder of why the delay in diagnosis mattered so much.

What does a T4/T5 injury mean?

T4 and T5 are vertebrae in the upper-to-mid back, roughly at nipple level. An injury at that level typically means paralysis of the legs and some trunk muscles, with full arm and hand function preserved. It is the level of injury most compatible with wheelchair sport, which is part of why Fowler could do what she has done.

How would someone get into adaptive sport?

In the UK and Ireland, spinal injury units and organisations like WheelPower and the Irish Wheelchair Association run introductory sessions. In the US, national bodies including Move United and Adaptive Sports USA maintain directories of local programmes. Many collegiate and community programmes actively want beginners — the biggest barrier is usually not knowing they exist.

Is it realistic to expect this kind of outcome?

Honestly, no — not this specific outcome. Fowler is an elite athlete who was an elite athlete before her injury, and she had unusually good access to programmes and support. What is realistic for most people is finding *some* form of sport or physical activity that they want to keep doing, which is a genuinely valuable thing and a much lower bar.

If you wanted to build a replacement part for an injured spinal cord, you might reasonably assume that what matters is the finished part. Get a nerve cell that looks right, behaves right, and expresses the right markers, and job done.

A study published in *Nature Communications* suggests it is not that simple. The finished cell carries a memory of how it was made — and that memory changes what it can do.

What are V2a neurons, and why do they matter?

V2a interneurons are one of the more hopeful characters in spinal cord injury research. They are excitatory "middle-men" neurons: they don't run the whole length of the cord like the long descending fibres damaged in injury, and they don't connect directly to muscle. Instead they sit inside the cord and relay signals between other neurons.

That relay role is exactly why they are interesting. After an injury, surviving V2a neurons have been shown in animal studies to sprout new connections and help re-route signals around the damaged area — effectively building a detour. They also help drive rhythmic activities like breathing and stepping. Several research groups are therefore exploring V2a neurons as a candidate for cell therapy: grow them in a dish from stem cells, transplant them into the injured cord, and give the nervous system extra relay stations to work with.

To do that, you have to be able to manufacture them reliably. That is where this study comes in.

Two roads to the same destination

Here is the wrinkle the researchers, working across UC San Francisco and the Gladstone Institutes, set out to investigate. In a developing embryo, V2a neurons don't come from one single place. They arise at different levels along the head-to-tail axis, from different pools of progenitor cells. So the "same" cell type actually has more than one origin story.

The team took human pluripotent stem cells — the versatile cells capable of becoming almost anything — and pushed them down two different developmental routes:

- The NEP route (neuroepithelial progenitors), which produces cells with a *hindbrain* identity — the region at the base of the brain. - The NMP route (neuromesodermal progenitors), which produces cells with a *cervical spinal cord* identity — the neck region of the cord.

From day five onwards, both batches got identical treatment: the same media, the same growth factors, the same signalling molecules, for two full weeks. If the finished cell is all that matters, the two batches should have ended up essentially the same.

They did not.

What the cells remembered

The team used single-nucleus multiomics — a technique that reads, in individual cells, both which genes are switched on and which stretches of DNA are physically open and available to be read. Think of it as checking not just what a library is currently lending out, but which shelves are even accessible.

Two weeks of identical treatment did not erase the difference. The two populations had:

- Different open regions of DNA, with dozens of distinct transcription factor binding sites enriched in each. Cells from the spinal-identity route were dominated by homeodomain and retinoid-related factors; cells from the hindbrain route leaned toward bHLH and EBF-family factors. - 742 genes expressed at different levels, including ion channels, axon guidance molecules, and transcription factors. - The same jobs done with different tools. This is the elegant part: 22 biological processes were enriched in *both* populations, but driven by mutually exclusive sets of genes. Both groups were building axons — they were just using different genetic toolkits to do it.

The researchers also spotted functional differences. Using calcium imaging to watch electrical activity, the spinal-identity neurons fired more actively early on, at around day 23, though this difference evened out by day 34.

Finally, they identified two specific regulators — CREB5 and TCF7L2 — that appear to be responsible for maintaining the spinal-cord-specific identity.

The shortcut that didn't work

There is a second, more pointed finding here. There is a popular fast route to making neurons: rather than walking cells step by step through development, you force-feed them a couple of powerful transcription factors and let those factors override the cell's identity. It is quicker, cheaper, and more reproducible — which is why many labs use it.

The team tried it, using NGN2 and LHX3. Initially fewer than 1% of cells came out as genuine V2a neurons. Adding retinoic acid, a caudalising signal, got that up to roughly 40%. But when they compared the resulting cells against both developmentally-grown V2a neurons *and* real human tissue, the shortcut cells didn't match either. They were their own thing.

The authors' conclusion is blunt: if you want authentic cells, you have to follow the developmental steps.

What this actually means for spinal cord injury

Let's be clear about what this study is and isn't. Nobody was transplanted. No animal recovered function. This is bench work in dishes, aimed at the manufacturing question that sits *upstream* of any future therapy.

But that question matters. If cell therapy for spinal cord injury ever reaches the clinic, someone will have to decide exactly how the transplanted cells are made — and this work says that decision is not a technicality. Two batches of cells that pass the same quality checks may behave differently in a spinal cord, because they carry different genetic wiring for growing axons and handling calcium. It also implies that matching origin to destination may matter: cells with a cervical spinal identity might be the more sensible choice for transplanting into a cervical injury.

It is the kind of finding that doesn't make headlines but quietly saves years of confusing results down the line.

Reader Q&A

Is this a treatment I could get?

No, and not for a long time. This is laboratory research on how to grow cells properly. There is no trial attached to it, and no transplant was performed.

Have V2a neurons ever actually helped anyone with a spinal cord injury?

Not yet in humans. The excitement around V2a neurons comes from animal work, where transplanted or surviving V2a neurons have helped restore some function — particularly breathing — after injury. That is genuinely promising, but the jump from rodents to people is where most spinal cord therapies have stumbled.

So is the "shortcut" method for making neurons useless?

Not useless, but this study suggests it produces something different from a real V2a neuron. For basic research questions that may be fine. For making cells you intend to put into a human spinal cord, "different from real human tissue" is a meaningful concern.

What's the honest limitation here?

Everything in this study happened in cell culture. Cells behave differently in a living, injured spinal cord than in a dish, and the paper cannot tell us whether the two populations would actually perform differently after transplantation. It tells us they are *not the same*, which is a reason to test, not a proof of anything.

Almost all the attention in spinal cord injury research goes to the first few weeks. That is where the drama is: the surgery, the neuroprotection window, the stem cells, the question of whether anything can be salvaged.

But most people with SCI are not in that window. They are years or decades past it, and what shapes their life is not a regeneration trial — it is bladder management, bowel routine, pressure care, blood pressure, breathing, pain and spasticity. A review published in *Annals of Medicine* this summer turns the spotlight there, surveying how the multisystem complications of chronic SCI are managed with current evidence.

What chronic SCI actually involves

The review frames chronic SCI as a condition defined by persistent motor, sensory and autonomic deficits below the level of the lesion — with that word *autonomic* carrying more weight than most people outside the community realise.

The spinal cord is not just a cable for movement and sensation. It carries the wiring of the autonomic nervous system: the involuntary control of blood pressure, heart rate, breathing effort, gut motility, bladder function, temperature regulation and sweating. Cut or damage that cable and you disrupt all of it, in patterns that depend heavily on the level of injury.

The authors group the major long-term problems into systems:

- Respiratory — weakened breathing and cough, higher risk of chest infection, sleep-disordered breathing. A leading cause of hospital admission and death in cervical injuries. - Cardiovascular — autonomic dysreflexia, low resting blood pressure, and accelerated cardiovascular disease risk over decades. - Gastrointestinal — neurogenic bowel, which most surveys find people rank among the most life-limiting consequences of SCI. - Urinary — neurogenic bladder, recurrent infection, and long-term kidney risk. - Motor — spasticity, contracture, weakness, and the secondary musculoskeletal cost of years of transfers and wheelchair propulsion.

The review's blunt observation is that these complications drive rehospitalisation rates and impose substantial economic burden on health systems — in other words, they are not a footnote to the injury, they *are* the long-term condition.

Where treatment has got to

The review is honest on the headline point: no curative therapy exists. What has changed is that management has become what the authors call a comprehensive, multilayered framework — rehabilitation, pharmacological treatment, and a widening set of other approaches used in combination rather than in isolation.

That is a modest-sounding conclusion, and it is worth understanding why it matters anyway. Twenty or thirty years ago, complications after SCI were largely treated reactively, system by system, as they presented. The shift towards proactive, coordinated, multisystem management is a substantial part of why life expectancy and quality of life after SCI have improved without any breakthrough cure arriving.

A caveat on this write-up

This is a narrative review, not new research — it synthesises existing evidence rather than generating any. Reviews are useful for orientation and for clinicians deciding what current practice looks like, but nothing in it constitutes a new finding.

We were also unable to access the full text of the paper, so this summary is based on the abstract and the review's stated scope. The specific recommendations, the strength of evidence behind each, and any new treatment options the authors highlight are not captured here. If chronic complication management is your area, the paper itself is worth reading directly.

Reader Q&A

Is there anything actionable in this for me personally? Not directly — it is a clinician-facing overview rather than a self-management guide. Its useful function for a non-specialist reader is as a map: if you are trying to understand why your SCI team wants to monitor your kidneys, your blood pressure and your chest as well as your mobility, this is the reasoning.

"No curative therapy is currently available" — is that too pessimistic given all the trial news? It is accurate as of today, and the review is right to say it. There are genuinely promising things in trials — stem cell transplants, neuromodulation, regenerative approaches — and we cover them regularly. None of them is an approved treatment that restores function in chronic SCI. Both facts are true at once, and it does nobody any favours to blur them.

Why is the economic burden point in there? Because it is the argument that moves health systems. Preventing pressure injuries, urinary tract infections and chest infections is dramatically cheaper than treating them in hospital, and reviews like this exist partly to make the case for funding specialist SCI services rather than leaving complications to general medicine.

Which complication should I be most concerned about? It depends heavily on your level and completeness of injury, and it is a question for your SCI team rather than an article. Broadly, respiratory issues dominate risk in higher cervical injuries, while bladder, bowel and skin complications are the near-universal long-term concerns across levels.

We have covered the double neural bypass several times over the past few weeks — the system that helped Keith Thomas, paralysed from the neck down, feed himself, drink from a cup and feel touch in his wrist again. This week the story took a different kind of turn. It stopped being purely a research result and started becoming a business.

Neuvotion, Inc. — founded by Chad Bouton, who led that work during his time at the Feinstein Institutes for Medical Research — has announced it is commercialising the underlying technology. That is a meaningful step, because the gap between "it worked in a trial" and "you can actually get it" is where an enormous number of promising SCI technologies quietly die.

What the announcement actually says

Neuvotion describes itself as building a "Brain-Body Interface" platform. In plain terms, that means three things stacked together: wearable electrical stimulation of muscles, stimulation of the spinal cord, and a minimally invasive brain-computer interface that reads movement intent. The AI layer sits in the middle, working out what the user is trying to do and delivering stimulation to help them do it.

The company is explicit that the recently published *Nature Medicine* paper is the scientific foundation. In that study, over roughly three years of testing, Keith Thomas regained 86% arm strength on his right side and 62% on his left — and, importantly, those gains persisted for months after the stimulation was switched off. A technique the team calls "cortical mirroring" restored his ability to feel touch at the wrist, an area that had been numb since his injury. The decoder read his neural signals with over 84.6% accuracy, sustained for five months without needing retraining. He could pick up an empty eggshell without crushing it 87% of the time.

The important detail: the first product isn't the implant

This is the part worth reading carefully, because headlines about "commercialising brain-computer interfaces" invite an assumption that is not correct here.

The first product Neuvotion is bringing to market is NeuStim, and it does not involve brain surgery at all. It is a non-invasive device that delivers high-resolution electrical stimulation to muscles through the skin, guided by AI. It is already FDA-cleared, and the company says it will launch this autumn for people recovering from stroke and spinal cord injury.

The clever bit is practical rather than futuristic. Conventional functional electrical stimulation requires a clinician to physically peel electrodes off and reposition them to find the right muscle target — fiddly, slow, and a real constraint on how much therapy you can fit into a session. NeuStim uses a high-density electrode array and a touchscreen, so the stimulation point is moved *electronically* in a matter of minutes. The AI component is meant to infer what movement the user is attempting and assist with it.

So: the near-term offering is a smarter, faster, intention-aware version of an existing rehab tool. The implanted brain-computer interface remains further down the road.

Why this matters more than another press release

There is a well-worn pattern in SCI research where a spectacular single-participant result gets global coverage, and then nothing reaches anybody. Commercialisation announcements are not glamorous, but they are the mechanism by which a lab result becomes something a rehab centre can actually buy and use.

Neuvotion says it is working with rehabilitation centres to expand clinical adoption. That is the honest measure to watch: not the press release, but whether units appear in clinics, whether they get used, and whether outcomes in ordinary rehab settings look anything like the trial.

It is also worth flagging that this is a company announcement, not independent verification. Neuvotion has a commercial interest in framing the *Nature Medicine* results as the foundation of a product line. The study itself is peer-reviewed and genuinely impressive; the leap from that study to "NeuStim will help you" is a leap the company is making, not one the paper made.

Reader Q&A

Can I get any of this now? Not yet. NeuStim is FDA-cleared and slated to launch this autumn in the US, initially through rehabilitation centres rather than direct to individuals. There is no announced timeline or pricing for a UK or European launch, and the implanted brain-computer interface part of the platform is not a commercial product.

Is NeuStim the same thing that helped Keith Thomas? No — and this is the key distinction. Keith Thomas had brain implants combined with stimulation of the spinal cord, skin and brain. NeuStim is the non-invasive muscle-stimulation piece of that broader platform, sold on its own. It shares the AI guidance and the high-resolution electrode approach, but not the surgery, and it should not be expected to produce the same results.

Does the "lasting gains after the system is switched off" finding apply to NeuStim? That finding came from the full implanted system in one participant. Whether non-invasive stimulation alone can drive similar lasting neuroplastic change is an open question. The theory is plausible — repeated, intention-linked stimulation is the mechanism thought to drive the rewiring — but it has not been demonstrated for this product.

Is one participant enough to build a company on? It is enough to build a hypothesis on. Dr Bouton's group has been working on this for over two decades and this is the latest in a series of studies, so it is not a single isolated result. But n=1 for the headline outcome is genuinely small, and larger trials will be needed before anyone can say how generalisable those gains are.

What NPCs are supposed to do — and what they might actually be doing

Neural progenitor cell (NPC) transplantation is one of the most researched approaches in spinal cord injury therapy. The original logic is straightforward: SCI destroys neurons, oligodendrocytes, and astrocytes; transplanted NPCs can become all three; therefore, transplant NPCs and let them rebuild.

That logic is correct as far as it goes. But there's a growing body of evidence that transplanted cells aren't just builders — they're also broadcasters. They secrete cocktails of growth factors, cytokines, and other signalling molecules that alter the inflammatory and regenerative environment around them. This paracrine signalling — cell communication through secreted factors — may be doing at least as much therapeutic work as any direct cellular replacement.

If that's true, it matters enormously for therapy design. Two cell preparations that look identical under a microscope could have very different effects because of what they're secreting. And it means that the molecular identity of what a transplanted cell secretes — its "secretome" — becomes a critical parameter that needs to be characterised, not just assumed.

A new study from the Fehlings lab at the Krembil Research Institute, University of Toronto, published as a conference abstract in the McMaster University Medical Journal in July 2026, has started mapping this for oligodendrogenic NPC lines — pre-programmed cells designed to push the spinal cord toward myelin repair.

What oNPCs are and why they were created

Standard NPCs are versatile: under the right conditions, they can become neurons, astrocytes, or oligodendrocytes. In the injured spinal cord, that versatility becomes a problem — differentiation is inconsistent, and not enough cells become the types most needed. After SCI, one of the most damaging secondary processes is oligodendrocyte loss. Oligodendrocytes provide the myelin sheath around axons; when they die, axons lose their insulation and their ability to conduct signals reliably. Axons that aren't physically severed by the original injury often lose function because their myelin is stripped away.

To address this, the Fehlings lab created oligodendrogenic NPCs (oNPCs) — standard human NPCs reprogrammed toward an oligodendrocyte fate by introducing three specific transcription factors. These cells have already shown therapeutic potential in SCI models. What hasn't been clear is *how* they work. The new study begins to answer that by asking: are the different oNPC lines secreting different things into their environment?

What they measured

The team plated 600,000 cells per group — standard NPCs and three oNPC lines (oNPC-1, oNPC-2, and oNPC-3) — and collected the conditioned media after 24 hours. This conditioned media contains everything the cells secreted. It was sent to McGill University for analysis using the Olink Target 48 cytokine panel, a high-sensitivity proteomics platform that can detect low concentrations of cytokines and signalling proteins. Of 45 proteins on the panel, 14 were detectable.

What was different — and what wasn't

The four cell lines produced meaningfully different secretory profiles:

IL-6 was highest in oNPC-1 specifically. Interleukin-6 is multi-functional — it can be pro-inflammatory or neuroprotective depending on context, and plays roles in immune modulation and neural repair.

IL-7 and MMP1 were elevated in all three oNPC lines compared to standard NPCs. IL-7 supports immune regulation; MMP1 is a matrix metalloproteinase enzyme involved in remodelling the extracellular matrix — important after SCI, where the glial scar and degraded matrix are barriers to regeneration.

CXCL10 was downregulated across all three oNPC secretomes. CXCL10 (also known as IP-10) is a pro-inflammatory chemokine that attracts activated immune cells. Its reduction in all oNPC lines suggests that shifting toward an oligodendrogenic fate is consistently associated with a less pro-inflammatory secretory profile.

CXCL8 was specifically reduced in oNPC-3; VEGFA was reduced in oNPC-2. Even within the oNPC family — all three produced by the same transcription factor method — there are meaningful differences in what each line secretes.

EGF (epidermal growth factor) was consistent across all lines — not everything changes when cells shift fate.

What this tells us — and doesn't

This is early-stage characterisation work, and the study is appropriately modest. It's a conference abstract from a group still building this line of research — no in vivo data is included, and the functional consequences of these secretory differences haven't yet been tested. The next step, which the group explicitly plans, is testing the oNPC lines in a rat cervical SCI model, where differences in recovery outcomes can be correlated with differences in secretome.

Whether oNPC-1's elevated IL-6 improves or worsens recovery; whether the consistent CXCL10 reduction helps transplant survival by creating a less hostile immune environment; whether MMP1 elevation helps remodel the scar — these are all open questions. What the study establishes is that the oNPC lines are not secretory equivalents, even when made by the same general method.

Why it matters

Cell therapies for SCI have generally been developed and evaluated on the basis of what the cells differentiate into — how many neurons form, how much myelin is produced. The secretome dimension is less well characterised, and it may be equally important.

If two oNPC lines produce similar numbers of new oligodendrocytes but very different cytokine environments, they could have substantially different clinical effects. Characterising the secretome alongside the differentiation profile gives researchers a richer picture of what a candidate therapy actually does — and opens the door to selecting or engineering cell lines on the basis of their secretory properties, not just their differentiation potential.

That's still years of development away. But knowing that the chemical language each oNPC line speaks is distinct is the necessary first step.

Reader Q&A

Does this mean NPC transplants don't actually become new cells?

Not at all — they do differentiate into neurons, astrocytes, and oligodendrocytes. The point is that cellular replacement may not be the only mechanism of benefit, and possibly not even the dominant one early after transplantation. Secretory activity happens from day one; differentiation into mature cells takes much longer. Understanding both dimensions matters for designing better therapies.

Why would reducing CXCL10 be beneficial?

CXCL10 attracts activated immune cells to sites of inflammation. In the context of a transplant into an already-inflamed spinal cord, a lower CXCL10 signal might mean a less hostile immune response toward the graft — potentially improving transplant survival. This is plausible biology, but it's speculative in the current context. The in vivo work will help test whether it holds.

How reliable are these results given it's a conference abstract?

Conference abstracts present preliminary findings without the full methodological transparency and peer review of a journal paper. The results here should be treated as suggestive rather than definitive. The group will publish fuller results once the in vivo work is complete.

When will we know if the secretome differences actually affect recovery?

That depends on when the in vivo rat work is completed and published. Conference abstracts are typically a year or more ahead of the full paper. We don't have a timeline for publication of those results.

Bowel dysfunction after SCI is one of the most underreported and underestimated quality-of-life issues in the condition. Surveys consistently show that 40–80% of people with SCI rate neurogenic bowel as severely impacting their daily life — and for many, the difficulty, unpredictability, and time required to manage their bowels ranks as more disabling, day to day, than the paralysis itself.

Despite this, the gut's internal nervous system — the enteric nervous system (ENS), which operates semi-autonomously from the brain and spinal cord — has been relatively understudied in the SCI context. Much of the research focus has been on the brain-gut axis, the descending spinal pathways that normally coordinate bowel function, and how those are disrupted by SCI. Less attention has been paid to the ENS circuits themselves: the neurons embedded within the gut wall that drive motility and transmit sensory signals from the inside out.

A new preprint from Washington University St. Louis (the Gereau lab), posted this week on bioRxiv, doesn't study SCI at all. It studies healthy mice. But it identifies and characterises a specific neuronal subpopulation in the gut wall — cells expressing the gene Pdyn (prodynorphin) — that plays dual roles: driving stool movement through the colon and generating visceral pain or discomfort signals in living animals. For SCI bowel research, that duality is directly relevant.

This preprint has not yet been peer-reviewed.

The gut's own nervous system

The enteric nervous system contains somewhere between 200 and 500 million neurons — more than the spinal cord. These neurons are embedded in the walls of the gut in two main layers: the myenteric plexus (between the muscle layers, controlling movement) and the submucosal plexus (closer to the inner lining, controlling secretion and absorption). Together, they coordinate peristalsis, fluid secretion, and — critically — the sensory detection of gut contents.

The ENS can function independently of the brain and spinal cord, which is why gut motility continues even after complete SCI. But it is normally coordinated with the central nervous system through ascending sensory pathways and descending regulatory signals. When those descending signals are disrupted by SCI, the gut's motility patterns become abnormal — too slow, too irregular, or both. The ENS circuits themselves are intact; it's the regulation of those circuits that's lost.

Understanding the specific neuron types within the ENS — which ones drive contraction, which ones send sensory signals upward, which ones can be targeted pharmacologically — is the prerequisite for developing therapies that work with the ENS directly, rather than requiring intact spinal pathways.

Finding the Pdyn neurons

The Gereau lab at Washington University identified Pdyn-expressing neurons through a cross-referencing strategy: comparing RNA-sequencing datasets from mouse enteric neurons and dorsal root ganglia neurons (the sensory neurons that innervate the gut from outside) to find genes expressed specifically in enteric neurons and not in surrounding non-neuronal cells.

Pdyn — the gene encoding the neuropeptide prodynorphin — stood out. In RNA-sequencing data, it was specific to neurons in the mouse intestine, with negligible expression in non-neuronal colonic cells and only rare expression in the dorsal root ganglia. This specificity made it a clean genetic target.

To label and track these cells, the researchers used a Pdyn reporter mouse: a line where any cell that expresses Pdyn gets permanently marked with a red fluorescent protein (tdTomato). In cross-sections of the mouse colon, tdTomato-labelled cells were found in both the myenteric and submucosal plexuses, co-localising with neuronal markers — confirming they were neurons, not other cell types.

What kind of neurons are these?

Electrophysiology on cultured Pdyn-expressing myenteric neurons revealed a characteristic firing pattern: phasic — generating one or two action potentials at the start of a current pulse, then stopping. About 90% of the recorded cells also showed a prolonged after-hyperpolarisation following each action potential. These properties are characteristic of AH-type neurons — also called intrinsic primary afferent neurons (IPANs) — which are the sensory neurons of the enteric nervous system: cells that detect stretch, chemical stimuli, and luminal contents, and coordinate reflex responses.

In short: the Pdyn-expressing cells look, electrically, like the sensory neurons of the gut wall — the cells that detect what's happening inside and trigger responses accordingly.

What happens when you activate them

To test their function, the researchers used optogenetics — a technique where neurons are genetically engineered to express a light-sensitive channel (channelrhodopsin-2), then activated using blue light. This allowed them to switch the Pdyn neurons on and off with high precision, independent of all other neurons.

In ex vivo colon (gut removed from the body, kept alive in a bath): When the proximal (upper) colon was illuminated with blue light at 10Hz, stool pellets within the colon began moving forward (anterograde) significantly more frequently and faster than in control colons exposed to the same light. The Pdyn neurons are driving propulsion — coordinating the peristaltic contractions that move contents forward.

In vivo (living, freely moving mice with implanted wireless LEDs): When the Pdyn neurons in the proximal colon were activated optogenetically, the animals displayed two clear behavioural responses: freezing (cessation of movement) and orbital tightening (a contraction around the eye that is a standardised proxy for the mouse grimace scale — a validated measure of pain and discomfort in rodents). Critically, no significant difference in actual stool output was seen between stimulated and control animals during the in vivo experiments.

The interpretation is striking: activating these neurons in a living animal produces visceral discomfort or pain behaviour — not more stool movement. In the isolated gut, they drive motility. In the intact animal, their dominant perceived output is discomfort.

What this duality means

The divergence between the ex vivo and in vivo results points to something important. The Pdyn neurons appear to be sensory neurons that, when activated, trigger both motor reflexes (propulsion in the gut wall) and aversive interoceptive signals (discomfort or pain communicated upward to the brain). In the whole animal, the sensory signal may dominate — or the two functions may be coupled: the same act of propulsion that moves stool also signals "something is happening here" to the brain.

The researchers note that the Pdyn-expressing cells also express receptor subunits for pro-inflammatory cytokines (IL-1R1 and IFNgR1), suggesting they may respond directly to inflammation. This raises the question of what happens in an inflamed or dysregulated gut — a situation common in SCI bowel dysfunction.

The SCI angle

This paper doesn't mention SCI. Its implications for SCI are indirect but real:

After spinal cord injury, the descending control signals that normally regulate the ENS are disrupted. The gut's intrinsic circuits — including neurons like the Pdyn-expressing cells characterised here — continue to function, but without their normal modulatory input from above. The result is slow transit, incomplete emptying, difficulty initiating defecation, and in people with thoracic SCI or above, a risk of autonomic dysreflexia triggered by bowel distension.

Current bowel management — suppositories, digital rectal stimulation, irrigation systems — works by activating or assisting the local reflex arcs in the ENS, essentially bypassing the lost descending control. It works, but it's time-consuming, often inconvenient, and for many people unreliable.

Identifying the specific neuron types that drive colonic propulsion — and understanding their sensory properties — opens the door to targeted pharmacological approaches. If a drug could selectively activate Pdyn-expressing neurons (or the downstream circuits they trigger), it might initiate coordinated propulsion without requiring the descending control signals SCI has taken out. The fact that these neurons also appear to signal discomfort adds a critical caveat: any such approach would need to understand and ideally separate the motor and sensory functions of these cells, to avoid causing pain while triggering motility.

That's not a solved problem. But it becomes a defined, tractable problem once the neurons are identified. Before this kind of foundational work, targeting specific ENS subpopulations therapeutically wasn't feasible. The Pdyn mouse model now provides a tool to study these neurons across conditions — including, in future work, in models of gut dysfunction.

Reader Q&A

What exactly is the enteric nervous system and why does SCI affect it?

The enteric nervous system is the network of neurons embedded in the gut wall — sometimes called the "second brain" because of its size and autonomy. It can control digestion without any input from the central nervous system. However, the central nervous system normally regulates it through the vagus nerve and descending spinal pathways. SCI disrupts those spinal pathways, leaving the ENS working but unregulated, which leads to the pattern of slow, unpredictable gut motility called neurogenic bowel.

Does this research suggest a new treatment for SCI bowel dysfunction?

Not directly — this is foundational neuroscience in healthy mice. But it provides the mechanistic and genetic tools needed to eventually target these neurons therapeutically. Future work will need to test Pdyn neuron function in gut dysfunction models, identify drugs or stimulation approaches that selectively activate them, and assess whether doing so improves motility without triggering pain responses. That's a research programme, not an immediate therapy.

The paper says activating these neurons causes pain — wouldn't that make them a bad drug target?

Potentially, and this is exactly the kind of nuance that comes out of foundational work like this. The motor function (propulsion) and sensory function (visceral discomfort) of these neurons may be separable — through pharmacology targeting specific downstream receptors, or by activating the circuit at different intensities or timings. Alternatively, they may not be separable, which would make direct activation undesirable and push the focus toward the downstream circuits. Either finding is useful — the worst outcome would be not knowing.

When will this kind of research lead to better SCI bowel treatments?

Foundational neuroscience like this takes a long time to translate. The immediate next step is understanding what these neurons do in different gut conditions — inflammation, dysregulation, and SCI-like states. After that, identifying druggable targets within these circuits. Then testing in relevant animal models of neurogenic bowel. A realistic timeline to a clinical therapy, if the science holds, is a decade or more. But the field cannot skip the foundational steps, and this kind of work is how those steps get done.

Most media coverage of spinal cord injury follows one of two scripts. There is the tragedy — the accident, the moment everything changed. And there is the triumph — the marathon, the charity climb, the recovery against the odds. Both are real. Neither is what most days actually look like.

'I Didn't Plan On This', released in February 2026 by the Spinal Injuries Association, was built to occupy the space in between. This month it won podcast/audio campaign of the year at the UK Content Awards, competing against content campaigns from across every sector, not just health or disability.

What it does differently

The series is hosted by Gary Dawson, who works as network support manager at SIA, and Zoe Fox. The editorial decision that seems to have won it the award was to go directly at the subjects usually left out: intimacy, trauma, fertility, identity, family planning.

"We took creative risks, discussing topics often avoided — intimacy, trauma, fertility, identity, family planning — and did so with dignity and care," Zoe Fox said.

The judges' comment is worth quoting because it names the difficulty precisely: they called it a really worthwhile content series, tackled appropriately and delicately enough, without being patronising. That last clause is the hard part. A great deal of disability content manages to be either sanitised into uselessness or so relentlessly upbeat that it reads as a form of avoidance.

Why a podcast, specifically

Gary Dawson made the case bluntly: "For newly injured people often isolated, scared and unsure of their future, this podcast provided something no clinical leaflet or rehab session can offer: the chance to hear real voices, real challenges and real hope."

There is something to that beyond the sentiment. In the weeks after injury, a person is typically flat on their back, exhausted, and being handed information at a pace nobody could absorb. Reading is hard. Concentration is shot. Audio you can listen to at 3am, in a ward, without needing to hold anything or explain to anyone what you are looking up, fits that reality in a way a booklet does not.

Every two hours, someone in the UK sustains a spinal cord injury. That is a steady stream of people arriving in exactly that situation.

The framing SIA is pushing back on

SIA's own comment on the win goes after the standard narrative directly: "This podcast brings more than the usual triumph over tragedy narrative that exists in many media outlets around spinal cord injury and reflects the truth often missing from public perception."

And then the qualifier they were careful to include: many people build fulfilled and ambitious lives despite the barriers they face — *but only with the right support* from family and from charities connecting them to lifetime support.

That "but" is doing deliberate work. The inspirational framing quietly implies that outcomes come down to individual grit. The reality is that they come down substantially to whether you get specialist care, equipment, housing adaptation, peer support and money. It is a more useful message and a much less comfortable one.

Reader Q&A

Where can I listen? 'I Didn't Plan On This' is available on Spotify and through the Spinal Injuries Association. All episodes from the February 2026 series are out.

Is it aimed at newly injured people, or is it worth it if you've been injured for years? It is pitched at anyone whose life is shaped by SCI — including partners, parents and friends. The subject matter (fertility, intimacy, identity) is arguably more relevant to people some years in than to someone still in acute care, though Gary Dawson's point about newly injured listeners is that hearing unfiltered voices early changes what you think your life is going to be.

Does an award like this actually change anything? Directly, not much. Indirectly, it matters that a disability-led series won a mainstream content award rather than a disability-sector one — that puts SCI storytelling in front of commissioners and marketers who otherwise never encounter it, and it makes a case that honest content performs.

When a stem cell transplant is placed into an injured spinal cord, it faces a gauntlet. It has to survive. It has to form connections with host neurons. And those connections have to last long enough to matter.

Most research on spinal cord transplantation tests the first two conditions. Very little has tested the third — because following experimental animals for a year or more is expensive, complex, and rarely done. A new preprint from Drexel University has done it, and the result is one of the more important — and sobering — findings in recent cell transplantation research.

The transplants worked at one month. At one year, the benefit was largely gone. The cells survived. The connections didn't.

This preprint has not yet been peer-reviewed. The findings are from a rat model of cervical SCI. But the implications for how transplant therapies need to be designed — and maintained — are significant.

Why cervical SCI and breathing

About 60% of all spinal cord injuries affect the cervical region — the neck. Cervical SCI is particularly consequential because the breathing muscles are controlled from that level: the diaphragm receives its signals from phrenic motor neurons in the C3-C5 region of the spinal cord. A cervical injury above that level can knock out breathing control entirely, leaving people dependent on ventilators. Even partial injuries in the cervical cord can compromise diaphragm function, reducing breathing capacity and increasing vulnerability to respiratory complications — the leading cause of death in people with SCI.

Partial restoration of diaphragm function is therefore one of the most clinically meaningful targets in cervical SCI research. Even modest improvements in respiratory drive can translate to real differences in ventilator weaning, respiratory infection susceptibility, and quality of life.

The Drexel study: what they did

The research group at Drexel University, led by Lyandysha Zholudeva and colleagues, used a well-established model: a lateralised contusion injury at C3/4 in rats, which damages the left side of the cord and denervates the left hemi-diaphragm. One week post-injury, half the animals received a transplant of embryonic spinal cord tissue into the lesion site. The other half received vehicle (injured controls).

Animals were assessed at two time points: one month (1-M) and one year (1-Y) post-transplantation. At both points, researchers measured diaphragm function directly via electromyography (EMG) — placing electrodes in the diaphragm and recording its activity during baseline breathing and during respiratory challenges (hypercapnia, hypoxia, and inspiratory restriction). These challenges stress the breathing system and reveal whether the neural control of breathing is intact.

To assess how well transplanted neurons had integrated with the host breathing circuit, the team used pseudorabies virus (PRV) transneuronal tracing — a method where a virus injected into the diaphragm travels backwards through the nervous system, labelling any neurons that are synaptically connected to the diaphragm. PRV-labelled donor cells are donor neurons that have formed functional synaptic connections with the phrenic network. Counting them tells you how much integration has occurred.

What happened at one month

At one month, the transplants were working. Animals that received the transplant showed significantly better diaphragm responses than injured controls when challenged with hypoxia (reduced oxygen; p=0.028) and inspiratory restriction (p=0.011). The transplanted neurons had integrated with the host phrenic network, and the enhanced connectivity was translating to better breathing.

PRV tracing confirmed the connectivity: transplant-recipient animals at one month had donor neurons labelled by PRV — cells that had sent or received synaptic signals linked to the diaphragm circuit.

What happened at one year

By one year, the picture had changed substantially. The improved responses to respiratory challenges that distinguished transplant recipients from injured animals at one month were no longer present at one year. Transplant recipients at 1-Y responded to hypercapnic challenge less well than age-matched uninjured controls, and their responses to hypoxia and inspiratory restriction were statistically indistinguishable from injured animals. The transplant's functional benefit had effectively disappeared.

Histological analysis revealed what had changed. Neuronal density within the transplant was significantly lower at one year than at one month (p=0.001) — suggesting some loss of donor neurons over time. More strikingly, the number of PRV-labelled donor neurons was significantly fewer at one year compared to one month (p=0.0002). The transplanted cells that remained were, on average, less connected to the phrenic motor network.

Importantly, transplant volume didn't change significantly — the grafts hadn't been rejected or resorbed. They were still there. But their connectivity to the host circuit had declined.

What stayed the same — and what increased

Not everything declined over time. Serotonergic (5-HT) innervation from host neurons into the transplant actually increased between one month and one year — the host spinal cord sent more serotonin-producing axons into the graft over time, not fewer. Iba1+ cells (microglia/macrophages) were also present at one year, with variability that correlated positively with functional outcomes at that time point.

This suggests the transplant remains an active interface between host and donor tissue at one year — but the dominant directionality of connectivity had shifted. Host axons were growing into the graft; donor neurons were becoming less connected to the host phrenic circuit.

The researchers also note a meaningful finding in the correlation data: at one year, the number of surviving PRV-positive donor neurons correlated strongly with diaphragm responses to hypercapnic challenge (r=0.812, p=0.004). Animals that retained more connected donor neurons had better diaphragm function. This confirms the interpretation: connectivity is what drives recovery, and when connectivity declines, function follows.

Why connectivity might decline

The researchers discuss several possible explanations. Some donor neurons appear to be lost over time — the lower NeuN density suggests cell death, possibly driven by the chronic inflammatory environment. Beyond outright cell loss, the loss of PRV labelling exceeded the apparent loss of neurons, suggesting that surviving donor neurons may become less synaptically active or form weaker connections that the 72-hour PRV tracing window doesn't capture.

A third possibility: synaptic pruning. The immune cells (microglia/macrophages) present in the transplant may, over time, prune connections that aren't being actively used — a normal process in the developing nervous system that may be working against therapeutic connectivity in the chronic SCI environment.

The injured spinal cord itself provides insufficient signals to guide long-term donor integration. Transplanting cells without any supporting intervention relies on the host environment to guide connectivity — and that environment, after SCI, is inhospitable. The discussion draws an analogy: providing cells without other support is like giving someone tools but no scaffolding or guidance. They may start building but lack what's needed to finish.

What needs to come next

The paper's authors are direct about what this finding means for the field. The transplants possess "the intrinsic capacity to reconstruct host circuitry and transiently improve respiratory activity" — but that capacity needs to be sustained. They identify several strategies worth combining with transplantation to preserve connectivity: activity-based therapies (like intermittent hypoxia, which can strengthen neural connections through use-dependent plasticity), neuromodulatory stimulation, trophic factor delivery, and transplanting defined neuronal subtypes that are more specifically matched to the circuits being repaired.

The idea is not that transplantation doesn't work — it does, in the sub-acute period. It's that transplantation alone may not be sufficient for durable recovery. The field has focused heavily on getting cells to survive and form connections. This paper is the first to systematically follow those connections for a year and show that maintaining them is a distinct, unsolved challenge.

Limitations

This is a rat model — the timeline, anatomy, and immune context of human SCI are all different. The one-year timepoint in rats doesn't map directly onto a human equivalent. The study also uses embryonic spinal cord tissue (a tissue type not used in current human trials, which use iPSC-derived or adult stem cells), and the lateralised C3/4 contusion is not representative of all cervical SCI patterns. The preprint has not yet undergone peer review.

The PRV tracing has an important caveat: reduced labelling at one year could mean fewer connections, or it could mean connections that are anatomically present but functionally weaker and therefore less efficiently labelled by the virus. The researchers acknowledge this, and note that longer tracing windows would help distinguish these interpretations.

Reader Q&A

Does this mean spinal cord transplants don't work?

No — they clearly worked at one month, which is itself a meaningful result. The finding is that they don't maintain their effect at one year without additional support. That's a critical piece of information for designing future therapies. "Doesn't work" and "works but fades" point toward very different solutions.

Is this the first time anyone has tracked a spinal cord transplant for this long?

For the phrenic/breathing network after cervical SCI, yes — this is the first paper to specifically track transplant function and connectivity in that circuit at one year. Some prior work has assessed transplants in other circuits beyond a year, generally finding that integration was limited at long timepoints. The present work adds the breathing circuit to that picture and measures it more precisely using EMG and transneuronal tracing.

What's the clinical relevance for people with SCI now?

The direct clinical translation is years away. But the design implications matter now: any cell therapy being developed for human use should be asking whether it can maintain its effect long-term, not just show initial promise. This paper provides a clear experimental template for doing that — and identifies the targets (connectivity maintenance, synaptic stabilisation) that future combination approaches should address.

Could electrical stimulation or rehabilitation maintain the connections?

Possibly. The paper specifically calls out activity-based therapies — including intermittent hypoxia, which can strengthen neural connections through use-dependent mechanisms — as candidates for combining with transplantation to sustain connectivity. This is an active area of research for the field. There is prior evidence that activity-based therapies enhance network plasticity in SCI, and combining them with cell transplants is a logical next step.

Why is breathing the focus rather than walking?

The phrenic motor network is one of the most precisely characterised spinal circuits, making it ideal for studying transplant integration — you know exactly which neurons to trace and exactly what function to measure. It's also clinically critical: respiratory failure is the leading cause of death in SCI. Recovery of breathing is arguably more important than recovery of walking for many people with high cervical injuries.

There is a particular kind of loneliness in being a teenager with a spinal cord injury. The rehab system is built around adults. The people you meet in clinic are decades older. And the questions that actually keep you awake — what happens with friendships, independence, dating, university, a job — are not the ones a physiotherapy session is designed to answer.

True Grit exists for that gap. Run by RWJBarnabas Health's Children's Specialized Hospital in New Jersey, in partnership with Rutgers University School of Health Professions and supported by the Christopher & Dana Reeve Foundation, it is a week-long residential summer camp for adolescents and young adults living with SCI. This year, its third, it ran from 12 to 18 July and brought together fifteen young people from across the United States.

Therapy that doesn't feel like therapy

The structure is deliberate. Participants get goal-directed therapy aimed squarely at independence — the practical business of doing more for yourself — but it is wrapped inside a week of adaptive sport, swimming, cooking and shared living. The staff are occupational therapists, physiotherapists, recreational therapists and nurses, alongside peer mentors who have been there.

That peer mentor detail is easy to skim past and shouldn't be. For a young person recently injured, sustained time with someone slightly further along the same road tends to shift more than any single therapy block. It is the difference between being told what is possible and watching it.

This year's keynote came from Eric LeGrand, the former Rutgers footballer who sustained a spinal cord injury on the field in 2010 and has since built a career as a speaker, entrepreneur, author and sports analyst. His talk was about entrepreneurship — not recovery, not inspiration in the abstract, but building something.

Adding golf

The new element in 2026 was golf, introduced at Rutgers Golf Course and led by the NJ Golf Foundation, the charitable arm of the New Jersey PGA Section. Participants worked on chipping and putting using adaptive equipment: single-rider golf carts that raise the player into a supported standing or semi-standing position, and SNAG clubs designed for beginners.

Golf is a smart choice for this group, and not only because it is pleasant. It is a sport you can play for the rest of your life, at your own pace, alongside non-disabled friends and family, at a facility in most towns. That is a very different proposition to a sport that requires a specialist club, a specialist chair and a two-hour drive.

Kassie Boyd, the occupational therapist at Children's Specialized Hospital who created True Grit, said several participants had already started looking up courses near home that offer single-rider adaptive carts so they could keep playing after camp. That is arguably the clearest measure of whether a week like this worked.

The honest limitation

Fifteen places. One week. One state, albeit drawing participants nationally.

Programmes like this are genuinely excellent and reach almost nobody. There is no equivalent guaranteed provision in most healthcare systems, including the UK, where specialist peer support and adaptive sport exposure for young people with SCI depend heavily on charity funding and postcode. The value of True Grit is real; so is the fact that the great majority of young people with spinal cord injuries will never be offered anything like it.

Reader Q&A

Is there anything comparable in the UK? Not in this exact residential-with-clinical-team form as a routine offering. Back Up runs multi-activity courses for young people with SCI, and organisations like Aspire and the Spinal Injuries Association run mentoring and activity programmes. Availability is limited and depends on funding rather than being part of standard NHS care.

What is a single-rider adaptive golf cart? A powered cart with a swivel seat that lifts and supports the player in an upright or near-upright position so they can swing a club without needing to stand independently. Some courses have them; many do not, which is why the participants were researching which local courses do.

Does adaptive sport actually help with anything measurable, or is it mainly about confidence? Both, and the confidence part is not trivial. There is reasonable evidence that participation in adaptive sport after SCI is associated with better cardiovascular fitness, fewer secondary complications and better mental health outcomes. What is harder to measure — and what programmes like this are really after — is the shift from "I can't" to "I can, differently".

Most walking exoskeletons ask something of you that a spinal cord injury may have taken away: balance. They move your legs, but you supply the stability, usually through crutches or a walking frame, which means you need working arms, decent trunk control, and enough strength to hold yourself up.

Wandercraft's Atalante X is built around removing that requirement. It balances itself. The user's hands are free.

This week Ecuador's health regulator, ARCSA, cleared the device for rehabilitation use in people with spinal cord injuries from C4 to L5, as well as stroke-related hemiplegia and multiple sclerosis. La Clínica de Lesiones Deportivas in Quito will be the first centre in the country to offer it.

Why "self-balancing" is the whole story

Think about what a crutch-dependent exoskeleton excludes. Someone with a cervical injury and limited hand function cannot grip crutches. Someone with poor trunk control cannot stay upright between steps. Someone whose shoulders are already carrying the load of daily transfers may not want to spend a therapy session loading them further.

Atalante X uses powered hip, knee and *ankle* joints together with an active balance controller. That powered ankle matters more than it sounds — ankle control is central to how humans actually keep themselves upright while walking, and most exoskeletons skip it. The result is a machine that can stand, step, shift weight, turn and move in more than one direction while the person inside keeps their hands free.

For rehabilitation, that unlocks a specific and well-evidenced principle: high-dose, task-specific overground gait training. Not treadmill walking, not partial-weight-supported stepping in place, but repeated real walking over ground, in volume. The number of steps you can get into a session is one of the things that actually correlates with rehabilitation outcomes.

What this clearance is, and what it isn't

Being clear-eyed here: this is a regulatory clearance in a single country for a device that already exists and is already in use at more than 150 clinical and research sites worldwide. It is not a new technology, a new trial result, or evidence of new benefits. Nobody has proven anything this week.

What it does represent is access. Advanced rehabilitation equipment clusters heavily in wealthy healthcare systems, and Latin America has been thinly served. Wandercraft says Ecuador is a foundation for wider regional expansion, with Costa Rica and Chile under evaluation. For someone with an SCI in Quito, the difference between "this device exists somewhere" and "this device is at a clinic I can reach" is not a small one.

It is also a clinical-use device, not a personal one. Atalante X lives in rehabilitation centres and is used in supervised sessions. Wandercraft's separate personal exoskeleton, Eve, is aimed at indoor personal use, but that is a different product on a different path.

Reader Q&A

Does this mean people with C4 injuries can walk in it? The clearance covers injury levels C4 to L5, which is a broad range, but "cleared for use" is not the same as "suitable for everyone in that range". Eligibility for any given person depends on height, weight, joint range of motion, skin integrity, bone density, spasticity and cardiovascular tolerance to being upright. The clinical team makes that call individually. What the self-balancing design changes is that upper-body strength and trunk control are much less of a barrier than with crutch-based systems.

Is walking in an exoskeleton actually good for you, or is it symbolic? Both, honestly. The lived benefits people report from standing and stepping — bowel and bladder function, spasticity, pain, mood, being at eye level with people — are real but under-studied and vary a lot between individuals. The rehabilitation case is stronger: intensive overground gait training is a core principle of neurological rehab, and a device that lets you do more of it, more safely, with fewer therapists physically supporting you, has a clear rationale. It is not a treatment for the injury itself.

Will this ever be something I could own? Atalante X is designed for clinics — it is large, expensive and requires trained staff. Personal-use exoskeletons are a separate and much harder problem, and the ones that exist remain costly and limited. This clearance does not move that needle.

Should I read anything into the Ecuador approval specifically? Only that the company is expanding into Latin America and that a regulator there reviewed and accepted the device. It is a commercial and access milestone rather than a scientific one, and the announcement came from Wandercraft itself.

Calvin Cheyne's ordeal did not start with an accident or a fall. It started with a piece of toast.

The 26-year-old from St Fergus, just outside Peterhead in Aberdeenshire, had gone into Aberdeen Royal Infirmary for surgery to treat a Chiari malformation — a condition where part of the back of the brain sits too low and presses on the spinal cord, causing severe headaches. The operation itself went well. But in recovery, Calvin choked on a piece of toast. It went into his lungs, which collapsed, and he was rushed to intensive care and placed in a medically induced coma.

What followed was the kind of cascade families dread. His lungs collapsed repeatedly. He needed a tracheotomy and spent months on a ventilator, able to communicate only by mouthing words. An MRI scan showed that part of his spinal cord and brain stem had been permanently damaged, and doctors warned he might never walk again. For a young father — Calvin has a seven-year-old daughter, Emily, and had just moved into a new home with his partner Stephanie — it turned everything upside down.

Now, according to the latest update his family have shared, there is cautious good news: Calvin has begun to move again.

What "moving again" really means

It is worth being careful with a headline like this, because recovery stories are easily flattened into something simpler and more miraculous than they are. Calvin's injury was not a clean cut to the spinal cord from trauma. It was damage caused by oxygen loss and the complications that followed his choking incident, affecting both the brain stem and the cord. Damage like that is unpredictable — which cuts both ways. It can mean a very long, uncertain road, but it can also mean that some function, thought lost, gradually returns as swelling settles and the nervous system reorganises.

Even early in his stay, his family noted that Calvin still had sensation in his arms and legs — a detail that matters, because preserved feeling can hint at surviving nerve pathways that rehabilitation may, over time, be able to build on. Regaining movement is a genuine and hopeful milestone. It is not the same as a full recovery, and Calvin's family have been open throughout about how uncertain the road ahead remains.

A family that refused to wait

Much of what has kept Calvin's story moving has come from the people around him. When he was taken into intensive care, his sister Lainey made a 42-hour journey home from Australia to be at his bedside. His partner, parents and brothers kept a near-constant vigil. And when the family learned that specialist rehabilitation could cost close to £2,000 a day at a private unit, they launched a fundraising appeal — one that drew an extraordinary response, raising thousands within hours as strangers shared it online.

That combination — early sensation preserved, intensive family support, and access to rehabilitation — is exactly the sort of context in which small, hard-won gains in movement become possible. None of it guarantees where Calvin ends up. But it is the difference between a story that stops in an ICU and one that keeps going.

Reader Q&A

Was this a spinal cord injury in the usual sense? Not quite. Calvin's paralysis came from damage to his spinal cord and brain stem caused by complications after choking — oxygen loss and repeated lung collapses — rather than a direct traumatic blow to the cord. The end result, loss of movement, overlaps heavily with what many people with spinal cord injuries experience, which is why his story resonates with the SCI community.

Does regaining movement mean he will walk again? It is too early to say, and his family have been careful not to promise that. Regaining some movement is an encouraging sign that not all function was lost, but recovery from this kind of injury is slow, partial for many people, and impossible to predict. It is a milestone worth celebrating without treating it as the finish line.

Why does this kind of story matter to people with SCI? Because it is honest about both the fear and the hope. It shows how quickly life can change from something as ordinary as a meal, how much family and rehabilitation access shape what happens next, and that even after a devastating prognosis, some people do regain function. Those are realities the SCI community knows well.

*Note: this write-up draws on the family's public account of Calvin's condition and the latest news report that he has begun moving again. We could not access the full recovery article directly, so the specifics of his current progress should be treated as the family's own update rather than a confirmed clinical assessment.*

There's a quiet assumption that hangs over a lot of spinal cord injury care: that once the early rehab window closes, what you can do is what you'll always be able to do. A recent Texas Public Radio "Petrie Dish" segment featured a physical therapist who has spent her career pushing back against exactly that idea.

Selina Morgan, an assistant professor in the Department of Physical Therapy at UT Health San Antonio, has worked in spinal cord injury for decades. Her argument is simple but pointed: not everyone with an injury will walk again, but you can't know who might until you actually give them the chance to try. As she put it, "Not everyone's going to get up and walk, but we don't know who they are unless we try."

What "locomotor training" actually means

The approach at the centre of her work is called locomotor training. In practice, it usually involves supporting a person's body weight over a treadmill — often with a harness system — while their legs are guided through the stepping motion of walking. The idea is to give the nervous system repeated, task-specific practice of the movement itself, tapping into the spinal cord's own capacity to relearn patterns rather than treating the legs as simply "switched off."

It's not a magic switch, and it's not a cure. What Morgan is describing is closer to giving the body a fair, sustained shot at whatever recovery is possible — including for people with complete or incomplete paralysis, not just those with obvious residual movement.

The access problem

The harder part of the story isn't the science; it's availability. The specialised, body-weight-supported treadmill systems this kind of training needs are expensive, and many rehab settings simply don't have one. That's the gap Morgan is trying to close. Her project — built around the theme of increasing access to locomotor training after paralysis — has drawn support including a grant from the Christopher and Dana Reeve Foundation, aimed at bringing this equipment and approach to more of the people who could benefit.

Her broader point is about mindset as much as machines. She believes there are thousands of people using wheelchairs who were never given a real trial of intensive recovery-focused training, and that the default expectation in a clinic shapes what patients are even offered. Changing that culture — getting everyone who works in SCI to start from "let's try" rather than "let's manage" — is the mission she keeps returning to.

Reader Q&A

Is this a new treatment? No. Locomotor training and body-weight-supported treadmill work have been used in SCI rehab for years. What's newer here is the focus on access — getting the equipment and the recovery-minded approach into more clinics — rather than a new device or drug.

Does locomotor training mean I'll walk again? Not necessarily, and Morgan is careful about this herself. The honest position is that outcomes vary a lot depending on the injury, and some people won't regain walking. The argument is that more people deserve the chance to find out through proper training.

Why does availability vary so much? A big factor is cost. The supported treadmill systems and the trained staff time they require are expensive, so not every rehab centre offers them. That's precisely the barrier this project and its Reeve Foundation funding are trying to address.

Where can I hear the original? The segment aired on Texas Public Radio's "Petrie Dish," which covers bioscience and medicine. It's a short listen and a good example of a clinician making the case for recovery-focused care.

If you live with a spinal cord injury, you may already know that a warm afternoon can hit you differently than it does everyone else around you. There's a good reason for that, and it's worth understanding — because getting too hot isn't just uncomfortable after SCI. In some cases it can become a genuine medical emergency.

Why heat is different after SCI

Your body normally keeps itself cool in two main ways: it sweats, and it sends more blood to the surface of the skin so heat can escape. Both of those responses are controlled by the sympathetic nervous system, which runs signals down through the spinal cord. When the cord is injured, those signals can't always get past the level of the injury. The result is that below the level of injury, the sweat glands stay more or less "switched off," and the blood vessels don't open up to release heat the way they should.

This matters most for people with higher injuries — roughly at the mid-thoracic level (around T6) and above — and for those with complete injuries, because more of the body is cut off from that cooling response. With less of your skin able to sweat, heat builds up inside faster than it can get out. That's what raises the risk of heat exhaustion and, in more serious cases, heat stroke.

The autonomic dysreflexia connection

There's a second reason to be careful in the sun, and it's one that's specific to SCI. Sunburn, or even skin that's simply overheated or irritated, can act as a trigger for autonomic dysreflexia — a sudden, dangerous spike in blood pressure that affects people with injuries at T6 and above. Because AD is a life-threatening emergency, protecting your skin from burning isn't just about comfort; it's part of staying safe. Watching your skin carefully also guards against sunburn turning into a pressure wound or infection, which are slower-burning but serious problems in their own right.

Practical steps that help

None of this means summer is off-limits. It means planning ahead. Some things that genuinely help: staying in shade or air conditioning during the hottest part of the day, keeping a spray bottle or damp cloth handy to wet your skin (evaporation does some of the cooling your body can't), drinking fluids steadily rather than waiting until you feel thirsty, and dressing in light, loose, breathable clothing. Cooling vests and neck wraps can be worth the investment if you spend time outdoors. And because you may not feel the usual warning signs of overheating below your level of injury, it's smart to check in with yourself — and let people around you know what to watch for — rather than relying on how hot you feel.

If you start to feel unwell, get flushed, develop a pounding headache, or notice your skin isn't behaving normally, treat it as a signal to cool down and, if it doesn't settle, to seek help. Knowing your own body and your own injury level is the most useful tool you have here.

Reader Q&A

Does this apply to everyone with a spinal cord injury? The risk is greatest for people with injuries at T6 and above, and for those with complete injuries, because more of the body loses its normal cooling response. Lower or incomplete injuries may be less affected, but heat is still worth respecting — everyone's injury is a little different.

Why can't I just rely on feeling hot to know when to cool down? Because the same nerve disruption that stops you sweating can also blunt the sensations that normally tell you you're overheating. That's exactly why overheating can sneak up on people with SCI, and why planning ahead beats waiting for a warning.

Is autonomic dysreflexia really that serious? Yes. AD causes a rapid rise in blood pressure that can be dangerous if not addressed. Sunburn and overheated skin are among the many possible triggers, which is why sun protection is part of heat safety after SCI, not just an afterthought.

This is general information — should I make my own plan? This piece is a general explainer, not medical advice. Your rehab team or SCI specialist can help you build a heat-safety plan that fits your injury level and your day-to-day life.

More than half of people with spinal cord injury live with chronic pain. For many, it ranks as one of the most debilitating aspects of their condition — sometimes worse, in terms of day-to-day impact, than the paralysis itself. Yet chronic pain after SCI remains poorly understood and poorly treated. Most research has focused on what's happening at the injury site: the spinal cord, the damaged nerves, the disrupted pain pathways. A new systematic review from the University of Porto asks a different question — what's happening in the brain?

The answer, based on a comprehensive survey of animal research published this month in *International Journal of Molecular Sciences*, is: quite a lot. The brain is inflamed. And when that brain inflammation is reduced, pain improves.

Pain after SCI — the basics

In an uninjured nervous system, pain works like a relay. Signals from the body travel up through the spinal cord to the brain, where they're processed across multiple regions — the thalamus (a relay hub), the anterior cingulate cortex (involved in the emotional experience of pain), the amygdala (threat processing), the periaqueductal gray (pain modulation), and others. The brain then sends signals back down to modulate what comes through. It's a dynamic, two-way system.

After SCI, this system is disrupted at every level. The descending modulation pathways — which normally help suppress pain — are damaged. Ascending signals are distorted. The spinal cord itself becomes sensitised, amplifying pain signals that would normally be filtered out. This is well understood and is the basis of most SCI pain research.

What is less understood is what happens in the brain itself. When the spinal cord is injured, does the inflammation stay at the injury site — or does it spread upward? And if the brain becomes inflamed, does that inflammation make chronic pain worse?

The systematic review: what they looked for

The Porto team — from the Faculty of Medicine's pain neurobiology group — conducted a rigorous search of three major scientific databases, following PRISMA systematic review guidelines. They searched for animal studies that: used a rodent SCI model; measured neuroinflammatory markers or cellular responses specifically in brain regions (not just at the spinal cord); and also assessed pain-related behaviours. Starting from 1,229 records, they whittled down to nine studies that met all the criteria.

That small number — nine out of over a thousand — tells you something important: most SCI pain research doesn't look at the brain at all. The field has been almost entirely focused on the spinal cord. This review maps the small body of work that has looked upward, and finds it consistent and suggestive.

What the brain looks like after SCI

Across all nine studies, SCI was associated with clear signs of neuroinflammation in brain regions involved in pain processing. The specific markers varied by study, but the patterns were consistent:

Microglial activation — microglia are the brain's resident immune cells. After SCI, they became reactive in multiple regions, including the anterior cingulate cortex, amygdala, thalamus, and periaqueductal gray. Reactive microglia shift into a pro-inflammatory state, releasing cytokines and chemokines that amplify inflammatory signalling.

Astrocyte activation — astrocytes, the brain's structural support cells, also showed reactivity (measured by elevated GFAP expression) across cortical, limbic, and brainstem regions. Reactive astrocytes contribute to the inflammatory environment and can alter synaptic function.

Pro-inflammatory cytokines — elevated levels of TNF-α, IL-1β, IL-6, and related molecules were found in brain tissue after SCI. These are the same molecules that drive inflammation throughout the body; their presence in pain-processing brain regions suggests they may be contributing to the brain's altered processing of pain signals.

Chemokine signalling — a pathway involving CX3CL1 (fractalkine) and its receptor CX3CR1 appeared repeatedly across studies. This axis is a known regulator of microglial activation; its upregulation in the brain after SCI hints at a specific molecular route through which peripheral injury drives central neuroinflammation.

The brain regions affected weren't random — they were consistently the regions most involved in pain processing and its emotional and cognitive dimensions. The anterior cingulate cortex processes the suffering and unpleasantness of pain. The amygdala processes threat and fear, deeply entangled with chronic pain experience. The periaqueductal gray is a key hub for descending pain control. All of these were showing inflammatory changes in SCI animals.

Does treating brain inflammation help the pain?

Six of the nine studies included an intervention — something designed to reduce the brain inflammation — and then measured whether pain behaviours improved. The interventions ranged from natural compounds (polyphenolic extracts from grape stalks and coffee, docosahexaenoic acid — an omega-3 fatty acid) to pharmacological agents (minocycline, deferoxamine, the cyclin-dependent kinase inhibitor CR8) to a physical approach (transcranial direct current stimulation — tDCS — applied via electrodes on the skull).

In all six intervention studies, reducing supraspinal neuroinflammation was associated with improvement in pain-related behaviours. Animals showed less mechanical allodynia (hypersensitivity to touch) and thermal hyperalgesia (exaggerated response to heat). The inflammatory markers in the brain went down, and so did the pain signals.

This is the most clinically interesting finding in the review. It suggests the brain inflammation is not just a bystander effect — it is functionally connected to the pain experience. Dampen it, and the pain improves.

What the review is honest about

The Porto team are careful not to overclaim. The review has a detailed risk of bias assessment, and most of the nine studies did not score well — eight out of nine had moderate to high risk of bias, with common problems including inadequate randomisation, lack of blinding in behavioural testing, and incomplete outcome reporting.

The interventions were mostly systemic — drugs given to the whole animal, not targeted specifically at the brain. This means it's impossible to be certain whether the pain improvements came from reduced brain inflammation specifically, or from effects elsewhere in the nervous system or body. Only tDCS was genuinely supraspinal in its targeting.

Correlation between reduced inflammation and reduced pain is not the same as causation. The review identifies an association, not a proven mechanism. And the methodological variety across the nine studies — different animal strains, different SCI models, different brain regions assessed, different inflammatory markers — makes direct comparison difficult and limits how confident any conclusions can be.

Most studies also used reflexive tests to measure pain (withdrawal from heat or pressure), which largely reflect spinal processing. The supraspinal dimensions of chronic pain — the suffering, the emotional toll, the cognitive disruption — are harder to measure in rodents, and were mostly not captured.

Why this matters for people with SCI

The clinical relevance of this research is in what it points toward. Chronic SCI pain is notoriously difficult to treat. Conventional analgesics are often ineffective or have intolerable side effects. Spinal cord stimulation helps some people but not others. The reasons for these failures may partly lie in the fact that treatment has been aimed at the wrong target — or an incomplete target. If the brain is independently maintaining chronic pain through its own neuroinflammatory loop, then treatments that address only the spinal cord may never be sufficient.

Non-invasive brain stimulation approaches — including tDCS and transcranial magnetic stimulation (TMS) — are already used in some SCI pain clinics with variable results. Anti-inflammatory interventions targeting brain pathways are a less explored direction but one this review suggests is worth pursuing.

This is early-stage science. Nine rodent studies are not a clinical blueprint. But the picture they paint is coherent: after SCI, the brain doesn't sit passively above the injury — it becomes an active participant in chronic pain, through neuroinflammation that reshapes how pain is processed at the highest levels of the nervous system. That's a target worth understanding.

Reader Q&A

Does this mean I have brain damage if I have chronic pain after SCI?

"Brain damage" is not the right frame here. Neuroinflammation in the brain means the brain's immune cells have become reactive — which is a functional change, not structural damage in the way people usually mean that phrase. These changes can be dynamic and, as the intervention studies suggest, potentially reversible. Chronic pain after SCI reflects a maladaptive state of the nervous system, not a fixed, permanent injury to the brain.

Why is treating SCI pain so difficult?

SCI pain is complex because it involves changes at multiple levels simultaneously — the injury site itself, the spinal cord above and below the lesion, and now, as this review suggests, the brain. Treatments that target just one level often have limited effect because the problem is distributed. There's also enormous variability between individuals in how chronic pain develops and what drives it. Better characterisation of what's happening in the brain — which this type of research moves toward — may eventually help match people to more targeted treatments.

What is tDCS and could it help with SCI pain?

Transcranial direct current stimulation (tDCS) is a non-invasive technique that passes a very weak electrical current through the skull to modulate brain activity. It's used experimentally for several neurological conditions including SCI pain. One of the nine studies in this review found that tDCS reduced both brain inflammation and pain behaviours in SCI rats. Clinical trials of tDCS for SCI pain exist but results have been mixed. It's a promising but still investigational approach.

When might any of this lead to new treatments?

The immediate next steps are better designed animal studies that directly target brain inflammation — using agents that don't cross into the spinal cord, to isolate the supraspinal effect — and that use more sophisticated measures of pain experience beyond simple reflex tests. After that, translational work in humans would be needed. This review usefully maps where the field is; new treatments targeting brain neuroinflammation specifically for SCI pain are still years away at minimum.

Every so often a spinal cord injury story arrives wrapped in extraordinary promise, and it can be genuinely hard to tell whether you are looking at a breakthrough or a false dawn. The case of polylaminin, a protein developed in Brazil, is a textbook example — and a feature published this week in the journal *Science* lays out both the excitement and the serious concerns in a way worth reading carefully.

What polylaminin is

Polylaminin is a specially assembled form of laminin, a protein that occurs naturally in the body and helps guide the growth of nerve cells. It was developed over roughly 25 years by biologist Tatiana Sampaio and colleagues at the Federal University of Rio de Janeiro (UFRJ). The idea is to inject it into the spinal cord within about 24 hours of a fresh injury, in the hope that it protects tissue and creates a more welcoming environment for nerves to survive and reconnect.

In laboratory and early human use, its backers report unprecedented results. And then came the moment that turned a research project into a national phenomenon.

The hype

In September 2025, one of Brazil's leading television newscasts aired a dramatic story: a participant named Bruno Drummond, previously paralysed, was shown walking, going down stairs, and even dancing. The reaction was enormous. Sampaio became a national celebrity, met the country's president, and appeared on the cover of Forbes. Understandably, people with spinal cord injuries and their families wanted access immediately. According to the *Science* report, more than 30 people have now received polylaminin injections — many of them outside the structure of a formal clinical trial.

It is not hard to understand why. If you or someone you love has just been paralysed, and the television is showing someone walking again after a single injection, waiting years for careful trials can feel unbearable. That very human pressure is exactly what makes this story so difficult.

The concerns

This is where scientists are urging caution, and their reasons are important rather than dismissive.

The pilot study behind the headlines was small — too small, several Brazilian researchers say, to show reliably that polylaminin can treat spinal cord injury. Some point to methodological weaknesses in how the work was done and reported. And crucially, spontaneous recovery is known to happen in some spinal cord injuries, especially incomplete ones, in the weeks and months after the event. Without a properly designed, controlled trial — where similar patients are compared with and without the treatment — it is impossible to know whether an individual's improvement came from the injection or would have happened anyway.

There is also a safety dimension. People receiving an experimental treatment outside a trial may not be monitored as thoroughly for side effects or complications, and they are taking on unknown risks with a substance that has not been through the full evidence process. A single striking recovery, however moving, is an anecdote — not proof.

Holding two ideas at once

It would be wrong to simply write polylaminin off. Decades of work went into it, the early signals have interested serious people, and laminin biology is a legitimate avenue for spinal cord repair. But it would be equally wrong to treat a handful of dramatic recoveries as a proven cure. The honest position — the one the *Science* feature lands on — is that polylaminin represents real hope but very preliminary science, and the only way to find out if it truly works is the slow, unglamorous route of rigorous clinical trials.

For our community, this is a story to watch with cautious interest and a healthy dose of scepticism about any "miracle" framing.

Reader Q&A

Has polylaminin been proven to cure paralysis? No. There are striking individual stories, but no large, controlled trial has yet demonstrated that it works. Some improvements seen in patients could be due to natural recovery rather than the drug, and that is precisely what a proper trial is designed to untangle.

Should I try to get this injection? This site can't give medical advice, but the researchers quoted in the coverage are clearly worried about people receiving it outside formal trials — both because the evidence is thin and because safety monitoring may be inadequate. If polylaminin interests you, the safest route is to follow whether registered, controlled clinical trials open, and to discuss it with your own medical team.

Why are scientists so cautious if patients say it helped them? Because spinal cord injuries — especially incomplete ones — sometimes recover on their own, and because the placebo effect and the drama of a single case can be very persuasive. Individual testimonies are important and real to the people involved, but they can't separate the effect of a treatment from what would have happened anyway. Only controlled trials can do that.

Is this the same as the other injectable therapies I've read about? No. Polylaminin is its own approach, distinct from the growth-factor drugs, stem-cell therapies and scaffolds covered elsewhere on this site. What it shares with the more credible programmes is the target — protecting and repairing the cord soon after injury — but it is much earlier and less tested than its media profile suggests.

Most of the treatments that make headlines on this site are aimed at people living with an injury that happened months or years ago. This one is different: it is designed for the first few days after the accident, when the damage is still spreading and there may still be a chance to limit it. Kringle Pharma, a small biotech based in Osaka, has been quietly working on this idea for two decades, and it is now lining up an additional Phase 3 trial of its lead drug — recently given the generic name oremepermin alfa.

What the drug actually is

Oremepermin alfa is a lab-made copy of a natural human protein called hepatocyte growth factor, or HGF. Despite the name — which comes from its original discovery in the liver — HGF does useful things all over the body, including in the nervous system. In animal studies it protected nerve cells from dying and encouraged damaged nerve fibres (axons) to grow. That combination is exactly what you would want in the immediate aftermath of a spinal cord injury.

To understand why timing matters, it helps to know that a spinal cord injury happens in two stages. The "primary injury" is the physical damage from the accident itself — the crush, the tear, the bruise. There is nothing a drug can do about that; it has already happened. But over the following hours and days, a "secondary injury" unfolds, in which inflammation, swelling and chemical stress spread the damage into nearby tissue that survived the initial blow. Kringle's bet is that giving HGF during this window can calm that secondary wave and preserve nerve tissue that would otherwise be lost.

How it is given

The drug is delivered by intrathecal injection — into the fluid-filled space around the spinal cord — starting about 72 hours after injury and repeated once a week for five weeks. That is a practical detail worth noting: it means the treatment has to begin in an acute hospital setting, very soon after someone is injured, which is a very different logistical challenge from a therapy someone chooses years down the line.

What the trials have shown so far

Kringle's earlier Phase 1/2 study enrolled 45 people with severe cervical (neck-level) injuries and compared the drug against a placebo. The honest headline is mixed. On its main pre-specified measure — the change in ASIA motor score at 24 weeks — there was no statistically significant difference between the drug and placebo. In plain terms, the study did not hit its primary target.

But the secondary results were encouraging enough to keep the programme alive. Among people who started out completely paralysed (graded "A" on the ASIA scale, the most severe category), 26.7% of those given HGF improved to an incomplete injury with some function below the injury level, compared with 6.3% on placebo. That is a small number of patients — four out of fifteen versus one out of sixteen — so it has to be read cautiously. Still, for people who began with complete paralysis, any recovery of function is meaningful, and the pattern was consistent enough that regulators granted the drug orphan status.

A follow-up Phase 3 study in Japan, in which all 25 evaluated participants received the drug (no placebo group this time), finished enrolling patients back in 2023. Kringle has said it is now preparing an additional study, and has been building the machinery to take the drug internationally: it recently set up a US subsidiary, Kringle Pharma USA, and has collected orphan drug designations from Japan, the US Food and Drug Administration, and the European Medicines Agency. Orphan status is a regulatory designation that gives incentives to companies developing treatments for conditions with relatively few patients — it is a signal of official encouragement, not proof that a drug works.

Why it matters

There is still no approved drug that treats the spinal cord injury itself. Care today means stabilising the spine, surgery where needed, and rehabilitation to make the most of whatever function remains. A treatment that could reliably nudge even a fraction of people from complete to incomplete injury would be a genuine shift. Oremepermin alfa is not there yet, and the mixed Phase 1/2 result is a real caution. But it is one of a small handful of drug candidates that have made it as far as late-stage human trials for acute injury, and that alone makes its next steps worth following.

Reader Q&A

Could this help me if my injury was years ago? Unfortunately no — at least not as it is currently being developed. Oremepermin alfa is aimed squarely at the acute phase, the first days after injury, when secondary damage is still spreading. It is not designed to repair an old, established injury. Different approaches (stem cells, scaffolds, nerve-stimulation techniques covered elsewhere on this site) are the ones targeting chronic injury.

Does it "cure" paralysis? No. The most it has shown so far is that a minority of people with complete injuries recovered some function below their injury level — and even that came from a secondary measure in a study that missed its main goal. It is a potential way to reduce the severity of an injury, not to reverse it.

When could it actually be available? That is genuinely uncertain. The company has completed one Phase 3 study in Japan and is preparing an additional trial, with US plans in the works. Even in the best case, additional trials, regulatory review and manufacturing would take years. This is a "watch this space" story, not an available treatment.

Is Kringle Pharma reliable, or is this hype? It is a real, publicly listed company that has been developing HGF therapies since 2001 and has published its trial results in peer-reviewed journals such as the Journal of Neurotrauma. That is a good sign. But "in late-stage trials" is not the same as "proven," and the earlier study's mixed result is the honest counterweight to the optimism.

Seth Kurpiel remembers the moment with unnerving clarity. "I was lying on the ground, facing up, fully conscious. And it was the scariest moment of my life."

The 47-year-old father of two from Great Neck, New York, had fallen from a swing set — a freak accident that left him paralysed from the shoulders down with a serious spinal cord injury. Fifteen months later, he walked out of hospital unassisted, in front of the staff who had treated him. For a story that began in the worst possible way, it is a remarkable place to end up.

A long road, not a miracle switch

It is worth being honest about what "walked again" means here, because recovery stories like this are often flattened into something simpler than they really are. Kurpiel was a marathoner and an athlete before his injury, and his doctors said that fewer than five percent of people with his type of injury walk again. His recovery took more than a year of work, not an overnight turnaround.

What made a difference, according to his care team, was the combination of timing and location. Kurpiel was close to North Shore University Hospital's Trauma Center, and getting rapid, specialist trauma care after a spinal cord injury can shape everything that follows. Early treatment does not guarantee a good outcome — but delays can foreclose one.

Why some people recover and others do not

Spinal cord injuries are not all the same, and that is the key to understanding a story like this. Injuries are described as "complete" or "incomplete" depending on whether any signal is still getting through the damaged section of the cord. Someone with an incomplete injury has surviving nerve pathways that, with intensive rehabilitation, can sometimes be trained to do more over time. That is very different from a complete injury, where no signals cross the injury site.

The fact that Kurpiel regained the ability to walk suggests his injury preserved at least some function that rehabilitation could build on — which is exactly why his doctors framed his recovery as rare rather than impossible. It is a genuine achievement earned through months of effort, and also a reminder of why the same injury can lead to very different outcomes for different people.

Reader Q&A

Does this mean paralysis can be reversed? No — and it is important not to over-read it. This is one person with a specific injury who, through fast trauma care and long rehabilitation, regained the ability to walk. Many spinal cord injuries do not allow for this kind of recovery, and nothing here changes that. His doctors were clear that his outcome is uncommon.

Why does timing and proximity to a trauma centre matter so much? After a spinal cord injury, swelling and secondary damage can worsen the initial harm. Rapid specialist care helps stabilise the injury and manage those secondary processes, which can protect whatever function remains. It is one of the reasons trauma systems and quick transfer to specialist units matter.

Is this connected to any new treatment or device? Not in this case. Kurpiel's recovery came through emergency trauma care and sustained rehabilitation rather than an experimental implant or drug. It is a human-interest recovery story, not a technology breakthrough.

Some fundraising stories start with a grand plan. This one started with a daughter wanting to do something meaningful for her mum.

Kate, 28, has signed up for her first-ever marathon — the Sydney Marathon on 30 August — and she is running it for Spinal Research, the UK's leading charity funding research into treatments for spinal cord injury. The reason is personal: her mum lives with a spinal cord injury, and Kate wanted to turn her own training into something that might help.

How it started

Kate only discovered running while living in London for three years. What began as a way to keep fit gradually turned into something she wanted to push further, and a first marathon felt like the right kind of challenge — big enough to be daunting, personal enough to matter.

Choosing Spinal Research as her cause was not a difficult decision. Watching her mum manage the daily realities of life with a spinal cord injury gave Kate a clear sense of perspective about her own effort. "Any pain I feel is nothing compared to what mum goes through daily," she said — a line that neatly captures why these challenges tend to mean so much to the people taking them on.

Why Spinal Research

Spinal Research funds scientific work aimed at developing life-changing treatments for spinal cord injury, and ultimately a cure for paralysis. The charity points out a sobering statistic to put the need in context: every two hours, someone in the UK is paralysed as a result of a spinal cord injury.

That is the gap fundraisers like Kate are trying to help close. Marathon places raise money that goes directly toward the research the charity supports — the kind of steady, unglamorous funding that keeps laboratories running and trials moving forward.

The bigger picture

It is easy to focus on the science when covering spinal cord injury — the trials, the implants, the stem cell work. But a lot of that research is only possible because of ordinary people who lace up their trainers, sign up for a challenge, and ask their friends and family to chip in.

Kate's marathon is one of many taking place around the Sydney event this year, and it is a reminder that behind every research headline there is usually a chain of people quietly raising the money that makes it happen.

Reader Q&A

Is the Sydney Marathon linked to spinal cord injury research specifically? Not exclusively — it is a major international marathon that runners take on for all sorts of causes. But Spinal Research is one of the charities people can run for, and Kate has chosen to dedicate her run to it.

Does money raised through a run like this actually reach research? Yes. Charity marathon places are structured so that the funds a runner raises go to their chosen charity. In this case, that means Spinal Research's programme of funding spinal cord injury studies.

How can I support a runner like Kate? Most charity runners set up an online fundraising page you can donate to directly. If you would like to support Spinal Research more generally, the charity's website has details of its work and other ways to give.

A lot of spinal cord injury research chases a single villain: block one harmful chemical, calm one type of inflammation, bridge one gap. The trouble is that a spinal cord injury doesn't do damage one thing at a time. It sets off a whole cascade at once — electrical signalling breaks down, cells are poisoned by a flood of chemicals (excitotoxicity), inflammation flares, and oxidative stress builds. A new study in Advanced Functional Materials takes a different approach: build one material that pushes back on several of these problems together.

The result is what the researchers call a biomimetic aerogel conduit. That's a mouthful, so let's unpack it.

What they actually built

An aerogel is an ultra-light, sponge-like solid — mostly empty space held in a fine, interconnected structure. "Biomimetic" means it's designed to imitate biology: in this case, the architecture of the natural spinal cord, with tiny directional channels that could guide regrowing nerve fibres in the right direction rather than letting them wander.

The material itself is a blend chosen for what each ingredient does. A soft gelatin-and-polymer fibre matrix gives it a texture close to real spinal tissue, so it doesn't sit in the cord like a hard foreign object. Polypyrrole nanoparticles make it electrically conductive, helping carry the electrical signals that injury disrupts. And it's dosed with tannic acid and magnesium ions, which mop up damaging molecules and calm the immune response.

The team describe the combined effect as an "electro-ionic-immune" strategy: *electro* for restoring conductivity, *ionic* for rebalancing the chemical environment, and *immune* for dialling down harmful inflammation. Rather than betting everything on one mechanism, the scaffold works on all three fronts at the same time.

Why this is promising — and why it's early

The appeal is obvious. If a single implantable material can protect surviving tissue, guide regrowth, and quiet inflammation, that's a much more realistic match for the messy, multi-pronged reality of a spinal cord injury than any single-target drug.

But this is firmly laboratory-stage work. Studies like this are typically validated in cell cultures and animal models, and there's a long, uncertain road between an elegant scaffold that performs well in the lab and a therapy that helps people. Materials that look outstanding in a dish or in a rat don't always translate to humans, and "reversing the pathological cascade" in an experimental model is not the same as restoring function in a person. This is a design worth watching, not a treatment on the horizon.

What's genuinely encouraging is the philosophy behind it. The field is increasingly recognising that spinal cord repair probably won't come from a single magic bullet, but from combined approaches that address several problems together — and this scaffold is a clean example of that thinking put into a physical object.

Reader Q&A

What's an aerogel, simply put? An extremely lightweight, sponge-like solid made mostly of empty space held in a fine network. Here it's engineered to be soft and channelled like spinal tissue.

What does "electro-ionic-immune" mean? It's shorthand for the three problems the scaffold targets at once: restoring electrical conductivity, rebalancing the chemical (ionic) environment, and reducing harmful immune inflammation.

Has this been tried in people? No. This is early laboratory and preclinical research. It has not been tested as a treatment in humans, and it would need years of further work to get there.

Why does the "three fronts at once" idea matter? Because a spinal cord injury damages tissue through several processes simultaneously. A material that addresses several of them together may stand a better chance than a therapy aimed at just one.

Keith Thomas broke his neck at the bottom of a swimming pool in the summer of 2020, leaving him paralysed from the chest down. This month his story has been making the rounds again across the news, and for good reason: he can now move his hand, drink on his own, wipe his own face — and feel the fur of his family's dog, Bow, under his fingers.

The technology behind it is called a "double neural bypass," and it's one of the more striking demonstrations of what brain-computer interfaces can do for spinal cord injury. Because the story is resurfacing rather than brand new — the surgery itself took place in 2023 — it's a good moment to look calmly at what's actually been achieved, and what it means.

What a "double neural bypass" is

When the spinal cord is damaged, the problem isn't usually that the brain or the muscles have stopped working. It's that the wiring between them is broken. The brain still forms the intention to move a hand; that signal just can't get past the injury to reach the arm.

A neural bypass builds a detour around the damage. Surgeons at the Feinstein Institutes for Medical Research at Northwell Health in New York, led by Professor Chad Bouton, implanted electrodes in the part of Thomas's brain that controls movement. Those electrodes read his intention to move, a computer interprets it, and the signal is routed — bypassing the injured spinal cord entirely — to stimulators that activate the muscles in his arm and hand.

The "double" part is what makes it stand out. Most systems only handle the outgoing direction: brain to muscle. This one also runs sensation back the other way. Pressure sensors on Thomas's fingertips send touch information back to the sensory areas of his brain, so he doesn't just move his hand — he can feel what he's touching. That two-way loop is why he can register the softness of his dog's fur.

What actually changed for him

Before the implant, Thomas could lift his arms only about an inch. During the trial he was able to move his arm at will and feel touch again. What surprised the research team most was that some improvement lingered even when the system was switched off — suggesting the therapy may be encouraging the nervous system itself to recover a little, not just acting as an external bridge. His gains in arm and wrist strength have carried over into everyday life outside the lab.

The honest caveats

This is genuinely remarkable, and it's also important not to oversell it. This is one participant in an early clinical trial, not an approved treatment you can go and receive. The setup involves major brain surgery — Thomas's operation lasted around 15 hours — and a system that, for now, largely lives in a research lab. It restores specific hand and arm function; it does not reverse paralysis or let him walk. The path from a single extraordinary result to something widely available is long, and honesty about that is part of respecting how hard the work still is.

Still, the direction is real. Every function restored — a hand that grips, a fingertip that feels — is a piece of independence handed back. And the hint that the nervous system might partially heal alongside the technology is exactly the kind of clue researchers build the next decade of work on.

Reader Q&A

Is this available as a treatment? No. It's an experimental system tested in a clinical trial with a small number of participants. It is not an approved therapy you can currently receive.

How is it different from other brain implants I've read about? Most brain-computer interfaces are one-way: they read movement intention and drive a device or muscle. This one is two-way — it also feeds touch sensation from the fingers back to the brain, so movement and feeling are restored together.

Why is the story in the news again now? The surgery took place in 2023, and the system has since been widely recognised as a landmark. Coverage has resurfaced this month, which is why you may be seeing it across several outlets.

Did the improvements last? Some gains in arm and wrist function persisted even when the system was turned off, and carried into daily life — a hint that the therapy may be helping the nervous system recover, not just substituting for it.

One of the most frustrating facts about spinal cord injury is that, in the crucial first days after a severe injury, doctors still have almost nothing to give. Surgery to stabilise the spine, careful management of blood pressure and breathing — yes. But an actual drug that protects the injured cord and improves the odds of recovery? There isn't a widely accepted one. A new Phase III trial published in the Journal of Neurotrauma is part of a long effort to change that.

The drug is hepatocyte growth factor, usually shortened to HGF. Despite the name — it was first identified for its role in the liver — HGF turns out to be a powerful protective and pro-repair signal in the nervous system too. In animal studies it reduces the wave of secondary damage that follows a spinal cord injury and supports the survival of nerve cells. This trial is the culmination of a research programme (led by teams including Kitamura, Nagoshi and colleagues) that has moved HGF step by step from the lab bench toward the clinic.

What the trial tested

The study looked at intrathecal delivery of recombinant human HGF — meaning the drug is injected into the fluid around the spinal cord, so it reaches the injured tissue directly rather than being diluted through the whole body. Timing is central to the design: treatment is given within 72 hours of injury, during the narrow window when limiting secondary damage can matter most.

What stands out is the population. The trial focused on people with AIS grade A injuries — the most severe, "complete" category, where there's no movement or sensation preserved below the level of injury. This is deliberately the hardest group to help and the one where existing treatments have least to offer. Testing a therapy here is ambitious; it's also exactly where a success would mean the most.

How to read a result like this

A couple of honest caveats matter. First, this summary is based on the published abstract rather than the full paper, so the fine detail of how much benefit was seen — and how confidently — needs to be read in the complete results. Second, HGF's earlier human testing was a Phase I/II safety and early-efficacy study, and the reported Phase III work has been a relatively small, focused trial rather than a huge multi-thousand-patient study. That's normal for a condition as specific as acute severe cervical injury, but it means results should be read as an important step, not a finish line.

The reason this is worth flagging at all is the target. Most of the exciting SCI research we cover is about chronic injury — helping people months or years down the line. This is different: it's about intervening in the first hours and days, in the most severely injured people, to change the trajectory before scar and damage set in. If HGF holds up, it would fill one of the biggest gaps in spinal cord injury care.

Reader Q&A

What is HGF in plain terms? Hepatocyte growth factor is a natural signalling protein. In the injured spinal cord it appears to protect nerve cells and limit the "second wave" of damage that follows the initial trauma.

Why inject it into the spinal fluid? Delivering it intrathecally — into the fluid around the cord — gets the drug straight to the injured area at a useful concentration, rather than relying on it travelling through the bloodstream.

Who was this trial for? People with the most severe (AIS grade A) acute cervical injuries, treated within 72 hours. That's the group with the fewest options today.

Does this mean a treatment is coming soon? Not immediately. A published Phase III is a significant milestone, but regulatory approval and real-world availability depend on the full results and on regulators' review. This is an encouraging step, not a treatment you can request yet. (Note: this write-up is based on the abstract.)

If you've been following spinal cord injury news over the past year, the name ARC-EX may already be familiar. It's the non-invasive stimulation system from ONWARD Medical that earned regulatory clearance on both sides of the Atlantic, and we've written before about the wider UK programme testing it in real rehabilitation settings. This week brings a concrete next step: STEPS Rehabilitation, a residential centre in Sheffield, has become one of the first rehab providers in Europe to bring ARC-EX in-house for its clients.

That distinction — a device moving out of the trial and into the day-to-day rehab gym — is exactly the kind of milestone worth paying attention to.

What ARC-EX actually does

ARC-EX is a form of transcutaneous (through-the-skin) spinal cord stimulation. Electrodes are placed on the skin over the back of the neck, and the device delivers gentle electrical pulses to the spinal cord below the level of injury. The idea isn't to override the nervous system but to "wake it up": the stimulation makes the surviving nerve pathways more responsive, so signals from the brain that were once too weak to get through can have more of an effect.

Crucially, it's non-invasive. Unlike epidural stimulators, which require surgery to implant electrodes directly onto the spinal cord, ARC-EX sits on the outside of the body. That lowers the barrier considerably — no operation, no surgical risk — which is a big part of why it's realistic for a rehab centre to offer it as part of a programme rather than only in a hospital research setting.

ARC-EX is the first system to receive a CE Mark in Europe specifically for improving hand and arm strength and sensation in adults living with chronic, incomplete spinal cord injury. The strongest results so far have come when the stimulation is paired with intensive, task-specific rehabilitation — in other words, the device isn't a replacement for the hard work of therapy, it's a way of making that work go further.

Why a rehab centre adopting it matters

There's an important difference between a technology being approved and a technology being available. Regulatory clearance means a device has cleared the safety and evidence bar. Actual availability means a person with a spinal cord injury can walk into a centre and access it as part of their rehab. STEPS bringing ARC-EX into its residential programmes is a small but real example of that second step happening in the UK.

It's worth keeping expectations honest. ARC-EX is aimed at people with incomplete injuries — those who retain some nerve signalling below the injury — and it's about improving hand and arm function, not restoring walking or reversing paralysis. For the right person, better grip and hand strength can translate into meaningful independence: managing a phone, holding cutlery, transferring more safely. That's not a cure, but it's not nothing either.

Reader Q&A

Is this the same as the surgical stimulators I've read about? No. Those are epidural stimulators, implanted onto the spinal cord during surgery. ARC-EX is non-invasive — the electrodes sit on the skin over the neck, so there's no operation involved.

Who is ARC-EX for? It's approved in Europe for adults with chronic, incomplete spinal cord injury, to improve hand and arm strength and sensation. It's not aimed at complete injuries or at restoring walking.

Does it work on its own? The evidence so far suggests it works best combined with intensive, task-specific rehabilitation. Think of it as amplifying the benefit of therapy rather than replacing it.

How do I access it? It's newly available at STEPS Rehabilitation in Sheffield and through the wider UK rollout. Availability is still limited and early, so anyone interested would need to contact providers directly to understand eligibility and cost.

Kenny Salvini was left paralysed after a skiing accident 22 years ago. Out of that came something he now calls his "passion project": the Here and Now Project, a social support network for people with spinal cord injuries and other mobility disabilities, running gatherings up and down Washington's I-5 corridor and on the Olympic Peninsula.

Seattle Sounders FC recently featured the organisation as part of its "Change Champions" initiative, a partnership with Boeing that spotlights local groups making a difference in their communities. The club has a long-running relationship with the Here and Now Project as part of its broader push to make sport, and community life more generally, accessible to people with disabilities.

Why peer support matters this much

Salvini describes the organisation's purpose simply: it's a way to "get knee to knee with people that have been where you've been." That's a distinction worth sitting with. Rehab teams, doctors, and family can offer enormous support after a spinal cord injury, but there's a particular kind of understanding that only comes from someone who has actually lived through it — the practical stuff nobody puts in a discharge pamphlet, the emotional weight of adjusting to a new normal, the small wins that don't seem small at all when you're the one experiencing them.

That's the gap peer-support organisations like this one are built to fill. They don't replace clinical care, but they offer something clinical care often can't: community, on equal footing, with people who simply get it.

A small story with a real point

There's no clinical trial here, no new device or drug. But stories like this matter for a different reason — they're a reminder that quality of life after spinal cord injury isn't just about what medicine can restore physically. It's also about whether people have somewhere to belong. Organisations like the Here and Now Project, and the local partnerships that help amplify them, are part of what makes that possible.

Reader Q&A

What exactly does the Here and Now Project do? It runs regular social gatherings for people with spinal cord injuries and other mobility disabilities across the Seattle area and Pacific Northwest, built around peer connection rather than clinical treatment.

Who runs it? Kenny Salvini, who was paralysed in a skiing accident 22 years ago, leads the organisation as executive director.

Is this only for people in Seattle? The gatherings are regional, focused on Washington State's I-5 corridor and the Olympic Peninsula, so it's most relevant to people in that area — but it's a good example of the kind of peer-support model that exists in many communities.

Why is a football club involved? Seattle Sounders FC's "Change Champions" programme, run with Boeing, spotlights local nonprofits doing meaningful community work — it's a way of using the club's platform to raise awareness and support for groups like this one.

Of all the concerns that have surrounded stem cell therapy for spinal cord injury over the decades, the one that matters most is this: could transplanted cells go rogue? Could they multiply out of control and form a tumour in the spinal cord?

That question has held back clinical translation for years. Animal studies were encouraging. Non-human primate studies were encouraging. But no-one had injected iPSC-derived neural cells into a living human spinal cord and watched what happened — until now.

Published today in *Nature Medicine*, a research team from Keio University School of Medicine in Tokyo reports results from a first-in-human Phase 1 trial. Four men with complete cervical spinal cord injuries received transplants of iPSC-derived neural stem/progenitor cells. The primary finding: across two to four years of follow-up, no tumour formed. No graft-related serious adverse events occurred. The cells appear to have been safe.

That's the headline. Everything else — the neurological changes, the grade improvements, the comparison with registry data — is secondary, and the researchers are careful to say so.

What iPSC-NS/PCs are, and why they matter

iPSC stands for induced pluripotent stem cell. The key word is *induced*. Ordinary adult cells — in this case, cells from umbilical cord blood — can be reprogrammed in the laboratory back to a stem-cell-like state, then directed to become the specific cell type you want. In this trial, those stem cells were guided to become neural stem/progenitor cells (NS/PCs): cells that, once in the right environment, can differentiate into neurons, astrocytes, and oligodendrocytes — the main cell types of the nervous system.

The practical advantage of iPSC-derived cells over earlier stem cell approaches is significant. The cell line used in this trial came from a single healthy donor with a common HLA (immune) profile, manufactured under pharmaceutical-grade conditions at Kyoto University's Centre for iPS Cell Research and Application. That single donor's cells, cryopreserved and quality-controlled, can potentially be used for many different patients — a much more scalable and standardised approach than therapies requiring cells from each individual patient.

The cells were prepared with an additional safety step: before transplantation, a γ-secretase inhibitor was applied to suppress a cell-growth pathway (Notch signalling) that had previously been linked to tumour-like overgrowth in preclinical work. This purification step was one of several quality controls that allowed the team to feel confident enough to proceed to human trials.

Who received the treatment

Seven candidates were screened; four met the eligibility criteria. All were male, aged 26 to 66, with complete cervical SCI (AIS grade A — the most severe category, indicating no voluntary motor or sensory function below the injury) at levels between C4 and C6. The injury had to be confirmed complete, confirmed stable, and in the subacute phase (14–28 days post-injury) — a window the researchers had identified in preclinical work as most likely to support cell integration.

Two million cells were injected directly into the injury epicentre under ultrasound guidance during a single surgical procedure. Immunosuppression (tacrolimus) was started the day before transplantation, maintained for six months, and then tapered off by nine months. Standard rehabilitation was continued throughout.

Follow-up ranged from two to four years depending on when each patient was enrolled — patient 1 has now had four years of surveillance.

The safety results

The primary endpoint was safety, and it was met. Serial MRI scans showed no evidence of abnormal cell proliferation at any time point across any participant. FDG-PET imaging at 24 weeks — which would show metabolically hyperactive tissue, a signature of tumour growth — was normal in all four. During long-term follow-up, no imaging or clinical findings suggestive of tumour formation were identified.

Across all participants, 84 adverse events were recorded — most mild, and most attributable to the immunosuppressive drug tacrolimus rather than to the cells themselves. The most frequent issues were hypomagnesemia (low magnesium, a known tacrolimus effect) and urinary tract infections (common after SCI generally, but listed as possibly related to tacrolimus). One serious adverse event occurred: a transient high potassium reading in one patient, based on a single blood test, resolved spontaneously and was considered most likely a sampling artefact. No serious adverse events were linked to the transplanted cells.

Notably, after tacrolimus was withdrawn at nine months, there were no signs of immune rejection or neurological deterioration. The transplanted cells — which came from a different person — appear to have been tolerated over the long term without immunosuppression.

The neurological picture

This is where the results become interesting, with an important caveat: this trial was not designed or powered to test efficacy. It was a safety study. Any neurological changes are exploratory secondary data, and they cannot be attributed to the transplant rather than to natural recovery. The team is explicit about this, and so should any reporting be.

With that said: all four participants improved on neurological scores. Total ISNCSCI motor score (a 100-point scale measuring voluntary movement across muscle groups) increased in all four from baseline to week 52. The median gain was 13 points, with individual improvements ranging from 10 to 40 points.

Two patients changed AIS grade. Patient 1 moved from AIS A to AIS C — meaning they regained both sensory function and some voluntary motor activity below the injury. Patient 3 moved from AIS A to AIS D — meaning they regained substantial motor function below the injury (AIS D is defined as most key muscles below the level having a grade of 3 or higher on the 0–5 scale). Patient 3's total motor score went from 38 at baseline to 78 at 52 weeks — a gain of 40 points. His independence score (SCIM III) also improved meaningfully.

Patients 2 and 4 did not change AIS grade, though both showed numerical improvements in motor and sensory scores. Gains in all patients remained largely stable during long-term follow-up — there was no late regression.

For comparison, the team identified 52 patients in the Japan SCI registry with comparable injuries (same severity, level, and eligibility profile). The median motor score change in this registry cohort was 7 points at 52 weeks in the available-case analysis and 4 points using last-observation-carried-forward analysis. AIS C or above at 52 weeks was achieved by 12–15% of the registry cohort, compared with 50% (2 of 4) of the transplant participants.

These numbers are suggestive. But they come from a trial of four people compared against a registry, not a randomised trial. The researchers use the word "numerically greater" carefully — not "significantly greater." The differences are encouraging rather than conclusive.

What this study does and doesn't tell us

It tells us that injecting iPSC-derived neural cells into the injured human spinal cord is feasible and does not, at least over two to four years, cause tumours or other graft-related serious harm. That is an important finding. The principal concern that has stood between this technology and human trials has been addressed, with real patients and real follow-up data.

It does not tell us that the cells work. Two patients improved substantially — but so do some people with complete SCI without any stem cell treatment. Recovery from complete cervical SCI is rare but not impossible, especially in the first year. Without a randomised control group, it is not possible to know whether the transplant contributed to the recovery in patients 1 and 3, or whether those patients would have improved anyway.

The team also cannot confirm that the transplanted cells survived and integrated. In animals, you can sacrifice the subject and examine the tissue. In living humans, that's not possible. The evidence for graft persistence is indirect — the absence of deterioration after stopping immunosuppression, some parallels with other CNS cell transplant work — but the direct evidence isn't there.

Why it's still a significant moment

Phase 1 trials exist to answer one question: is it safe enough to keep going? This one answers yes. Four patients, up to four years, no tumour growth — that's a meaningful green light for phase 2 trials with actual control groups, larger numbers, and the statistical power to detect whether the treatment works.

The iPSC platform itself is important beyond this specific trial. A quality-controlled cell product derived from a single donor and manufacturable at scale — with no ethical controversy over embryonic tissue sources, no need for patient-specific cell derivation — is a fundamentally more practical foundation for a scalable therapy than most of what came before it. The infrastructure required to move this into controlled trials exists. Keio University's group has been building toward this for over fifteen years.

The next step is a phase 2 trial with a comparator arm. That trial hasn't been announced yet, but the logic and the evidence now point toward it.

Reader Q&A

Does this mean stem cell therapy for SCI is available now?

No. This was a four-person safety trial in Japan. The treatment is not available outside this research setting, and it would not be appropriate to seek it outside a properly regulated trial. Anyone offering iPSC-based SCI treatment outside a clinical trial should be approached with great caution.

What does AIS A to AIS D actually mean in practice?

AIS is the American Spinal Injury Association Impairment Scale, the standard way of classifying SCI severity. AIS A means no voluntary motor or sensory function below the injury level — a complete injury. AIS D means most key muscles below the injury level have voluntary movement with enough strength to work against gravity. The gap between A and D is large. If the transplant contributed to that in patient 3, it would be remarkable. The honest answer is we don't yet know.

Why did only two patients change AIS grade?

The researchers observed that the two who improved most had "relatively preserved spinal cord structure" on MRI. This matches preclinical evidence suggesting that residual neural networks help transplanted cells find something to work with. If there are very few surviving axons and circuits to build on, the cells may have less to integrate with. This might mean that future trials need to think carefully about patient selection, or combine cell therapy with other approaches for the most severe lesions.

Is it safe to stop immunosuppression after nine months?

In this trial, no harmful effects were observed after tacrolimus was withdrawn. The cells appear to have been immunologically tolerated despite coming from a different person — which is somewhat surprising, but is consistent with animal work suggesting that the central nervous system is a relatively immune-privileged site. That said, the optimal duration of immunosuppression isn't yet established, and this will need to be studied further.

When might a proper efficacy trial happen?

No phase 2 trial has been publicly announced as of this writing. Given the phase 1 results, the logical next step is a randomised controlled trial — probably with more participants, a control arm, and standardised rehabilitation. Given the time it takes to design, fund, and recruit for trials of this kind, a phase 2 result is realistically several years away.

Zebrafish can do something humans can't: fully repair a severed spinal cord and swim normally again within weeks. Scientists have studied this for years hoping to find the "trick" — some magic molecule humans are missing. A new study from Karolinska Institutet, published in *Science Advances*, suggests the real trick isn't a single molecule at all. It's timing.

What the researchers found

The team, led by Konstantinos Ampatzis at Karolinska's Department of Neuroscience, studied adult zebrafish after a complete spinal cord injury. First, they found that neurons near the injury site don't simply die off if they survive the initial trauma — they go quiet for a while, temporarily changing how they fire and how they talk to neighbouring cells, before coming back online.

At the same time, the tissue surrounding the injury changes too. A group of molecules called chondroitin sulphate proteoglycans (CSPGs) — long blamed as one of the biggest obstacles to spinal cord regeneration, because they form a dense barrier around damaged tissue — briefly spike after injury.

Here's the twist: when the researchers used an enzyme to clear away CSPGs early after injury, healing sped up at first, but the fish ended up worse off. Long-term regrowth and swimming ability were both impaired. It turns out CSPGs aren't just a barrier — early on, they protect and stabilise the injured neurons. It's only later that they start getting in the way of regrowth.

Why this matters beyond zebrafish

A lot of experimental spinal cord treatments — including some in human trials — work by trying to clear away CSPGs to "unblock" regeneration. This study suggests that approach might backfire if the timing is wrong. Strip away the protective barrier too soon, and you could be removing something the injured tissue actually needs in those first hours or days.

The researchers now want to identify exactly which cells produce these matrix molecules after injury, and how the process is controlled, with the eventual goal of designing therapies that protect neurons early and only encourage regrowth once that protective phase has done its job.

The honest caveat

This is zebrafish research, not a human trial, and it's early-stage. Human spinal cords are far more complex, and turning "timing matters" into an actual treatment is still a long way off. But it's a genuinely useful piece of the puzzle — it helps explain why some regeneration-focused drugs have underperformed in past trials, and it gives researchers a clearer roadmap for sequencing future treatments rather than just removing barriers all at once.

Reader Q&A

Does this mean a cure is coming soon? No. This is basic biology research in fish, aimed at understanding *why* spinal cord healing succeeds or fails — not a treatment ready for people. But findings like this shape how future human therapies get designed and timed.

Why do scientists study zebrafish for spinal cord injury at all? Zebrafish are one of the few vertebrates that can fully regenerate a severed spinal cord. Because they share a lot of basic biology with humans, studying what makes their repair process succeed can point researchers toward what's missing or going wrong in mammals, including us.

Could "clearing barriers" treatments already in human trials be doing harm? This study doesn't test that directly in humans, so we can't say for certain. But it's a reasonable flag that timing needs more attention in how these treatments are designed and tested going forward.

What happens next in this research? The team plans to figure out exactly which cells are producing the matrix molecules after injury and how that process is controlled, with the long-term goal of designing treatments that protect neurons early and support regrowth later.

Doctors don't always lead with encouragement, and for Nguyen Thi Thanh Loan and Bui Duc Hanh, they didn't. When the Vietnamese couple — both living with the lasting effects of spinal cord injuries — decided they wanted a child, the first response they got was a list of risks.

Two different injuries, one shared reality

Hanh, now 45, was a truck driver until an accident at age 25 left him with a cervical vertebral fracture and lasting effects that make it difficult for him to sit steadily. Loan, 40, was injured in an accident at age three, resulting in a spinal cord injury, a fractured pelvis, and a deformed spine — she has used a wheelchair ever since. When the couple decided to pursue having a child together, doctors flagged a genuinely serious combination of risk factors: Loan's history of pelvic fractures, her spinal deformity, her age over 40, and the general risks of pregnancy layered on top of all of it. They were told that carrying a pregnancy could endanger both her and the baby.

Choosing to try anyway

Rather than treating that warning as a final answer, the couple sought a second, more specialised opinion from fertility specialists. After a full evaluation, the guidance shifted from "don't" to "if you're going to try, don't wait" — Loan's age meant her ovarian reserve would keep declining, narrowing the window for a viable pregnancy.

What followed was a demanding process: repeated trips from their home in Ninh Binh to fertility clinics in Hanoi for consultations, ovarian stimulation injections, egg retrieval procedures, and embryo transfers. Their first IVF cycle didn't go to plan — both mature eggs Loan produced were released naturally before doctors could retrieve them. They didn't stop. In a second cycle, Loan produced eight eggs, though Hanh's sperm quality and motility presented their own obstacles. After embryo culture, the couple had four viable embryos to work with — fewer than many couples going through treatment at the same time, but enough. On 5 December 2023, they welcomed their first child.

Why this story belongs here

Fertility and parenthood after spinal cord injury are rarely discussed openly, and when they are, the framing is often clinical rather than personal. This is a story about two people navigating real medical risk factors, a healthcare system that initially discouraged them, and a fertility process that didn't go smoothly the first time — and choosing to keep going regardless. For a community that's frequently told what it can't do, that's worth telling plainly.

Reader Q&A

Is pregnancy generally considered high-risk for women with spinal cord injuries? It can carry specific risks depending on the level and completeness of injury — including autonomic dysreflexia, altered sensation that can mask labour signs, and mobility-related complications — which is why specialist obstetric involvement is typically recommended. Loan's case involved additional risk factors (pelvic fracture history, spinal deformity, age) on top of her SCI.

Does a spinal cord injury affect fertility for men? It can, depending on the injury, often through effects on ejaculation and sperm quality — which the article notes was a challenge the couple had to work through during IVF.

Why did it take two IVF cycles? The first cycle's eggs were released naturally before retrieval could occur — a recognised risk in IVF timing generally, not specific to SCI. The second cycle produced more eggs and ultimately usable embryos.

Is this an unusual outcome, or does it suggest parenthood is broadly achievable after SCI? Every case depends heavily on individual injury level, associated complications, and access to specialist fertility and obstetric care. This story documents one couple's specific, successful path — not a general guarantee — but it's a meaningful data point for anyone facing similar decisions.

One of the frustrating truths about the adult nervous system is that it's very bad at repairing itself. When the spinal cord is injured, the biological "grow" programs that worked so well when the nervous system was first forming in the womb are largely switched off in adulthood. Scientists have spent years trying to figure out how to flip pieces of that developmental switch back on. A new study, posted as a preprint, adds a promising new tool to that effort.

The problem with retinoic acid

Retinoic acid, a derivative of vitamin A, is one of the best-known signals for triggering nerve growth during development, and it's shown modest regenerative effects when applied after injury too. The trouble is practical, not conceptual: retinoic acid is chemically unstable and breaks down quickly in the body, and it only "docks" with its receptor briefly before disengaging. That makes it a poor candidate for an actual therapy, however promising the underlying biology looks.

Building a more stable stand-in

The research team designed a small synthetic molecule called DM04, engineered to trigger the same downstream effects as retinoic acid — without needing to bind the same way or break down as fast. In lab tests, DM04 encouraged neurons to grow new projections (neurites), switched on the same genes retinoic acid normally activates, and even helped guide human stem cells toward becoming neurons. Notably, it achieved these effects through a different molecular route than retinoic acid typically uses, rather than simply being a more stable copy of the same key.

What happened in mice

When tested in a mouse model of spinal cord injury, DM04 treatment led to improved motor recovery compared to untreated animals. Genetic analysis of the treated tissue showed that DM04 switched on many of the same genes retinoic acid does, but also activated its own distinct set — particularly genes involved in remodelling the extracellular matrix, the structural scaffolding that surrounds cells and can either support or block nerve regrowth depending on how it's organised after injury.

Why a "mimic" molecule matters

The appeal here isn't just replicating what retinoic acid already does — it's building something with the beneficial signalling profile but the chemical durability to actually function as a drug candidate. That combination — mimicking a natural regenerative signal while sidestepping its practical weaknesses — is a common and valuable strategy in translating promising biology into something that could eventually be tested in patients.

Reader Q&A

Is DM04 a treatment people can access? No. This is preclinical research in mice, released as a preprint, meaning it has not yet completed formal peer review. Human trials, if they happen, would be years away.

Did the mice fully recover? The study reports improved motor recovery, not full reversal of paralysis. Preprints in this area rarely claim complete recovery, and this one doesn't either.

What does 'preprint' mean for how much to trust this? A preprint is research shared publicly before undergoing formal peer review by other scientists. The findings are real data from a real experiment, but they haven't yet been independently vetted to the same standard as a published, peer-reviewed paper — worth keeping in mind as a caveat.

Why focus on a vitamin A-related pathway specifically? Retinoic acid signalling is one of the most well-established drivers of nerve growth during embryonic development, which is exactly why researchers keep returning to it as a target — the biological machinery for growth already exists, the challenge is switching it back on safely and durably in an adult nervous system.

Jon Cook has spent years figuring out how to keep doing the sport he loves after his body changed the rules on him. This August, he's turning that adjustment into a fundraising challenge that covers nearly 300 miles.

Cook, a senior oarsman with Dover Rowing Club, is an incomplete paraplegic following treatment for a rare spinal tumour. Rather than stepping back from endurance sport, he's taking on the Para Arch to Arc Challenge — travelling from Marble Arch in London to the Arc de Triomphe in Paris using a hand bike and a rowing boat. At 290 miles, organisers believe it's the first challenge of its kind attempted by a disabled athlete in this format.

Why this kind of story matters

It's easy for spinal cord injury coverage to focus entirely on lab breakthroughs and clinical trials — the "when will there be a cure" stories. But a huge part of life with SCI is what Cook is doing here: adapting a sport, a routine, or a goal to a body that now works differently, and doing it well enough to take on something genuinely difficult. Incomplete paraplegia covers a wide range of ability and Cook's approach — hand bike for the road sections, rowing boat for the water crossing — is a practical example of matching equipment to what the body can do rather than what it used to do.

Cook is raising funds specifically for the organisations that supported him through his own diagnosis and treatment, which gives the challenge a direct, personal throughline: this is fundraising built from lived experience, not a generic awareness campaign.

Reader Q&A

What is incomplete paraplegia? It means some nerve signal function is retained below the level of injury, even though leg function is significantly affected — as opposed to complete paraplegia, where no signal gets through at all. The degree of retained function varies enormously between individuals, which is part of why adaptive sport equipment is so individually tailored.

Why a hand bike and a rowing boat specifically? These are established adaptive sport formats that let an athlete generate power and cover distance using upper body strength and trunk control, without requiring leg-driven propulsion. Combining them lets Cook cover both road and water sections of the London-to-Paris route.

Is this connected to a specific charity? The article identifies the challenge as raising funds for the organisations that supported Cook through his own treatment and adaptation, though it functions as a personal fundraising challenge rather than a single named charity campaign.

Is this the first event of its kind? It's reported as the first challenge of its kind attempted in this specific format (hand bike plus rowing boat, covering this distance) by a disabled athlete.

If you've been through inpatient rehab after a spinal cord injury, you'll know that recovery doesn't look the same for everyone. Some people make significant gains in leg strength; others plateau early. A new study published in the journal Spinal Cord set out to find one of the reasons why — and it points to something measurable at admission: muscle mass.

What they measured

Researchers at a single rehabilitation hospital studied 204 adults with paraplegia (thoracic or lumbar spinal cord injury, meaning the legs are affected but the arms are not) who were admitted within six months of their injury. Using a bioelectrical impedance scan — a quick, non-invasive test similar to some bathroom body-composition scales — they measured each patient's appendicular skeletal muscle mass index, or ASMI. In plain terms: how much muscle mass someone was carrying in their arms and legs relative to their body size, taken at the point they arrived for rehab.

The team then tracked whether each patient achieved a "minimal clinically important difference," or MCID, in their lower extremity motor score during their rehab stay. MCID is a rehab research term for an improvement large enough that patients or clinicians would actually notice it in daily life — not just a statistically detectable blip.

What they found

Just over half the patients (111 of 204, or 54.4%) achieved this clinically meaningful improvement. Higher ASMI at admission was independently linked to a greater chance of reaching that threshold — even after accounting for other factors that affect recovery. The researchers also identified specific cut-off points: above roughly 6.97 kg/m² of muscle mass index for men, and 5.85 kg/m² for women, patients were considerably more likely to show meaningful improvement in leg strength and overall function at discharge. The effect was strongest in women.

Muscle mass alone wasn't a perfect predictor — used by itself, it only modestly separated patients who improved from those who didn't. But combined with other clinical information already collected during rehab, it added meaningfully useful information for predicting who was on track for a good recovery trajectory.

Why this matters beyond the numbers

This isn't a treatment — it's a prediction tool, and prediction tools matter because they change how care is targeted. If a clinician can flag early that a patient's low muscle mass may be working against their recovery, that opens the door to targeted nutritional and strength interventions during the rehab window, when the nervous system is most responsive to physical input. It also gives patients and families a slightly clearer picture of what factors are — and aren't — within their control during recovery.

Reader Q&A

Does this mean building muscle before injury protects you? The study measured muscle mass after injury, at the point of rehab admission, not before injury. It's a snapshot of nutritional and muscular status at a critical recovery window, not a claim about pre-injury fitness.

Can I do anything to change my ASMI during rehab? The study didn't test an intervention — it identified an association. But muscle mass is influenced by nutrition and activity, both things rehab teams already work on. This research strengthens the case for prioritising them early.

Does this apply to tetraplegia (arm and leg involvement) too? This study specifically looked at paraplegia. Whether the same relationship holds for tetraplegia would need separate research.

Is this a cure or a treatment breakthrough? No — it's a predictive marker, not a therapy. Its value is in helping clinicians identify who might benefit from more intensive early support, not in directly improving recovery on its own.

Before he became "Coach" to a generation of kids with physical disabilities, Rodriguez was a 23-year-old learning to survive a gunshot wound that changed the direction of his life. He was shot in 2001, just before he was set to deploy to Afghanistan. The injury damaged his T6 vertebra, and he became a wheelchair user almost overnight.

From patient to peer mentor

Rodriguez had been an athlete since he was young, and he wasn't willing to let that identity go. He started powerlifting in 2004, working his way back into competitive sport from a wheelchair. It was a chance encounter at the gym — with a man he called his "Mr. Miyagi," who turned out to be a priest — that changed his path again. That connection led him to a hospital room, where a woman recovering from a car accident was overwhelmed with fear about her future. Rodriguez, still processing his own trauma, ended up spending hours answering her questions and sharing what his recovery had actually looked like.

He didn't plan to make that a habit. But hospital staff started calling him directly, asking him to visit other patients newly diagnosed with spinal cord injuries — people at the exact moment when a diagnosis feels like the end of the story, not the start of a new one. He kept showing up.

Building something bigger

That informal peer support eventually grew into One Chair at a Time, the nonprofit Rodriguez founded in 2013 to provide adaptive sports opportunities, sports wheelchairs, and education for kids with physical disabilities. The organisation's newest project is a published book collecting true stories of people persevering through the hardest chapters of life-altering injury — turning the same kind of hospital-room conversations Rodriguez started having in the 2000s into something that can reach people who'll never meet him in person.

Why this story belongs here

Peer support is one of the most consistently cited needs in the SCI community, and one of the hardest things to formalise — it depends on people willing to sit with someone at their lowest point and be honest about what recovery and adaptation actually involve. Rodriguez's path from newly injured 23-year-old to founder of a peer-support and adaptive sports nonprofit is a concrete example of how that need gets met in practice, one hospital visit and one wheelchair at a time.

Reader Q&A

What does One Chair at a Time actually provide? Based on its founder's account, the organisation provides adaptive sports opportunities, sports wheelchairs, and education for kids with physical disabilities, alongside informal peer mentoring for people newly navigating spinal cord injury.

Is peer support proven to help recovery outcomes? This article is a human-interest profile, not a clinical study, so it doesn't offer outcome data. But peer support is widely recognised across SCI rehabilitation literature as valuable for psychological adjustment, even where it's hard to formally measure.

What is a T6 injury, roughly? T6 refers to the sixth thoracic vertebra, located in the mid-back. An injury at this level typically affects the legs and lower trunk while sparing arm and hand function, which is consistent with Rodriguez's described ability to return to powerlifting.

Where can people learn more about the book? The article describes it as a recently published collection of true stories about persevering through the hardest parts of injury and disability, produced by the nonprofit; specific purchasing details weren't part of the source article.

Back in 2020, a team at Japan's Keio University did something no one had done before: they transplanted neural progenitor cells made from induced pluripotent stem (iPS) cells directly into the spinal cords of people newly injured. It was the world's first clinical study of its kind. This week, they reported the results that matter most in any cell therapy trial — not "did it work," but "was it safe, and did it stay safe."

What actually happened

Between 2020 and 2025, Professor Hideyuki Okano's team transplanted around two million iPS cell-derived neural progenitor cells into each of four patients, all treated within four weeks of their spinal cord injury — the "subacute" window when the injury site is still able to accept new cells but hasn't yet been walled off by scar tissue.

A year after the surgeries, the team reported no major safety concerns, along with some improvements in physical function in a few of the patients. That was encouraging, but short-term safety data only tells you so much. Cell therapies carry a specific long-term risk: because iPS cells are reprogrammed to behave like embryonic stem cells, there's a theoretical risk they could keep dividing uncontrollably and form tumours years after transplant.

This new report addresses exactly that. Two to four years after surgery, none of the four patients has shown tumour formation or any other major safety issue. Just as importantly, none of them has shown a decline in physical function either — the improvements gained appear to have held.

Why this connects to a bigger picture

This is the same Keio University group we covered back on 10 July, when Okano's team presented preclinical data on a related but distinct cell type — gliogenic neural stem/progenitor cells, aimed at chronic (long-standing) SCI rather than fresh injuries. That announcement described this subacute trial as the foundation the newer chronic-injury work is built on. This week's update is effectively the "how did the original patients do" follow-through on that foundation.

With this long-term safety data in hand, the team now plans to launch an investigator-initiated clinical trial as early as next year, moving the subacute approach from four patients under a research protocol toward something closer to routine clinical use.

What this doesn't tell us

Four patients is a very small number, and this update is about safety, not proof that the therapy meaningfully improves recovery across a larger population. Larger trials with control groups will be needed to establish how much benefit the therapy provides and for whom. But in cell therapy, "we didn't see cancer show up two to four years later" is a genuinely important box to tick before scaling up.

Reader Q&A

Does this mean iPS cell therapy is now approved for spinal cord injury? No. This is long-term follow-up on a small, early-stage research trial. Approval for wider use would require larger controlled trials, which the planned 2027 trial is a step toward.

Why does the tumour risk matter so much for iPS-derived cells specifically? iPS cells are adult cells reprogrammed back to an embryonic-like, highly flexible state before being guided into neural progenitors. That flexibility is what makes them useful, but it also means any cells that don't fully mature down the intended path could, in theory, keep dividing. Multi-year monitoring without tumour formation is a strong reassurance, though not an absolute guarantee for all future patients.

Did any patients get worse? The report states no clear deterioration in physical function was confirmed in any of the four patients, two to four years on.

How does this differ from the chronic SCI programme covered here in July? This trial treated patients within four weeks of injury (subacute). The chronic SCI programme covered separately targets people whose injuries are months or years old, using a different cell type aimed at rebuilding myelin rather than replacing neurons. They're related efforts from the same lab, at different stages, for different patient groups.

One of the most striking phenomena in spinal cord injury research is the difference in recovery between newborns and adults. An adult with a complete SCI — one where the cord is fully severed — faces persistent paralysis below the injury. But in very young animals, the story can be different. Mice injured in the first days of life can, over weeks, regain the ability to walk.

Why? A new study from Jinan University in Guangzhou, China, has dug into that question with unusual rigour — and found a detailed answer. Published this week in the journal *Biology*, it maps the structural rewiring that happens below the injury site in neonatal mice, and shows that recovery doesn't come from the brain reconnecting. It comes from the spinal cord itself.

First, the crucial question: did the cord actually heal?

Studies of recovery after SCI are sometimes muddied by incomplete injuries — residual fibres that survived the procedure and act as hidden bridges. The Jinan University team went to considerable lengths to rule this out.

They performed complete removal of the T9 spinal cord segment in both newborn (postnatal day 7) and adult mice — not just a cut, but full excision of a section of cord, with the gap packed with a gelatin sponge to prevent reconnection. They then verified the completeness of the injury histologically in all animals. Imaging of the lesion site confirmed: in both adult and neonatal mice, there was a clear gap, no continuous axonal bridge, and no NF200-positive (neurofilament) fibres crossing the injury site.

So the recovery in neonatal mice is not explained by the cord healing or supraspinal axons sneaking through. Whatever is happening, it's happening below the injury.

What the neonatal mice actually achieved

Starting from complete hindlimb paralysis immediately after injury, the P7 (postnatal day 7) mice showed progressive recovery over the following weeks. By week three, they had weight support and stepping. By eight weeks, BMS locomotor scores reached approximately 5 — a level that includes plantar stepping and some coordination. By 16 weeks (about four months after injury), scores had improved further.

Adult mice with the identical injury barely moved at all. Their BMS scores stayed below 1 — ankle movement at best — throughout the entire observation period. The difference between the two groups is stark and consistent across all the measures used: BMS, CatWalk gait analysis, weight-bearing, foot-fault testing (accuracy of paw placement), and swimming.

Forelimb activity was also analysed — to rule out the possibility that front-leg pushing or dragging was artificially boosting the hindlimb scores. It wasn't: forelimb parameters didn't improve in a way that could account for the hindlimb recovery.

What was different in the lumbar cord

The researchers examined the lumbar spinal cord — the section below the injury, which controls hindlimb movement — and compared neonatal versus adult injured mice at multiple time points. The findings at each level of analysis were consistent:

Motor neuron survival was similar in all groups. The injury didn't cause motor neuron death in the lumbar cord for either neonates or adults. So the neurones controlling the legs were alive in both groups — but only in neonatal mice were they driving useful movement.

Synaptic coverage around motor neurones (measured by synaptophysin staining, a general marker of synaptic contacts) was better preserved in neonatal mice and partially recovered over time. In adult mice, synaptic coverage was more severely and persistently reduced.

Excitatory versus inhibitory balance shifted over the recovery period in an informative way. Excitatory inputs to motor neurones (measured by VGLUT1, a marker of glutamatergic synapses) progressively increased in recovering neonatal mice. Inhibitory inputs (VGAT) increased early and then subsided. In adult mice, the pattern was different — inhibitory inputs stayed high and excitatory inputs didn't recover — a pattern associated with poor motor output.

Myelin (the insulating sheath around nerve fibres, marked by MBP) was significantly better preserved in neonatal compared to adult injured mice. Better myelin means better signal conduction in the local circuits.

Neuromuscular junctions — the connections between nerve fibres and muscle — were also more intact in neonatal mice by 16 weeks, with partially recovered EMG (electrical muscle response) amplitudes compared to adult mice.

The big picture: CPGs and developmental plasticity

What the lumbar cord in neonatal mice appears to be doing is something researchers call central pattern generator (CPG) activity. CPGs are networks of spinal cord neurones that can produce rhythmic, coordinated motor outputs — like walking — without instruction from the brain. They're present in all vertebrates and are what allows a human to walk on autopilot while having a conversation, or allows the spinal cord to produce stepping reflexes even in a completely anaesthetised animal.

In adult SCI, these CPG networks survive physically but become functionally suppressed — partly by the collapse of excitatory input, partly by the shift toward excessive inhibition, and partly by the loss of descending signals that normally prime them.

In neonatal SCI, something different happens. The circuits below the injury are young and highly plastic — they haven't yet fully matured into fixed patterns. The loss of descending input arrives before those patterns are locked in. Instead of suppressing the circuits, the injury may trigger them to reorganise around the remaining inputs. The progressive increase in excitatory synapses, the recovery of synaptophysin coverage, the better preservation of myelin — these together describe a cord that is actively reshaping its local network to support locomotor output.

Limitations to be clear about

This is a mouse study, and the neonatal mouse spinal cord is very different from a human infant's — let alone an adult's. The recovery observed here, while striking, was partial: even the 16-week neonatal mice didn't walk normally. The mechanisms identified are structural correlates of recovery, not proven causes — the relationship is associative, not causal.

The study used only female mice at endpoint (male neonatal mice were included in early analyses but excluded from the final structural comparisons for sex-matching). And complete transection at postnatal day 7 doesn't map cleanly onto any common human SCI scenario — it's a model for understanding developmental plasticity, not a clinical analogue.

Reader Q&A

Does this mean something can be done for people injured as infants?

The research is about understanding the biology of why young nervous systems recover better — it's not a clinical finding about human infants. But the mechanisms identified here (synaptic reorganisation, excitatory/inhibitory rebalancing, CPG activation below the injury) are being actively studied in adults too. Understanding why neonatal circuits rewire successfully is one route toward identifying what would need to happen to get adult circuits to do something similar.

Does this have any relevance to rehabilitation in adults?

Indirectly, yes. Rehabilitation approaches like locomotor training, functional electrical stimulation, and epidural spinal cord stimulation are already known to influence CPG activity in adults. The detailed picture of what structural changes accompany successful recovery — better excitatory input, preserved myelin, more synaptic coverage around motor neurones — gives researchers and clinicians a clearer target for what they're trying to produce in adults through rehabilitation.

What are CPGs and why haven't I heard of them?

Central pattern generators are well-known in neuroscience, less so in the broader SCI community. They're networks of spinal interneurones that can produce rhythmic outputs (like walking or breathing) independently. After complete SCI in adults, CPGs persist but are typically too suppressed to produce useful movement. Epidural stimulation research (including work on people re-learning to walk after complete injuries) works partly by activating these circuits. This study adds to the evidence that CPGs are a real therapeutic target — and shows in fine structural detail how they can reorganise in favourable conditions.

Could any of this lead to a treatment?

The specific findings — identify what remodelling allows neonatal mice to recover — could guide the search for interventions that promote similar remodelling in adult animals and, eventually, in humans. Candidates might include drugs that shift the excitatory/inhibitory balance in lumbar circuits, or rehabilitation protocols timed to promote synapse formation. That's years of research away, but the map provided by this study is the kind of knowledge that makes that research possible.

After a spinal cord injury, the initial mechanical damage isn't the whole story. What happens in the hours and days afterwards — the so-called secondary injury cascade — accounts for a large portion of the total cell death and tissue loss. Researchers have been trying for years to interrupt this cascade, and a new study from Tianjin Medical University in China targets one of its most damaging components: a process called ferroptosis.

The treatment they've developed involves a specially engineered hydrogel that, when exposed to gentle ultrasound from outside the body, generates molecular hydrogen directly at the injury site. In rats, it worked — reducing cell death, preserving nerve fibres, and improving motor function at eight weeks. The findings were published this week in the journal *Materials & Design*.

The iron problem: what ferroptosis is and why it matters after SCI

Ferroptosis is a form of programmed cell death that was only formally defined in 2012, and understanding it has become one of the more active areas of SCI research. It's driven by iron — specifically by a chain reaction in which excess iron reacts with hydrogen peroxide to produce hydroxyl radicals, a highly destructive form of reactive oxygen species (ROS). These hydroxyl radicals attack lipids in cell membranes, triggering a spreading wave of damage called lipid peroxidation. The cell's membrane breaks down, and it dies.

After SCI, iron overload at the injury site is common. The blood-spinal cord barrier is disrupted, haemoglobin breaks down, and iron floods into the lesion environment. This sets up exactly the conditions for ferroptosis to run unchecked. Cells that might otherwise survive — neurons and supporting glia — die not because of the original impact but because the post-injury chemistry kills them.

The body has a natural defence against ferroptosis: an antioxidant enzyme called GPX4 (glutathione peroxidase 4), which, working alongside glutathione (GSH), neutralises lipid peroxides before they can spread. After SCI, GPX4 and GSH are depleted — leaving cells increasingly vulnerable.

The solution: hydrogen, delivered on demand

Molecular hydrogen (H₂) has an interesting property: it selectively neutralises hydroxyl radicals — one of the most damaging ROS — without interfering with other reactive molecules that cells actually need for normal signalling. This selectivity makes it an attractive therapeutic target. The problem is getting enough of it to the right place at the right time. Hydrogen gas is highly volatile, poorly soluble in biological fluids, and hard to deliver in controlled amounts.

The CSVC hydrogel developed by the Tianjin team addresses this delivery problem through an elegant engineering solution. The gel is made of three components:

- C3N4 nanosheets — a piezoelectric material that generates electrical charge when vibrated by ultrasound. This charge drives a chemical reaction that splits water, producing hydrogen gas. - Vitamin C — which acts as a "hole scavenger" in the chemistry, improving the efficiency of hydrogen generation and extending the reaction. - Methacrylated chitosan (CSMA) — a biocompatible hydrogel matrix that holds the other components together and keeps them localised at the injury site.

In practice: the gel is applied directly to the surface of the injured spinal cord during surgery. Then, over the first three days after injury, low-intensity ultrasound is applied from outside — through the skin — for five minutes per session. The ultrasound activates the C3N4 nanosheets, which generate hydrogen within the gel, which diffuses into the surrounding tissue and scavenges hydroxyl radicals.

What happened in rats

The researchers tested CSVC in a standard rat T10 contusion model — a well-validated approach where a controlled weight drop creates a mid-thoracic SCI. They compared four conditions: injury only, ultrasound only, hydrogel without ultrasound, and hydrogel plus ultrasound (CSVC + US). The key results:

At three days post-injury, tissue analysis showed that CSVC + US significantly increased GPX4 expression and restored GSH levels in neurons at the injury site — markers of ferroptosis suppression. It also reduced lipid peroxidation (measured by MDA and 4-HNE staining). Neither ultrasound alone nor the gel alone produced these effects — both components were needed together.

At eight weeks, the CSVC + US group had significantly better BBB locomotor scores (the standard measure of hindlimb function in rat SCI models) than injury controls from week three onward. They also performed better on swimming tests, sensory testing (hot plate), and detailed gait analysis (CatWalk). Histology showed denser, more continuous axonal fibres at the lesion site, and electrophysiology confirmed better neural conduction across the injury.

What the researchers are honest about

The paper includes a careful limitations section. Ultrasound parameters were not yet optimised — the dose that balances safety and hydrogen output still needs refinement. Hydrogen generation was measured in the lab but not directly in living tissue; the in vivo effects are inferred from the biological markers rather than from direct H₂ measurement. And the hydrogel's long-term degradation in the spinal cord wasn't tracked — an important gap before any human application could be considered.

Vitamin C's contribution is also slightly ambiguous: it's there to improve catalytic efficiency, but it also has independent antioxidant properties. The researchers argue that the control group (gel without ultrasound, which includes the VC) showed minimal protective effect, suggesting the catalytic hydrogen generation is the active mechanism. But they acknowledge this needs cleaner controls.

This is animal model research. The translation to humans — with different anatomy, longer injury-to-treatment windows, and much harder-to-manage logistics — is a significant step that would require extensive further development.

Why it's worth watching

What makes this study interesting beyond the specific result is the design principle. Targeting ferroptosis is mechanistically sound — the pathway is real, well-characterised, and operating in human SCI. The ultrasound-activated delivery system sidesteps the hard problem of getting hydrogen into deep tissue in controllable amounts. And the materials — piezoelectric nanosheets, chitosan, vitamin C — are not exotic; they're relatively accessible and have established biocompatibility track records.

The field of "gas therapy" for SCI (hydrogen being the most studied, but also nitric oxide and carbon monoxide in other contexts) is still young, but the logic is solid and the experimental results are increasingly consistent. This is a study that advances the engineering of the delivery system, which is often the harder part of the problem.

Reader Q&A

What is ferroptosis, and is it definitely happening in human SCI?

Ferroptosis is an iron-dependent form of programmed cell death characterised by runaway lipid peroxidation. It has been documented in human SCI tissue — it's not just a rodent phenomenon. The iron overload conditions that trigger it (disrupted blood-spinal cord barrier, haemoglobin breakdown) are well-established features of human SCI. Whether the scale and timing of ferroptosis is the same in humans as in rat models is less certain, but it is a genuine component of secondary injury.

Does this mean hydrogen gas treatments for SCI are coming?

Not soon, but this is a real research direction. Hydrogen inhalation therapy has been tested in some clinical contexts (stroke, cardiac surgery) and shown some safety signals. The challenge for SCI is targeting the hydrogen to the spinal cord specifically. This study's approach — a localised, surgically implanted gel activated by ultrasound — solves that targeting problem in rats; whether the same approach is practical in humans is a different question.

Is the ultrasound safe? Does it not risk additional damage?

The researchers explicitly checked this. They used low-intensity pulsed ultrasound (0.6 W/cm², well below therapeutic ultrasound levels used in physiotherapy), verified that it didn't cause temperature increases or additional cell death in their models, and found no sonothermal harm. That said, safety in the specific context of acute SCI in humans would need to be established independently.

When would anything like this be tried in humans?

There's no clinical trial for this specific system. For a novel implantable biomaterial in SCI, the typical path involves larger animal studies, rigorous biocompatibility and degradation characterisation, and safety studies before any human phase. Realistically, that's a minimum of five to ten years if development continues without setbacks.

When we picture a spinal cord injury, most of us imagine a young person after a car crash or a diving accident. That picture is still partly true, but a new study published today in the Journal of Clinical Medicine suggests it is slowly going out of date. Drawing on ten years of worldwide data, researchers found that the population living with spinal cord damage is getting older — and the health systems built to care for them may not be ready for it.

What the researchers actually did

A team based mainly at the Medical University of Warsaw took a decade of figures — 2014 to 2023 — from the Global Burden of Disease study, the enormous international project that estimates how much illness and disability different conditions cause around the world. They pulled out two categories the project tracks: spinal cord lesions "at neck level" (cervical, the highest and usually most serious injuries) and "below neck level."

Two things are worth knowing up front. First, these are modelled population estimates, not a headcount of individual diagnosed patients, so they capture the broad shape of the problem rather than an exact tally. Second, the researchers looked at two measures: how many people are living with these injuries (prevalence), and how many years of healthy life are lost to the resulting disability each year (a measure researchers call Years Lived with Disability, or YLDs).

The headline: rates down, real numbers flat

On the surface, there is good news. Once you adjust for the world's changing age profile, the rate of spinal cord lesions fell by about 12% over the decade, and the disability rate fell by 14%. Injury-prevention efforts, safer roads and better trauma care are all plausible reasons.

But here is the catch. The *actual number* of people living with these injuries barely moved — from roughly 27.3 million in 2014 to 27.5 million in 2023. In other words, the world is doing a better job of avoiding these injuries relative to its growing, ageing population, yet the total number of people who need care and support has not gone down. For anyone planning services, the real numbers are what matter, and they are stubbornly flat.

The real story is about age

The most striking finding is a split between the young and the old. Among people aged 15 to 49 — the traditional "typical" spinal cord injury patient — the disability burden fell by nearly 12%. But among people aged 70 and over, it rose by 31.5%. The number of older adults living with these injuries jumped by a third.

Why? The study can't prove the cause, but the authors point to an obvious suspect: falls. As populations age, more older people are living long enough to suffer a serious spine injury from a relatively minor fall — the kind of low-energy accident that a younger body might shrug off. By 2023, the over-70s accounted for more than one in ten of all the disability from spinal cord lesions worldwide, up from around one in twelve a decade earlier. And this ageing shift showed up in every region of the world, rich and poor alike.

Neck injuries do the most harm

The study also confirmed something clinicians have long understood: injuries high up the spine, at the neck, cause a disproportionate share of the disability. Cervical injuries made up 63.5% of the global disability burden in 2023, even though they are not the majority of injuries by count. Neck-level injuries can affect the arms, hands, breathing and much more, so each one tends to carry a heavier long-term cost. Interestingly, this share was highest in wealthier countries — likely because better emergency care means more people survive these severe injuries and live for years with the consequences.

Why this matters

This isn't a breakthrough treatment or a new device. It's a map — and maps are how you plan a journey. The message to health systems is that the demand for rehabilitation, long-term care and support is not fading away, and it is increasingly coming from older people whose needs (other health conditions, frailty, different rehab goals) can look quite different from those of a 25-year-old. Fall prevention for older adults turns out to be spinal-cord-injury prevention too.

Reader Q&A

Does this mean fewer people are getting spinal cord injuries? Relative to the size of the population, yes — the rates are falling. But the absolute number of people living with these injuries has stayed essentially flat, because the population is growing and ageing at the same time.

I'm a younger person with an SCI. Is this relevant to me? Very much so. Younger adults still make up the largest group living with these injuries. The study's point is that services will increasingly have to stretch to cover a wider age range, not that younger people no longer matter.

Should older people be worried about falls? Falls are a leading cause of serious injury in later life, and this study adds spine injury to the long list of reasons that fall prevention — good footwear, home safety, strength and balance exercise, medication reviews — is worth taking seriously.

How reliable are these numbers? They come from careful statistical modelling rather than a direct count, so they show trends and broad patterns rather than exact figures. The authors are upfront that the data can't tell us about injury severity, individual causes, or the quality of care people received. It's best read as a big-picture snapshot.

Most people associate creatine with gym bags and protein shakes. It's one of the most widely used sports supplements in the world, popular for boosting short-burst power and muscle recovery. But researchers have been looking at it from a completely different angle: can this molecule, which sits at the heart of cellular energy production, help the nervous system survive and recover from spinal cord injury?

A review paper published this month in the Indonesian journal Intisari Sains Medis brings together the available evidence and tries to answer that question honestly. The short answer: there's a reasonable scientific rationale and some encouraging preclinical results, but the clinical evidence in humans remains thin, and creatine is not yet an established therapy for SCI. Here's where things actually stand.

The energy crisis after SCI

To understand why creatine is being studied in SCI, you need to understand what happens at the cellular level after the injury itself.

The initial mechanical damage — the moment of impact — is called the primary injury. But the majority of cell death and tissue loss happens in the hours and days afterwards, in what's called secondary injury. One of the key drivers of secondary injury is mitochondrial dysfunction: the energy-producing machinery inside cells gets disrupted, and cells start running out of adenosine triphosphate (ATP) — the molecule all cells use as fuel.

When cells can't make enough ATP, a cascade of damaging processes follows. Sodium and calcium ions flood into cells. Oxidative stress builds up. Cells trigger their own death pathways (apoptosis). Inflammatory signals escalate. The result is a zone of damage that extends far beyond the original injury site.

This is where creatine becomes interesting. Creatine's primary biological role is to support rapid ATP regeneration — specifically through a molecule called phosphocreatine, which acts as a fast-access energy reserve. When ATP is depleted, phosphocreatine can donate its phosphate group to replenish ATP almost instantly, buying cells critical time. The question is whether supplementing creatine before or after SCI can shore up this system enough to limit secondary damage.

What the animal studies show

The preclinical evidence is genuinely encouraging. Rat studies using 2% dietary creatine for four weeks after SCI have shown improvements in functional motor recovery measured by the Basso, Beattie, and Bresnahan (BBB) locomotor scale — a standard test of hindlimb function in rodent SCI models. Other animal studies have found that creatine reduces oxidative stress markers, attenuates apoptosis (programmed cell death), and appears to support mitochondrial function in injured neural tissue.

The mechanisms proposed in the research are plausible: creatine may stabilise cell membranes under metabolic stress, reduce the production of reactive oxygen species (damaging molecules generated during the energy crisis), and support the survival of neurons that would otherwise die in the hours after injury.

It is worth noting that this is all animal model evidence. Rat SCI models are useful for understanding mechanisms, but they don't always translate to human outcomes — a challenge that has frustrated many promising SCI research directions.

What the human studies show

Here the picture becomes more cautious. Human clinical trials on creatine in SCI are limited in number and scope. The most relevant evidence suggests that creatine supplementation can improve upper-extremity work capacity in people with cervical SCI — meaning they may be able to sustain arm and shoulder effort for longer during rehabilitation activities. This is a meaningful finding for people whose upper limbs are their primary means of independence and mobility, but it is a functional/performance benefit rather than evidence of neurological recovery or neuroprotection.

No clinical trial has yet shown that creatine supplementation improves neurological outcomes — motor or sensory scores — after SCI in humans. The studies that have been done tend to be small, vary in their methodology, and don't establish creatine as a treatment that changes the trajectory of SCI recovery.

What the review concludes

The authors from Udayana University in Bali are measured in their conclusions. Creatine has a solid scientific rationale, a plausible mechanism of action in secondary SCI injury, and encouraging results in animal models. The early human data on physical performance is positive. But the evidence base is not yet sufficient to recommend creatine as a neurorestorative therapy after SCI. Larger randomised controlled trials are needed, and fundamental questions remain unanswered — including the optimal dose, the best timing (before injury? immediately after? during rehabilitation?), and whether the preclinical neuroprotective effects translate to humans at all.

The review is a useful stocktake of where the field is, not a green light for creatine as an SCI treatment.

Reader Q&A

Should I be taking creatine after my SCI?

This isn't something to start based on this review alone. The human evidence is limited, and there's no established clinical recommendation for creatine as an SCI therapy. That said, creatine is widely considered safe for most people at standard doses, and it has some evidence for improving upper-body exercise capacity. If you're interested in it as a supplement to support your rehabilitation training, it's worth raising with your rehabilitation doctor or physiotherapist — they can advise based on your specific situation, any medications you're on, and your rehabilitation goals.

Is there any harm in taking creatine?

At typical doses used in research (3–5g per day after an initial loading phase), creatine is generally well tolerated. Common side effects are minor — some people experience water retention and a small initial weight gain. People with pre-existing kidney problems should discuss it with their doctor before supplementing, as creatine metabolism places some load on the kidneys. There are no specific safety concerns flagged for people with SCI in the reviewed literature.

If it helps athletes, why wouldn't it help people with SCI?

The mechanism that makes creatine useful for athletic performance — supporting rapid ATP regeneration during short bursts of intense effort — is the same mechanism that theoretically makes it interesting for neuroprotection. But the contexts are very different. Athletic performance benefits are reliably measured; neuroprotective benefits after SCI are far harder to detect and much less certain to occur. The body of evidence just isn't there yet.

What would it take to establish creatine as an SCI therapy?

A well-designed randomised controlled trial: people with acute SCI randomised to creatine versus placebo, with neurological outcomes tracked over at least six months to a year. Ideally multiple such trials from different centres. That kind of evidence doesn't currently exist for creatine in SCI — and building it is the researchers' key recommendation.

Here's something that might surprise you: your spinal cord already has its own repair cells. They're called ependymal cells, they line the fluid-filled central canal that runs the length of the spinal cord, and under normal circumstances they sit quietly doing very little. But after a spinal cord injury, they wake up.

The problem is that they don't wake up enough, or for long enough, to make a meaningful difference. The repair response they mount is real but limited — far short of what would be needed to close the injury cavity or restore lost function. Scientists have been trying for years to understand what triggers their activation, hoping that if they could identify the switch, they could find a way to turn it up.

A new study from Wenzhou Medical University and Westlake University in China has found that switch — or at least a critical part of it. Published in the journal *Neurobiology of Disease*, the research identifies a metabolic reprogramming process in ependymal cells that drives their activation after SCI, and shows that enhancing this process with a vitamin B6 derivative improves outcomes in mice.

What ependymal cells actually are

The central canal of the spinal cord is a tiny fluid-filled tube that runs from the brain down through the cord. It's lined with ependymal cells — a type of cell that, in adults, behaves somewhat like a dormant stem cell. They have the capacity to divide and differentiate into other cell types (neurons and glia), but in the normal adult spinal cord, they rarely do.

After SCI, ependymal cells partially shed this dormancy. They begin to proliferate — dividing and producing daughter cells — and migrate towards the injury site. They contribute to the formation of the glial scar, which serves as a partial barrier to further damage, and they generate some new cells. But the scale of this response falls well short of meaningful regeneration.

Understanding what drives the activation of ependymal cells — and what limits it — is an important piece of the regenerative medicine puzzle.

What the researchers did

The team used single-cell RNA sequencing — a technology that reads the gene activity of individual cells rather than averaging across thousands — to analyse what happens to ependymal cells in mouse spinal cords after injury. This approach gives a much finer-grained picture of cellular behaviour than traditional methods.

What they found was striking: after SCI, the ependymal cells that went on to activate and proliferate underwent a dramatic shift in their metabolic programme. Specifically, they upregulated a pathway called polyamine metabolism — the production of small molecules called polyamines (putrescine, spermidine, and spermine) that play essential roles in cell growth, division, and survival.

The central enzyme in this switch is called ODC1 (ornithine decarboxylase 1). ODC1 converts ornithine into putrescine, the first step in the polyamine production chain. For ODC1 to work, it requires a cofactor: PLP (pyridoxal 5'-phosphate), which is the biologically active form of vitamin B6.

In cells with high ODC1 activity, polyamine production surges, which in turn supports cell proliferation. In ependymal cells that didn't activate this pathway after SCI, the regenerative response was limited.

What happened when they enhanced the pathway

The researchers tested whether boosting this pathway could improve outcomes after SCI. They gave mice PLP — the active vitamin B6 derivative — after inducing a T10 (mid-thoracic) spinal cord contusion injury, and compared them to untreated mice with the same injury.

The results, at 28 days post-injury, were encouraging:

- Ependymal cells in PLP-treated mice showed significantly higher ODC1 activity and polyamine production - There was more ependymal cell proliferation at the injury site - The injury cavity (the area of lost tissue at the injury site) was smaller in treated mice - Motor function scores (assessed using the BMS locomotor scale, which tests hindlimb movement) were meaningfully better in treated mice

They also confirmed the specificity of the effect: when they used a genetic approach to block ODC1 in ependymal cells specifically, the beneficial effects of PLP disappeared — confirming that the pathway they had identified was genuinely the mechanism at work, not a side effect of something else PLP was doing.

What this doesn't mean yet

This is mouse research. That is not a criticism — mouse SCI models are essential tools for understanding mechanisms, and the experimental design here is rigorous. But the history of SCI research is littered with findings that worked in rodents but didn't translate to humans, for reasons ranging from differences in spinal cord anatomy to timing of the injury response to dose-response issues.

PLP is also not the same as taking vitamin B6 supplements. B6 in food or standard supplements exists in other forms that need to be converted to PLP in the body. The dosing and delivery in this study was direct administration of PLP — not the kind of self-supplementation a person could replicate. Any human application would require careful pharmacological work to establish dose, timing, delivery method, and safety profile.

The researchers are appropriately cautious: they present this as a mechanistic finding that opens a pathway for further investigation, not a treatment ready for clinical translation.

Why it matters

The significance of this research is in the conceptual advance. The spinal cord's own cells are trying to repair the injury — ependymal cells really do respond to SCI and really do have regenerative potential. This study identifies, with unusual molecular precision, the metabolic programme that drives that response and shows it can be enhanced.

That makes it a legitimate candidate for therapeutic development. If PLP or an equivalent agent can be shown to safely enhance ependymal activation in larger animal models, and eventually in humans, it represents a form of treatment that works *with* the spinal cord's own biology rather than imposing something entirely external. That's an appealing strategy — it means the cord's intrinsic repair machinery does the work, just at greater scale.

Reader Q&A

Does this mean vitamin B6 supplements could help after SCI?

No — not based on this research. PLP is the active form of B6, but the study involved direct administration at a controlled dose in an experimental mouse model. Taking B6 supplements as a person with SCI is not the same thing, and there is no human evidence that it affects ependymal cell activity or SCI outcomes. Please don't read this as a reason to take B6 supplements.

What are ependymal cells, and why hadn't they been focused on before?

They have been studied, but they're hard to study — there aren't many of them, they're deep inside the cord, and standard research methods that average across large numbers of cells don't pick up the subtle signals from small populations. Single-cell RNA sequencing has made it much more practical to study rare cell types like ependymal cells in detail, which is partly why this kind of finding is emerging now.

Could this be combined with other SCI repair strategies?

Potentially — and that's one of the reasons it's interesting. Approaches like cell transplantation, growth factor delivery, and electrical stimulation are each working on different aspects of the repair problem. An endogenous approach that amplifies the cord's own stem cell response could, in principle, complement rather than compete with these strategies. That's a long way off, but it's the kind of question researchers will be asking.

When might this be tested in humans?

There's no clinical trial on the horizon yet. The next steps would typically involve larger animal models (non-human primates), safety studies, and dose optimisation before any human trial could be designed. Realistically, that is a pipeline of at least five to ten years if everything goes well — which it often doesn't. But the mechanism is now identified, which is the necessary first step.

One of the frustrating truths of spinal cord repair is that promising cells, injected on their own, often don't stick around long enough to do their job. Put them into an injured spinal cord and many are swept away in the bloodstream within days. A new study from Jinan University in Guangzhou, published in the journal Gels, tries to solve that problem with a simple idea: give the cells a place to stay.

The problem they set out to fix

The cells in question come from what's called the stromal vascular fraction, or SVF — a mixed bag of cells harvested from fat tissue that includes stem cells, immune cells and blood-vessel-forming cells. SVF is attractive because it's relatively easy to obtain and the different cell types seem to work together. The trouble, as the researchers put it, is that after transplantation SVF is "rapidly cleared" and survives poorly, which undercuts any benefit.

The two-part solution

To keep the cells in place, the team built a scaffold: a self-assembling peptide gel (with the unwieldy name HGF-RADA16-IKVAV) that forms a soft, nerve-friendly mesh right at the injury site. Think of it as scaffolding around a building under repair — it holds everything together while the real work happens, and it's laced with a growth factor to encourage nerve tissue to knit back together. The cells were embedded in this gel and implanted into the injured spinal cords of rats.

What happened

In the rats that received the combined treatment, the researchers reported several improvements over the injury alone: the damaging inflammation that follows spinal cord injury was calmed, more neurons survived, and a denser network of nerve fibres (axons) grew across the wound. Crucially, these cellular changes translated into something you can see — better restoration of limb movement — along with reduced signs of neuropathic pain, the burning, hypersensitive pain that plagues many people after spinal cord injury. A protein-level analysis backed this up, showing the treatment shifted the injury's molecular environment, especially in immune and inflammatory pathways.

The all-important caveat

This is a study in rats, not people. That distinction matters enormously, because the history of spinal cord research is full of therapies that worked beautifully in rodents and then failed to translate to humans, whose spinal cords are larger, more complex and injured in messier ways. Nothing here shows that this approach will help a person, and there is a long road — safety testing, larger animals, and carefully designed human trials — before anyone could know. What the study does offer is a well-reasoned strategy and encouraging early evidence that combining cells with a retaining scaffold beats using cells alone.

Why it's still worth knowing about

The interesting thing isn't the specific gel or cell mix — it's the principle. A lot of spinal cord research is converging on the idea that no single ingredient will be enough: you need to protect surviving tissue, calm inflammation, and give new nerve fibres both a reason and a physical structure to regrow. This study is one more careful test of that combination approach, and it adds to a growing body of work suggesting that "cells plus scaffold" is a more realistic recipe than cells by themselves.

Reader Q&A

Could this be a treatment for me or a family member? Not yet, and not for a long time. This is early laboratory work in rats. It's a step in a research direction, not a therapy you could ask a doctor about.

What's special about using fat-derived cells? They're comparatively easy to collect and contain a useful mix of cell types that appear to cooperate. The challenge the study tackles is that these cells don't survive well once transplanted — hence the gel scaffold to hold them in place.

Why does reducing inflammation matter so much? After a spinal cord injury, a second wave of damage from runaway inflammation can harm tissue that survived the initial trauma. Calming that response is one of the main goals of many experimental treatments, because it may preserve function that would otherwise be lost.

Has anything like this reached human trials? Various cell therapies and scaffolds for spinal cord injury are being studied in people, but this particular combination is at the animal stage. Progress in the field is real but slow, and honest reporting means not overstating how close any single study brings us.

Fertility after spinal cord injury is a subject that doesn't always get the attention it deserves. SCI affects a lot of young men, and for many of them, the question of whether they can have biological children is one of the most important quality-of-life issues they face. The honest answer is that most men with SCI will need medical help to have children — but the good news, reinforced by this new study, is that help is available and it works.

The problem isn't sperm production. Research consistently shows that the testicles themselves keep working normally after SCI — sperm are still being made. The issue is getting them out. Ejaculatory dysfunction affects the vast majority of men with SCI, particularly those with higher-level injuries. Some men retain the ability to ejaculate with vibration; many do not.

When natural ejaculation isn't possible, there are two main clinical approaches. A new study from the Yazd Reproductive Sciences Institute in Iran — one of the region's most active fertility centres — compared them directly.

The two methods

The first is electroejaculation (EE). This is a non-surgical procedure where a small probe is placed internally and low-voltage electrical pulses stimulate the prostate and seminal vesicles to produce an ejaculation reflex. It works in 85–100% of cases. General anaesthesia isn't required, and the procedure is repeatable. The main clinical caution is autonomic dysreflexia in men with injuries above T6 — a risk that can be managed with proper monitoring.

The second is testicular sperm extraction (TESE). This is a minor surgical procedure under local anaesthesia where a small tissue sample is taken directly from the testicle and examined under a microscope for sperm. It's used when EE either doesn't produce sperm or can't be performed safely.

In both cases, the retrieved sperm is used for ICSI — intracytoplasmic sperm injection — where a single sperm is injected directly into an egg in a laboratory. This is the standard IVF technique used for male-factor infertility.

What the study found

Researchers followed 37 men with SCI who underwent fertility treatment between 2017 and 2023, covering a range of injury levels from C4 to L2. Across 54 IVF cycles, they tracked three outcomes: whether a pregnancy occurred on a blood test (chemical pregnancy), whether a foetal heartbeat was detected on ultrasound (clinical pregnancy), and whether a live birth resulted.

The overall results were encouraging. Around 35% of cycles resulted in a confirmed clinical pregnancy, and the live birth rate across all cycles was just over 20% — comparable to general IVF success rates in this age group.

More importantly for the central question: there was no meaningful difference between the EE and TESE groups on any of these measures. Chemical pregnancy rates were 44.4% for EE vs. 36.1% for TESE. Clinical pregnancy rates were 33.3% vs. 36.1%. Live birth rates were 22.2% vs. 19.4%. None of these differences were statistically significant — in other words, the data don't support one method being better than the other.

Hormone levels — testosterone, FSH, LH — were also similar between the two groups, which the researchers interpret as confirmation that SCI primarily disrupts ejaculatory function while leaving sperm production itself intact.

Why this matters

Previous research had suggested that TESE sperm might be biologically superior for IVF because testicular sperm haven't been exposed to the inflammatory environment of the seminal tract — and men with SCI often have elevated oxidative stress in their semen, which can damage sperm DNA. On paper, this would predict better outcomes with TESE. In practice, this study (and others like it) suggests those biological differences don't translate into better pregnancy rates, likely because modern ICSI techniques are good enough to select the best sperm regardless of source.

The clinical implication is that EE — which is less invasive, avoids surgery, and can be repeated — makes sense as the first approach to try. TESE remains the right option when EE fails to retrieve sperm, when autonomic dysreflexia risk makes EE unsuitable, or based on individual assessment.

Limitations

This is a relatively small study (37 men, 54 cycles) from a single centre, and the groups weren't randomised — which method was used depended on clinical judgement, not a coin flip. The researchers also note that they didn't analyse sperm DNA fragmentation or other molecular measures that might reveal differences not captured in pregnancy rates alone. Larger prospective studies are needed.

Reader Q&A

If I have SCI, what are my chances of having a biological child?

Based on this study and others, IVF using sperm retrieved by either EE or TESE gives roughly a 20% live birth rate per cycle. That's broadly similar to IVF success rates in the general male-factor infertility population. Chances across multiple cycles are higher. The key first step is a fertility consultation at a centre experienced with SCI patients — not all fertility clinics have this expertise.

Which method would I be offered first?

In most centres, EE is the first-line approach because it's non-surgical and repeatable. TESE is typically used if EE doesn't retrieve viable sperm, if there's a high autonomic dysreflexia risk, or based on your specific injury characteristics. Your fertility specialist and SCI team would make this decision together.

Does the level or severity of my SCI affect the chances of success?

The study included men with injuries from C4 to L2 — a wide range — and injury level didn't emerge as a major predictor of IVF outcome. Sperm production is generally preserved regardless of injury level. Time since injury does matter: there's some evidence that sperm quality declines over many years post-injury, which is why earlier fertility evaluation is generally recommended for men with SCI who may want children in the future.

What about fertility preservation — should I bank sperm after injury?

Many clinicians now recommend discussing sperm banking early after SCI, before any potential decline in sperm quality over time. This is a conversation worth having with your medical team, especially if having children is something you want in the future.

Most brain-computer interface stories you read about focus on movement: a person thinks about moving, and a machine translates that thought into action. That is remarkable on its own. But movement is only half of how we actually use our hands. The other half is feeling — knowing how firmly you are gripping a cup so you don't crush it, sensing when your fingers have found the object you're reaching for. Without touch, even a hand that moves is clumsy and unreliable.

A team at the Feinstein Institutes for Medical Research in New York has now reported, in a peer-reviewed paper in Nature Medicine, a system that tackles both halves at once — and produced results that lasted.

The person at the centre of the study

The participant is Keith Thomas, who sustained a spinal cord injury at the C4–C5 level in a diving accident in a swimming pool in 2020. That level of injury left him unable to move or feel his hands and arms. In 2023, surgeons at the Feinstein Institutes carried out a long, complex operation to implant five small microchips into regions of his brain responsible for movement and for the sense of touch.

What followed is what the team calls a "double neural bypass" — a way of routing signals around the damaged spinal cord in both directions.

How the double bypass works

In one direction, the implants read the electrical activity in Keith's motor cortex when he thinks about moving his hand. A computer decodes that activity in a fraction of a second and sends commands to flexible electrode patches on his forearm, which stimulate the muscles to produce the intended movement. This is the "brain to muscle" pathway that restores movement.

In the other direction, pressure sensors on his fingertips detect contact and force. That information is fed back to the touch-processing region of his brain through the implanted electrodes, recreating a sensation of touch and grip. This is the "hand to brain" pathway that restores feeling.

Put together, the two pathways create a closed loop: he intends to move, the movement happens, and he feels the result — all bypassing the injured cord entirely.

What actually improved

After a structured programme of training that ran for around 35 weeks, the changes were substantial. The team reported that strength in his right arm increased by roughly 86% and in his left arm by roughly 62%. His sensation improved markedly too. In everyday terms, Keith was able to drink from a cup unaided, wipe his own face, and handle delicate objects while controlling how hard he gripped.

The most scientifically interesting finding, though, is what happened when the system was switched off. Some of his recovered movement and sensation remained even without the device running. That points to something beyond a machine simply substituting for lost function: the sustained pairing of intention, movement and feeling appears to have encouraged Keith's own surviving neural connections to strengthen and reorganise — a process scientists call neuroplasticity. In other words, the technology may have helped his nervous system partly heal itself.

Why the "lasting" part matters so much

Many assistive technologies work only while they are actively in use. A device that boosts function while switched on but leaves nothing behind when switched off is still valuable, but it is fundamentally a prosthesis. Evidence that a training approach produces durable, device-independent recovery is different in kind — it suggests the intervention is changing the underlying biology, not just compensating for it. That is the direction the whole field hopes to move in.

Important caveats

This is a single-participant study. One person's results, however encouraging, cannot tell us how well the approach will generalise to others with different injury levels, different amounts of surviving tissue, or different amounts of time since injury. The surgery is major — five implanted microchips and a lengthy operation — and the training is intensive and lengthy. The system as it stands relies on laboratory equipment and expert support, not something a person could take home today.

None of that diminishes the achievement. But the honest framing is that this is a landmark proof of concept, not a treatment ready for the clinic. The next steps are to test the approach in more people and to work toward systems that are less bulky and less dependent on constant expert oversight.

Reader Q&A

Does this cure spinal cord injury?

No. The spinal cord itself was not repaired. The system routes signals around the damaged area, and the training appears to have strengthened some of Keith's own neural pathways. That is a meaningful, lasting improvement in function — but it is not a cure, and the study involved one person.

How is this different from other brain-computer interfaces I've read about?

Most restore movement only. The distinctive feature here is that it restores the sense of touch as well, feeding sensation from the fingertips back into the brain — and that the combination produced improvements that partly persisted after the device was turned off.

Could I get this?

Not currently. This is early-stage research carried out with implanted devices and intensive, supervised training. It is not an approved or available treatment, and would require much larger studies before it could become one.

Why did some function remain when the device was off?

The leading explanation is neuroplasticity — the nervous system's ability to reorganise and strengthen connections with repeated, meaningful use. By repeatedly pairing the intention to move with actual movement and genuine touch feedback, the training seems to have reinforced surviving pathways. This is a hopeful sign but still needs to be confirmed in more people.

One of the most frustrating patterns in regenerative medicine is the therapy that works beautifully in the lab and then disappoints in people. Cells that regrew in a dish fail to regrow in a patient. A growth factor that repaired tissue in an animal model does little in a clinical trial. It happens often enough that researchers have started asking whether something more fundamental is being missed.

A team at the University of Oregon's Knight Campus has proposed an answer that is both simple and unsettling: maybe we have been delivering the right signals in the wrong sequence.

Healing is a sequence, not a switch

When the body repairs an injury, it doesn't fire off all its repair instructions at once. It follows an ordered programme. Certain signals — proteins called growth factors — need to appear first, do their job, and then quiet down so that the next set of signals can take over. Inflammation ramps up and then must resolve. Scaffolding is laid down and then remodelled. The steps overlap, but they have an order, and that order matters.

Most regenerative therapies, by contrast, tend to flood the injury site with a growth factor all at once, or release it steadily over time. If the biology actually depends on a specific sequence — this cue now, that cue later — then dumping everything in simultaneously could blunt the effect or even push the repair process in the wrong direction. The signal is correct; the choreography is not.

What the Oregon team built

To test and exploit this idea, the researchers engineered small proteins called affibodies. An affibody can be designed to grab onto a specific growth factor and hold it — temporarily blocking its activity. By tuning how tightly the affibody holds on, the team can control the rate at which a growth factor becomes available to the surrounding tissue.

In effect, this gives them a dial for timing. Rather than releasing a repair signal all at once, they can delay it, meter it out, or schedule it to become active only after an earlier signal has done its work. That level of control over the sequence of cues is what has been missing from many earlier approaches.

The findings were reported across two papers, in the journals Biomacromolecules and the Journal of Controlled Release.

Where spinal cord injury comes in

The team is applying this timing-control approach to several kinds of repair, including bone healing, muscle repair, and spinal cord regeneration. Spinal cord injury is a particularly hard test case: the injured cord contains a mix of processes that need to be encouraged and processes that need to be held back, and their timing relative to one another is thought to be crucial. A tool that can impose an order on regenerative signals is exactly the kind of thing that could make previously underwhelming spinal cord therapies work better.

It is worth being clear about what this is and isn't. This is foundational bioengineering work — a new method for controlling when regenerative signals act, tested in laboratory and preclinical settings. It is not a spinal cord injury treatment that has been tested in people. Its value for SCI is a well-reasoned hypothesis backed by early evidence, not a clinical result.

Why it's still worth paying attention to

If the central idea holds up, it reframes a lot of past disappointment. Therapies that were written off as ineffective might have been effective all along, just mistimed. That would mean the path forward isn't necessarily finding new signals — it's learning to deliver the ones we already have in the right order. For a field that has spent decades searching for the missing ingredient, the suggestion that the ingredient was there but out of sequence is a genuinely useful shift in thinking.

Reader Q&A

Is this a treatment for spinal cord injury?

Not yet. It is a laboratory method for controlling the timing of regenerative signals, being applied to spinal cord regeneration among other targets. It has not been tested as a therapy in people with SCI.

What is a growth factor, in plain terms?

A growth factor is a signalling protein the body uses to tell cells what to do — for example, to grow, divide, or move to repair damaged tissue. Different growth factors do different jobs at different stages of healing.

What's an affibody and why does it help?

An affibody is a small engineered protein designed to latch onto a specific target — here, a growth factor. By holding onto that growth factor and releasing it in a controlled way, the researchers can decide when and how quickly the signal becomes active, giving them control over the sequence of repair cues.

Why would timing matter so much?

Because healing is a staged process. If a signal that should come second arrives first, it can interfere with the step that was supposed to happen before it. Getting the order wrong can weaken or misdirect the whole repair, even when every individual signal is correct.

Last Sunday, a surgical team at Huashan Hospital — one of China's most prominent neurosurgical centres, affiliated with Fudan University in Shanghai — spent six hours implanting a small array of electrodes into the brain of a 35-year-old man who had lost voluntary use of his hands following a cervical spinal cord injury.

This wasn't an experimental procedure in the usual sense. The device they used — the NEO system, developed by Chinese company Neuracle Technology — had just received commercial approval from China's National Medical Products Administration (NMPA), the country's equivalent of the FDA. This surgery was the first performed under that approval.

If that sounds significant, it is. Until last week, no implantable brain-computer interface had ever been granted commercial approval anywhere in the world. Every previous BCI implanted in a person with paralysis — including those in US Neuralink trials — was done under research exemptions, not as a licensed product a doctor could simply prescribe. We covered the regulatory milestone when it was announced earlier this week; Sunday's surgery is the next chapter.

What the device does

The NEO system is designed for people with cervical SCI — specifically those with injuries between C3 and C7 — who have lost voluntary control of their hands and fingers. The device consists of electrodes implanted into the motor cortex, the part of the brain that controls voluntary movement. It reads the electrical signals the brain generates when the person *thinks* about moving their hand, and translates those signals into commands that can stimulate muscles or control external devices.

The goal is what researchers call "thought-controlled muscle rehabilitation" — restoring functional hand use by creating a new pathway between brain and muscle that bypasses the damaged cord.

Following the surgery, the patient will need to commit to six hours of rehabilitation per day to train the system and rebuild functional connections. That's intensive, and it underscores that this isn't a passive implant — it requires significant sustained effort from the person receiving it.

Why China, and why now

China has an estimated 3.7 million people living with spinal cord injuries — one of the largest SCI populations in the world. Neuracle Technology has been developing the NEO system for several years, with clinical trials demonstrating safety and some functional benefit sufficient for the NMPA to grant commercial approval.

The specific evidence package used to support the approval hasn't been published in full, but the fact that a sovereign national regulator — with its own evidence standards — granted commercial status to an implantable BCI is notable. No other country has done this yet.

What this doesn't mean yet

It would be easy to read "commercially approved BCI" and assume this technology is now broadly available. It isn't. The NEO system is approved in China. It has not been reviewed by the FDA, the European Medicines Agency, or the MHRA. The approval pathway in China, while rigorous, differs from Western jurisdictions, and each regulator will require its own evidence review.

Access will also depend on cost, surgical infrastructure, and — critically — post-surgical rehabilitation resources. Six hours of therapy daily is a serious commitment, one that requires substantial clinical support to sustain.

None of this diminishes what happened on Sunday. For the first time in history, an implantable BCI for paralysis has moved from experimental to commercial, and the first patient has received it. The regulatory door has been opened. The scientific and commercial pressure to bring equivalent devices through the FDA and European processes will only grow.

Reader Q&A

Could someone with SCI get this surgery right now? Not outside China, and even within China, access will depend on cost, clinical eligibility, and availability of surgical centres experienced with the procedure. This is a brand-new commercial product — the first surgery was performed last Sunday.

Is the NEO system the same as Neuralink? No. Neuralink is a US company with its own design still in clinical trials. Neuracle Technology is a separate Chinese company whose device has now received commercial approval — a stage Neuralink has not yet reached.

Does this mean there's a cure for hand paralysis after SCI? No. The NEO system creates a new communication pathway between brain and muscles, but it doesn't repair the spinal cord. It's an assistive technology that, with intensive rehabilitation, may allow some people to regain functional hand use. The extent of recovery will vary by individual.

When might something like this be available in the UK, US, or Europe? Genuinely unknown. It would require separate regulatory submissions, clinical trials acceptable to the FDA or MHRA, and likely several more years of development. The China approval is a significant milestone, but it doesn't shorten any other regulator's pathway.

If you have a spinal cord injury — particularly at a cervical or high thoracic level — the muscles that control your breathing are likely affected. Most people with SCI know this in a general way: reduced lung capacity, difficulty clearing the chest after illness, or shortness of breath with effort. What's been less clear is which training approach actually improves this, and whether the severity of your injury limits what's possible.

New research from the Swiss Paraplegic Centre in Nottwil — one of Europe's leading SCI rehabilitation hospitals — gives a more concrete answer than we've had before. The headline finding is both simple and actionable: train hard, train often, and keep going for at least three months. Almost everything else is secondary.

What the study did

Researchers analysed data from 81 people with SCI who completed respiratory muscle training programmes at the Swiss Paraplegic Centre. Participants spanned a range of injury levels and severities — both complete and incomplete injuries — as well as different ages, body types, and baseline fitness levels. This mix was deliberate: the researchers wanted to understand which factors predicted better respiratory outcomes at the end of training.

The training used inspiratory muscle training (IMT) devices — small handheld tools that add resistance to your breathing, similar in principle to a breathing weight. Participants trained at varying intensities and for varying durations as part of their rehabilitation plans.

What they found

When the researchers modelled which factors predicted improvement in respiratory muscle strength, training intensity and programme duration emerged as the dominant predictors — by a significant margin. Personal characteristics like age, sex, and body weight had comparatively little predictive power. Injury characteristics — level, AIS classification (complete vs incomplete), and time since injury — also mattered far less than the training variables themselves.

The practical implication is striking: someone with a complete C4 injury who trains consistently at high intensity for four months is likely to see more improvement than someone with an incomplete C6 injury who trains at moderate intensity for six weeks. The injury doesn't cap your gains as much as the training approach defines them.

The researchers' specific recommendations: train at the highest intensity you can sustain, three to five times per week, for a minimum of three months.

Why respiratory muscle strength matters so much

Pneumonia is the leading cause of death in people with AIS A (complete motor and sensory loss) and AIS B (complete motor loss, some sensory preserved) spinal cord injuries. The primary reason is that impaired respiratory muscles make it harder to cough forcefully and clear the airways of secretions — a problem that becomes critical during a chest infection.

Stronger respiratory muscles translate directly into a more effective cough, better ability to manage respiratory illness at home, and — critically — a reduced risk of pneumonia requiring hospitalisation or mechanical ventilation. The stakes are high enough that this is one area of rehabilitation where the evidence really matters.

Why this study is worth paying attention to

The Swiss Paraplegic Centre treats around 300 new SCI patients a year and carries one of the largest longitudinal SCI rehabilitation datasets in the world. Research from this centre tends to be grounded in clinical reality rather than tightly controlled experimental conditions — these were real patients doing real rehabilitation, not a highly selected research cohort. That makes the findings more directly applicable to practice.

The study also addresses a question that's been genuinely uncertain: does it matter who you are, or does it matter what you do? The answer, clearly, is the latter. That's useful information for patients deciding whether to invest in a training programme, and for clinicians deciding how to structure one.

Reader Q&A

Should I be doing respiratory muscle training? If you have a cervical or upper thoracic SCI and you ever notice difficulty clearing your chest, shortness of breath, or recurring respiratory illness, then yes — it's worth discussing with your physiotherapist or rehabilitation doctor. The evidence is now reasonably strong that structured training helps, and the risk is low.

What kind of device is used? Inspiratory muscle training (IMT) devices are small handheld tools you breathe through against adjustable resistance. They're available without prescription and relatively inexpensive. Your physiotherapist can advise on the right resistance level and technique for your situation.

Does this apply to incomplete injuries too? Yes. The study included both complete and incomplete injuries, and the key finding — that training intensity matters more than injury characteristics — applied across the range.

What if I've had my SCI for years? Is it too late to benefit? Time since injury was not a strong predictor of training response in this study, which suggests it's never too late to benefit. That said, starting respiratory training earlier in rehabilitation tends to establish better habits and baselines — so earlier is generally better, but later is still worth doing.

Every year, United Spinal Association brings wheelchair users to Washington to sit across from their elected representatives and explain, in plain terms, what their daily life actually looks like. This year's Roll on Capitol Hill took a virtual format for its meetings — 176 sessions held online — but the conversations were the same as they've always been: personal, specific, and grounded in the reality of living with a disability.

194 advocates from 37 states participated in ROCH 2026 on July 14. Three issues were on the table.

The bills they came to support

Faster wheelchair repairs. The FAST Repairs for Wheelchairs Act, introduced by Rep. Ayanna Pressley (D-MA), would prohibit Medicare Advantage plans from requiring prior authorisation before approving wheelchair repairs. For people who rely on a wheelchair for everything, a broken chair that can't be fixed without jumping through insurance hoops isn't an inconvenience — it's a health crisis. Minnesota advocate Joey Carlson, attending his fifteenth ROCH since 2012, put it directly: "We shared how disruptions in getting our wheelchairs repaired negatively affected our health."

There was also good news to report here: advocate Gatwiri Mwiti from California noted that the FAST Act passed — in part due to sustained advocacy from events like this one over recent years.

Better coverage for better chairs. The Choices for Increased Mobility Act would create new Medicare billing codes for carbon fibre and titanium wheelchairs. These materials produce chairs that are lighter, stronger, and more responsive than standard aluminium frames — meaningfully better for daily use. But right now, Medicare doesn't recognise them as distinct from standard models. If you want one, you pay the full cost yourself. The bill aims to fix that by acknowledging these chairs as the legitimate clinical equipment they are.

Home care access. The third issue was access to personal support services — the carers and attendants that allow people with disabilities to live in their own homes and communities rather than in institutional settings. This is a persistent pressure point: the supply of qualified carers hasn't kept up with demand, and funding structures vary widely by state.

Why showing up matters

"The real power of an event like Roll on Capitol Hill is that legislative staff get to hear stories from actual constituents on how policies can impact people's everyday life," said Carlson. That's the mechanism. These aren't professional lobbyists — they're people with SCI, families, occupational therapists, and advocates who live these issues. When they sit across from a congressional staffer and explain what it means to wait weeks for a replacement wheelchair part, the abstract policy question becomes a real one.

"As both an occupational therapist and a person with a disability, I see firsthand how policies around home care, medical equipment and assistive technology impact people's everyday lives," said Christie Cyktor, advocacy coordinator for United Spinal Pittsburgh. "It was empowering to help ensure that the voices of wheelchair users were heard."

What's next

United Spinal's Action Center allows anyone to send an email directly to their congressional representatives about both bills — the Choices for Increased Mobility Act and the FAST Repairs Act. Their grassroots advocacy network is approaching 3,000 members. If you're in the US and want to add your voice, it's a five-minute action at unitedspinal.org.

Reader Q&A

Is this only relevant to people in the US? ROCH is a US event focused on US legislation, but the underlying issues — wheelchair repair timelines, equipment funding, home care — are familiar in most countries. The advocacy tactics also translate: showing up, sharing personal stories, and engaging consistently with decision-makers works everywhere.

What happened with the FAST Act? It passed — a win that advocates at events like ROCH have been pushing for over several years. The Choices for Increased Mobility Act is still working through Congress.

How can I get involved? United Spinal's Action Center (unitedspinal.org) lets you send messages to your representatives directly. You can also join their grassroots advocacy network to stay informed about upcoming actions.

Most people with a spinal cord injury know their injury level from the moment they leave the emergency room. A C5 injury is a C5 injury — and while recovery varies in the weeks and months that follow, the basic neurological picture is usually established within the first 24 to 72 hours.

For a small number of people, that picture doesn't stay fixed. In the days after an SCI, their neurological function begins to deteriorate — sometimes dramatically — as the injury level appears to ascend upward in the cord. Someone who initially presented with a T6 injury might, over the following days, develop the deficits of a C5 or C4 injury. This complication is called post-traumatic ascending myelopathy, often abbreviated to SPAM.

SPAM is rare, which makes it hard to study systematically. A new case series published in *Spinal Cord Series and Cases* (a Nature journal) adds to the small body of literature with three carefully documented cases treated at Vall d'Hebron Hospital in Barcelona over seven years.

What is ascending myelopathy?

The spinal cord doesn't always remain stable after a traumatic injury. In some cases, a combination of secondary injury mechanisms — including oedema (swelling), disruption to blood supply, and inflammatory processes — can cause the damage to extend upward from the original injury site. This is distinct from the normal secondary injury cascade that causes some deterioration in the first few days. SPAM involves more pronounced and sustained upward progression that continues beyond the acute phase.

The mechanisms aren't fully understood. Disruption of the anterior spinal artery (the main blood supply to the front of the cord), inflammatory swelling, and syrinx formation (fluid-filled cavities that develop within the cord) have all been proposed as contributors in different cases. The literature reports mortality rates of around 10%, and survivors face the potential for significant additional permanent disability above their original injury level.

The Barcelona cases

The Vall d'Hebron team identified three cases of SPAM from their SCI population between 2018 and 2025 — representing 0.54% of SCI patients treated at the centre during that period. All three presented with progressive neurological deterioration in the days after their initial injury, with the ascent confirmed on imaging.

The clinically interesting part of the paper concerns treatment. Two of the three patients received methylprednisolone, a specific type of corticosteroid. Both showed a pattern of neurological stabilisation and some recovery. The third patient received dexamethasone — a different corticosteroid — with a less favourable outcome.

The authors suggest that methylprednisolone may have properties particularly relevant to SPAM's mechanisms, including effects on membrane stabilisation and oedema reduction that differ from dexamethasone's profile. However, they are explicit that three cases is far too small a sample to draw clinical conclusions. The difference in outcomes could reflect patient factors, injury characteristics, timing, or any number of other variables unrelated to the choice of drug.

What this paper contributes

Case series like this one exist not to provide definitive answers but to document a condition that's difficult to study precisely because it's rare. The value is in the careful clinical description: what SPAM looked like in these cases, how it was identified on imaging, what was tried and what happened. This adds to the handful of published case reports in the literature and helps build the recognition framework that better-powered studies will eventually test.

For clinicians managing an acute SCI patient whose neurological status is worsening beyond what's expected, this kind of documented clinical experience — even from small numbers — matters. For researchers, it reinforces the case for a multicentre SPAM registry that could finally accumulate enough cases to draw meaningful conclusions.

Reader Q&A

How would I know if ascending myelopathy was happening? The key sign is progressive neurological deterioration — new weakness, sensory changes, or respiratory compromise — in the days after an SCI, when imaging shows changes above the original injury level. This is something acute SCI unit teams monitor for specifically; it's not something a patient would typically identify themselves.

Is this something that can happen long after injury? No — post-traumatic ascending myelopathy occurs in the acute and subacute period, typically within the first days to weeks after injury. A separate condition, progressive post-traumatic myelopathy (often due to syrinx formation), can develop months or years later but is a different entity with different mechanisms.

Should I worry about this if I already have a stable SCI? Once past the acute phase with a stable neurological picture, the risk of SPAM is very low. It's a complication of the acute period immediately following injury.

Does this study tell us what treatment to use? Not definitively. It describes three cases and notes that methylprednisolone appeared associated with better outcomes than dexamethasone in this small group — but three cases cannot establish a treatment protocol. The authors are clear that larger, ideally prospective data is needed before firm recommendations can be made.

Not every spinal cord injury happens in an instant. For one man — we'll call him by the name Aspire shared, though it isn't given — the injury unfolded slowly over six months, a quiet catastrophe that was repeatedly missed before becoming impossible to ignore.

A fracture that hid in plain sight

It started with a fall in November 2024. He'd always been an active, outdoors kind of person — spending much of his time volunteering at Ladybower Reservoir in Derbyshire, rearing fish for a local fly-fishery. After the fall, he developed severe back pain and pins and needles in his legs. His GP prescribed pain medication and physiotherapy and sent him home.

The symptoms seemed to ease, and he kept going to the reservoir. Months passed. Then one day he arrived as usual and had to go home after a couple of hours — the back pain had become unbearable. By the time he got there, he couldn't get out of the car. Both legs had stopped working properly. He took a taxi to A&E, where the driver had to lift him out of the vehicle. The A&E assessment concluded: back pain. He was sent home again.

Shortly afterwards, his condition deteriorated rapidly. An ambulance was called. By that point, he was completely paralysed.

An MRI scan finally revealed what had been happening all along: the fall six months earlier had fractured a vertebra, and it had been slowly grinding against his spinal cord ever since.

Rehabilitation and a different kind of support

He was transferred to Princess Royal Spinal Injuries Centre, where, he says, the staff were fantastic and he began to make some recovery.

It was there that he met Alex, an Aspire Independent Living Advisor (ILA). Alex wasn't a physio or a medic — his role was different. He came to the ward, sat down, and had a conversation.

"Alex first came to see me on the ward and simply stopped by for a chat," the man told Aspire. "We spent a lot of time talking about my life before my injury, my hobbies, and the huge changes I was now facing. Being able to speak openly with someone who genuinely understood what I was going through made an enormous difference."

That conversation — and others like it — helped him start to see a possible future, not just the loss of the life he'd had. Over time, with Aspire's support around practical matters like housing, equipment, and independent living, he worked towards a life that felt like his own again.

He's now back at Ladybower Reservoir, volunteering at the fly-fishery.

Reader Q&A

What does an Aspire Independent Living Advisor actually do? An ILA is typically a peer support worker — someone who has personal experience of spinal cord injury and works with newly injured people on the ward and after discharge. They're not there to provide clinical care, but to offer practical guidance and emotional support: helping people think through housing adaptations, benefits, equipment, and what life after SCI might look like. The peer element — talking to someone who genuinely gets it — is often what people describe as most valuable.

Is it common for spinal cord injuries to develop gradually like this? Most SCI is traumatic and sudden, but gradual or progressive SCI does happen. Conditions like cervical stenosis, tumours, or — as in this case — an unrecognised vertebral fracture can cause the cord to be compressed over time. The symptoms (back pain, weakness, pins and needles) can easily be mistaken for more common musculoskeletal problems, which is part of why delayed diagnosis occurs. If you have persistent neurological symptoms following any injury or trauma, it's worth being specific with medical staff about any earlier fall or incident.

Can people with SCI really return to the activities they loved before? Often, yes — in some form. The nature of the return will depend on the level and completeness of the injury, but adaptive sports, modified volunteering, and accessible outdoor activities are more widely available than many people realise. Organisations like Aspire, Spinal Injuries Association, and local disability sports charities can often help people find pathways back to the things that matter to them.

One of the most frustrating things about spinal cord injury is that the body seems to know how to repair other tissues — skin heals, broken bones knit — but when the nerves that carry signals from your brain to your limbs are damaged, they almost never regrow. Now a team at the University of Cambridge has used a remarkable new laboratory tool to find out exactly why that is, and shown that the block may not be permanent.

What the team built

The Cambridge researchers created what they call a brain-spinal cord organoid model. Organoids are three-dimensional clusters of cells grown in the lab from stem cells — essentially miniature, simplified versions of real organs. By differentiating human embryonic stem cells into both brain tissue and spinal cord tissue, the team coaxed them to self-organise into connected structures that mimic the neural circuits of the human central nervous system.

This is a significant achievement in itself. Creating organoids that model a single organ is already tricky; creating two different tissue types that communicate with each other the way the real brain and spinal cord do is considerably harder. But it gave the researchers a way to study human nerve biology without needing human spinal cord tissue — and, crucially, to observe the same nerves at different stages of development.

The key nerves: corticospinal neurons

The team focused on a specific type of nerve cell: corticospinal neurons. These are the cells that form the long communication highway from your motor cortex (the brain region that controls movement) down through the spinal cord to your muscles. When you decide to pick up a cup of tea, it's corticospinal neurons that carry that instruction. When they're damaged in a spinal cord injury, voluntary movement below the injury site is lost — and unlike many other types of cells, corticospinal neurons are notoriously reluctant to regrow their axons (the long projections that transmit signals).

"When the brain and spinal cord are damaged, the nerve fibres that carry movement signals from the brain to the spinal cord rarely grow back. That's why paralysis is usually permanent," said Dr András Lakatos, senior author of the study and a researcher in the Department of Clinical Neurosciences at Cambridge.

What they discovered

By comparing younger and older versions of their organoids after inducing injury to corticospinal axons, the team found a clear pattern: axons in more mature organoids had a much lower capacity for regrowth than those in younger ones. Something changed during development that switched off the nerves' ability to repair themselves.

The culprit they identified is FGF2 — fibroblast growth factor 2. This is a signalling molecule that plays a key role during normal development. The researchers found that as organoids matured, FGF2 signalling changed in a way that progressively suppressed axon regrowth. When they blocked FGF2 signalling in the mature organoids, regrowth was restored.

In plain terms: the nervous system appears to flip a switch during development that turns off the regeneration programme. And when the researchers found that switch and turned it back, the nerves started growing again.

What this means — and what it doesn't

This is genuinely exciting, but it's important to keep perspective on what stage this research is at.

First, this is a laboratory finding using organoids, not a clinical trial and not a treatment for people living with SCI. There is a long road between identifying a molecular mechanism in a lab model and delivering a therapy to a patient.

Second, FGF2 signalling is one piece of a very complex puzzle. The researchers themselves are clear that many other factors also limit nerve regeneration after spinal cord injury — including the glial scar that forms at the injury site, immune responses, and the physical structure of damaged tissue. Addressing FGF2 alone wouldn't overcome all of those barriers.

What this work does provide is a genuinely useful model — a way to study human corticospinal neuron biology and test potential strategies in a system that reflects human development more closely than animal models do. That's a meaningful tool that the field has lacked.

Dr Lakatos summed it up carefully: "Our model provides a good indication that this block happens during development, and it can still be reversed after this point."

Reader Q&A

Does this mean a cure for paralysis is on the way? Not in any near-term sense. This is foundational research that identifies a mechanism — it's a step toward understanding the problem at a deeper level. Clinical treatments based on this discovery would require many more years of research, safety testing, and trials. The honest answer is that this is promising science that opens a door, not a treatment that's coming soon.

Why is the brain-spinal cord organoid model significant? Most spinal cord research uses animal models (typically rodents) to study nerve biology, which don't always translate well to humans. Human organoids give researchers a way to study human nerve cells and their behaviour directly. They're not perfect representations of the full spinal cord, but they're a much closer approximation for certain types of questions — especially developmental ones like this.

Is FGF2 already targeted by any existing drugs? FGF2 signalling is studied in the context of cancer and wound healing, and there are compounds that modulate it. However, the specific context of corticospinal neuron regeneration is different, and a lot of work would be needed to understand whether any existing drug could be safely used for this purpose — or whether an entirely new approach would be needed.

Could this help people with chronic (long-standing) SCI, or only acute injuries? The study doesn't address this directly. The organoid model investigates the developmental loss of regenerative ability, not the secondary damage that occurs in the weeks and months after injury. Whether this mechanism is relevant specifically to acute or chronic injury — or both — is a question future research will need to tackle.

For years, brain-computer interfaces (BCIs) have lived in the research lab. Impressive results in small clinical trials, lots of scientific papers, a handful of landmark demonstrations — but no commercially approved product, and no clear path to reaching patients outside of research programmes.

That changed in March 2026, when China's National Medical Products Administration (NMPA) granted market approval to the NEO device, developed jointly by Neuracle Medical Technology (based in Shanghai) and researchers at Tsinghua University. The NEO is now the world's first invasive brain-computer interface to receive commercial regulatory approval anywhere in the world.

It is specifically designed for people with cervical spinal cord injuries.

How the NEO Device Works

The NEO works by implanting a coin-sized device in the skull that records brain signals in real time. For someone with a cervical SCI, the connection between the brain and the hands is disrupted — they have the intention to move, and the brain sends the signal, but the damaged spinal cord blocks it from getting through.

The NEO picks up those signals from the motor cortex — the part of the brain that controls movement — and decodes them. It then translates that decoded intention into commands that control a pneumatic glove worn on the hand. The glove responds in real time to the person's brain signals, allowing them to perform grasping movements: picking up objects, holding a cup, drinking water.

The brain does the thinking. The device and glove do the moving.

Who It's For

The commercial approval specifically covers adults aged 18 to 60 with quadriplegia caused by cervical SCI at levels C2 to C6 (from the second to the sixth cervical vertebra). To qualify, patients must also have a confirmed injury grading of A to C on the standard ASIA scale, a diagnosis confirmed for at least a year, and documented stability of their condition for at least six months after standard treatments.

These are people who have chronic, established injuries — not acute cases. They have had time for their condition to stabilise, and existing treatments haven't restored hand function.

The Clinical Evidence

The approval was based on a clinical trial involving 36 implant procedures — four feasibility cases followed by 32 multicenter confirmatory cases. Participants were followed for 18 months. The key finding: all patients achieved home-based, brain-controlled grasp assist using the device. There were no serious adverse events related to the device itself.

Eighteen months of follow-up across 36 people is a modest dataset by the standards of most pharmaceutical approvals, but for a first-generation invasive BCI it's meaningful. The safety record across the trial was clean.

What "Commercial Approval" Actually Means

It's worth being precise about what this approval does and doesn't mean. NMPA market approval means the device can be sold and implanted in China as a regulated medical product — hospitals can offer it, it can be reimbursed through health systems, and it doesn't require patients to enrol in a clinical trial to access it.

It does not mean the device is widely available, cheap, or accessible to most people who might benefit. The infrastructure for implanting and supporting BCIs, and the cost of the device and surgery, remain significant barriers. But the regulatory milestone matters: it establishes that this class of device is real enough to be regulated, that the evidence is strong enough to support approval, and that the transition from research tool to medical product is underway.

What This Means for the Broader BCI Field

China's move is likely to accelerate activity globally. The NMPA approval provides a regulatory template that other agencies will study. Companies and academic groups working on BCI technology elsewhere — including in the US and Europe — will be watching closely. Regulatory agencies will now have a reference point for evaluating similar applications.

For people with cervical SCI specifically, who typically have severely limited hand function, a working BCI that enables grasping has profound quality-of-life implications. Hand function is consistently ranked by people with high cervical SCI as one of the things they most want to regain.

Reader Q&A

Is this available outside China? Not yet. The NMPA approval covers China only. BCI devices for SCI are still in clinical trial phases in the US and Europe, and no equivalent commercial approval has been granted in those regions.

Is the NEO the same as Neuralink? No. Neuralink is a US company developing a BCI platform, and its device (the N1) is currently in human trials under FDA oversight. NEO is a different device developed in China and is the first of its kind to receive full commercial approval. The underlying principles are similar — brain implant decodes neural signals — but the companies, devices, approval status, and current applications are all different.

Does this mean the person can move their hand normally? The current technology enables grasping movements via a pneumatic glove — enough to hold objects, pick things up, and drink. It's not full restoration of natural hand movement. But for someone with C3 or C4 tetraplegia who has no hand function at all, this represents a meaningful practical gain.

What are the risks of an implanted BCI? Any brain implant carries risks: infection, bleeding, device failure, and the need for eventual replacement. In the NEO trial, there were no serious device-related adverse events, which is encouraging. But long-term safety data beyond 18 months isn't yet available, and this is an area that will continue to be monitored.

If you've followed SCI research in recent years, the names Jocelyne Bloch and Grégoire Courtine will be familiar. The two scientists, based at EPFL and CHUV in Lausanne, Switzerland, lead NeuroRestore — a lab that has spent more than a decade working on treatments for spinal cord injury. Their work has resulted in some of the most striking demonstrations in modern neuroscience: patients with complete paralysis of their legs regaining the ability to walk, cycle, and swim, using a technology called a brain-spine interface.

That work has now received major recognition from the French scientific establishment. Bloch and Courtine, together with Guillaume Charvet from CEA-Leti in Grenoble, have been awarded the 2026 Grand Prix scientifique by the Fondation NRJ – Institut de France, carrying a prize of €150,000.

What Is a Brain-Spine Interface?

The brain-spine interface is exactly what it sounds like: a connection between the brain and the spinal cord that bypasses the damaged section.

In a healthy nervous system, movement starts in the brain. The motor cortex sends signals down through the spinal cord to the muscles. When the spinal cord is injured, those signals can't get through. The brain still tries to send them, but they don't arrive.

The brain-spine interface intercepts those signals at the brain and delivers them where they're needed. Specifically, it uses a brain implant called WIMAGINE® — developed at Clinatec (CEA-Leti) — to record electrical activity from the motor cortex in real time. Algorithms then decode this activity to figure out what movement the person is intending. That decoded intention is immediately translated into precisely targeted electrical stimulation of the spinal cord, delivered via an implanted pulse generator below the level of injury.

The stimulation reactivates the circuits in the lower spinal cord that control the muscles for walking. The result is that a person whose brain signal can no longer reach their legs can, in effect, route it around the damage.

More Than a Lab Result

The crucial thing about NeuroRestore's approach is that it doesn't just work in a controlled lab environment. Patients with the system have walked outdoors, on uneven ground, and have continued to improve over time — suggesting that the technology is also prompting neurological recovery beyond what the device alone provides.

This is significant because it means the benefit may compound: the device enables movement, and that movement drives neuroplasticity, which may lead to further gains even when the device is off.

What the Prize Means

The Fondation NRJ – Institut de France focuses specifically on neuroscience. Its Grand Prix scientifique is one of the highest honours in the field in France. That this year's award has gone to a team working on SCI reflects both the scientific quality of the work and the growing recognition that brain-spine interfaces represent a genuinely new class of treatment.

Following more than a decade of work moving from animal models to human clinical trials to real-world demonstration, the technology is now at a stage where serious attention from funding bodies and regulatory agencies is warranted.

Reader Q&A

Who can currently get a brain-spine interface? At present, this technology is available only in clinical research settings. It's not yet a commercially available treatment. The work is progressing toward clinical translation, but a timeline for broader availability hasn't been announced.

Is this the same technology as Neuralink? Both involve brain implants, but they're different systems with different goals. NeuroRestore's brain-spine interface is specifically designed to restore movement in SCI by coupling a brain implant to targeted spinal stimulation. Neuralink is developing a broader platform for brain-computer interfaces with multiple potential applications. The underlying approaches and current stages of development are quite different.

What happens if the device is turned off? Patients who have used the brain-spine interface have reported retaining some of the gains even when the device is not active — likely because the movement enabled by the device is driving neuroplasticity. But this varies by individual, and the device is generally needed for ongoing function.

Why does it matter who wins a science prize? Science prizes are one signal that a body of work is considered credible and important by the scientific community. They also bring funding attention, public awareness, and — in this case — recognition that SCI research is producing real, landmark results worth investing in.

In 2018, Fergus 'Gussie' Farrell's life changed in an instant. A workplace accident left the former Galwegians and Connacht Rugby player paralysed from the waist down. Doctors gave him a 5% chance of ever walking again.

A few years later, he's planning to walk from New York to Los Angeles.

The Challenge

The "Fergus Walks" challenge — set to begin in August 2026 — will see Fergus cover more than 4,500 kilometres over 75 consecutive days, averaging the equivalent of a marathon and a half every single day. If he completes it, he will become the first person with a spinal cord injury ever to walk coast-to-coast across America, and the first Irishman to make the crossing on foot in over a century.

That's not a marketing line — it's a genuine historic milestone. The route itself is brutal for anyone. For someone who was told they'd never walk again, the undertaking is almost impossible to put into words.

Why He's Doing It

Fergus isn't walking for personal glory. He's walking to raise funds and awareness for Spinal Injuries Ireland, the organisation that supports people rebuilding their lives after SCI. His campaign has also partnered with the Christopher & Dana Reeve Foundation, the leading SCI charity in the United States, to raise the profile of the walk on both sides of the Atlantic.

The money raised will go directly toward supporting SCI survivors — the kind of practical help, peer support, and advocacy that makes a difference long after hospital discharge.

A Story Worth Knowing

What makes Fergus's story particularly striking is the gap between where he was told he would be and where he actually is. Recovery from a serious spinal cord injury is never linear, and most people who have been told they had a 5% chance of walking again do not go on to walk a marathon and a half a day for 75 days. Fergus is the exception — and his willingness to channel that into something for others says a great deal about him.

He's not claiming this is easy. Pushing his body and mind to their absolute limits over two and a half months will take a toll. But he's prepared, supported, and clear about what he's doing and why.

Reader Q&A

Is Fergus fully recovered from his SCI? The story doesn't say he's "fully recovered" — people don't always recover completely after SCI, and each person's outcome is different. What we know is that Fergus can now walk well enough to attempt a coast-to-coast challenge. That's remarkable, but it doesn't mean everyone with a similar injury will have the same outcome.

How can I support the walk? The campaign has its own site at ferguswalks.ie, where you can follow progress and donate. The walk is also supported by Spinal Injuries Ireland and the Christopher & Dana Reeve Foundation.

When does the walk start? Fergus is set to begin in August 2026, with the challenge running for 75 consecutive days.

Does this mean the 5% prognosis was wrong? Not necessarily — a 5% chance is not zero. Prognoses after SCI are statistical averages across many patients, and individual outcomes can vary significantly depending on the exact nature of the injury, the care received, and many other factors. Fergus's outcome is inspirational precisely because it's relatively rare.

For people with spinal cord injuries in Winnipeg, First Steps Wellness Centre was more than just a gym. It was the only local provider of intensive activity-based therapy — a specialised form of rehabilitation that goes beyond standard physiotherapy to focus on what the nervous system can still do, even after a serious injury.

In June 2026, it closed.

The closure left a significant gap for SCI patients in Manitoba who depended on the centre's services. And it left one local mother determined not to let that gap go unaddressed.

What First Steps Offered

Activity-based therapy (ABT) differs from conventional rehabilitation in an important way. Standard physiotherapy after SCI tends to focus on adapting to disability — learning to use a wheelchair, building arm strength, managing the effects of injury. ABT takes a different approach: it focuses on activating the nervous system below the level of injury through repetitive, task-specific movement, even when that movement is assisted or passive.

The theory — backed by growing evidence — is that sustained activation of the circuits below a spinal cord injury can drive neuroplasticity and, in some cases, promote meaningful recovery. Some ABT patients have regained function they were told they wouldn't recover. Others have seen gains in sensation, bowel and bladder control, or pain reduction.

First Steps Wellness Centre provided this kind of therapy in Winnipeg. Its clients included people who, with support, had been able to walk with parallel bars or a walker — gains that depended on continued access to specialised sessions.

A Community Without Services

When a specialised facility like First Steps closes, the impact isn't abstract. It means specific people lose specific appointments. In some cases, it means losing access to the only therapy that was producing results for them.

Manitoba's SCI community faces a particular challenge: the province's main alternative for this kind of intensive therapy has historically been centres in Saskatchewan, requiring families to travel or relocate for care. That's not a realistic option for everyone.

The Winnipeg Free Press report highlights a local mother who has stepped forward to champion the community's needs — working to identify what services can be restored, by whom, and where. Her campaign reflects a pattern seen wherever specialised SCI services are cut: the community mobilises, because it has to.

Why This Story Matters Beyond Winnipeg

The closure of First Steps in Winnipeg isn't an isolated event. Specialist SCI rehabilitation services are expensive to run, often depend on charitable funding, and are vulnerable to financial pressures that don't affect mainstream healthcare. When they close, there's rarely an automatic replacement.

The fight to restore services in Winnipeg is the same fight that happens in cities around the world: SCI patients and their families pushing back against a healthcare system that too often treats spinal cord injury as a condition to manage rather than one to actively rehabilitate.

Reader Q&A

What is activity-based therapy, exactly? ABT is a rehabilitation approach that uses repetitive, task-oriented movement to stimulate the nervous system. Unlike standard physiotherapy, it's specifically designed to activate circuits below the level of a spinal cord injury, with the goal of promoting neuroplasticity and potentially recovering function. It typically involves equipment like functional electrical stimulation bikes, body-weight-supported treadmills, and standing frames.

Is there evidence that ABT works? Yes, though the evidence base is still growing. There's good evidence for benefits in secondary health outcomes (like bone density, cardiovascular health, and pressure sore prevention), and emerging evidence for neurological gains in some patients. Outcomes vary by injury level, completeness, and how soon after injury therapy begins.

What happens to people who lose access to these services? For some, it means a plateau or reversal of gains that took months of work to achieve. For others, it means relying on standard physiotherapy that isn't designed to target neurological recovery. In practical terms, it can mean reduced quality of life, worsening secondary health complications, and loss of function that had been hard-won.

How can people support the campaign? The Winnipeg Free Press article covers the mother's ongoing campaign. Following local SCI advocacy groups and Spinal Cord Injury Canada (SCI Canada) would be the best way to stay informed and show support.

When Anthony Guzman had his spinal cord injury at 13, he didn't leave the house by himself for years. By 19, he had his driver's licence, a job at a movie theatre, and a place at the University of Massachusetts.

True Grit didn't do all of that. But it helped.

What True Grit Is

True Grit is a week-long residential summer camp at Rutgers University in New Jersey, run by Rutgers School of Health Professions in partnership with Children's Specialized Hospital, part of RWJBarnabas Health. It's open to young people aged 16 to 21 with spinal cord injuries.

The camp takes place in accessible campus housing — which matters, because part of the programme is the experience of living away from family. For teenagers and young adults with SCI who haven't had that opportunity, the camp week is often a first.

The schedule is built around activities designed to increase independence and help participants think about what comes next: college, careers, relationships, and life beyond the medical system. Supported by therapists, nurses, and peer mentors, participants work through practical challenges and, perhaps more importantly, spend time with other young people who are navigating the same experiences.

The Peer Mentor Effect

Some of the most important people at True Grit are the peer mentors — several of whom have SCI themselves. This matters more than it might seem. Teenagers and young adults with SCI often spend most of their time around people without SCI: family, teachers, carers, clinicians. True Grit gives them access to people who've been through similar things and come out the other side.

Seeing someone who uses a wheelchair and also has a job, a social life, and plans for the future can shift something that clinical therapy can't. It replaces "people like me don't do that" with "actually, people like me do."

Filling a Gap That Rehab Doesn't Cover

Standard rehabilitation after SCI focuses heavily on the physical: regaining function, learning to use equipment, preventing complications. All of that is essential. But it doesn't always address the social, psychological, and practical challenges of becoming an adult with a disability — which is what True Grit specifically targets.

How do you navigate a college campus in a wheelchair? How do you talk to an employer about your needs? How do you handle the social anxiety of being the only person at the party who uses a chair? These aren't medical questions, but they shape quality of life just as profoundly.

True Grit creates space for those conversations, in a community of people who actually get it.

This Year's Camp

The 2026 camp is running this week — July 13 to 19 — at Rutgers' Livingston Campus in New Brunswick, New Jersey. This is the programme's fourth year in its current form, and applications have continued to grow.

Reader Q&A

Who can attend True Grit? The programme is open to young people aged 16 to 21 with spinal cord injuries. You don't need to be from New Jersey — applications come from across the US. The Rutgers School of Health Professions website has details on how to apply.

Is True Grit the only programme like this? It's described as the first of its kind specifically for teens and young adults with SCI in a residential university setting. There are other camps for people with physical disabilities more broadly, but True Grit's focus on SCI, independence, and the transition to adult life makes it relatively unique.

Does the camp offer clinical rehabilitation? The programme includes therapists and nurses, but it's not primarily a clinical programme. It's more about independence skills, peer community, and preparing for adult life. Clinical rehabilitation happens elsewhere.

What happens if someone can't attend in person? The current programme is residential and in-person. For young people who aren't in a position to attend, the Rutgers School of Health Professions and Children's Specialized Hospital both offer other SCI resources and support.

If you live with a spinal cord injury above T6, you've probably heard of autonomic dysreflexia — or you've experienced it. It's a sudden, sometimes severe spike in blood pressure triggered by stimulation below the level of injury that the nervous system can't process properly. Common triggers include a full bladder, catheter problems, constipation, or — critically — surgical procedures on the bladder or urethra. Left untreated, it can cause stroke, seizure, or cardiac events.

Managing anaesthesia in people with high-level cervical SCI during urological procedures is genuinely difficult. General anaesthesia is often used, but it doesn't reliably block the abnormal reflex pathways that drive AD. A team from the China Rehabilitation Research Center in Beijing tried something different: low-dose epidural anaesthesia. The results, published in the Journal of Spinal Cord Medicine, are small in number but striking in their consistency.

The five patients

All five participants had C4–C6 injuries classified as AIS A or B (meaning complete or nearly complete loss of motor and sensory function below injury level). All had documented AD episodes during their regular daily catheterisation — these weren't people with mild or occasional symptoms. They were undergoing urological procedures: four bladder lithotripsies (stone removal) and one bladder neck incision.

Instead of general anaesthesia, the team performed lumbar epidural anaesthesia using ropivacaine at 0.2–0.5% concentration, injecting 4–10 mL depending on the individual. Because sensory testing below the injury level isn't reliable in this population, adequacy of the block was judged indirectly — by observing spasticity control and haemodynamic stability.

What happened

None of the five patients developed intraoperative AD, defined as a systolic blood pressure rise of more than 20 mmHg above baseline in response to surgical stimuli. All five completed their procedures without interruption.

Four of the five had systolic BP that stayed within 20 mmHg of baseline throughout. One patient, who had significant preoperative anxiety, showed a reduction in BP to stable levels (not a dangerous drop — the anxiety itself had elevated it beforehand). One patient required a single dose of atropine for a transient bradycardia (slowing of the heart rate) that resolved quickly.

In the authors' experience, the same procedures under general anaesthesia had previously produced AD episodes in similar patients. That context is important: this isn't a controlled trial, but the comparison to historical experience adds weight.

Why epidural might work better than general anaesthesia

The nerve pathways involved in AD are in the spinal cord, not the brain. General anaesthesia works at brain level — it suppresses consciousness and pain perception but doesn't block the spinal reflex arc responsible for AD. Epidural anaesthesia, delivered into the spinal canal, interrupts signal transmission at the level where the reflex originates. For urological procedures — where the trigger stimulus is coming from the bladder and urethra — a well-placed epidural can block the signal before it ever gets into the ascending pathways that drive the reflex.

The honest limits

Five patients is five patients. This is a retrospective case series — no control group, no randomisation, no blinding. The authors are clear: this is preliminary evidence suggesting epidural anaesthesia warrants further formal investigation. It's not a practice guideline change.

There are also practical challenges. Performing lumbar epidurals in people with severe cervical SCI requires anaesthetists experienced in this population. Positioning may be difficult. And the inability to confirm sensory block level in these patients adds a degree of uncertainty about whether the block is adequate.

Reader Q&A

Does this apply to all SCI, or only cervical injuries? The dysreflexia risk is generally associated with injuries at T6 and above. This study specifically looked at C4–C6, which is among the highest-risk group. The underlying rationale — blocking spinal reflex arcs rather than suppressing brain activity — would theoretically apply across the T6-and-above range, but the study doesn't test that.

Should I ask for epidural rather than general anaesthesia for my next urological procedure? This paper is a starting point, not a prescription. If you have cervical SCI and a history of AD, it's worth discussing your anaesthetic options with your treating anaesthetist and spinal unit team before any urological surgery — and making sure whoever is doing the anaesthetic is familiar with SCI. This paper gives you one more piece of evidence to bring to that conversation.

What's the next step in research? The authors call for prospective studies with larger numbers and, ideally, comparisons between epidural and general anaesthesia in the same population. Given how serious AD can be, and how commonly people with high-level SCI need urological procedures, this feels like an important gap to fill.

When someone sustains a traumatic spinal cord injury, surgeons typically focus on removing bone fragments or disc material pressing on the cord. But there's a second source of pressure that usually gets left alone: the dura, the tough outer membrane that wraps the cord like a sausage casing. After acute SCI, swelling inside this fixed tube can compress the cord further. Some surgeons choose to cut it open — a procedure called a durotomy — to release that pressure. Others don't, for fear of complications.

A new systematic review published in the journal Spinal Cord tries to settle the question by pooling data from eight existing studies. The finding: durotomy is associated with meaningful neurological improvement, and the complication risk appears manageable.

What the numbers show

The meta-analysis included eight observational studies comparing outcomes in patients who received intradural decompression (durotomy, with or without duroplasty — adding a patch to expand the dural space) against those who did not. Pooling the data produced a standardised mean difference in motor recovery of 0.82 — a statistically significant effect (p<0.00001) with a moderately wide confidence interval (0.62–1.02). Translated into clinical terms, this means patients who had durotomy recovered considerably more motor function than those who didn't.

The overall neurological improvement rate pooled across studies was approximately 82%. That sounds high, but it comes with important caveats: heterogeneity between studies was substantial (I²=59–77%), meaning the studies weren't all measuring the same things in the same population at the same follow-up points. The result should be read as "consistent signal in a diverse set of studies," not as a precise prediction.

Who benefits most?

This is where the findings get clinically interesting. Subgroup analysis found a strong effect in people with incomplete or mixed SCI (SMD 1.40, CI 0.05–2.75), but the effect in complete SCI was not statistically significant (SMD 1.21, CI −0.36–2.78). In other words: if there's any preserved function below the injury level, durotomy may offer substantially more benefit.

This makes biological sense. In complete injuries, the cord's circuits below the lesion are already too disrupted for releasing dural pressure to make much difference. In incomplete injuries, preserving the function that remains — by reducing secondary compression — could be the difference between walking and not.

What about complications?

The main concern with cutting the dura is cerebrospinal fluid leakage — the clear fluid that cushions the brain and spinal cord. CSF leaks can cause headaches, infection risk, and wound healing problems. The meta-analysis found no statistically significant increase in CSF-related complications from durotomy (OR 2.29, CI 0.79–6.63). The odds ratio suggests a possible elevation in risk, but the confidence interval crosses 1.0, meaning the evidence doesn't confirm harm.

Sensitivity analyses confirmed the main findings were robust — they held up when individual studies were removed one at a time.

The honest limitations

The review's authors are careful to point out that all eight included studies are observational, not randomised trials. This matters: surgeons didn't randomly assign patients to durotomy or no durotomy. They chose based on injury severity, presentation, and clinical judgment — meaning the groups being compared may not be equivalent. Higher heterogeneity and small study effects were also detected, which can inflate apparent benefits.

The conclusion is appropriately cautious: durotomy *may* improve recovery, particularly in incomplete injuries, but randomised controlled trials are needed before it becomes standard practice.

Reader Q&A

Does this mean I should have wanted a durotomy after my injury? Not necessarily — and this review doesn't change surgical guidelines yet. Many decisions in acute SCI surgery are made under intense time pressure, and durotomy adds surgical complexity and risk. This paper builds the evidence base for a procedure that some neurosurgeons already use selectively; it doesn't tell us it should be universal.

Is this common practice? Durotomy in acute SCI is practised at some specialist centres, particularly in Europe, but it's not a standard of care anywhere. The variation in practice is part of why a meta-analysis is valuable — it aggregates the scattered experience into one picture.

What is 'duroplasty' when mentioned alongside durotomy? Duroplasty means adding a patch (often a synthetic or biological material) after opening the dura, creating extra room inside the membrane rather than just releasing the immediate pressure. Some studies in this review used durotomy alone; others used durotomy with duroplasty. The meta-analysis looked at both together under the term 'intradural decompression.'

When would an RCT happen? This review is partly designed to build the case for exactly that. The authors argue the current observational evidence is strong enough to justify a well-designed prospective trial. Given the logistical complexity of acute SCI surgery research, that could still be several years away.

One of the biggest frustrations with stem cell research in spinal cord injury has been the gap between lab results and actual treatment. Promising findings in animals are common. Approved human trials are not. That gap is closing.

A new trial published in BMJ Open describes a phase I study that has received regulatory clearance from both China's National Medical Products Administration and the US Food and Drug Administration. It will test an off-the-shelf formulation of iPSC-derived motor neuron progenitor cells — shortened to MNPs — in adults with subacute SCI (injury sustained within the past few months). The trial is multicentre, enrolling at two Chinese hospitals, and can take 12 to 24 participants.

What makes this different

Most stem cell therapies under development require cells grown from the patient's own tissue — a time-consuming and expensive process that's hard to scale. This study takes a different approach. The MNPs are derived from induced pluripotent stem cells (iPSCs), which are essentially reprogrammed adult cells that have been wound back to an embryonic-like state. Crucially, the cells are allogeneic — meaning they come from a donor bank rather than from each patient. Think of it like blood typing: with the right preparation, donor cells can be used in multiple recipients without triggering rejection. The result is a standardised product that can be manufactured in advance and stored until needed.

The "motor neuron progenitor" label matters too. These aren't generic stem cells. They're cells that have already been guided partway toward becoming motor neurons — the nerve cells responsible for movement — before being delivered. Preclinical studies suggest they work through two mechanisms: directly replacing lost or damaged motor neurons, and supporting the survival of existing cells by releasing protective signals.

How the trial works

Participants will receive the cells via intrathecal injection — a needle into the spinal canal, the same route used for some anaesthetics and chemotherapy drugs. This puts the cells close to where they're needed without requiring open surgery.

The trial runs in two sequential phases. In the first (single ascending dose, or SAD), each participant gets one injection. In the second phase (multiple ascending dose, or MAD), participants receive four injections spaced two weeks apart. Within each phase, doses step up from 50 million cells to 150 million cells, with safety reviews between each step. The escalation only continues if no serious dose-limiting toxicities emerge in a 28-day window.

The primary goal is safety — the trial is too small to prove effectiveness. Researchers will track adverse events, serious adverse events, and whether any dose causes unacceptable harm. But they'll also collect a rich set of secondary data: ASIA Impairment Scale grades, motor and sensory scores, bladder function, spinal cord imaging, cerebrospinal fluid biomarkers, and neurophysiological measurements. Follow-up visits run to 360 days after the last injection.

Who can join

The study targets adults with subacute SCI — those who sustained their injury within a specific time window that makes cells more likely to integrate and survive (the early months after SCI, before scarring hardens the injury environment). The trial excludes people with complete, long-standing injuries.

Reader Q&A

This is a protocol paper — no results yet. Why is it worth writing about? Because the regulatory approvals are real, the cell manufacturing approach is novel, and the subacute window means people who are currently in early recovery could potentially be eligible — or know someone who is. Knowing a trial exists is the first step to finding out if you qualify. Enrolment is at Third Affiliated Hospital of Sun Yat-sen University (Guangzhou) and Third Hospital of Hebei Medical University.

What does 'off-the-shelf' actually mean for safety? It means the cells are from a donor, not the patient. The team has included immunosuppression protocols to manage any rejection response, but this is a key part of what the safety monitoring is watching for. It's not assumed to be risk-free — that's what phase I is for.

Could this help people with older, chronic SCI? This specific trial is for subacute injury only. The biology of chronic SCI — heavy scarring, years of tissue change — is quite different, and the cell types needed may be different too. There are separate programmes working on chronic SCI (the gliogenic NSPC approach from Dr. Okano's group, for example, which we covered here recently). This trial isn't a path forward for everyone, but it may be a door opening for a subset.

When will we see results? The trial is structured around 360-day follow-up per participant, so published results are likely at least 18 months away. This is normal for phase I — patience is the price of rigour.

Getting the right care in the acute phase after spinal cord injury matters enormously — that much is accepted. What's less well documented is exactly *how much* it matters, and what the consequences look like over time when people don't get specialist input. A study published in BMC Health Services Research addresses that gap with one of the larger datasets assembled on the question: 1,733 people with incomplete traumatic SCI, followed for up to a year after discharge, drawn from British Columbia health records linked to the Rick Hansen Spinal Cord Injury Registry.

The headline finding: receiving both specialised acute care *and* specialised rehabilitation reduces the odds of an unplanned hospital readmission within a year by roughly half, compared to receiving neither.

How the study was designed

Researchers pulled data on everyone in BC who sustained an incomplete traumatic SCI between 2001 and 2017. They divided participants into four groups based on where they received their acute and rehabilitation care: fully specialised (both acute and rehab in specialist settings), partially specialised in different combinations, and fully non-specialised. The analysis adjusted for differences between groups — age, injury severity, and other factors — to try to isolate the effect of specialised care itself.

The numbers

The fully specialised group (N=421) was the reference point. Against that benchmark:

Non-specialised acute care (regardless of rehab setting, N=810): OR 2.06, p<0.01. Roughly double the odds of unplanned readmission within the year.

Specialised acute care only (no specialist rehab, N=411): OR 1.59, p=0.05. Still elevated compared to full specialist care, though the p-value sits right at the significance threshold.

Specialised rehab only (no specialist acute, N=38): OR 2.54, p=0.02. Interestingly, having specialised rehab without specialised acute care was associated with *higher* odds of readmission than the reverse — possibly because people in this group sustained complications from their initial non-specialist acute management that drove later readmissions.

In total, 536 unplanned readmissions were recorded across the 17-year period.

What people were being readmitted for

This is where the study adds real texture. In the specialised care group, the most common cause of readmission was urinary tract infection (UTI). That's sobering — even with expert management, UTI remains a persistent challenge after SCI.

In the non-specialised group, the most common readmission cause was injury and surgical complications: femur fractures, problems with internal orthopaedic implants or grafts, and similar issues. These are the kinds of secondary complications that specialist SCI centres are specifically trained to prevent — proper positioning, skin monitoring, fall prevention, and the management of spasticity and mobility. Finding them as the dominant readmission driver in non-specialist settings is a direct signal of what specialist input protects against.

The honest limits

This is an observational study based on administrative health records, which means the researchers couldn't randomly assign people to specialist or non-specialist care. There may be unmeasured differences between groups — for example, people with more severe injuries or more complex presentations might have been more likely to reach specialist centres, which could bias the comparison. The study spans 17 years, during which BC's healthcare system evolved, though the researchers note SCI specialisation patterns were fairly stable across the period.

The study focuses only on incomplete injuries, so findings can't be directly applied to complete SCI.

What this means practically

British Columbia isn't unique in having a mix of specialist and non-specialist facilities. The same pattern exists in most countries: a handful of designated SCI centres handling the complex cases, with smaller hospitals managing many others. This study quantifies the cost of that fragmentation in terms of downstream readmissions — and, by implication, quality of life and healthcare spending.

For people who've recently been injured or are supporting someone who has: wherever possible, advocate for access to a specialist SCI unit. The acute phase matters, but so does the rehabilitation phase — and this study suggests missing specialist input at *either* stage carries a measurable cost.

Reader Q&A

Does this study cover Ireland or the UK? No — it's a Canadian dataset from British Columbia. But the principles apply wherever you are. Ireland has the National Rehabilitation Hospital in Dún Laoghaire and a small number of spinal units. Access to those services isn't equal across the country, and studies like this make the case for pushing to change that.

What counts as 'specialised' care in this study? The researchers used the Rick Hansen SCI Registry to classify whether each participant's acute and rehabilitation care was delivered at a designated SCI specialty centre. In BC, this means centres with specialist neurosurgical and rehabilitation expertise, SCI-specific nursing protocols, and dedicated therapy teams.

If I'm already past the acute phase, is it too late? The study is about early-phase care, but it doesn't mean later specialist input is useless. What it shows is that the foundation matters: complications established in the acute phase (poor pressure care, UTI management, surgical complications) can have ripple effects that last a year or more. If you're in ongoing care, pushing to see an SCI-specialist team — even years after injury — is always worthwhile.

Ask people living with spinal cord injury what's hardest about daily life, and pain often features near the top of the list. Not the pain from the injury itself — that acute period passes — but the persistent, often burning or electric-shock-like pain that can develop months or years later. It's called neuropathic pain, and it's the nervous system misfiring: signals being generated, amplified, or misdirected in ways that no longer serve any protective purpose. For many people, it's both debilitating and resistant to conventional pain management.

Spinal cord stimulation (SCS) — the delivery of gentle electrical pulses to the spinal cord via implanted or surface electrodes — has emerged as one of the more effective options. A review published in Neural Regeneration Research pulls together what's known about how it works and what the clinical evidence shows for SCI-related pain specifically.

Understanding SCI-related chronic pain

Chronic pain after SCI comes in several flavours. At-level pain sits at or near the injury site. Below-level pain affects areas where sensation has been lost, which is particularly strange to experience: pain in a limb you can't feel. Above-level pain can develop too, driven by the same rewiring processes. What they have in common is that they're centrally generated — the source is the nervous system itself, not tissue damage at the site you feel the pain.

This is why analgesics that work at injury sites (anti-inflammatories, opioids at lower doses) often fail: there's no peripheral injury to block. The pain is coming from the spinal cord and brain directly.

How spinal cord stimulation intervenes

SCS works through several overlapping mechanisms described in the review:

Gate control. The best-established explanation comes from gate control theory, originally proposed in the 1960s but still holding up well. The spinal cord contains interneurons that act as gatekeepers — when large-diameter sensory fibres are active (the ones that carry touch, vibration, and proprioception), they suppress the transmission of pain signals from smaller C fibres. SCS activates those large fibres electrically, effectively closing the gate before pain signals get through. This is why early SCS users often described a tingling or buzzing sensation replacing the pain — the large-fibre signals were physically competing with the pain pathway.

Neurochemical regulation. SCS also shifts the balance of neurotransmitters in the spinal cord. It increases levels of inhibitory transmitters — GABA (the main 'off switch' in the nervous system), serotonin, and acetylcholine — while reducing excitatory ones. This is a more diffuse effect than gate control, operating across broader circuits rather than at a single point.

Anti-inflammatory and neuroprotective effects. SCS downregulates pro-inflammatory signalling molecules in the spinal cord and upregulates anti-inflammatory responses. It also promotes the release of neurotrophic factors — proteins that support nerve survival and can facilitate axonal repair. These effects may partly explain why some patients report ongoing improvement even after stimulation periods end.

What the clinical evidence shows

The review summarises clinical studies showing that SCS has demonstrated efficacy for below-level SCI pain — the type that develops in anaesthetic regions, which is often the most treatment-resistant. Results for at-level pain are more mixed; some patients respond well, others less so.

Reported outcomes include reductions in pain intensity scores, reduced reliance on opioid medication, and improvements in sleep and daily function. Response rates are not universal — like most neuromodulation therapies, SCS works well for some patients and modestly or not at all for others. Patient selection and programming (the specific pattern of electrical pulses) appear to matter significantly.

Newer SCS approaches — including high-frequency stimulation (which avoids the tingling sensation of conventional SCS) and burst stimulation (a patterned delivery mimicking natural nerve firing) — have shown promising results in chronic pain generally and are beginning to be studied in SCI populations.

How it's delivered

SCS can be delivered in two ways. Epidural SCS involves implanting a small lead under the skin near the spine, connected to a pulse generator (similar to a pacemaker) implanted in the abdomen or buttock. This is the established surgical route, used for decades in chronic pain management. Transcutaneous SCS (tSCS) applies the current through electrodes on the skin surface — non-invasive and reversible, which makes it attractive for research and for patients who aren't surgical candidates. Both appear to reduce pain, though the evidence base is stronger for the implanted route.

Reader Q&A

I already use SCS for pain — am I getting the right kind? SCS is a broad category, and the specific programming matters. Conventional SCS produces a tingling (paresthesia) that overlaps the pain area; high-frequency and burst modes don't. Some pain clinics are still primarily using conventional programming. If your current setup isn't giving you the relief you hoped for, it's worth asking your pain specialist about alternative programming modes or different electrode placements.

Is SCS covered by health insurance / the HSE? In Ireland, implanted SCS for chronic pain is available through the HSE for certain indications, though access varies considerably. In the UK, NICE has guidance supporting SCS for various chronic pain conditions. Whether SCI-related neuropathic pain specifically qualifies depends on the clinical centre and available funding. Your pain specialist or SCI nurse can advise on the pathway in your area.

Could this help with spasticity as well as pain? There's evidence that SCS can reduce spasticity in some SCI patients — this is a separate but related effect, probably driven by similar modulation of spinal interneurons. This paper focuses on pain specifically, but research into the dual benefits of SCS for both pain and spasticity is ongoing.

What if I've tried medications and nothing works? SCS is often considered after medications (gabapentinoids, amitriptyline, duloxetine, opioids at appropriate doses) have been tried without adequate effect. The review supports its use as an effective option for treatment-resistant SCI pain, but the decision should be made with a specialist pain clinic that has SCI experience.

There's a particular moment in Ian Burkhart's story that researchers are still trying to make sense of. Burkhart became the first quadriplegic person to regain hand movement using a brain implant. He's been living with a neural interface for years. And somewhere along the way, the relationship between him and the device stopped feeling like a person using a tool.

A new paper published in *Neuroethics* captures that shift. Titled *"The Brain-Computer Interface is Changing Me,"* it's based on a first-in-human trial in which a Brain-Computer Interface (BCI) was implanted into a quadriplegic patient — and the research team then followed him closely, not just to measure what his hands could do, but to document what the experience was doing to his sense of self.

Burkhart is one of the paper's co-authors, which is itself significant. This isn't a study *about* a patient. It's a study that includes the patient as an investigator — someone with standing to interpret their own experience.

What is a BCI, exactly?

A Brain-Computer Interface records electrical signals from neurons in the brain and translates them into commands for an external device. In the case of intracortical BCIs like the one used here, a small electrode array is surgically implanted into the motor cortex — the part of the brain that controls movement. The signals it picks up are decoded in real time and used to drive things like a robotic limb or, in Burkhart's case, functional electrical stimulation of the muscles in his own paralysed hand.

The loop doesn't run just one way. As the patient tries to move, the system responds. That response feeds back into how the patient learns to use the system. Over time, the brain and the device begin to adapt to each other — a process that makes the boundary between "person" and "technology" surprisingly hard to locate.

The unexpected finding

The study's central finding is that this sustained feedback loop does something beyond restoring function. Participants described an enhanced sense of empowerment and ownership — feeling that the device was becoming part of them, not merely attached to them. The sense of agency, of being the author of your own movements, was amplified rather than diminished.

But the researchers — neuroethicist Frederic Gilbert, Ian Burkhart, and J. Morrill — were careful to document the other side too. There are complex ethical tensions at work. When you become deeply integrated with a machine that decodes your neural signals, questions arise about who is really in control. The device is learning from you. You are learning to use it. The line between "I decided to move my hand" and "the algorithm decoded my intention and executed it" is harder to draw than it sounds.

For someone whose identity has already been reshaped by injury, adding another layer of technological transformation raises real questions about continuity, autonomy, and what it means to remain yourself.

Why does this matter for SCI?

BCIs are moving — slowly but steadily — from research settings into real-world use. Neuralink, Synchron, and academic programmes worldwide are now trialling devices in humans with paralysis, ALS, and stroke. The published literature has focused heavily on what these systems can do: how many electrode channels, how accurately they decode intent, what functions they restore.

This paper asks a different question: what does it do *to* the person?

Ian Burkhart has been unusually candid about his experience over the years, co-founding the BCI Pioneers Coalition specifically to ensure that people who actually live with these devices help shape how they're designed and deployed. His role as a co-author here positions him not as a study subject but as a scientist — someone whose experiential knowledge is treated as legitimate evidence.

That shift in framing matters. As BCIs get closer to clinical use, the question of what they do to identity, agency, and wellbeing will need answers that come from people living with these devices, not just researchers observing them.

Reader Q&A

Does this mean a BCI can "change your personality"? Not in any dramatic science-fiction sense. What the paper describes is more subtle: a shift in how the user understands their own agency and bodily ownership. Most participants reported this as positive — a feeling of empowerment, a greater sense of being the author of their movements. But the researchers are appropriately cautious, noting that prolonged integration with a device that reads and responds to your neural signals raises questions that haven't been fully answered.

Is this relevant to most people with SCI right now? Intracortical BCIs — the kind requiring surgery to implant electrodes in the brain — are only available through research trials at a small number of specialist centres. Most people with SCI won't have access to this technology for some years yet. Non-invasive BCIs and transcutaneous spinal stimulation are further along for most users. But this research shapes the trajectory of where the technology is heading.

Who is "in control" when a BCI executes a movement? This is the most interesting tension the paper surfaces. The patient initiates an intention; the algorithm decodes and executes it. Over time, users often feel that *they* are doing the moving, even though the machine is doing the decoding. Whether that's a psychologically accurate account or a useful construct is one of the core questions neuroethics is now grappling with.

Will we see more research like this? Almost certainly. As more people enter BCI trials, researchers are starting to treat the experiential and psychological dimensions as seriously as the engineering. This paper is part of a growing body of work that positions the human experience of living with a neural device as evidence worth collecting — and people like Ian Burkhart as co-investigators, not just participants.

There's a version of coping after spinal cord injury that can fool almost everyone — including the clinical teams treating it.

Writing on KevinMD, a physician draws on years of experience treating veterans with SCI at a hospital in Puerto Rico. What they noticed during their residency was striking: many young veterans had, by any conventional measure, adapted remarkably well to life in a wheelchair. They were engaged, socialising, meeting rehabilitation goals. Outwardly, they looked like success stories.

And then, sometimes, something would shift.

The gap between looking adjusted and being adjusted

The article describes what this physician came to recognise as a kind of protective performance — not dishonesty, but a genuine effort by patients to show the world (and sometimes themselves) that they were managing. Depression, when it arrived, didn't always announce itself. It hid behind the very resilience that made these young men and women so impressive to care for.

This pattern matters because SCI depression is common and chronically underdiagnosed. Studies consistently find that rates of clinical depression in people with spinal cord injuries run at roughly two to four times the rate in the general population — yet it's routinely missed in clinical settings, partly because the signs can overlap with the normal grief and adjustment that follow a life-changing injury, and partly because people with SCI often have strong reasons — social, personal, and cultural — to present as coping.

Why younger patients may be at higher risk

One of the article's key observations is that depression can hit younger SCI patients particularly hard, even when they appear most resilient. This aligns with research suggesting that the very qualities that help someone look adjusted — a strong pre-injury identity, high activity levels before the accident, a presentation of control — can also make it harder for depression to surface or be acknowledged.

The veteran context adds a further layer. Military culture has historically stigmatised mental health difficulties, and a young soldier who adapted physically and publicly to his injury might find it significantly harder to admit that, internally, he was struggling. The very success of his visible adjustment could work against him in clinical encounters.

What to do with this

The article is a physician's reflection rather than a clinical protocol — but it carries a clear practical implication: routine screening for depression in SCI care should not be scaled back because someone seems fine. Seeming fine, in this context, is not sufficient evidence that someone is fine.

For anyone in the SCI community — whether living with injury, or as a family member, partner, or carer — the piece is a useful reminder that resilience and distress are not mutually exclusive. They can share the same face. Checking in regularly, and making it genuinely normal to talk about mental health, is not the same as looking for trouble. It's attentiveness.

Reader Q&A

How common is depression after SCI? Common. Studies consistently estimate clinical depression in the SCI population at two to four times the general population rate, though exact figures vary by study design and population. Depression can occur acutely after injury or emerge months to years later — and it can recur. It is one of the most significant contributors to reduced quality of life after SCI.

Are there effective treatments? Yes. Both psychological therapies — particularly cognitive behavioural therapy (CBT) and acceptance and commitment therapy (ACT) — and medication have evidence behind them for post-SCI depression. Peer support and social connection also have consistent evidence. The challenge is identification, which is precisely what this article addresses.

Should I be worried if someone close to me with SCI seems to be coping well? Not necessarily — but "seeming fine" shouldn't be taken as conclusive on its own. Regular, genuine checking-in matters more than watching for obvious signs of distress. If you're genuinely concerned, a conversation with their clinical team is worth having. You don't need certainty to raise a concern.

Does this apply only to veterans? No. The article is set in a VA context, but the pattern it describes — depression hiding behind apparent resilience — applies across the SCI population regardless of how the injury occurred. Veterans may face additional barriers because of military culture, but the phenomenon isn't confined to that group.

The world's largest annual wheelchair sports event started earlier this week, and it's running until Sunday in Detroit.

The 45th National Veterans Wheelchair Games (9–14 July 2026) has brought together more than 600 US military veterans from across the country. To participate, veterans need a qualifying condition — spinal cord injury, amputation, multiple sclerosis, or other neurological conditions requiring a wheelchair for athletic competition — and a service record. That's it. Elite athletic background is not a requirement.

The sports on offer span a wide range: wheelchair basketball, track and field, archery, air rifles, hand-cycling, boccia, billiards, swimming, and more, with events designed to accommodate different levels of function and different types of injury. For many participants, competing here isn't simply about winning. It's about what happens to a person's sense of themselves when they compete.

From 77 athletes to 600

The Games were launched by the Department of Veterans Affairs in 1981, starting small: seven events, 77 athletes. Paralyzed Veterans of America (PVA) joined as co-organiser four years later, and the event has grown steadily every decade since. Today it's one of the most visible proof points that wheelchair sport at scale works — that competition, community, and physical challenge are meaningful parts of life after serious injury.

The underlying philosophy is about mindset as much as movement. Veterans who enter the Games as patients often leave thinking of themselves differently — as athletes, competitors, teammates.

Rehabilitation through competition

There's a solid evidence base linking adaptive sports participation to improved psychological wellbeing, reduced depression, better pain management, and stronger social connection in people with SCI and related conditions. The Games are one of the most sustained institutional expressions of that principle.

Uniti, which manufactures wheelchairs and mobility equipment, has supported the Games for the sixth consecutive year in 2026, contributing to the equipment and logistics that allow veterans from across the country to participate.

The Michigan Paralyzed Veterans of America is the host chapter for this year's event, and the state's disability sport infrastructure has been a visible part of the build-up.

Reader Q&A

Can civilians with SCI attend or participate? The National Veterans Wheelchair Games are open only to US military veterans with qualifying conditions. But many of the sports featured have civilian equivalents — through organisations like US Paralympics, Wheelchair Basketball USA, and others. In the UK and Ireland, organisations including the British Wheelchair Basketball Association, Wheelchair Sports Ireland, and ASPIRE run equivalent programmes.

What's the difference between the Wheelchair Games and the Paralympics? The Paralympics is an elite competition for the world's best adaptive athletes. The Veterans Wheelchair Games prioritise participation and rehabilitation over elite performance — any veteran with a qualifying condition can enter, regardless of athletic ability or experience. It's closer in spirit to a community games than to the Olympics, though some participants do go on to compete at Paralympic level.

Is this just a US thing? The National Veterans Wheelchair Games are US-specific, but comparable events exist in other countries. The Invictus Games, which also focuses on military veterans with injuries, has an international format. The Cybathlon (based in Switzerland) takes a different approach, using assistive technology as the competitive medium.

Is there any connection to SCI research at these events? Indirectly, yes. Adaptive sports events generate interest in assistive technology, wheelchair design, and rehabilitation science. They also provide a pipeline of participants for research studies, and several academic partnerships operate in and around events like this. Visibility matters: what's seen as achievable tends to expand what researchers and clinicians try to make possible.

In the long road from promising biology to approved treatment, pharmacokinetics and immunogenicity data are not the most dramatic milestone — but they matter. A new paper in Future Science OA provides that data for E3112, a recombinant human hepatocyte growth factor (HGF) that has been in clinical development for acute spinal cord injury in Japan for several years.

The drug is also referred to as KP-100IT, its development-programme name. It has been studied in Phase 2 trials in people with acute SCI, where earlier results suggested some improvement in motor function. This paper is not a new efficacy readout — it focuses on how the drug behaves in the body (pharmacokinetics, or PK) and whether the immune system produces antibodies against it (immunogenicity).

Why pharmacokinetics and immunogenicity matter

When a drug is a protein — which recombinant HGF is — two questions become important that are less relevant for small-molecule drugs. First: how does it move through the body, how long does it stay active, and how consistently does it do so across different patients? Second: does the body's immune system recognise it as foreign and mount an antibody response against it?

These questions matter for safety and for understanding whether the drug works as intended. If a protein drug provokes an immune response, those antibodies can neutralise the drug's effect or, in some cases, cause adverse reactions. The published data here provides the clinical assessments of both — showing how E3112 behaves pharmacokinetically and what the immunogenicity profile looks like in the patient population studied.

Background: what HGF does in SCI

Hepatocyte growth factor is a naturally occurring protein that has multiple roles in the body, including promoting cell survival, reducing inflammation, and supporting nerve growth and repair. Its potential relevance to SCI comes from preclinical evidence that it supports neural survival and regeneration after injury, and that it may reduce the secondary injury cascade that extends damage in the hours and days after the initial trauma.

The idea behind KP-100IT/E3112 is to deliver recombinant HGF directly to the spinal cord — via intrathecal administration — during the acute injury window, when the cord is still in the process of secondary damage and when interventions have the best chance of preserving function.

Earlier clinical data from the Japanese programme suggested motor function improvements in some patients, which was enough to support continued development. The PK/immunogenicity paper represents the kind of detailed characterisation needed to understand how to dose the drug correctly and what to watch for in larger trials.

Where this sits in the development timeline

E3112/KP-100IT has been in development for longer than many SCI drugs, and the fact that it has reached the stage of publishing PK and immunogenicity characterisation suggests the programme is moving forward methodically. Japan has been a relatively active space for SCI drug development — several programmes including cell therapies have originated there and progressed to clinical testing.

This paper is not a signal of a breakthrough, and it does not provide new evidence that the drug works. It is the kind of characterisation data that sits behind the scenes of any serious drug development programme, filling in the picture that regulators and future trial designers will need.

Reader Q&A

Is this drug available?

No — E3112/KP-100IT is in clinical development in Japan and is not commercially available.

Has it been shown to work in SCI?

Earlier Phase 2 data from Japan showed some motor improvement in patients with acute SCI. That was encouraging, but Phase 2 trials are not definitive — they are designed primarily to assess safety and gather preliminary evidence of effect. Larger, controlled trials would be needed to confirm efficacy.

What is intrathecal administration?

Intrathecal means delivered directly into the space around the spinal cord and brain (the subarachnoid space), rather than taken orally or given intravenously. It is used for drugs that cannot cross the blood-brain barrier effectively and where direct delivery to the spinal cord is important. It requires a lumbar puncture or similar procedure.

Most spinal cord injury research focuses on the acute phase — the hours, days and weeks just after injury. But the majority of people living with SCI were injured years or even decades ago, and for them, the research picture has historically looked bleak. That may be starting to change.

At the International Society for Stem Cell Research (ISSCR) 2026 Annual Meeting, Dr. Hideyuki Okano from Keio University in Japan presented new preclinical efficacy data for a stem cell-based approach targeting chronic incomplete SCI — along with plans for a physician-initiated clinical trial expected to begin recruiting patients in 2027.

Why myelin matters

When a spinal cord injury occurs, several things go wrong at once: nerve fibres are severed, inflammation damages surrounding tissue, and the insulating sheath around surviving nerve fibres — called myelin — breaks down. Those demyelinated fibres are at the heart of Okano's approach.

The key insight is that in many people with incomplete SCI, the underlying nerve fibres are still physically present — they just lack adequate insulation. Without myelin, nerve signals can't travel properly, even if the fibre itself is intact. Restore the myelin, and those dormant fibres might start working again.

A different kind of stem cell

Many stem cell approaches in neurology try to replace lost neurons — an extremely difficult task. Okano's team took a different route. Their cells are called gNS/PCs (gliogenic neural stem/progenitor cells), and the word "gliogenic" is the important part. Rather than generating neurons, these cells are specifically designed to produce the nervous system's support cells: oligodendrocytes (which make myelin) and astrocytes (which maintain the neural environment). It's a more targeted strategy — rebuilding the infrastructure around surviving nerve fibres rather than trying to regenerate severed connections from scratch.

Critically, these are clinical-grade cells — produced under the standards required for human use — which brings them closer to the clinic than earlier experimental formulations.

Building on a first-in-human milestone

This isn't the team's first step in humans. Okano's group previously completed what they describe as the world's first first-in-human clinical study of gNS/PCs in patients with subacute SCI (injury within weeks). That study demonstrated a promising safety profile, which is a crucial foundation before moving to a harder clinical problem.

The new work extends the approach to chronic SCI — injuries that are months or years old. The cellular environment changes significantly over time after injury: scar tissue forms, inflammation subsides, and the window for certain interventions narrows. Developing a strategy that works in that chronic environment is a separate (and more difficult) scientific challenge from the subacute case.

Who would this help?

The planned clinical trial will focus on people with chronic, incomplete SCI who retain dormant but demyelinated nerve fibres. This is an important distinction: the approach is specifically designed for patients who still have surviving fibres that could potentially transmit signals if their myelin were restored. It is not expected to benefit people whose fibres are largely severed.

This profile — chronic, incomplete, with demyelinated but surviving fibres — applies to a significant proportion of the people currently living with SCI.

Reader Q&A

Is a treatment available now? No. The preclinical data is promising and a clinical trial is planned to start recruiting in 2027, but this is still in early stages for chronic SCI specifically. The timeline from a Phase 1 safety trial to a widely available therapy typically spans several more years.

How is this different from other stem cell approaches for SCI? Most previous approaches have tried to regenerate neurons — a very difficult goal. This strategy targets remyelination: rebuilding the insulating sheath around nerve fibres that survived the original injury. It's a different biological target, and arguably a more achievable one for a significant subset of patients.

Would someone with a complete injury benefit? The approach as described focuses on patients with incomplete injury who still have surviving fibres. For complete injuries, where most fibres are severed, the biological challenge is different and this strategy as currently designed may not apply directly.

Is this connected to earlier Keio University SCI research? Yes. The same group made news in early 2025 for work on stem cell treatment in acute/subacute SCI patients. This July 2026 announcement represents the next logical step — applying the approach to chronic patients, which is the larger and harder population.

One of the less-discussed consequences of spinal cord injury is what happens to sensation below the injury level. Motor function — movement — tends to get most of the attention in research and in public conversation. But sensory loss can be just as disabling in practical terms. If you cannot feel when your foot is touching the ground, or where the pressure is, walking and balance become far harder — even if your muscles are working.

A team at the Georgia Institute of Technology has been working on this problem directly, and a new interview published by The Naked Scientists gives a detailed look at what they have built and where it has reached.

What the device does

Matthew Flavin, who runs a wearable bioelectronics lab at Georgia Tech, describes the approach as sensory substitution. The idea is that if one part of the body has lost its ability to receive sensory information, you can route that information to another part of the body where sensation is intact — and the brain can learn to interpret it.

The system has two main components. First, pressure-sensing insoles sit inside the shoe and capture what is happening at the foot in real time: where pressure is being applied, how much, and from what part of the sole. Second, a set of small actuator devices — wearable units that can vibrate and generate heat — are placed on the forearm, where sensation is typically preserved after many SCI and stroke injuries.

The mapping is designed to be spatially intuitive. Pressure at the toe produces vibration near the wrist. Pressure at the heel produces vibration near the elbow. The brain can learn to read those signals as information about the foot.

Who might benefit

The conditions Flavin identifies as target populations are stroke, spinal cord injury, and diabetic neuropathy — three conditions that can each damage the sensory pathways from the feet, through different mechanisms. In SCI, the injury interrupts the spinal pathways that carry sensory signals from the lower limbs to the brain. In stroke, the damage occurs higher up. In diabetic neuropathy, the peripheral nerves themselves degrade over time.

What they have in common is the practical consequence: the person cannot reliably feel what is happening at their feet, and that affects balance, gait, and confidence in movement. Falls become more likely. Going outside becomes more effortful.

What the early testing showed

The team tested the system in two groups: twelve neurotypical adults with normal sensation, and eight participants with lower-limb sensory impairments from stroke or spinal cord injury.

The core test was a sensory matching task. The researchers applied different patterns of vibration to the forearm actuators and asked participants to identify which part of their foot corresponded to each pattern — essentially testing whether the signal-to-meaning mapping was working. Both groups — neurotypical participants and those with SCI or stroke — performed well on this task.

Flavin is careful about what this means. The study was designed as a proof-of-concept test of the system itself: can the devices deliver the signals reliably, and can people interpret those signals? Those questions were answered. The next step — showing that the system improves balance and gait outcomes in real-world conditions, in controlled trials — has not yet been done.

The balance application

One concrete example Flavin gives is balance recovery in people with stroke. When the stimulation is working and a person can feel where their foot pressure is, they can use that feedback to shift their weight distribution — putting more balance in the centre of their stance. That is the kind of functional change that would matter day-to-day.

For people with SCI, particularly those with incomplete injuries who retain some lower-limb motor function, the same principle applies: knowing where and how the foot is in contact with the ground is important for walking, and losing that information is a real obstacle to rehabilitation.

What is not yet known

The study is early stage. It has not yet shown that the sensory substitution system actually improves walking or balance outcomes compared to not using it — that comparison would require a controlled trial with outcome measures like gait speed, step length, or fall rates. The participants in the current study had a range of different conditions (stroke and SCI are quite different), and the number of participants with sensory impairments was small (eight people).

Flavin also notes that one of the design challenges is the variability between patients. Even among people with SCI at the same injury level, the pattern of motor and sensory loss can differ significantly — which means a device intended to help a broad population may need to be adaptable. That adaptability is something the team is working toward.

Reader Q&A

Does this restore sensation, or is it a workaround?

It is a workaround — a substitute, not a restoration. The foot itself is still not feeling anything; the device is taking the information the foot would have transmitted and rerouting it to a part of the body that can. The brain receives the signal, but it arrives through a different pathway and a different body location. The hope is that with training, the brain learns to use that signal effectively. It does not repair the damaged sensory pathways.

Is this already available?

Not commercially. This is a research prototype being tested at Georgia Tech. The researchers describe a commercially available, adaptable version as the "aspirational goal" — something they are working toward, but not something that exists yet.

Could this help with motor rehabilitation as well?

Not directly — the device is designed for sensory symptoms, not motor function. But sensation and motor control are linked. If a person with incomplete SCI can feel where their foot is during walking practice, that feedback can help them walk more safely and potentially make rehabilitation more effective. Whether using this kind of sensory substitution during motor rehabilitation would lead to better outcomes is a question for future trials.

What about diabetic neuropathy?

Flavin specifically mentions diabetic neuropathy patients as a group who could benefit but have not yet been tested. A well-known problem in diabetic neuropathy is that patients can't feel small wounds or pressure sores developing on their feet, leading to serious infections. A device that routes foot-contact information to a place the patient can feel could, in principle, help with this — though again, that specific application has not been tested yet.

For people with cervical spinal cord injury, regaining upper limb and hand function is often the single change that would most improve daily independence. Two rehabilitation technologies — transcutaneous spinal stimulation (TSS) and robotic exoskeleton training — have each shown promise on their own. A new study asked whether combining them is better, and more importantly: for whom, and why.

The paper, published in the Journal of NeuroEngineering and Rehabilitation on 29 June 2026, was led by J. Oh, M.S. Scheffler, S.T. King, E.E. Mahan, M. Lee and colleagues working with the research group of David A. Friedenberg. Eleven participants completed the full study: five with chronic stroke and six with chronic SCI affecting upper limb function.

The two technologies explained

Transcutaneous spinal stimulation (TSS) is a non-invasive technique that uses electrode patches placed on the skin over the spine to deliver mild electrical currents. These modulate the activity of spinal cord circuits without surgery — which makes TSS more accessible and lower-risk than implanted (epidural) stimulation systems. It doesn't directly move the limb; instead it primes or modulates the spinal networks that control movement, potentially making them more responsive to training.

Robotic exoskeleton training uses wearable mechanical devices that guide the arm through controlled movements. The repetitive, assisted practice supports motor learning — the process by which the brain and spinal cord reorganise to regain function after injury. These systems can perform far more consistent repetitions than a human therapist can manage, and can precisely track force and range of motion over time.

Both approaches leverage a core principle of neurorehabilitation: neuroplasticity — the nervous system's capacity to reorganise and adapt in response to experience.

How the study worked

The trial used a crossover design, meaning each participant received both treatments in sequence (with a washout period between), rather than being randomly assigned to just one. This allows each person to serve as their own control — a useful design when participant numbers are small.

Over 14 weeks, each participant went through: four weeks of assessment, four weeks of robotic training with sham (non-active) TSS, a two-week washout, and then four weeks of the same robotic training with active TSS (or vice versa — the order was randomised). Sessions lasted one hour and ran three days per week, combining robotic exoskeleton-assisted arm movements and hand grip training while receiving either real or sham stimulation.

Individual responses — the key finding

The title of the paper flags something important: "individual neurophysiological and clinical responses." Rather than reporting a single averaged treatment effect, the researchers examined how each participant responded — both in the nervous system (neurophysiological changes, such as alterations in nerve signal patterns) and in function (clinical changes, such as grip strength or arm movement scores).

This reflects a reality well-known in SCI and stroke rehabilitation: responses vary considerably between individuals. What significantly helps one person may have little effect on another. By examining individual-level patterns rather than group averages alone, studies like this help build the evidence base for matching specific interventions to specific patients — the goal of personalised rehabilitation.

What this adds to the field

Several previous studies have looked at TSS for lower limb or gait recovery in SCI. Research on TSS for upper limb function is more recent and less extensive. This study specifically addresses upper extremity recovery — the priority for many people with cervical SCI — and pairs TSS with robotic training rather than testing either in isolation.

The combination matters because the two approaches may work better together than apart: TSS may make the spinal circuits more receptive to the motor learning that robotic training drives. Understanding when and for whom that synergy is real is the work that studies like this begin to answer.

Reader Q&A

Is this combination available to me now? Robotic exoskeleton programs exist at some specialist rehabilitation centres, but combining them with TSS is not yet standard clinical practice. If you're interested, a physiatrist or rehabilitation specialist at a larger SCI centre would be the right person to ask about research programmes or emerging clinical access.

How is transcutaneous stimulation different from the epidural stimulation I've read about? Epidural stimulation involves surgically implanting electrodes near the spinal cord, delivering a more precise and powerful signal. Transcutaneous stimulation uses skin-surface pads and requires no surgery — it's weaker and less targeted, but much more accessible and carries no surgical risk, making it well-suited for use during outpatient rehabilitation.

Is this relevant to people with cervical SCI? Yes — the study focused on upper limb impairment, which is the defining challenge of cervical SCI. All six SCI participants in this study had upper extremity involvement.

Why is the title so focused on "individual responses"? Because it's an important finding in itself. If the response to TSS + robotics were uniform, you could simply recommend it to everyone with upper limb impairment after SCI. The fact that responses vary suggests there are meaningful differences between individuals — possibly related to injury level, completeness, how long ago the injury happened, or underlying neurophysiology — that future research can use to predict who will benefit most.

Most people who have been living with spinal cord injury for some time are aware of the pressure sore risk, the bladder complications, the muscle changes. But one consequence that gets less attention — even though it affects nearly everyone with a complete injury — is what happens to bone.

After SCI, bones stop being loaded the way they normally would through walking and standing. Without that mechanical stimulus, bone mass drops rapidly and continuously. The lower limbs are worst affected, and the distal femur — the part of the thigh bone just above the knee — is particularly vulnerable. Fractures at this site, sometimes triggered by something as minor as a transfer or a fall from a wheelchair, are a serious and common complication. They are difficult to treat surgically in people who lack sensation, and they extend disability significantly.

Several approaches to maintaining bone mass after SCI have been explored over the years — electrical stimulation to activate muscles, functional electrical stimulation cycling, standing frames. Some show modest effects, but none are widely used, partly because they are burdensome and partly because results have been inconsistent.

A team at the University of Strathclyde and the Scottish Centre for Innovation in Spinal Cord Injury is taking a different approach: applying very high-frequency, very low-amplitude vibrations directly to the bone itself, using a device worn around the knee.

Why vibration, and why at that frequency?

The physics of bone stimulation by vibration is not new research. Laboratory and animal studies have shown that very small vibrations — at the nanometre scale in terms of actual displacement — at frequencies around 1,000 Hz can activate bone cells and stimulate the processes involved in maintaining and building bone density. The key is that the vibration needs to be delivered at the right frequency, at a consistent amplitude, and to the right location.

Previous work on vibration therapy for SCI bone loss has typically applied vibration through the feet or to larger body segments. The Strathclyde team reasoned that the distal femur — the most at-risk site — could be targeted more precisely and more effectively by applying vibration directly at the knee.

What the device does

The device is a wearable unit that straps around the knee. It delivers 1,000 Hz vibrations to the skin surface overlying the distal femur. The vibrations are at nanoscale amplitude — far smaller than what you can feel as conventional vibration — generated by a specialised transducer. A gel interface between the device and the skin helps transmit the vibration into the underlying tissue, including the bone.

Before settling on the knee as the target, the team compared three different placement sites — the distal femur (front of the knee), the proximal tibia (just below the knee at the front of the shin), and the ankle. They measured how consistently and reproducibly they could deliver vibration to each site, and how well it transmitted through to the bone, using laser interferometry to measure vibration at the bone surface. The distal femur site came out ahead on both consistency and signal quality, and that became the target for further testing.

What the feasibility study showed

The main part of the study tested the device in a single participant: a person with a motor-complete spinal cord injury. The participant completed 61 sessions over 14 weeks, with each session lasting approximately two hours. In total, just under 120 hours of device use was accumulated.

The primary goal of this phase was to assess whether the device was safe and tolerable over repeated use — not whether it improved bone density. That is a question for a future, larger trial. On the safety side, there was no skin damage over the entire course of testing. The participant was able to use the device for the planned session durations without adverse events.

The gel interface was found to help transmit vibration more consistently compared to direct skin contact, even though it reduced the overall amplitude slightly. That trade-off appears to be worth it for reliability.

Practical limitations the team is working on

The researchers are candid about the practical challenges that emerged. The device can slip during sessions as the participant moves or adjusts position, which affects vibration delivery. The 1,000 Hz frequency produces an audible hum that may be noticeable and potentially distracting or intrusive over a two-hour session. And the current electronics unit is bulky — it needs to be made substantially smaller and more portable before the device could be used easily in everyday life.

These are engineering problems rather than fundamental barriers, and the team identifies them as the priority for the next development phase.

Where this sits

This paper is a preprint — it has not yet been through the peer review process. That means its methods and conclusions have not been independently scrutinised and may change. The study is also a single-participant feasibility trial: it was designed to show the device can be used safely and consistently, not to show that it improves bone. Whether vibration at this site, at this frequency, actually prevents or reverses SCI-related bone loss in the distal femur is the key scientific question — and answering it will require a larger randomised trial with bone density measurements over time.

Reader Q&A

Does this device currently prevent bone fractures in SCI?

That has not been tested yet. This study showed that the device can be worn safely over many sessions. The actual clinical question — whether it maintains or improves bone density, and whether that translates to fewer fractures — is for a future trial to answer.

How bad is bone loss after SCI, and why does it matter?

Very bad, and it matters a lot. Within the first year or two of a complete SCI, people can lose 30–50% of bone mass in the lower limbs. The distal femur and proximal tibia are the areas most severely affected. This makes fractures far more likely from relatively low-energy events — a fall from a wheelchair, an awkward transfer, even vigorous physiotherapy. Fractures are painful even without sensation in the usual sense, difficult to treat, and often extend hospital stays significantly.

Is this device available to use?

No. It is a research prototype and is not commercially available. The researchers are working on engineering improvements before a larger efficacy trial.

Could this work for people with incomplete injuries too?

The study only included a person with a motor-complete injury. People with incomplete injuries also experience bone loss, though typically less severe. Whether the device would be appropriate or beneficial for that group has not been tested.

Spinal cord stimulation has become one of the most actively researched areas in SCI rehabilitation over the past decade. Studies have shown that delivering electrical stimulation to the spinal cord — either through surgically implanted epidural leads or through non-invasive surface electrodes — can reactivate circuits below an injury and help people with incomplete injuries walk, stand, or move their arms. Some results have been striking.

But most of these systems share a fundamental limitation: the stimulation is essentially constant. It runs at a fixed rate and pattern, regardless of what the person is doing at that moment. That works up to a point, but it is not how the nervous system naturally operates. The body's own neural circuits constantly adjust their activity in response to feedback — from muscle sensors, from joint position sensors, from the vestibular system, from vision. To get the full benefit of spinal stimulation, the stimulation itself needs to become responsive in the same way.

That shift — from open-loop (fixed) to closed-loop (adaptive) stimulation — is the subject of a detailed review just published in the journal Sensors by researchers at the University of Louisville's Kentucky Spinal Cord Injury Research Center.

What closed-loop means in practice

In a closed-loop system, sensors detect what is happening in the body or environment in real time, and that information is fed back to adjust the stimulation parameters — the timing, intensity, or pattern of the electrical pulses — on the fly. The idea is that stimulation should be active when it is needed, at the right level, and timed to the right phase of movement or activity.

The review identifies five distinct categories of sensors being used or explored for this purpose in SCI rehabilitation.

The first category is kinematic sensors — devices like inertial measurement units (IMUs) and accelerometers that detect the position and movement of limb segments. These can identify what phase of a movement cycle the person is in (for example, the swing phase versus the stance phase of walking) and trigger stimulation accordingly.

The second category is force and pressure sensors — sensors placed in shoe insoles or under foot pads that detect when and where the foot is in contact with the ground and how much weight is being borne. This kind of information is central to controlling walking and balance.

The third category is electromyography (EMG) — measuring the electrical activity of muscles themselves. When a muscle fires (or tries to fire), that signal can be detected and used to trigger or modulate stimulation in real time. Surface electrode arrays that cover larger areas of muscle are making this more practical.

The fourth category is vision-based sensing — using cameras to detect features of the environment (a step, an obstacle, a change in terrain) and trigger adjustments in stimulation before the person encounters them, rather than reacting after the fact.

The fifth category is neural interfaces — recording directly from nerves or the spinal cord to detect the state of neural circuits below the injury. This is the most technically demanding approach and the furthest from routine clinical use, but it offers the most direct window into what the nervous system is doing.

What has been achieved so far

The review discusses where these technologies have reached in research settings, referencing several landmark studies.

In walking recovery, perhaps the most striking demonstration was the work published in Nature in 2023 by Lorach and colleagues — the so-called "digital bridge" study — in which a person with a complete thoracic SCI walked with the aid of a brain-spine interface that decoded his movement intentions and translated them into precisely timed epidural stimulation. That system used both neural recording (brain signals) and stimulation timing calibrated to gait phases. It demonstrated the principle that closed-loop systems timed to intended movement can produce functional walking in a way that continuous stimulation cannot.

Other studies have used EMG activity and body position sensors to create "activity-specific" stimulation programs — different patterns of stimulation for standing, for walking, for transitioning between the two — triggered automatically by the body's own movements. Research from Rowald and colleagues and from groups led by Grégoire Courtine and Jocelyne Bloch has demonstrated these approaches in people with incomplete injuries.

For upper limb function, a study from the Moritz group (referenced as a multicenter tSCS trial in the review) has shown that non-invasive spinal stimulation of the cervical spinal cord can improve hand and arm function after SCI. A very recent study from 2026 (Tazoe et al., published in Brain) demonstrated that EMG from the hand — recorded non-invasively — could be used to control stepping through spinal stimulation, creating a cross-limb closed loop that is novel and clinically interesting.

Why this matters beyond the lab

The review's central argument is that the sensor and control design — how stimulation is triggered and adjusted — is becoming the critical variable in whether these systems work outside of a research laboratory. Getting the hardware to work is increasingly well understood. Getting it to respond intelligently to the complexity of real-world movement and the individual variability between patients is the harder problem.

The authors make the point that each sensor type has trade-offs: IMUs are convenient but don't tell you about muscle state; EMG is informative but harder to use reliably in all conditions; neural interfaces are powerful but require surgery and careful implant management. The field is moving toward combining multiple sensor types to build a more complete picture.

Reader Q&A

Is closed-loop stimulation available clinically now?

In a limited sense, yes — some commercial epidural stimulation systems (like Medtronic's Intellis platform) offer basic adaptive stimulation features. But the kind of sophisticated, movement-responsive, multi-sensor closed-loop systems described in this review are still largely in research settings. A few clinical trials are underway.

Does this work for complete injuries as well as incomplete?

Much of the most dramatic walking recovery demonstrated with closed-loop stimulation has been in people with incomplete injuries — where some neural connections below the injury remain. The digital bridge study (Lorach 2023) was in a person with a complete injury and achieved walking with the assistance of the closed-loop brain-spine system. Results are more variable in complete injuries, and what is achievable depends heavily on the person, the injury level, and the system being used.

This sounds complicated — is there a risk of systems becoming too complex to actually use?

That is a real concern the review addresses. More sensors and more complex algorithms mean more things that can go wrong, more calibration required, and more technical expertise needed. A key challenge for the field is building systems that are robust and user-friendly enough to be operated by patients at home, not just in a clinic with a research team. The review identifies this as one of the central unsolved problems.

When researchers want to build a brain-computer interface (BCI) that lets a paralysed person control their hand, the most obvious place to put the electrodes is the motor cortex — the part of the brain that directly commands muscle movement. And that has been the dominant approach. It works, up to a point.

But grasping something — really picking up an object, shaping your hand to it, applying the right grip — is not just a motor cortex activity. The brain has a whole network of areas involved in planning, visually guiding, and coordinating reaching and grasping. Those areas encode information that motor cortex alone doesn't capture.

A team at the Cleveland Clinic and Case Western Reserve University, working within a broader clinical trial called ReHAB (Restoration of Hand and Arm function after tetraplegia), have been exploring what happens when you implant electrodes into those additional brain regions — and how to figure out, before surgery, exactly where in a given person's brain those regions are.

Their results, published in Neuroimage: Reports, describe the approach they used and what they found when they put it into practice in one participant.

The challenge of finding the right spots

The brain regions involved in grasping are well mapped at a population level — we know roughly where they sit in most brains. But "roughly" isn't good enough when you're implanting electrode arrays. Brains vary significantly from person to person, and after a spinal cord injury, the brain can reorganise in ways that shift where functional regions are located. A target identified purely from anatomy or standard brain atlases might land in the wrong neighbourhood.

There's an additional complication: several of the brain areas most important for grasping are very close to areas involved in speech and language. For someone who relies on their voice to communicate, accidentally impairing speech in the course of a surgery aimed at restoring hand control would be a serious harm.

And then there are the practical surgical constraints: current electrode arrays (including those from Blackrock Neurotech, which is what was used here) can only be implanted on the exposed surface of the brain — not in the folds (sulci). This rules out a number of otherwise-attractive targets.

The solution: map first, operate second

The team built a multi-step planning process centred on brain imaging.

Three months before surgery, the participant — a 47-year-old man with C5-level SCI, who had motor but not sensory impairment, from a car accident 2.5 years earlier — underwent an extensive MRI session. This included standard structural scans, diffusion-weighted imaging (which shows how different brain regions are connected to each other through white matter tracts), and a contrast scan to map the blood vessels on the brain surface (important for avoiding vasculature during surgery).

The team also used a software platform called Quicktome that aligns a person's individual brain anatomy with a large population database (the Human Connectome Project) to estimate where specific functional regions are likely to be, based on how this brain's structure compares to thousands of others.

But the most important step was a task-based fMRI session: the participant lay in a scanner and imagined grasping or reaching toward objects while the scanner measured blood flow across the brain. Regions that became more active during imagined grasping lit up. Separately, an auditory fMRI task was run — listening to reversed speech — to map out the speech and audio processing regions to be avoided.

The fMRI revealed something critical: the anatomical region that sulcal landmarks would suggest for one key target (the anterior intraparietal area, or AIP — a region involved in hand pre-shaping during grasping) actually contained two neighbouring sub-regions. One responded to grasping. The adjacent one responded to audio. Without the fMRI, anatomy alone would have pointed at the same general location and there would have been no way to know which sub-region was which. The team placed the electrode specifically in the grasp-responsive sub-region, away from the audio-responsive one.

A 3D-printed model of the participant's skull and brain — made to exact scale from the MRI data — was used to let the surgical team physically rehearse the electrode placement, including the craniotomy (the opening in the skull) and the routing of electrode leads.

Where the electrodes went

The team implanted eight electrode arrays (Blackrock Utah arrays, 96 channels each, 768 total channels). In addition to the standard primary motor cortex (M1) and primary somatosensory cortex (S1) placements — which are part of the standard ReHAB protocol — two additional arrays went into the putative AIP region, and two into the ventral premotor cortex (PMv), specifically into sub-regions called 6V and 6R.

The inferior frontal gyrus (IFG), another grasp-related area, showed grasp activation on fMRI but was excluded: the relevant sub-region sat mostly inside a sulcus and was largely obscured by blood vessels, making it surgically inaccessible.

What the electrodes recorded

Starting four weeks after surgery, the team began recording from all the implanted arrays while the participant attempted five different arm and hand movements: raising his right arm, moving his hand sideways, making a pinch grip, bending his wrist down, and rotating his wrist outward. Even though he could not physically complete these movements (his injury had paralysed his hand), his brain still generated movement signals as he tried.

Each individual brain region decoded the movements with accuracy ranging from 62% (for one PMv sub-region, 6V) to 92% (for AIP). Chance performance for five movements would be 20%.

When signals from all regions were combined, accuracy rose to 96%. Importantly, combining didn't just average things out — each region added information that the others didn't fully capture. This confirms that different parts of the grasp network encode complementary aspects of movement, not just redundant copies of the same signal.

Performance was stable across three recording sessions (one in April 2025, two in July 2025), with combined accuracy remaining between 85% and 96% across sessions.

Reader Q&A

How is this different from existing BCI systems?

Most existing human intracortical BCI systems record from motor cortex only. This study adds three additional brain regions (AIP, and two sub-regions of PMv) that are involved in higher-level aspects of grasping — planning, object shape recognition, visuomotor coordination. The result is a richer signal that can be decoded more accurately, and which encodes more information about what the person intends to do.

Can this person now use their hand?

Not reported in this paper — the paper focuses on the electrode targeting methodology and the decoding accuracy. The ReHAB trial's broader aim is to connect this decoded brain signal to a functional electrical stimulation system that would activate the hand muscles. That work is ongoing.

Why is this a single-participant study?

Clinical trials of implanted brain devices necessarily proceed carefully and slowly, with intensive study of each participant. This paper reports the planning methodology and initial results for one person. More participants will need to be enrolled to establish whether the approach generalises.

Is the fMRI mapping necessary every time?

That's an open question. The researchers argue it was essential in this case because it revealed that the AIP region contained both grasp-responsive and audio-responsive sub-regions that anatomy alone couldn't distinguish. Whether every person would show similar variability is not known. The authors suggest fMRI mapping should be standard for targeting non-primary motor regions.

One of the reasons spinal cord injury is so difficult to treat is that the cord is not just a bundle of nerve fibres — it has a specific, carefully organised architecture that is essential for how it works.

If you look at a cross-section of the spinal cord, you see two distinct zones. The outer ring — the white matter — is where long axons run in parallel bundles, carrying signals up and down the cord between the brain and the body. The inner region, shaped a bit like a butterfly, is the gray matter, where the cell bodies of neurons cluster together in circuits that process signals and coordinate movement.

After a spinal cord injury, this organised structure is destroyed. Scar tissue fills the injury site in a disorganised way. Even if axons try to regrow, they run into a chaotic environment with no clear direction to follow. The result is that reconnection across the injury rarely happens spontaneously.

Researchers at several institutions in China — including Shenzhen University and Guangzhou Medical University — have been working on a scaffold designed to restore that organisation at the injury site, giving axons the physical and chemical guidance they need to grow back in the right direction. Their results, just accepted in the journal Biofabrication, show this approach can make a meaningful difference in an animal model of complete spinal cord transection.

The scaffold's two-zone design

The core idea is to replicate the anatomy. The researchers built what they call a Gray/White Matter Zoned Scaffold (GWZS), constructed from two materials arranged to match the spinal cord's natural zones.

For the outer white matter region, they used aligned silk fibres — individual filaments drawn from silkworm cocoons and arranged so they run parallel to each other along the length of the scaffold, in the same direction axons would naturally travel. These fibres do two things: they act as physical guide rails for growing axons (which tend to follow aligned surfaces), and they give the scaffold mechanical structure.

For the central gray matter region, they used a hydrogel — a water-containing gel incorporating hyaluronic acid, a laminin-derived peptide, and collagen type VI. Hyaluronic acid is a natural component of the spinal cord's extracellular environment and helps reduce scar formation. The collagen type VI component specifically promotes neurons to cluster together and form network-like structures — something the gray matter normally does.

The two materials are integrated, not simply placed side by side: the hydrogel fills the spaces between the silk fibres in the white matter region, binding them in position and preventing them from moving. The central hydrogel-only region has no fibres at all, leaving it open for neuron clustering.

The researchers used anatomy directly to determine how many silk fibres to place in each region, using the actual proportions of white matter at the T10 level of the rat spinal cord as their blueprint.

What happened in cell culture

Before testing in animals, the researchers grew neurons and supporting cells inside the scaffold to see whether the two-zone design actually produced two different types of neural organisation.

It did. In the silk fibre region, 83% of axons grew aligned with the fibres — following the physical guidance. In the central hydrogel region, neurons formed clusters and network-like structures, more resembling gray matter. The scaffold produced something that looked structurally like a miniature spinal cord in a dish.

What happened in rats with complete spinal cord injury

The main test was in rats that had the spinal cord completely cut across at the T10 level — a 2mm gap created and then bridged with either the GWZS scaffold, a plain hydrogel alone, or nothing.

After 16 weeks, the GWZS group showed substantially better outcomes on two measures. On the BBB scale — a standard 21-point scoring system for rat hindlimb movement, where 21 is normal and 0 is no movement — the GWZS group averaged 11.4. The hydrogel-only group averaged 9.8. The untreated SCI group averaged 4.7. A score of around 11 indicates consistent weight-bearing walking, though not fully normal coordination.

Motor evoked potentials — the electrical signals that travel from the motor cortex down the cord to the muscles — were also measured at 16 weeks. In the GWZS group, signal amplitude recovered to 44.3% of what is seen in healthy animals. In the hydrogel-only group, it recovered to 30.4%. In the untreated SCI group, no signal was detectable at all.

What didn't work as well

The researchers are straightforward about the limitations. While the white matter zone showed axon regeneration that matched the scaffold's structure, the central gray matter zone did not regenerate well — only sparse neural tissue grew there. The researchers believe this is because the adult spinal cord doesn't have enough stem cells or regenerative capacity to repopulate that region without additional help, and the scaffold in this study did not include any added stem cells.

The silk fibres also degraded very slowly — at 8 weeks post-implant, they were largely intact. This might create long-term problems if the fibres remain while the cord is trying to remodel itself around them.

This is also an animal study in rats, using a complete transection model. Most human SCI involves crushing or bruising rather than a clean cut, and the human spinal cord is very different in scale from a rat's. Translation to humans is a long way off.

Reader Q&A

Why does it matter that the scaffold mimics the gray/white matter zones?

Because the structure of the spinal cord is not incidental to how it works — it is how it works. The axons in the white matter need to run in parallel bundles along the length of the cord to carry signals efficiently. If they grow back in random directions, the signal connections don't re-establish properly even if the axons physically cross the injury. Providing physical guidance that matches the cord's natural anatomy gives regenerating axons the best chance of connecting up in a functionally meaningful way.

Is this anywhere near clinical use?

No. This is animal model research — the experiments were all conducted in rats. Many promising scaffold approaches in rodents have not translated to humans, for a range of biological and mechanical reasons. The researchers themselves identify the need for primate studies before any consideration of clinical application.

Could stem cells be added to improve the gray matter result?

Yes, and that is exactly what the researchers propose as the next step — loading the central hydrogel region with neural progenitor cells (cells that can develop into neurons) to drive repopulation of the gray matter zone.

Something significant happened in the world of SCI rehabilitation this week. Spinal Research, the UK's leading charity focused on curing paralysis, has launched a programme to place Onward Medical's ARC-EX system in a network of specialist rehabilitation centres across the country. It's the first time a treatment specifically approved by UK regulators for paralysis — not just pain or other conditions, but paralysis — has been deployed in a real-world setting.

What is the ARC-EX system?

ARC-EX, developed by Onward Medical, combines two components: targeted electrical stimulation of the spinal cord (applied non-invasively through the skin) and structured rehabilitation exercises. The idea is that electrical stimulation can help "wake up" dormant neural pathways, and pairing it with active therapy gives those pathways something useful to do.

In clinical trials, the ARC-EX system demonstrated improvements in hand strength and sensation in people with chronic cervical spinal cord injuries. Chronic here matters — these were participants who had been living with their injuries for an extended period, not people in the acute phase where some natural recovery would be expected anyway.

The device received approval from UK regulators, making it the first dedicated treatment for paralysis to clear that bar. Until now, most devices used in SCI rehabilitation have been approved for adjacent indications — pain management, for example — and then applied to paralysis care. ARC-EX was approved specifically for what it's being used for.

What is the Spinal Research programme doing?

Rather than simply making the device available for purchase, Spinal Research is creating a structured network of approved rehabilitation centres and loaning ARC-EX systems to them for a 12-month period. The idea is to gather real-world data — not just from controlled clinical trial conditions, but from day-to-day rehabilitation practice with a range of clients.

The first centre to join is the Matt Hampson Foundation's Get Busy Living Centre near Melton Mowbray in Leicestershire. The Foundation was set up by Matt Hampson, a former England Under-21 rugby player who was paralysed from the neck down in a training accident at age 20. It provides expert physical and emotional rehabilitation for young people following life-changing injuries.

Three more centres in Yorkshire, the North East, and the South West are set to follow. A fourth centre is being funded through a partnership with the Injured Jockey's Fund.

This programme is part of a broader initiative called the Spinal Research Recovery Alliance — an effort to bring together researchers, clinicians, industry partners, charities, and the SCI community to accelerate the path from laboratory discovery to real-world impact. The vision is ambitious: a nationally connected, data-driven ecosystem for spinal repair.

Why does this matter?

Two things make this particularly significant.

First, it brings an approved, evidence-based treatment to rehabilitation centres that might not otherwise have access to it. For people with SCI, the quality of rehabilitation available can vary enormously depending on where they live and which centre they attend. A national network helps address that inequality.

Second, the data gathered will be different from what clinical trials produce. Trials are tightly controlled, with selected participants, rigid protocols, and frequent monitoring. Real-world data reflects what actually happens when a technology meets a diverse population of people with SCI, across varied clinical settings, as part of their ordinary rehabilitation journey. That information matters for shaping future research and best practice.

"We have been part of Onward's journey from the start, and it's incredible to see that hope is now turning into real progress," said Spinal Research Chief Executive Louisa McGinn at the launch. "The next few years could change everything for people with spinal cord injuries."

One of the programme's first participants is Sophie Wilson, Head of Operations at the Matt Hampson Foundation, who was paralysed herself in a diving accident eight years ago. She is already using the ARC-EX system as part of the real-world programme.

Reader Q&A

Can I access the ARC-EX system myself? For now, the programme is being delivered through the four approved rehabilitation centres. If you're based in the UK, contacting Spinal Research directly would be the best way to find out if you're eligible and whether a centre near you is participating or planned. The charity is also launching a fundraising campaign to expand the network nationwide.

Is this available outside the UK? Onward Medical, the company behind ARC-EX, has been pursuing regulatory approval in multiple markets. The UK approval is a significant milestone, but availability in other countries will depend on local regulatory processes.

How does it compare to invasive epidural stimulation? The ARC-EX system delivers stimulation transcutaneously — through the skin — rather than through surgically implanted electrodes. This makes it far less invasive and more accessible, though it may also mean the stimulation is less targeted than implanted systems. For many people, a non-surgical option that can be used as part of regular rehab is a significant advantage.

What does "chronic cervical SCI" mean in this context? Cervical injuries affect the neck region of the spinal cord, which typically means both arm and leg function are affected. "Chronic" means the injury occurred more than six months ago — the period in which natural spontaneous recovery is most likely. Showing improvement in chronic injury is significant because it means the device is doing something beyond allowing natural healing to proceed.

When researchers talk about the scar that forms after spinal cord injury — the glial and fibrotic scar that blocks axon regeneration and is one of the central obstacles to recovery — they have largely described it as a chemical and cellular problem. The wrong cells are in the wrong place. The wrong proteins are blocking the wrong pathways. The wrong signals are suppressing the wrong growth factors.

A new preprint changes the frame. It asks: what if the scar is also a mechanical problem? And what if the changing stiffness of the tissue after injury is not just a consequence of what cells are doing, but is itself an active signal that tells cells what to do next?

The paper, from researchers at Cleveland State University and the University of Akron, used two powerful techniques — atomic force microscopy (AFM) and bulk RNA sequencing — to track how the spinal cord changes physically and genetically at one month and six months after a severe thoracic contusion injury in an animal model.

First: what the tissue does physically

The headline finding is straightforward to describe, even if the technique behind it is not. Using a nanoscale probe to measure tissue stiffness at the injury site — a technique called nanoindentation — the researchers found that spinal cord tissue gets dramatically softer in the weeks after injury, reaching its softest point at around one month. Then, over the following months, it gets progressively stiffer, eventually becoming harder than normal uninjured tissue by six months, as the scar matures.

This softening-then-stiffening pattern has been observed in other tissue injuries — scar tissue in skin, liver, and heart tends to become stiffer over time. But the detail here, and the techniques used to map it, are more precise than what has been published for spinal cord injury before. The researchers also measured viscoelasticity — essentially, how the tissue behaves when you apply and then release pressure, which reveals information about its composition at a structural level.

What they found was that chronic scar tissue is not just stiffer — it also has a slower relaxation response, meaning it stays stiff longer when compressed. This, the researchers argue, reflects the physical consequence of dense collagen deposition and the accumulation of proteoglycans: the two main structural components of fibrotic scar.

Then: what the cells do because of it

Here is where the study becomes more than an account of what scar looks like under a probe. Using RNA sequencing of tissue samples taken at the same time points, the researchers mapped which genes were active in the spinal cord at one month and six months post-injury.

The pattern was telling. During the early softening phase — the first month — the most active pathways were inflammation and matrix degradation. The tissue is in crisis, breaking down its normal structure, recruiting immune cells, and beginning the wound-healing process that will eventually produce scar.

During the later stiffening phase — by six months — the active pathways had shifted to collagen synthesis, ECM organisation, and fibrotic remodelling. The tissue was rebuilding, but in a way that locks in stiffness and locks out regeneration.

And critically: the genes governing mechanotransduction — the cellular machinery through which cells sense and respond to the mechanical properties of their environment — were active at both time points, and their activity patterns were coordinated with the changing stiffness of the tissue.

Mechanotransduction: cells listening to the scar

This is the concept that sits at the heart of what makes this preprint significant, and it is worth explaining.

Cells do not just exist in a mechanical environment — they sense it and respond to it. A cell sitting on stiff tissue behaves differently from the same cell on soft tissue. Stiffness signals can change which genes a cell expresses, how it moves, whether it proliferates, and whether it produces proteins that build up or break down the tissue around it.

This is well understood in other contexts — tumour biology, wound healing, cardiac fibrosis. It is much less studied in spinal cord injury.

What this preprint suggests is that the evolving mechanical stiffness of the spinal cord after injury is not simply a reflection of what cells are doing — it is also an active instruction to cells. The scar stiffens, and cells in that stiffening environment receive signals that tell them to produce more collagen, reorganise the matrix in fibrotic patterns, and maintain the stiff, restrictive microenvironment.

In other words: the scar may be partly self-reinforcing through its own mechanical properties. The tissue gets stiff, cells respond by making it stiffer, and that stiffer environment continues to suppress the conditions under which axons might regrow.

What this is not

This is a preprint — it has not yet been through peer review. It is an animal study, in a thoracic contusion model. The findings need to be replicated and extended before drawing clinical conclusions. The mechanotransduction story, while compelling and consistent with a lot of parallel research in other tissues, still needs causal experiments to confirm that the mechanical signals are driving the gene expression changes rather than just correlating with them.

The study also does not offer a treatment. It is mechanistic science — it describes a process and proposes a framework for understanding why the scar is so resistant to repair. The translation from "here is how the scar reinforces itself mechanically" to "here is a drug or intervention that interrupts that process" is a long road.

Why tracking this matters

Mike's approach to SCI science on this site has always included following the basic science — not just the trials and the approvals, but the upstream biology that eventually determines what becomes a target and what becomes a drug or device.

The mechanical biology of the SCI scar is one of those upstream questions. If it turns out that stiffness-driven mechanotransduction is a significant contributor to regenerative failure, then the therapeutic targets it opens up are distinctive from the cytokine and growth factor pathways that have dominated the field. Stiffness itself can be modified — through scaffold materials, through targeted enzyme delivery, through biomaterials that compete with fibrotic ECM. None of those are available treatments today. But the science describing why the scar fails axons mechanically is the foundation on which those approaches will eventually be built.

Reader Q&A

What is a preprint?

A preprint is a research paper that has been posted publicly before peer review — the formal process in which independent experts check the methods and conclusions before a journal publishes it. Preprints allow researchers to share findings quickly, but they should be treated with slightly more caution than peer-reviewed publications because they have not yet passed that external check.

What is AFM (atomic force microscopy) and why does it matter here?

AFM is a technique that uses a nanoscale probe — essentially a very fine tip attached to a flexible arm — to feel the surface of a material at a level of detail far beyond what light microscopy can achieve. In biology, it can measure the stiffness of individual cells or tissue samples with extraordinary precision. That is what makes it useful here: you can map stiffness changes in spinal cord tissue at the same sites you are measuring gene expression, correlating the two directly.

Does this mean scar stiffness is the main reason regeneration fails?

Not necessarily — and the authors do not claim that. The scar is a multi-layered problem: it includes chemical inhibitors like chondroitin sulphate proteoglycans (CSPGs), cellular barriers, immune regulation failures, and many other factors. Mechanical stiffness is one more dimension of that problem, and this study suggests it may be more actively involved in maintaining the scar than previously appreciated. How large that contribution is relative to other factors is still an open question.

What would a treatment targeting this look like?

Research in other fields has explored materials designed to match or progressively match the mechanical properties of target tissue (biomimetic scaffolds), enzymes that break down fibrotic ECM components, and pharmacological targets in the mechanotransduction pathways themselves. None are approved for SCI. But the science described in this preprint helps define what such a treatment would need to do.

For decades, the medical consensus on spinal cord injury was brutally simple: once nerves are damaged, they don't come back. But that consensus is cracking. A peptide drug called NVG-291, developed by the Canadian biotech company NervGen, has just completed a Phase Ib/IIa clinical trial with results that are turning heads — and giving a lot of people with SCI genuine reason for hope.

What is NVG-291 and where did it come from?

NVG-291 — also known as ISP, short for intracellular sigma peptide — traces its origins to the lab of the late Jerry Silver, a neuroscientist at Case Western Reserve University who spent his career asking a question most of his colleagues thought was pointless: what if paralysed nerves could regrow?

Silver's team identified a key culprit in why injured nerves fail to recover: a family of molecules called chondroitin sulfate proteoglycans, or CSPGs. Think of CSPGs as a molecular wall. After a spinal cord injury, the body rushes in to stabilise the damage, and one way it does that is by laying down CSPGs around the injury site. The problem is that these molecules don't just stabilise — they actively block nerve fibres from growing back through the damaged area.

Silver's lab developed ISP as a way to unlock that wall. The peptide binds to a specific receptor on nerve cells, essentially disabling the "stop signal" that CSPGs send. In animal studies, rats given ISP after a spinal cord injury showed dramatic recovery: hind legs that had been dragging began to function again, tails lifted, bladder control returned. A 60–80% response rate. The results were published in Nature, Nature Communications, and the Journal of Neurotrauma.

When NervGen licensed the ISP patents from Case Western, they renamed it NVG-291 and moved it into human testing. Jerry Silver, who passed away in January 2025, served as an advisor and saw the early human data before his death.

What did the Phase II trial show?

NervGen's Phase Ib/IIa trial (NCT05965700) wrapped up in late 2025 and early 2026. Ten participants with cervical spinal cord injuries received NVG-291 as a subcutaneous injection — the same delivery method used for insulin and GLP-1 weight-loss drugs. Participants could inject it themselves at home.

The team measured outcomes using GRASSP — the Graded Redefined Assessment of Strength, Sensibility, and Prehension. GRASSP tests fine motor skills: things like picking up a key, turning it in a lock, holding a cup. After 12 weeks on the drug, participants who received NVG-291 showed an average 3.7-point improvement in GRASSP quantitative prehension.

In clinical terms, this kind of improvement translates into tangible daily-life changes: the ability to brush your teeth, button a shirt, zip up a jacket, open a water bottle. For people who have lost fine hand function, these aren't small things — they're the difference between dependence and independence.

Perhaps the most striking finding came after the trial ended. In blinded exit interviews conducted almost a year after participants stopped taking the drug, those who had received NVG-291 reported that their improvements had continued — a stepwise increase in function even after discontinuing treatment. The drug appears to have kickstarted nerve regrowth that then kept going on its own.

"When you interview these individuals almost a year out from the study, those individuals that received the drug, their report was, 'Look, I stopped the drug and I continued to see a stepwise improvement,'" said NervGen CEO Adam Rogers. Five participants were so pleased with their results that they appeared on local television news to share their stories.

Why does this matter for the SCI community?

Most approaches to SCI rehabilitation work around the damage — teaching the body to compensate for what's missing. NVG-291 is attempting something different: it's trying to get damaged nerve pathways to actually reconnect and function again. The preliminary results suggest this isn't just a theoretical possibility.

The subcutaneous delivery is significant too. Many experimental SCI treatments require surgery or hospital procedures. If NVG-291 proves effective in larger trials, it's the kind of drug someone could manage at home, much like the millions of people who self-inject insulin or Ozempic.

NervGen went public on 21 May 2026, raising $60 million to fund their next phase of development. Phase III is planned to begin in mid-2026. The company is also exploring whether NVG-291 could have a role in other conditions where nerve damage is a factor, including Alzheimer's disease and ALS.

Reader Q&A

This sounds incredible — why haven't I heard about it before? Phase II trials involve small numbers of participants and aren't designed to prove effectiveness — they're primarily about finding the right dose and confirming early signs that a drug is working. NervGen's Phase II had just ten people on the drug. That's exciting for a signal, but it's a very small sample. Phase III, with hundreds of participants across multiple sites, will be the real test.

Will this work for complete injuries, or only incomplete ones? The Phase II trial included participants with cervical spinal cord injuries, but the trial report doesn't specify completeness of injury for all participants. The drug's mechanism — unlocking blocked nerve pathways — in principle applies to both complete and incomplete injuries, but complete injuries involve more extensive damage and may respond differently. Phase III will likely help answer this.

What are the risks? Phase I safety data cleared NVG-291 for human testing, and the Phase II trial didn't raise red flags. As with any drug, side effects are possible, and the long-term profile isn't yet fully established. The company will continue monitoring participants and gathering safety data in Phase III.

When could this be available? If Phase III results are positive, NervGen would then seek regulatory approval — a process that typically takes several years after the trial concludes. A realistic optimistic timeline might be 2029–2031, but that depends on how quickly Phase III enrols and what the results show. Rogers has said the company plans to start their Phase III study in mid-2026.

One of the most intuitive fears about experimental stem cell therapy for spinal cord injury is the idea of injecting cells directly into the spinal cord itself. The spinal cord is a delicate, critical structure. Interfere with it and you risk making things worse. The thought of needles going in — even to deliver potentially healing cells — raises obvious concerns about safety.

A new review published in the journal *Cell Transplantation* takes a careful look at the accumulated evidence and reaches a somewhat reassuring conclusion: the procedure appears to be safer than its reputation suggests.

What is intramedullary transplantation?

"Intramedullary" literally means "within the spinal cord" — as opposed to injecting cells into the spinal fluid or around the spinal cord. It's the most direct approach to getting therapeutic cells to the site of injury, but it's also the most intimidating. The review authors — Caroline Nonnarath and Nicolas Serratrice — assessed evidence from multiple early-phase clinical studies that used this approach, looking at a range of cell types including bone marrow stem cells, mesenchymal stromal cells (MSCs), and neural stem cells.

What did they find on procedural safety?

Despite the heterogeneity across the studies — different cell types, different doses, different delivery methods — a consistent picture emerged on procedural safety. Severe complications after injection were uncommon. Adverse events that did occur were predominantly mild and transient. Most importantly, the review found no reproducible signal of neurological deterioration caused by the procedure itself.

In plain terms: across multiple clinical studies, injecting cells directly into the spinal cord did not reliably make people worse. That's not the same as saying it's risk-free — no procedure involving the spinal cord is — but it does challenge the assumption that intramedullary delivery is inherently dangerous.

What about the risk of tumours?

This is the concern that many people in the SCI community will have heard about. Stem cells are, by definition, cells that can multiply and differentiate. In theory, if something goes wrong during that process, you could end up with abnormal cell growth — a tumour.

The review takes this concern seriously and doesn't dismiss it. It notes that theoretical risks of tumorigenesis, clonal selection, and genomic instability — particularly with MSCs that have been grown in the lab before transplantation — remain real biological possibilities.

However, the review also notes an important distinction: the clinical data gathered so far has not identified confirmed cases of cancer caused by these cell transplantation procedures, within the follow-up periods reported. The concern is theoretically grounded but has not yet been confirmed empirically in patients.

The authors also discuss an alternative approach: freshly isolated stromal vascular fraction (SVF), which uses cells taken directly from a patient's own fat tissue without laboratory expansion. Because SVF cells haven't been grown and multiplied in the lab, they don't carry the same theoretical risks associated with ex vivo expansion. This "minimally manipulated autologous" approach (using your own cells, minimally processed) is highlighted as a potentially safer route with its own interesting properties.

What does this mean for the SCI community?

Stem cell therapy for SCI is one of the most frequently asked-about topics in the community — and one of the most misunderstood. Countless clinics around the world offer stem cell treatments of dubious quality, often at enormous financial cost, targeting people who are desperate for any sign of improvement. The field has been muddied by this, and genuine scientific progress has sometimes struggled to cut through the noise.

This review is a piece of legitimate science doing what science should do: taking stock of what we actually know. Its message is nuanced. Yes, direct spinal cord injection of stem cells appears to be procedurally safer than we assumed. No, we don't have long-term cancer data yet. Yes, some approaches (like SVF) may carry lower theoretical risk. No, this is not a green light to seek unverified treatments.

The authors call for harmonised reporting standards, longer follow-up, and collaborative datasets to build the evidence base properly. That's the kind of careful, systematic work that will eventually give us real answers.

Reader Q&A

Does this mean stem cell treatments for SCI are safe? This review addresses one specific aspect of safety: the procedure of injecting cells directly into the spinal cord in carefully conducted clinical studies. It doesn't cover the wider landscape of stem cell clinics, which often operate outside rigorous clinical protocols and use uncharacterised cell products. The safety reassurance in this review applies to legitimate, regulated early-phase clinical trials — not commercial clinics.

Have any patients actually benefited from intramedullary stem cell transplantation? Early-phase studies are primarily designed to test safety, not effectiveness. Some participants in these trials have reported improvements, but the studies are too small and varied to draw firm conclusions about efficacy. Larger, properly controlled trials are needed to answer whether — and for whom — these approaches work.

What types of stem cells are being used? The review covers three main types: bone marrow mononuclear cells (mixed cells from bone marrow), mesenchymal stromal cells (MSCs, often from bone marrow or fat), and neural stem cells. Each has different properties, different theoretical risks, and different evidence bases.

Should I try to access a stem cell treatment based on this? The authors are specifically reviewing legitimate clinical studies, not commercial treatments. If you're interested in stem cell trials for SCI, the right route is through registered clinical trials — the ClinicalTrials.gov database lists registered studies. Seek advice from your spinal consultant before pursuing anything, and be very cautious of clinics charging large sums for unproven treatments.

A piece of news from the stroke rehabilitation world is worth tracking here, because the technology at its centre is exactly the same technology that SCI researchers have been developing for years — and what works (or does not work) in stroke recovery has direct implications for understanding how spinal cord stimulation could be used in SCI.

MindMaze Therapeutics has announced that its precision neurotherapy platform is being used in a University of Pittsburgh study testing a combination approach to post-stroke arm recovery. The trial is now enrolling.

The background: what cervical SCS already showed in stroke

The University of Pittsburgh has been one of the leading centres for epidural spinal cord stimulation research in both SCI and stroke. Earlier this year, results published in Nature Medicine showed that cervical epidural spinal cord stimulation can meaningfully improve arm and hand movement in people with chronic stroke — and that these gains could appear after just a few hours of training.

That is a striking finding. But it came with an important asterisk: the gains were largely assistive. The improvements in arm movement were present while the stimulation was active. When the stimulation was off, many of the gains faded.

The new University of Pittsburgh study is specifically designed to tackle that problem.

What the new trial is testing

The question the study is asking: if you pair the same cervical spinal cord stimulation with a high volume of intensive, intent-driven practice, can the gains outlast the stimulation itself?

The rationale is grounded in how the nervous system relearns movement. When spinal cord stimulation is active, it amplifies the pathways in the cord that drive the muscles — making movements that were barely possible suddenly achievable. If the patient is simultaneously making a deliberate effort to move, that intent pairs with the stimulation-driven activity. Repeat that pairing many times, and the theory is that the connections responsible for the movement get stronger and more stable — durable rather than transient.

Volume is key. The nervous system needs repetition to consolidate these changes. The question is whether MindMaze Therapeutics' platform can deliver that volume.

What MindMaze Therapeutics does

MindMaze Therapeutics (listed on the Swiss exchange as MMTX) develops precision neurotherapy platforms — essentially software and hardware systems designed to deliver structured, high-intensity, intent-driven rehabilitation exercises at scale. The claim the company makes is that their platform can provide the volume and specificity of practice that recovery requires without placing a proportional burden on clinical staffing — meaning patients can complete more therapy sessions than a purely therapist-delivered model would typically allow.

In this trial, MindMaze's system pairs with the stimulation: the cervical SCS creates a window in which arm movement is more achievable, and MindMaze's platform provides the intensive practice to drive during that window.

Why this is relevant to SCI

The primary patient population in this trial is stroke, not SCI. But the technology and the scientific question are identical to central questions in SCI rehabilitation research.

Cervical epidural spinal cord stimulation has been used in SCI with similar rationale: stimulation plus intent plus practice. The challenge of making gains durable — of moving from assistive stimulation to lasting recovery — is the same challenge in both conditions. What the Pittsburgh team learns about the right dose of practice, the right timing, and the right combination will feed directly into how the approach is refined for SCI.

This is part of why it is worth following. Stroke research and SCI research are not the same, but they share the same nervous system. When a study as carefully designed as this one tests a combination of stimulation and intensive practice in the stroke context, the SCI research community will be watching closely.

What comes next

The trial is now enrolling. It will take time before results are available. MindMaze Therapeutics describes this as part of its broader strategy of positioning its platform alongside medical devices and pharmaceutical products to deliver combination therapies — not just standalone neurotherapy.

Whether this trial eventually shows that the combination makes gains durable where stimulation alone did not is still unknown. But the fact that it is being designed and run at all reflects how far the field has come from thinking of spinal cord stimulation as a simple pain-management tool.

Reader Q&A

Is this trial open to people with SCI?

No — this specific trial is enrolling people with post-stroke arm weakness, not SCI. The technology is the same, but the patient population is different.

Could the results change how SCS is used in SCI?

Potentially, yes. The central question — can intensive practice paired with stimulation produce durable gains? — is the same in both conditions. If Pittsburgh shows a clear answer in stroke, it will inform how researchers design the next generation of SCI stimulation trials.

What is MindMaze Therapeutics' relationship to the University of Pittsburgh?

MindMaze is supporting the trial by providing its neurotherapy platform. The University of Pittsburgh is the sponsor and research site. The press release describes this as MindMaze Therapeutics supporting the study, not running it independently.

Is cervical epidural SCS the same approach used in SCI rehabilitation?

Yes. Cervical epidural SCS targets the cervical spinal cord — the region that controls arm and hand function. It has been studied for both upper-limb recovery in cervical SCI and arm recovery after stroke. The electrode placement and stimulation parameters differ between applications, but the basic approach is the same.

Water has been used in rehabilitation for a long time, but rigorous clinical evidence for its specific benefits in spinal cord injury has been slow to accumulate. A new study from Spain fills in a piece of that gap — and the results are encouraging enough to warrant the larger controlled trials the researchers themselves are now calling for.

The study, published in the Journal of Spinal Cord Medicine, tested a structured programme called Water Specific Therapy (WST) in twelve people with subacute incomplete spinal cord injury — all of them injured between thoracic level 1 and lumbar level 5, and all within six months of their injury.

What is Water Specific Therapy?

WST is not simply swimming or gentle movement in a pool. It is a structured therapeutic approach in which a trained physiotherapist works with the patient in water, using the physical properties of the aquatic environment — buoyancy, resistance, hydrostatic pressure, and warmth — in a deliberate and planned way.

The programme in this study involved 18 sessions of 40 minutes each, structured into warm-up, balance training, aerobic exercises, and a cool-down phase. Effort was monitored throughout using the Rating of Perceived Effort scale, which lets patients and therapists track exercise intensity in real time.

The participants all had motor incomplete injury — meaning they retained some voluntary movement below their injury level — and all were in the subacute phase, within six months of injury. This window matters: it is when the nervous system is often most responsive to rehabilitation input.

What did the study measure?

The primary question was about feasibility: can this programme actually be delivered to people with incomplete SCI, and will they stick with it? Feasibility studies answer questions like: do people drop out? Is it safe? Do patients feel it's worthwhile?

On all three counts, the answer was yes. Adherence reached 83% — a strong figure for a rehabilitation study. There were only two dropouts, and both left for reasons unrelated to the therapy itself. Crucially, no adverse effects were recorded. The treatment was deemed safe.

And 88.9% of participants reported subjective improvement across three domains: balance, gait, and lower limb strength. That is a high figure — nearly all participants felt they were getting something from the therapy.

What did the objective measures show?

Beyond what participants reported, the study used five validated outcome measures to track gait and balance objectively:

The Berg Balance Scale (BBS) measures a person's ability to maintain balance during various tasks. The Timed Up and Go test measures how quickly someone can stand, walk a short distance, turn, and sit back down. The 10-metre walk test and 6-minute walk test assess walking speed and endurance. The Walking Index for Spinal Cord Injury II (WISCI-II) ranks how much assistance a person needs to walk.

All four of the last measures reached statistical significance — meaning the improvements were large enough to be unlikely to have happened by chance. Balance improved. Walking speed improved. Walking endurance improved. Independence in walking improved.

What the study could not show

One honest limitation: this was a feasibility study, not a randomised controlled trial. There was no control group — no matched group of participants doing conventional land-based therapy at the same time — so the study cannot prove that the water therapy caused the improvements rather than the natural recovery that can happen anyway in the subacute phase after SCI.

The researchers are clear about this. Their conclusion is that WST is feasible and safe, and that the improvements are promising enough to now justify a properly controlled study to test whether the therapy itself is responsible for what they saw.

The physiotherapists in the study also noted that it was sometimes difficult to push participants to higher intensity levels in water — the resistance is present, but it is distributed differently from land-based exercise, and some participants needed programme adaptations to reach their targets. That is a practical note for therapists implementing similar programmes.

Why this matters for the SCI community

Water-based rehabilitation is already used in some SCI rehabilitation centres, but not universally, and the evidence base for its specific use in SCI has been thinner than the clinical intuition that supports it. Studies like this one — structured, published, peer-reviewed — add to the evidence that justifies investing in aquatic therapy resources and training.

For people with incomplete SCI in the subacute phase, the specific appeal of water therapy is that the buoyancy reduces the effort required to move, potentially allowing people to practise movements — upright balance, stepping, arm movement — that would be impossible or unsafe on land at that stage of recovery. If the nervous system is in its most plastic, most responsive window in the first six months after injury, being able to practise more movement earlier could matter.

This study did not prove that case definitively. But it showed the approach is safe, well-tolerated, and associated with real improvements. That is a meaningful step forward.

Reader Q&A

Is this available in SCI rehabilitation centres now?

Some centres, particularly those with hydrotherapy pools, already incorporate water-based sessions into SCI rehabilitation. Whether a structured WST programme specifically is offered depends on the centre and the therapist's training. If you are in rehabilitation and interested, it is worth asking whether aquatic sessions are available.

Does this only apply to incomplete injuries?

This study looked specifically at motor incomplete SCI (T1-L5). People with complete injuries or cervical injuries were not included. Aquatic therapy is used more broadly, but whether it produces the same measurable outcomes in other injury profiles is a separate question.

Why subacute? What about chronic SCI?

The subacute phase — roughly the first six months after injury — is when the nervous system tends to be most responsive to rehabilitation input, and when spontaneous recovery is also ongoing. This makes it both the most important window to intervene and the hardest to study (because it is difficult to separate therapy effects from natural recovery). Aquatic therapy for chronic SCI is a different question with different considerations.

What is the next step for this research?

The authors explicitly call for controlled studies — ideally randomised controlled trials — to determine whether the improvements seen here are caused by the therapy or would have happened anyway. Until that evidence exists, the current study is best understood as proof that the approach is worth studying properly, not proof that it works definitively.

Something significant happened quietly in the world of spinal cord injury this week. A treatment that has already been approved by UK regulators is now being trialled in real rehabilitation centres across the country — and the organisation behind it wants to turn that into a national network.

The charity Spinal Research has launched what it is calling a pioneering programme: lending the ARC-EX system, developed by Onward Medical, to specialist rehabilitation centres so they can use it with their clients and gather data on how it actually performs in the real world.

This matters because there is often a long gap between a treatment being approved and it actually reaching people with SCI. This programme is designed to close that gap.

What is the ARC-EX system?

ARC-EX stands for Activity-based Rehabilitation with Cervical Electrical Stimulation. It is a non-invasive device that delivers targeted electrical stimulation to the spinal cord in the cervical region — the neck area — while the person is engaged in rehabilitation exercises.

The idea is that the electrical stimulation "wakes up" pathways in the injured spinal cord that are still present but not firing effectively. When that stimulation happens at the same time as active rehabilitation movement, it may help the nervous system relearn and strengthen those connections.

In clinical trials, it has been shown to improve hand strength and sensation in people with chronic cervical spinal cord injury. And crucially, it has been approved by UK regulators — making it the first dedicated treatment for paralysis to receive that approval.

What the programme actually involves

Spinal Research is loaning the ARC-EX system to a small number of approved specialist rehabilitation centres on a twelve-month basis. The centres use it with clients who have spinal cord injuries, alongside their normal activity-based therapy.

The trailblazer centre is the Matt Hampson Foundation Get Busy Living Centre, near Melton Mowbray in Leicestershire. Matt Hampson, the former England Under-21 rugby union player who was paralysed from the neck down in a training accident at age 20, founded the centre to support young people following life-changing injury.

Three more centres are set to join — one each in Yorkshire, the North East, and the South West — with a fourth being funded in partnership with the Injured Jockeys Fund.

Why this is different from a clinical trial

Clinical trials test whether a treatment works under controlled conditions. Real-world programmes test something different: does it actually work when used in the messy, variable reality of everyday rehabilitation?

The people using ARC-EX through this programme will vary in their injuries, their history, their goals, and their abilities. Collecting data across all of them will show something clinical trials cannot — how the device performs across the full range of people who might genuinely benefit from it.

That data feeds back into research and best practice, helping shape how the technology is eventually rolled out more widely.

The bigger picture: the Spinal Research Recovery Alliance

The programme is part of a wider initiative called the Spinal Research Recovery Alliance. This brings together researchers, clinicians, industry partners, and people with spinal cord injuries, with the goal of speeding up progress from the laboratory to real-world impact.

Louisa McGinn, Chief Executive of Spinal Research, put it plainly: "The next five years present an unprecedented opportunity to change what's possible for people living with spinal cord injuries. Breakthrough therapies are nearing clinical reality, and frontier technologies — from AI and robotics to gene therapy — are creating bold and quicker new pathways toward repair and recovery."

The ARC-EX programme is described as a first step in building a national network of community rehabilitation centres connected by shared data, research, and outcomes.

Why this matters for the SCI community

For many people with cervical SCI, improving hand and arm function is one of the most important goals they have. Even small gains can change independence: being able to hold a phone, press a switch, use a wheelchair joystick, or manage personal care are all tasks that depend on hand and arm strength.

ARC-EX is not a cure. It does not repair the spinal cord. But it is a tool — now approved and being tested in real rehabilitation settings — that may help some people with chronic cervical SCI make functional gains they would not otherwise make.

The fact that it is already approved, already in use, and now being systematically studied in real-world conditions is genuinely good news. Not the dramatic kind, but the steady, building kind that tends to matter most.

Reader Q&A

Is ARC-EX available to me right now?

It is being used through this specific programme at four selected rehabilitation centres in the UK. It is not yet widely available through the NHS. If you are interested, it may be worth contacting Spinal Research or the Matt Hampson Foundation to find out more about access.

Is it safe?

Yes. It is non-invasive — no surgery or implants — and it has already passed the UK regulatory approval process. The programme is now collecting further real-world safety and effectiveness data.

What is the Injured Jockeys Fund's involvement?

The Injured Jockeys Fund, which supports jockeys who have been seriously injured in racing, is co-funding one of the four centre placements — a nice example of different SCI communities working together.

Could this expand nationally?

That is the goal. Spinal Research has launched a fundraising campaign to expand the programme to more centres across the UK.

If you live with a spinal cord injury, you probably already know that bowel problems are one of the most persistent and frustrating consequences. What you may not know is that researchers are increasingly finding that the relationship runs the other way too — that what happens in your gut after SCI may actually be making the secondary damage to your spinal cord worse.

A review paper published this week in Frontiers in Cellular Neuroscience lays out the current state of knowledge on what scientists are calling the gut–spinal cord axis. The short version: after SCI, your gut changes, and those changes send signals that your spinal cord's immune cells pick up and respond to — in ways that can fuel further inflammation.

First, what happens to the gut after SCI?

The gut is not just a passive tube. It is controlled in large part by the autonomic nervous system — the part of the nervous system that handles automatic functions like heart rate, blood pressure, and digestion. After a spinal cord injury, this autonomic control is disrupted.

What follows is a chain of events. Bowel movements slow down. Gut motility — the movement that keeps food and waste travelling through the intestines — is reduced. The balance of bacteria in the gut (the microbiome) shifts. The lining of the intestine, which normally acts as a barrier keeping gut contents separate from the bloodstream, becomes leaker.

Most people with SCI are familiar with neurogenic bowel dysfunction as a daily management issue. This review is suggesting it may also be a secondary injury pathway — one that continues feeding inflammation into the already-injured spinal cord long after the initial trauma.

What gets through the leaky gut?

When the intestinal barrier is compromised, things that should stay in the gut start getting into the bloodstream. The review focuses on several key signals:

LPS (lipopolysaccharide) is a molecule from the outer wall of certain gut bacteria. When it gets into the bloodstream, it is a powerful trigger for the immune system. In the context of SCI, it can cross into the spinal cord and activate the cells there.

Short-chain fatty acids (SCFAs) are normally produced by healthy gut bacteria breaking down fibre. They have anti-inflammatory and protective properties. After SCI, with the microbiome disrupted, levels of SCFAs tend to fall — removing a natural brake on inflammation.

Tryptophan metabolism gets disrupted too. Tryptophan is an amino acid found in food. Healthy gut bacteria process it into compounds that help regulate immune responses. After SCI, that processing goes wrong, shifting the balance towards more inflammatory outcomes.

TMAO (trimethylamine N-oxide) is another gut-derived molecule that tends to rise when the microbiome is disrupted. Elevated TMAO has been linked to immune dysfunction and may affect the integrity of the protective barrier around the spinal cord itself.

What does this do to the spinal cord?

Inside the injured spinal cord, three types of cells play a major role in the immune response: microglia (the spinal cord's resident immune cells), astrocytes (support cells that help regulate the local environment), and infiltrating macrophages (immune cells that move in from the bloodstream after injury).

The gut-derived signals described above appear to influence all of these cells — pushing them towards more inflammatory states and helping sustain the local inflammatory environment in the injured cord rather than allowing it to settle down.

The review identifies several molecular pathways through which this happens, including TLR4/NF-κB signalling (essentially, a key that unlocks inflammatory responses when LPS arrives) and the NLRP3 inflammasome (a molecular alarm system that, when triggered, amplifies inflammation significantly).

In plain terms: the disrupted gut is sending signals that keep these immune cells stirred up in ways that may slow recovery and worsen secondary damage.

Is this a proven treatment target yet?

Not yet — and the review is honest about that.

The authors note that most existing studies have looked at correlations: people with SCI tend to have certain gut changes, and people with those gut changes tend to have worse outcomes. But correlation is not the same as causation, and most of the evidence comes from animal models rather than clinical trials in humans.

The review calls for studies that establish causal, cell-specific, and stage-specific mechanisms. In other words: we need to understand exactly which gut changes matter, at which point after injury, and for which cells in the spinal cord.

That is the scientific work still to be done before gut-targeted interventions — like specific probiotic strains, dietary changes, or drugs that target these pathways — can be prescribed with confidence.

Why this is still worth paying attention to

Even in its current early state, the gut–spinal cord axis research matters for a few reasons.

First, it reframes something SCI people already deal with. Neurogenic bowel is not just an inconvenient symptom to manage. It may be an active part of secondary injury that deserves the same attention as any other aspect of recovery.

Second, it opens a therapeutic window that does not require surgery or highly invasive interventions. If future studies confirm that improving gut health after SCI reduces secondary neuroinflammation, the tools to address it — diet, targeted probiotics, gut barrier support — are relatively accessible compared to many other SCI research directions.

Third, the biology described here fits with a growing understanding in neuroscience that the gut and brain (and by extension spinal cord) communicate constantly. SCI disrupts that communication in ways that are only now starting to be mapped properly.

Reader Q&A

Should I be taking probiotics after SCI?

There is not enough human evidence yet to make a specific recommendation. The research here is promising but mainly from animal studies. If you are interested, it is worth discussing with your healthcare team — but this is not a proven treatment.

Does this research change anything right now?

Not directly. But it does add scientific weight to the importance of bowel management after SCI. Managing neurogenic bowel well is already important for quality of life; this research suggests it may also matter for the broader recovery environment in the spinal cord.

What does "secondary neuroinflammation" mean?

After the initial spinal cord injury (the primary damage), a second wave of damage begins — driven by swelling, dying cells, and the immune system's response. This is called secondary injury. Neuroinflammation is the inflammation part of that process. The point of this research is that the gut may be contributing to that ongoing inflammation.

One hundred years ago, Gertrude Ederle became the first woman to swim the English Channel. This summer, a relay team of women decided to do it again in her honour — and raise money for people living with spinal cord injury while they were at it.

Louise, a triathlete from Torquay, is part of 10IronWomen, an all-female triathlon community whose motto is essentially that incredible things are within reach if you put your mind to them. When someone in the group floated the idea of crossing the Channel on the centenary of Ederle's swim, it stuck.

"When looking for my 2026 challenge my lovely 10IronWomen group had a mad idea — it's the 100 year anniversary of the first woman to swim the Channel, so why don't we do it too, in her honour!" Louise wrote for Aspire's blog.

The Aspire Dragonflies

The team swam as the Aspire Dragonflies, with Aspire as their chosen charity. Aspire is a UK charity that provides practical support to people who have been paralysed by spinal cord injury — help with housing, welfare benefits, assistive technology, independent living, and more. It is the kind of organisation that quietly changes lives in concrete ways.

The connection to 10IronWomen came through a team member called Bryony, who is taking on a solo Channel swim this year and recommended Aspire. Once the team heard about the charity and the work it does, the fit was obvious.

The swim itself

A relay Channel swim means the team members take turns in the water — each swimming for roughly an hour at a time — until the full 22-mile crossing from England to France is complete.

Louise was first into the water, which meant starting from a Dover beach in the dark at 2am. She ended up swimming three sections: the opening stretch out of Dover, a spell through the busy separation zone where cargo ships pass, and the final approach that landed the team on the French shore.

The conditions started choppy overnight but settled into something much more pleasant as the day progressed. "The sea was warm, not too choppy and we had glorious sunshine and blue skies," Louise wrote.

The crossing was not without its difficulties. One of Louise's teammates was seriously seasick — unable to keep anything down — but kept getting back in the water anyway. "She was swimming on pure empty. Both her swims were super tough for her but all of us were on the side keeping her going and she absolutely knuckled down and got us forward on the most crucial bit of the swim."

That, in a lot of ways, is the kind of thing that makes these challenges worth reading about.

What it means

Louise had not met anyone with a spinal cord injury before this challenge. But she heard Paula Craig MBE speak at an Aspire information day early in the process and it changed how she thought about the whole endeavour.

"The thought that one day this fitness and ability could suddenly be gone, and yet the dedication and motivation she had to carry on literally brought me to tears," she wrote.

"We are lucky and privileged to get to do this and we shouldn't forget it. If we can help to make someone's life that bit easier or that bit more fun we should."

Get involved

Aspire runs a range of swimming and endurance events throughout the year, including relay and solo Channel swims, Solent swims, and River Arun events. If you are an able-bodied swimmer looking for a challenge with meaning, or if you simply want to donate in support of someone already taking one on, Aspire's event calendar is the place to start.

You can find out more at aspire.org.uk, or sponsor Louise directly at the link below.

Brain-computer interface research has come a long way. There are now devices that let paralysed people control robotic arms, move cursor pointers, type text using only their thoughts, and in some cases stimulate their own muscles into movement. The technology is advancing fast.

But here is the question that does not get asked often enough: what do people living with high cervical spinal cord injury actually want from it?

A study published in the Annals of Rehabilitation Medicine set out to find exactly that. Researchers at Seoul National University Hospital ran a structured focus group with four individuals who all had chronic high cervical SCI — neurological levels of C4 or above. All four were living with paralysis that affected the majority of their voluntary movement.

The results are worth paying attention to, not just for what they reveal about patient priorities, but for what they suggest about how BCI research should be shaped going forward.

What they found: digital freedom first

When asked what they most wanted BCI to help them with, the participants were consistent: digital independence.

Specifically, they highlighted messaging, online banking, internet use, and smart home control as the things they most wanted to regain control over. Being able to send a text message without assistance. Managing their own finances without needing someone to type for them. Controlling the lights and temperature in their own home without depending on a carer to do it.

This is significant because a lot of BCI research focuses on restoring physical movement — the dramatic demonstration of a paralysed person moving a robotic arm or walking with exoskeletal support. Those are genuinely important goals. But for the people in this study, the daily reality was different. Digital access and independence in routine tasks came first.

The researchers organised their findings into five major themes: digital accessibility, offline physical activity, social interactions and psychological health, usability, and acceptance. Each one reflects a different dimension of what life with high cervical SCI actually involves.

Reducing reliance on caregivers

Beyond digital access, participants expressed a strong interest in BCI as a way to reduce how much they depended on caregivers. This was both a practical priority and an emotional one.

People with high C-SCI typically require round-the-clock assistance for many basic tasks. Even small gains in autonomy — being able to initiate a phone call, navigate to a website, adjust the heating — can have an outsized impact on quality of life and self-determination.

What the participants described was not necessarily a desire to do things physically, but a desire to be in charge: to initiate, decide, and act independently, even if the mechanism is a thought-controlled interface rather than a hand.

What people were willing to do — and what they worried about

The study also asked about acceptance of BCI technology, including invasive procedures like implanted electrodes. Most participants were open to training. Some were open to invasive options.

One of the more interesting findings was a shift that happened during the focus group itself. After the structured discussion — which was facilitated by experts in rehabilitation medicine and biomedical engineering — participants' willingness to undergo invasive procedures increased, while their expected functional outcomes became more realistic.

Put simply: talking it through with others who shared their experience and with knowledgeable facilitators changed how they thought about the technology. This is a point the researchers flag as important for how clinical education and shared decision-making around BCI should work.

Concerns were also clearly expressed. Surgical safety, device maintenance, reliability, and practical usability were all raised frequently. The enthusiasm for what BCI could offer was genuine — but so was the scepticism about whether current technology could actually deliver it consistently in daily life.

Why user-centred design matters in BCI development

This kind of research — qualitative, small, built around listening to patients — is not the kind that makes headlines about a breakthrough. But it does something important.

It documents the gap between what researchers are building and what users actually want and need. It asks: if this technology eventually works reliably, will it solve the right problems?

For the four participants in this study, the answer is: yes, but only if it prioritises daily independence and digital access alongside (or even ahead of) motor restoration.

The authors conclude that BCI should be seen as a pathway to greater independence, participation, and autonomy for people with high C-SCI — and that lived experience should actively guide assistive neurotechnology development. That is not a radical idea, but it is one that gets underweighted when research funding and attention follows the most visually dramatic applications.

How many people does this represent?

Four. This study has four participants. That needs to be said clearly. Qualitative focus group research is not designed to be statistically representative — it is designed to explore themes, capture nuance, and generate questions for larger research. That is valuable. But it is not a clinical trial, and four voices cannot speak for the full diversity of experience among people with high cervical SCI.

What this study offers is a starting point: a structured, expert-facilitated conversation about what matters to patients, published and peer-reviewed so it can inform future, larger research.

Reader Q&A

Is BCI available for people with high cervical SCI right now?

Some non-invasive systems exist that let people with high C-SCI control computers or communication devices using electrical signals from the brain or muscles. Invasive implanted BCIs, like those trialled by companies such as Synchron and Neuralink, are still in early clinical trial phases. Wide availability is still some years away, but the field is moving quickly.

What is the difference between invasive and non-invasive BCI?

Non-invasive BCIs sit on or near the skin — EEG caps and similar devices pick up brain signals without entering the body. Invasive BCIs involve implanting electrodes directly into or on the brain surface. They generally produce cleaner, more reliable signals, which is why some participants in this study became more open to the idea during the focus group discussion. The trade-off is surgical risk and device maintenance.

Why only four participants?

Finding people with chronic high cervical SCI willing and able to take part in a research focus group is not straightforward. The study is best understood as a carefully documented qualitative exploration rather than a definitive survey. That is still useful — but it is one of the reasons findings should be treated as preliminary.

Does this affect how I should think about BCI news?

Possibly. When you read BCI research coverage, it is worth asking whether the headline capability — moving a robotic arm, typing at speed — maps onto the things that would actually make the biggest difference to daily life. This study suggests the answer for high-level SCI is often: digital access and autonomy. Not just walking.

This is a company-reported result from NervGen Pharma on its Phase 1b/2a CONNECT SCI study of NVG-291 — a neuroreparative drug that targets the CSPG-PTPσ pathway (the molecular 'brake' scar tissue uses to block nerve regrowth after spinal cord injury). It is worth being clear up front: this is a small, early-phase trial with 10 patients on the drug and 10 on placebo, and the analysis, while independently conducted and blinded, is a company press release rather than a peer-reviewed publication.

The data released here is the biomechanical gait analysis, which tackles a long-standing problem in SCI research. When someone walks better after an incomplete injury, it is hard to tell whether their nerves are healing or whether they have simply learned compensation strategies — using momentum or extra muscle effort to mask the loss. To separate the two, NervGen used Newton Tech, an independent AI motion-capture company, to measure three hallmarks of genuine recovery: coordination, mechanical effort, and postural stability.

The headline finding: across a combined measure of all three, 100% (10/10) of NVG-291 patients were classified as 'responders', versus just 10% (1/10) of placebo patients (p=0.0001). The most telling result is what scientists call 'speed-effort dissociation.' Placebo patients who walked faster only did so by exerting much more effort — the textbook signature of compensation. NVG-291 patients walked faster *without* that spike in effort, consistent with genuinely restored neural control rather than muscling through.

In related company news: NervGen reached FDA alignment in April 2026 on the design of its Phase 3 trial, RESTORE, on track to begin mid-2026 across up to 60 sites in the US and Canada, and priced a US$60 million public offering in May 2026 to help fund it.

For people with cervical spinal cord injury, hand function is not a small detail. It can be the difference between needing help for almost everything and being able to control a little more of your own world.

A current recruiting trial is now testing Battelle's NeuroLife EMG-FES Sleeve System, a wearable forearm sleeve designed to help people with tetraplegia practise grasp and release movements.

The basic idea is simple but powerful. The sleeve tries to detect tiny muscle signals in the forearm when a person attempts to move their hand. These signals are called EMG, short for electromyography. Even when the hand does not visibly move, there may still be weak electrical activity showing that the person is trying.

The second part is FES, or functional electrical stimulation. This uses small electrical pulses through the skin to activate muscles. In the NeuroLife system, the sleeve can both listen for attempted movement and stimulate the muscles needed to help carry out that movement.

Source:

ClinicalTrials.gov study NCT06087445, Battelle's NeuroLife technology page, and previous NeuroLife research involving Ohio State University and Battelle.

What is being tested

The current study is testing the NeuroLife EMG-FES Sleeve System in adults with chronic tetraplegia due to spinal cord injury.

The system is non-invasive. It is worn on the forearm and uses surface electrodes rather than surgery or implanted parts. Trial descriptions say the sleeve can include up to 160 electrodes that record muscle activity and deliver stimulation.

Participants complete a 12-week rehabilitation programme, usually three in-person sessions per week. During these sessions, a therapist works with the participant while they wear the sleeve and practise functional hand and forearm activities.

Where this comes from

This device has a longer backstory than a typical new trial listing.

Battelle and Ohio State University were involved in the earlier NeuroLife neural bypass work, best known through Ian Burkhart. That earlier system used a brain implant, computer decoding, and a forearm stimulation sleeve to help restore voluntary hand movement in a laboratory setting.

That was an important proof of concept, but it was not a practical everyday solution for most people. It required brain surgery and specialist lab equipment.

The newer sleeve approach is different. Instead of reading movement intention directly from the brain, the current NeuroLife EMG-FES system aims to read intention from the forearm muscles themselves. This could make the technology much more practical if future trials show that it is safe and useful.

There was also an earlier completed SCI study, NCT05128994, focused on hand grasp after spinal cord injury. Public final results from that study do not appear to be fully posted yet, but the current recruiting trial suggests the programme has continued into a more structured rehabilitation study.

Why this matters in SCI

A small change in hand function can be a big change in daily life.

Being able to grasp a cup, release an object, use a phone, press a switch, type a few keys, or control a wheelchair joystick can all matter hugely after cervical SCI.

That is why this trial is interesting. It is not promising a cure. It is not claiming to repair the spinal cord overnight. It is asking a more practical question: can a wearable sleeve help people with tetraplegia turn attempted movement into assisted movement?

If the answer is yes, even modest gains could be meaningful.

What this does not prove yet

This remains investigational technology.

Battelle states on its NeuroLife page that the technology is not commercially available and has not been approved or cleared by the FDA for treatment.

The current trial is also small, with a planned enrolment of around 12 participants. It is mainly looking at safety, feasibility, early functional effects, and whether EMG signals could be used as a marker of recovery over time.

In other words, this is promising research, not an available treatment.

Reader Q&A

Is this recruiting now?

Yes. The current ClinicalTrials.gov study is NCT06087445.

Does the sleeve require surgery?

No. This version is non-invasive and uses surface electrodes on the forearm.

Is this the same as the original NeuroLife brain implant system?

No. It comes from the same wider NeuroLife research story, but this version aims to avoid brain surgery by using muscle signals from the forearm instead.

Could it restore normal hand function?

That is not proven. The realistic goal at this stage is to test whether the system is safe, usable, and shows early signs of helping hand and arm function after chronic cervical SCI.

Spinal cord stimulation is often discussed as a movement technology. But for many people with SCI, movement is not the only problem. Spasticity, pain, stiffness, clonus, and involuntary muscle activity can be just as limiting.

A new preprint study looked at a dual-mode epidural spinal cord stimulation approach designed to do two jobs: calm spasticity and support voluntary movement.

The idea is straightforward but important. One stimulation mode used high-frequency stimulation, around 1.2 kHz, to suppress spasticity. The other used lower-frequency stimulation, 30 to 60 Hz, to help motor facilitation during rehabilitation.

Instead of asking stimulation to do one thing, the researchers used different electrical settings for different nervous-system goals.

Author(s):

Yandong Fan, Mangsuer Nuermaimaiti, Hangfei Guo, Manli Zhu, Lei Ren, Yirizhati Aili, Mamutijiang Muertizha, Aihemaiti Aierken, and Kun Luo.

Source:

First Affiliated Hospital of Xinjiang Medical University, Xinjiang Medical University, and Second Affiliated Hospital of Xinjiang Medical University. Posted as a Research Square preprint.

What was tested

The study included 30 people with traumatic spinal cord injury. Participants were randomised to either epidural spinal cord stimulation plus physical therapy, or physical therapy alone.

The stimulation group received a 16-contact epidural electrode implanted close to the injury, one to two spinal segments above the lesion. The authors describe this as lesion-proximal placement.

This differs from many earlier stimulation approaches that mainly targeted intact lumbar circuits below the injury. Here, the researchers aimed to modulate the region nearer the damaged segment.

The stimulation was adjusted during surgery and then reviewed monthly.

Why two modes?

Spasticity and movement facilitation can pull in opposite directions.

Low-frequency stimulation may help activate motor circuits and support voluntary movement. But if someone has severe spasticity, making the nervous system more excitable can sometimes worsen stiffness, spasms, clonus, or unwanted co-contraction.

High-frequency stimulation can be used differently: to dampen overactive reflex pathways.

A simple analogy is driving a car with both a throttle and a brake. If the brake is stuck, pressing the throttle harder does not give smooth movement. This dual-mode approach tries to release the brake first, then support useful movement.

What the study reported

At 30 days, the stimulation plus physical therapy group showed better outcomes than physical therapy alone in several areas:

- Sensory improvement: 93.3% versus 60.0%. - Spasticity control: 73.3% versus 26.7%. - Pain reduction: 60.0% versus 20.0%.

At six months, the stimulation group showed sustained gains. ASIA sensory scores increased, motor scores improved, Modified Ashworth Scale scores fell, and pain scores improved.

The authors report that 80% of the stimulation group achieved clinically meaningful functional improvement, including recovery involving ankle dorsiflexors and gait-related muscles.

For readers, ankle dorsiflexion matters because it helps lift the front of the foot during stepping. Even partial improvement in that movement can be functionally meaningful.

Why this is relevant to spasticity

Spasticity is not just tight muscles.

It can include exaggerated reflexes, increased tone, clonus, involuntary spasms, and muscles firing against each other during attempted movement. That can make transfers, sitting, sleep, hygiene, bladder and bowel routines, and exercise harder.

Many drug treatments can help but may cause side effects such as weakness, tiredness, low tone, dizziness, or withdrawal problems. For some people, spasticity remains difficult to control.

This study is interesting because it treats spasticity as a central part of recovery, not as a side issue.

What this does not prove yet

This is a preprint, meaning it has not completed final peer review.

The study is also relatively small, with 30 participants. The results are promising, but they need independent confirmation, clearer reporting of safety outcomes, and longer-term follow-up.

Epidural stimulation also requires surgery. That means risks, screening, specialist implantation, programming, and rehabilitation support. It is not comparable to a simple external device.

The paper also sits in an interesting context. Other recent stimulation research warns that waveform, frequency, electrode placement, and target fibres all matter. High-frequency stimulation may help with some goals, such as suppressing spasticity, but it should not be assumed to be automatically useful for every recovery target.

Why this matters in SCI

The most useful part of this study is the treatment logic: one stimulation setting may not fit every symptom.

People with SCI may need stimulation programmes that change depending on the goal: relaxing spasticity, supporting stepping, assisting voluntary movement, reducing pain, or stabilising autonomic function.

If future trials confirm these findings, dual-mode stimulation could help move SCI neuromodulation toward personalised programming rather than fixed, one-size-fits-all settings.

Reader Q&A

Could this help someone with severe spasticity?

Possibly in the future, but this is still a preprint and involves implanted epidural stimulation. It should be viewed as promising clinical research, not an available general treatment.

Does high-frequency stimulation restore movement?

Not by itself. In this study, high-frequency stimulation was used mainly to suppress spasticity, while lower-frequency stimulation was used to support motor facilitation.

Why place electrodes near the injury?

The authors argue that placing electrodes close to the lesion may help modulate the injured segment itself, rather than only stimulating intact circuits below the injury. This needs further validation.

Some spinal cord injury breakthroughs are not treatments. They are better tools.

A new Scientific Reports paper describes a method for growing human spinal cord organoids from induced pluripotent stem cells, or iPSCs. These organoids were guided toward a lumbar spinal cord identity, meaning they resemble the lower spinal cord region more than previous models that often lean toward cervical or thoracic identity.

That matters because the lumbar spinal cord contains motor circuits involved in the legs. For SCI, ALS, spinal muscular atrophy, and other motor neuron conditions, researchers need better ways to study human spinal cord tissue in the lab.

Author(s):

Li Jun Loh, Pratibha Panwar, Shila Ghazanfar, Kwaku Dad Abu-Bonsrah, Forough Habibollahi, Joel Mason, Brett J. Kagan, Bradley J. Turner, and Samantha K. Barton.

Source:

Florey Institute of Neuroscience and Mental Health, University of Melbourne, University of Sydney, Charles Perkins Centre, Sydney Precision Data Science Centre, and Cortical Labs. Published in Scientific Reports.

What is an organoid?

An organoid is a tiny 3D tissue model grown in the lab.

It is not a full organ. It does not think, feel, or work like a complete spinal cord. But it can contain several cell types arranged in a more natural 3D structure than flat cells grown on a dish.

A useful analogy is the difference between studying a city from a list of buildings versus looking at a small 3D neighbourhood model. A flat cell culture can tell researchers a lot about one cell type. An organoid can show more of the relationships between cells.

Why lumbar identity matters

The spinal cord is not the same from top to bottom.

Cervical regions help control the arms and hands. Thoracic regions are involved in trunk and autonomic functions. Lumbar regions are important for lower limb circuits.

Many previous spinal cord organoid systems have been more cervical or thoracic in character. This new protocol aimed to push the organoids toward a caudal, or lower-spinal, fate. The researchers used developmental signals to increase HOXC10, a marker linked to lumbar identity, while reducing more anterior spinal cord identity.

In plain English, they tried to tell the stem cells: "do not become generic nervous-system tissue; become more like lower spinal cord tissue."

How the organoids were made

The team started with human iPSCs. These are adult-derived cells reprogrammed into a stem-cell-like state, meaning they can be guided to become many different cell types.

The researchers then used a sequence of chemical signals to mimic development. These included signals that help establish nervous-system fate, caudal spinal identity, ventral patterning, and motor neuron development.

Over time, the cells formed 3D spheres containing spinal cord-like cell populations.

What the researchers found

The organoids contained an enriched neuronal population along with several glial cell types.

Glia are support cells of the nervous system. They are not just background helpers. Astrocytes, oligodendrocyte-lineage cells, and other glial populations influence survival, inflammation, myelin, metabolism, and how neurons function.

That is important because SCI is not just a neuron problem. Injury affects neurons, glia, myelin, blood vessels, immune responses, and the tissue environment.

Single-cell RNA sequencing showed that the organoids contained diverse cell populations and better recapitulated ventral spinal cord identity than standard 2D motor neuron cultures.

The organoids also showed spontaneous electrical activity, suggesting that the cells were forming functional neural networks.

Why this could help SCI research

Animal models remain essential in SCI research, but they are not human.

Human spinal cord tissue is difficult to study directly, especially during early disease or injury processes. Organoids can help bridge that gap. They allow researchers to study human cells in a controlled environment, test drugs, explore disease mechanisms, and compare patient-specific cell lines.

For SCI, lumbar organoids could be useful for studying:

- How human motor neurons mature and connect. - How glial cells affect motor neuron survival. - How injury-like stress affects spinal cord cell networks. - How candidate drugs influence human spinal cord cells. - Why some motor neuron populations are more vulnerable than others.

This does not replace animal studies or clinical trials. It gives researchers another tool before moving into those harder and more expensive stages.

What this does not mean yet

These organoids are not transplant-ready tissue.

They are a model system. They do not contain the full structure of a spinal cord, long-distance body connections, blood supply, immune system, pain pathways, movement circuits, or the mechanical environment of an injured spine.

They also model development more than adult injury. Researchers would still need to adapt and validate them for specific SCI questions.

Why this matters in SCI

SCI research needs better human models. Too many potential therapies look promising in animals or simple cell cultures and then fail later.

A more realistic human lumbar spinal cord organoid could help screen ideas earlier and more accurately. It may also support personalised research in the future, where organoids made from a person's own cells are used to understand disease risk or test treatment responses.

This is not a cure story. It is a better-map story.

Reader Q&A

Could these organoids be implanted into someone with SCI?

No. This study is about creating a lab model, not a transplant therapy. Implantation would require a completely different level of safety and functional testing.

Why is this relevant if it is not a treatment?

Better lab models help researchers choose better treatments to test. They can reduce false starts and make it easier to study human spinal cord biology.

Why focus on the lumbar spinal cord?

The lumbar region contains circuits important for lower limb function. A lumbar-like model may be more relevant for studying leg-related motor neurons and lower spinal cord disease mechanisms.

One of the big problems after spinal cord injury is that the adult central nervous system is not very welcoming to regrowth.

Nerve fibres may try to sprout, but the injured spinal cord contains many stop signals. One of those stop signals is called Nogo-A. The name is unusually clear: it helps tell nerve fibres "no go", limiting growth inside the brain and spinal cord.

NG101 is an antibody designed to block Nogo-A. The hope is that by blocking this growth brake, the injured spinal cord may become more permissive to repair.

A new Nature Communications study looked at MRI data from the phase 2b NISCI trial to ask a more detailed question: does NG101 change the structure of the injured spinal cord in ways that can be measured?

Author(s):

Lynn Farner, Paulina S. Scheuren, Kiomars Shari, Tim M. Emmenegger, Maryam Seif, Michele Hubli, Martin Schubert, Marc Bolliger, Rudiger Rupp, Norbert Weidner, Rainer Abel, Doris Maier, Klaus Ruhl, Michael Baumberger, Margret Hund-Georgiadis, Marion Saur, Jesus Benito, Kerstin Rehahn, Mirko Aach, Andreas Badke, Jiri Kriz, Tim Killeen, Alan J. Thompson, Nikolaus Weiskopf, Martin E. Schwab, Armin Curt, Patrick Freund, and the Nogo Inhibition in Spinal Cord Injury Study Group.

Source:

Multicentre NISCI trial group, led by Balgrist University Hospital/University of Zurich and collaborating European spinal cord injury centres. Published in Nature Communications.

What is Nogo-A?

Nogo-A is a protein found in central nervous system myelin and nerve cell membranes. Myelin is the insulating layer around nerve fibres. After SCI, myelin damage is part of the injury environment, but myelin also carries molecules that can suppress new nerve growth.

A simple way to imagine Nogo-A is as a roadblock sign placed in front of damaged nerve fibres. Even if a nerve fibre has some ability to grow, Nogo-A helps tell it to stop.

NG101 is a recombinant antibody, meaning a lab-made immune protein, designed to neutralise Nogo-A. It does not replace lost spinal cord tissue. It aims to reduce one of the biological brakes on plasticity and sprouting.

What the researchers measured

This study analysed spinal cord MRI scans from 106 participants with acute traumatic cervical SCI who took part in the phase 2b NISCI trial. Participants received either NG101 or placebo.

The researchers tracked several MRI measures over six months:

- Lesion volume: how large the damaged area appeared. - Tissue bridges: strips of spared tissue crossing the injury site. - Cross-sectional cord area: a measure of spinal cord shrinkage or atrophy. - MTsat: an MRI marker sensitive to myelin and microstructure in specific spinal pathways.

They also looked at electrophysiology, including somatosensory evoked potentials, or SSEPs. These tests check whether sensory signals can still travel through the nervous system.

What they found

Compared with placebo, people treated with NG101 showed faster reduction in lesion volume over time.

They also showed a slower decline in spinal cord cross-sectional area and MTsat in important pathways, including the corticospinal tracts and dorsal columns.

In everyday language, the MRI signs suggested less ongoing structural loss in parts of the spinal cord important for movement and sensation.

The authors are careful about what this means. The findings could reflect reduced degeneration, better preservation of tissue, sprouting of nerve fibres, or a mix of biological changes around the injury.

The key point is that MRI detected treatment-related structural differences that may not always be obvious from clinical scores alone.

Why patient selection matters

SCI trials are difficult because no two injuries are exactly alike.

Two people can both have cervical SCI but differ in how much tissue is spared, which pathways remain connected, how swollen the cord is, how severe the injury is, and how much spontaneous recovery is possible.

This study found that combining MRI and electrophysiology helped identify subgroups where treatment effects were easier to detect. In particular, people with preserved tissue bridges and preserved sensory pathway signals showed clearer upper extremity motor recovery differences.

That matters because future trials may be smaller and more informative if they enrol people most likely to show a measurable biological response.

Why this is important for hand and arm recovery

Cervical SCI often affects hand and arm function. For many people with tetraplegia, even small improvements in hand control can change independence: feeding, phone use, wheelchair control, transfers, bladder management, pressure relief, and personal care.

NG101 has already shown exploratory signals that it may improve upper extremity motor function in motor-incomplete cervical SCI. This new imaging study adds another layer: it suggests the treatment may also be changing the spinal cord's structure in measurable ways.

That does not mean NG101 is proven as a standard treatment. It means the biological case is becoming stronger and more measurable.

What this does not prove yet

This was an MRI biomarker analysis from a phase 2b trial, not a final proof that NG101 restores function for all people with SCI.

The treatment was given early after injury, between 4 and 28 days after cervical SCI, through intrathecal injections into the spinal fluid. That makes it an acute SCI treatment approach, not a therapy for long-established chronic injuries at this stage.

The results also suggest that responders may need to be carefully selected. People with different injury patterns may not benefit equally.

Why this matters in SCI

This story matters for two reasons.

First, it keeps the Nogo-A pathway alive as a serious human SCI repair target. Blocking a growth brake is not science fiction anymore; it has reached multicentre human trial analysis with measurable MRI changes.

Second, it shows how future SCI trials may improve. Instead of judging treatments only by broad clinical scores, researchers can use MRI and electrophysiology to see whether the spinal cord itself is changing.

That kind of measurement is essential if the field is going to separate treatments that truly affect repair biology from those that only look promising in small or noisy datasets.

Reader Q&A

Could NG101 help someone with chronic SCI?

This study does not show that. NG101 was tested early after acute cervical SCI. Chronic SCI would need separate trials because the injury environment is very different once scarring and long-term degeneration are established.

Is this a cure?

No. It is a targeted attempt to reduce one biological brake on nerve sprouting and plasticity. It may support recovery in selected people, but it does not rebuild the spinal cord by itself.

Why are MRI and electrical tests so important?

They help researchers see what is happening inside the spinal cord, not just what a person can do on a clinical exam. That can reveal treatment effects earlier and help identify who is most likely to respond.

This is the microrobot story.

A new paper in the International Journal of Extreme Manufacturing reports a striking approach to acute spinal cord injury: use living immune cells as tiny treatment carriers, add magnetic nanoparticles so they can be guided, and steer them toward the injured spinal cord using an external rotating magnetic field.

The researchers call these "DC robots". DC stands for dendritic cell, a type of immune cell that helps organise immune responses.

The goal is not simply to move tiny machines around the body. The goal is to solve a real SCI problem: after injury, the spinal cord environment becomes inflamed, hostile, and short of growth-supporting signals. Treatments injected into the bloodstream often fail to reach the injury site in high enough amounts, while direct injection into the cord can risk extra damage.

Author(s):

Jiawen Niu, Chenlu Liu, Weiwei Zhang, Fawang Zhang, Chuanhua Li, Kunrong Xie, Sikai Wang, Zexuan Wu, Guanglei Li, Xuefeng Li, Jinglong Yan, Jing Li, Chengchao Song, Yan Shi, Jianing Zu, Fengtong Ji, Jie Zhao, Yufu Wang, and Tianlong Li.

Source:

The Second Affiliated Hospital of Harbin Medical University, Harbin Institute of Technology, University of Cambridge, Zhengzhou University, and collaborating laboratories. Published in International Journal of Extreme Manufacturing.

What are dendritic cells?

Dendritic cells are immune system organisers. They help show pieces of biological material, called antigens, to T cells and help shape how the immune system reacts.

In cancer research, dendritic cell vaccines have been studied as a way to train the immune system to attack tumours. In SCI, the idea is different. The goal is to push the immune response toward protection and repair rather than uncontrolled inflammation.

After spinal cord injury, inflammation is not automatically bad. The body needs immune activity to clean up damage. But if the response becomes too aggressive or prolonged, it can worsen tissue loss and block regeneration.

How the microrobots were built

The researchers created biohybrid microrobots using dendritic cells combined with magnetic iron oxide nanoparticles, Fe3O4.

They also incorporated components designed to support immune modulation and neurotrophic factor delivery. Neurotrophic factors are support signals that help nerve cells survive, grow, and maintain connections. Two important ones in this study were BDNF and NT-3.

In simple terms, each DC robot acts like a tiny immune-guidance vehicle:

- The dendritic cell provides the biological immune-regulating function. - Magnetic nanoparticles allow external steering. - Therapeutic cargo and cell signalling help shift the injury environment. - A rotating magnetic field helps guide the microrobots toward the spinal cord lesion.

How they were delivered

In the mouse experiments, the researchers created a T10 spinal cord contusion injury. Two hours after injury, they injected the DC robots through the tail vein.

Then they applied an external rotating magnetic field for 30 minutes to help guide the microrobots toward the injury site.

That matters because SCI disrupts the blood-spinal cord barrier, the protective boundary between blood and spinal cord tissue. During the early injury period, this barrier becomes more permeable. The researchers used that temporary opening as a window to help the microrobots enter the injured area.

Imaging suggested that magnetically guided DC robots accumulated at the injury site more effectively than unguided treatments.

What they changed at the injury site

The treated spinal cord environment shifted toward a more protective immune state.

The paper reports reduced pro-inflammatory signals such as IFN-gamma, GM-CSF, TNF-alpha, IL-1, IL-6, IL-12, and IL-17, alongside increased anti-inflammatory or repair-associated signals such as IL-4 and IL-10.

The DC robots also encouraged immune-cell patterns linked to repair, including more Th2 and Treg-type responses and more anti-inflammatory macrophage/microglial features.

A plain-language way to put this is: the microrobots helped change the injury site from a shouting, destructive immune environment into a calmer clean-up and repair environment.

Growth support: BDNF and NT-3

The study also found higher levels of BDNF and NT-3 at the injury site.

These are neurotrophic factors: molecules that support nerve cell survival and growth. They do not magically rebuild the spinal cord, but they can make the environment more supportive for axons, the long nerve fibres that carry signals.

The authors argue that the benefits came from both sides working together: immune modulation plus growth-factor support.

That is important because SCI repair probably needs combination effects. Reducing inflammation alone may not be enough. Delivering growth factors alone may not be enough. The injury site has to become less hostile and more supportive at the same time.

What happened in the mice

In mouse models of SCI, the magnet-guided DC robot group showed several repair-associated changes.

MRI suggested reduced lesion signal and smaller lesion volume compared with control injury groups. Diffusion tensor imaging suggested more organised nerve-fibre structure at the lesion site. Tissue analysis showed signs of more nerve fibres, less glial scarring, more remyelination-related activity, and improved myelin structure.

Functional testing also improved. The DC robot group showed better hindlimb movement measures, better gait-related CatWalk results, and improved activity measures compared with control groups.

These are promising findings, but they remain preclinical mouse results.

What this does not prove yet

This is not ready for human treatment.

The work was done in mice, in an acute injury window, with careful laboratory control over timing, injection, magnetic guidance, imaging, and analysis. Human SCI is larger, more variable, and medically more complex.

Safety also needs much more work before translation. The authors assessed organ safety and iron clearance in mice, but human use would require major testing around immune reactions, blood flow, clotting, infection risk, dosing, manufacturing, magnetic targeting accuracy, and long-term fate of the cells and nanoparticles.

The study also used female mice only, which the authors acknowledge as a limitation. Future work needs to test whether responses differ by sex.

Why this matters in SCI

This study is interesting because it combines three major SCI treatment ideas:

- Targeted delivery. - Immune reprogramming. - Growth-factor support.

Instead of flooding the whole body with drugs or directly injecting the spinal cord, the researchers used magnetically guided living cell-based carriers to concentrate treatment near the injury.

The bigger lesson is that future SCI therapies may need to be both smart and local. The right treatment has to arrive at the right place, at the right time, and change the injury environment in more than one way.

This does not mean microrobots will be treating people with SCI soon. But it is a creative and serious step toward precision medicine for acute spinal cord injury.

Reader Q&A

Are these real robots?

They are not robots like metal machines with motors. They are biohybrid microrobots: living dendritic cells combined with magnetic nanoparticles so they can be influenced by an external magnetic field.

Could this help chronic SCI?

Not based on this study. The treatment was given two hours after injury and is aimed at the early inflammatory phase. Chronic SCI would need different testing.

Why use magnets?

The magnetic field helps guide the treatment toward the injury site. That could improve targeting and reduce the need for risky direct injection into the spinal cord.